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Abstract 
 
The Calibrated Automated Thrombogram (CAT) thrombin generation assay is a 
technique that allows the characterisation of an individual’s capacity to produce 
thrombin in response to a procoagulant stimulus. As such it is a global screening test for 
both hyper and hypocoagulable bleeding disorders. This project focused on the 
introduction of the CAT assay into routine use in the haemostasis laboratory at the 
Royal London hospital and to assess its clinical utility.  
 
Initial experimentation focused on determining the suitability of the assay for routine 
use, including ascertaining the levels of inter and intra assay variation, the effects of 
sample handling and storage, the limits of detection, variation in an individual with time 
and establishing a normal range. All of these experiments returned favourable results. 
 
The assay was then used to characterise the thrombin generation profile of a cohort of 
women with pre-eclampsia. Women with pre-eclampsia were found to have higher 
thrombin generation parameters (Endogenous thrombin potential and peak height) when 
compared to normotensive pregnant women (p= <0.001). Re-analysis of the data 
showed the use of thrombin generation could detect pre-eclampsia with a specificity and 
sensitivity of 83% and 43% respectively when combined with the Pre-eclampsia 
community guideline screen. There were also statistically significant correlations 
between the measurement of thrombin generation and both birth weight and the length 
of stay in hospital at delivery. 
 
Further analysis by flow cytometry and studies involving filtration of plasma revealed 
that the sensitivity of the assay to the detection of pre-eclampsia may be associated with 
the increased levels of microparticles present in the blood of pre-eclamptic women. 
There were statistically significant correlations (p= <0.05) between changes in thrombin 
generation parameters and the number of microparticles post filtration. This suggests 
that the CAT assay is sensitive to the number of microparticles in a patient’s plasma. 
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1.1 The Coagulation Cascade 
 
The clotting of blood at the site of vascular injury involves a complex biological 
amplification process whereby a relatively small initiation signal can generate a large 
physiological response. The coagulation cascade is mediated via the sequential 
activation of serine protease enzymes which circulate in the blood as zymogens. The net 
result of the cascade is the formation of a haemostatic plug and the cessation of 
bleeding.  
 
Coagulation in vivo is thought to be initiated via the binding of factor VII to exposed 
tissue factor at the sites of vascular injury. This binding causes the activation of factor 
VII. Activated factor VII then activates both factors IX and X via proteolytic cleavage. 
Activated factor X initiates the production of thrombin from prothrombin. The 
production of low levels of thrombin leads to the activation of factors V, VIII (cofactors 
for factor Xa and IXa respectively) and XI. Activated factor XI further increases the 
production of activated factor IX. Factors VIIIa and IXa form the intrinsic factor Xase 
complex on a membrane surface that can be provided by platelets, microparticles and 
endothelial cells. The Xase complex can activate factor X at a rate of 50-100 fold 
greater than factor VIIa and tissue factor (Butenas and Mann 2002). The production of 
the Xase complex therefore leads to the initiation of a positive feedback loop 
consolidating the production of activated factor X and thereby the conversion of 
prothrombin to thrombin. 
 
The proteolytic activity of the clotting factors are dependent on the presence of both 
calcium ions and phospholipids, a number of the reactions are also surface-mediated, 
occurring on exposed collagen or platelets (Xase complex). The reactions are so 
dependent on the presence of cofactors and membrane binding sites that the absence of 
either is as significant as the absence of the clotting factor itself (Butenas and Mann 
2002). Factors Xa and Va form the prothrombinase complex, this occurs on the 
phospholipid rich surface of activated platelets at the site of vascular injury. The 
thrombin generated hydrolyses soluble plasma fibrinogen to form fibrin monomers and 
yield the fibrinopeptides A and B. The fibrin monomers spontaneously form hydrogen 
bonds linking them together to create insoluble fibrin polymers. The fibrin polymers are 
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then covalently cross-linked via the activity of activated factor XIII. Factor XIII is itself 
activated by thrombin. 
 
Coagulation in vitro can be stimulated by contact reactions between factor XII and high 
molecular weight kininogen (HMWK), this leads to the activation of factor XI and 
therefore factor IX, initiating the cascade. Individuals who demonstrate a deficiency of 
the contact factors do not however demonstrate abnormal bleeding, suggesting that 
these factors are not essential for in vivo coagulation. Factor XI is also non-essential in 
the initiation of coagulation in vivo although does play a role in the activation of factor 
IX and may have an important role at sites of major trauma. 
 
The generation of thrombin via the clotting cascade can be divided into two distinct 
phases; the initiation phase and the propagation phase
 
(Butenas and Mann 2002). The 
initiation phase begins following the addition of tissue factor and is characterised by the 
formation of femtomolar to picomolar levels of factors VIIa, IXa, Xa and XIa, partial 
platelet activation, the activation of cofactors Va and VIIIa and nanomolar levels of 
thrombin generated at a comparatively low rate. The initiation phase is roughly 
analogous to the clotting times measured in the laboratory. The propagation phase is 
characterised by the completion of platelet aggregation and the rapid generation of 
thrombin resulting in the formation of a solid clot. 
 
In order to prevent the formation of pathogenic occlusions in blood vessels such as deep 
vein thrombosis (DVT) and pulmonary embolism (PE) the generation of thrombin and 
therefore the production of fibrin clots must be limited to the site of vascular injury. 
There are multiple negative regulators of the haemostatic system. The major negative 
regulator of the initiation phase is tissue factor pathway inhibitor (TFPI). TFPI is 
present in both plasma and platelets and accumulates at sites of injury due to local 
platelet activation. TFPI acts by inhibiting factors Xa and VIIa, the balance between the 
clot formation and inhibition therefore depends on the relative strength of the pro-
coagulant and anti-coagulant signals. Once the cascade has reached the propagation 
phase the inhibitory effect of TFPI is diminished. Antithrombin is another potent 
inhibitor of the clotting cascade which circulates in the plasma. Antithrombin 
inactivates factors IXa, Xa, XIa and thrombin via irreversible binding to form stable 
high molecular weight complexes. In contrast to TFPI antithrombin has limited 
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inhibitory effect during the initiation phase of the cascade and a more pronounced effect 
on the propagation phase. This is also true of protein C; a vitamin K dependent serine 
protease which is activated in response to thrombin binding to the endothelial cell 
surface receptor thrombomodulin. Activated protein C inactivates factors Va and VIIIa 
via proteolytic cleavage, its activity is enhanced by the presence of its cofactor protein 
S. An overview of the clotting cascade is shown in figure 1.1 
 
Figure 1.1 
 
 
Figure 1.1 Diagrammatic representation of the clotting cascade and a number of the negative regulators 
involved. Inhibition is shown via red arrows. Figure adapted from: 
kuwaitmd.hsc.edu.kw/main/index.php?q=node/60 
 
The inhibitors of the clotting cascade act in a synergistic manner; the presence of 
multiple inhibitors has a more pronounced effect than would be predicted by the 
presence of one alone (Butenas and Mann 2002). 
 
 
 
APC + Protein S 
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1.2 Thrombin Generation and the Coagulation Cascade 
 
Routine clotting screens include the prothrombin time (PT), which is converted to the 
international normalised ratio (INR), and the activated partial thromboplastin time 
(APTT). These tests effectively measure the time to clot formation when coagulation is 
stimulated via the extrinsic or intrinsic pathway respectively. As mentioned above this 
is roughly analogous to the duration of the initiation phase of the cascade. At this time 
only 10-20 nM of thrombin is formed, this constitutes less than 5% of the total thrombin 
that can be generated by the cascade (Hemker and Béguin 1995). This essentially means 
that the clotting time of a patient does not always correlate with their capacity to 
generate thrombin, for example a patient taking low molecular weight heparin has 
compromised thrombin generation but only a modestly prolonged APTT. A similar 
scenario is also posed by those patients with antithrombin, protein C or protein S 
deficiencies, factor V Leiden and activated protein C (APC) resistance. All of those 
conditions result in an increased thrombin generation capacity and hence a potentially 
pro-thrombotic state in the patient. Patients with these conditions all have a normal INR 
and APTT however, showing that these tests are insensitive to hypercoagulative states.  
 
In contrast the endogenous thrombin potential (ETP) is a global assay that is sensitive to 
both hyper and hypocoagulant states and is a parameter that both increases and 
decreases in proportion to the thrombin forming capacity of a sample (Hemker and 
Béguin 1995). ETP was first described in 1993
 
as a way of quantifying the level of 
thrombin that a patient’s plasma was capable of generating (Hemker et al., 1993). The 
assay itself measures the production of thrombin in a patient’s plasma by continuously 
monitoring the amidolytic activity of thrombin on a substrate after the coagulation 
cascade is initiated via the addition of tissue factor. The substrate should be cleaved 
specifically by thrombin and cleaved at a rate slow enough to ensure it is not consumed 
before the process of thrombin generation is complete. When the substrate is cleaved by 
thrombin it yields a product that can be quantified (e.g. by the production of a 
fluorescent signal) thus the activity of thrombin can be measured over a specific time 
course yielding a bell shaped curve when plotted. The area under the curve is the 
patient’s ETP. The curve also has other parameters that can be interpreted these include 
the lag time (the time before thrombin production is initiated), the peak height which is 
representative of the maximum velocity of net thrombin production and the time to 
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peak, which is the time taken to reach the peak height. These parameters are shown 
graphically in figure 1.3. 
 
1.3 The Use of Thrombin Generation in Hypocoagulable States 
 
Since the measurement of the ETP provides a clear indication of an individual’s 
capacity to generate thrombin it should be sensitive to those with a hypocoagulable 
disorder, such as haemophilia. This was indeed shown to be the case in individuals who 
were deficient in factors V, VII, X, XI, XII and Prothrombin (Al Dieri et al., 2002). 
These experiments showed that there was no difference in the ETP of these patients 
when the clotting cascade was initiated via either the intrinsic or extrinsic pathway for 
patients deficient in factors VII, X and prothrombin. Patients who were deficient in 
factors XI and XII had ETPs which were only abnormal when examined following 
stimulation via the intrinsic pathway, although this was an anticipated result.  
 
Interestingly it was shown that of the factor deficiencies examined only the level of 
prothrombin correlated with the ETP in a linear fashion. For factors V, VII, X and XI 
increasing concentration produced a hyperbolic curve which approached normal ETP 
the higher the concentration became. It was shown that relatively low levels of clotting 
factor could produce ETPs that approached a normal level. The levels of clotting factor, 
that could produce an ETP that was 50% of that of a pool of normal plasma were, 1% 
for factor V, 2% for factor VII, 5% for factor X and 1% for factor XI. As a general rule 
it was the peak height and the lag time that were affected by decreasing the clotting 
factor concentration. The levels of ETP remained relatively normal until the levels of 
clotting factor were markedly reduced. This implies that the bleeding tendency seen in 
patients with these factor deficiencies may be due to the speed that they produce 
thrombin rather than the level of thrombin production they are capable of. This also 
lends weight to the theory that the levels of clotting factors which circulate in the blood 
are in excess of that which is necessary to induce coagulation. The severity of bleeding 
was also found to correlate well with the patients ETP, it was discovered that the 
patients with a history of severe bleeding had an ETP which corresponded to less than 
20% of normal. This neatly dovetails with the bleeding of anti-coagulated patients who 
have a marked increase in bleeding severity when their INR is in excess of 3.5 (Azar et 
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al., 1996), this was shown to correspond to an ETP of roughly 17% of normal (Hemker 
and Béguin 2000). 
 
The correlation of bleeding severity of haemophilia patients to ETP is of great interest 
since bleeding severity does not always correlate with the level of clotting factor 
activity a patient demonstrates (Walsh et al., 1973). The correlation between ETP and 
bleeding severity was also demonstrated in patients with haemophilia A and B (factor 
VIII and IX deficiencies respectively) (Dargaud et al., 2005). Although in this study it 
was suggested that patients with a severe clinical bleeding tendency had an ETP of less 
than 50% normal, and that this roughly corresponded to a clotting factor activity of 
10%. A number of exceptions to these rules were highlighted. Some of the patient 
cohort who were diagnosed as severe haemophiliacs (factor VIII activity <1%) 
demonstrated an ETP of greater than 50% normal and presented with mild bleeding 
tendencies. There were also a few cases of patients having a reduced ETP but no 
clinically significant bleeding. Over the course of the study 25% of the haemophilia 
patients had an ETP that did not correlate with the level of factor activity demonstrated 
by the patient and in the majority of these patients there was poor correlation between 
their clinical bleeding severity and the level of factor activity. It was also shown that 
patients who were treated with recombinant factor VIII, who had identical levels of 
residual factor VIII 24 hours post infusion could have markedly different ETPs. So 
perhaps the measurement of ETP could be used to help evaluate the efficacy of 
haemophilia treatment in a patient specific manner and therefore improve patient care 
and the cost effectiveness of the treatment regimen.  
 
The above experiments were performed using platelet poor plasma (PPP), with the 
platelets having been removed by centrifugation. In these experiments the platelets were 
effectively replaced with phospholipid vesicles, which provide a platform for the 
surface mediated cascade reactions. It has been shown that the ETP of haemophilia A 
and B patients can be affected by decreasing platelet counts, when it is measured using 
platelet rich plasma (Siegemund et al., 2003). The ETP can be altered in a linear fashion 
with decreasing platelet count, when the count falls below 100 x10
9
/l. There is no effect 
on the ETP of a patient when the platelet count exceeds 100 x10
9
/l. It was also shown 
that the effects of reducing the platelet count were greater in patients with haemophilia 
B than those with haemophilia A; it is hypothesised that this may be due to the role in 
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platelets in the assembly of the Xase complex. The reduction of ETP caused by this 
thrombocytopenia could be overcome by increasing the levels of clotting factor in the 
patients’ samples thereby implying that the effect is not simply due to a decreasing 
surface area for the assembly of the Xase complex. 
 
Some of the variation in these experiments may be due to the concentration of tissue 
factor used to initiate the coagulation cascade in these assays. Although thrombin 
generation assays performed in PPP are sensitive to the levels of both factor VIII and IX 
when a tissue factor concentration of 5 pM is used to initiate coagulation (Hemker et al., 
2003) it has been shown that thrombin generation assays show greater sensitivity to the 
intrinsic pathway factors when the tissue factor concentration is reduced to 1-2 pM 
(Beltran-Miranda et al., 2005). The use of low concentrations of tissue factor is not 
without flaws however, since it can lead to increasing assay variability (van Veen et al., 
2008) (Dargaud et al., 2007) and also an increase in contact factor activation (van Veen 
et al., 2008) (Dargaud et al., 2007) (Luddington and Baglin 2004) (auto activation of 
factor XII) leading to erroneous results. The use of corn trypsin inhibitor (CTI) can 
overcome these effects (Luddington and Baglin 2004), but significantly increases the 
costs of the assay. CTI is not required when 5 pM tissue factor is used (van Veen et al., 
2008). A comparative study was carried out to determine the sensitivity of two different 
tissue factor concentrations (1 and 5 pM) when used to discriminate between patients 
with haemophilia A (of varying severity) and a healthy male population (van Veen et 
al., 2009a). It was shown that there was no practical advantage in using a tissue factor 
concentration of 1 pM to initiate thrombin generation rather than 5 pM. Both 
concentrations were able to distinguish between the patient and control groups, although 
interestingly the use of 1 pM tissue factor failed to significantly distinguish between 
mild and severe haemophiliacs. This was not the case with 5 pM tissue factor. This is 
highlighted by the authors as being at odds with other studies (Dargaud et al., 2005) 
(Beltran-Miranda et al., 2005) which have shown a difference between mild, moderate 
and severe haemophiliacs. It was postulated that this difference was due to the 
methodologies employed; where CTI was either not used or was added subsequently to 
the patient’s plasma, when it is most efficacious when the sample is taken directly into 
CTI. The analysis of patients with mild haemophilia using a tissue factor concentration 
of 1 pM in the absence of CTI can lead to an overestimation of thrombin generating 
capacity due to contact factor activation, thereby making the discrimination between 
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mild and severe haemophiliacs more pronounced. The study also highlighted that the 
main differences in the thrombin generation profile of haemophiliacs when compared to 
normal individuals is a decreased ETP, peak height and an increased time to peak. This 
is because the abnormalities in haemophilia primarily affect the propagation phase of 
thrombin generation and have a minor difference in the initiation phase. Interestingly 
this finding is contradictory to that of Al Dieri et al. (2002) above. 
 
It has also been shown that thrombin generation assays can potentially be used to 
monitor haemophilia patients who are treated with factor eight inhibitor bypassing 
activity (FEIBA
®
) and recombinant activated factor VII (rVIIa) (van Veen et al., 
2009b). Both FEIBA
®
 and rVIIa are used in the treatment of patients with haemophilia 
who have developed inhibitors (antibodies against factor VIII concentrate). FEIBA
®
 is 
derived from human plasma and contains activated factor VII and non activated factors 
II, IX and X. Traditional coagulation tests are unsuitable in the monitoring of both rVIIa 
and FEIBA
®
. It was shown with in vitro spiking experiments of plasma samples taken 
from 10 severe haemophiliacs that there was a linear dose-response to FEIBA
®
 with 
both the ETP and peak height and inverse hyperbolic relation of both the lag time and 
time to peak when the reaction was initiated with 1 pM of tissue factor. Similar results 
were shown for the use of rVIIa. Both agents normalised the thrombin generation 
parameters of the patients following spiking with therapeutic doses. Interestingly the 
use of 5 pM tissue factor led to substrate depletion for FEIBA
® 
concentrations >0.5U/ml 
(therapeutic dose is believed to be 0.5-1.0Um/l) meaning it is impossible to calculate the 
ETP. Similarly the use of 5 pM of tissue factor was also unsuitable for the monitoring of 
rVIIa with no observable effect on either the ETP or peak height with increasing dose of 
rVIIa. This observation is similar in nature to a study which showed that a reduction in 
clotting time by a given concentration of rVIIa was inversely proportional to the tissue 
factor concentration (Butenas et al., 2002). These observations mean that while the 
diagnosis of haemophilia may be performed using either 1 or 5 pM tissue factor as a 
reaction trigger, monitoring of either rVIIa or FEIBA
® 
requires 1pM tissue factor. 
Spiking patients’ plasma with both rVIIa and FEIBA® showed that the agents were 
capable of acting synergistically. This is probably due to the increased level of 
prothrombin in the sample since synergy has been shown between the factor II (present 
in FEIBA
®) 
and rVIIa(van Veen et al., 2009 B)(Allen et al., 2006), implying that the 
baseline level of factor II is important in the response of an individual to rVIIa. Again 
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this study suggests a potential role for thrombin generation assays in assessing the 
efficacy of treatment regimens, with the aim of both lowering the costs of the treatment, 
whilst optimizing both the effects and safety of the therapy. 
 
ETP could potentially be used to great effect in the detection/treatment of factor 
deficiencies; however it does not distinguish which factor a patient is deficient in and so 
cannot completely replace the current screening methods. It does have benefits 
however, since an abnormality should be obvious immediately.  
 
1.4 Thrombin Generation and Anticoagulation Therapy 
 
Thrombin generation assays could potentially be used to monitor those patients 
undergoing anti-coagulant therapy, especially those undergoing combination therapy 
and those who are taking low molecular weight heparin, as these patients cannot be 
monitored using the standard clotting screen techniques. ETP has been shown to be 
sensitive to Warfarin and heparin (Hemker and Béguin 1995) (Hemker and Béguin 
2000) (Nieuwenhuys et al., 2000) (Kakkar et al., 2002) and has been used as a method 
of comparing different heparin treatment regimens (Kakkar et al., 2002). 
 
Heparins can be quantified in a patient’s plasma using assays to detect the anti-IIa 
and/or anti-Xa activity of that heparin. The detection of heparin activity does not always 
correlate with clinical effectiveness however since there is high variability in heparin 
pharmacodynamics between individuals (Dieri et al., 2004), with varying levels of 
heparin carrying proteins and anti/procoagulant factors. Measuring the effect of heparin 
on a patient’s plasma is believed to be a more effective way of monitoring a response to 
treatment. This is usually performed using the APTT ratio. A comparison between 
APTT and ETP parameters of a cohort of patients injected with a fixed dose of four 
heparins of varying molecular weight showed that the ETP was more sensitive to the 
presence of heparin than the APTT (Dieri et al., 2004). An anti-IIa activity of 0.1 IU of 
any heparin can cause an APTT ratio of 1.2-1.4 but an inhibition of ETP of between 50-
80%. Thrombin generation assays therefore may be of use in clinically monitoring those 
patients in whom standard doses of heparin do not produce the desired effect, since dose 
adjustment may have little impact on the APTT ratio but a larger impact on the ETP, 
allowing more effective monitoring. 
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Further studies have not only shown that thrombin generation assays are more sensitive 
to the detection of different heparins/heparinoids, including unfractionated heparin 
(UFH), low molecular weight heparins (LMWH), Danapariod and Fondaparinux than 
the traditional APTT and anti-Xa assays but they are also more sensitive to detecting 
their reversal by agents including protamine sulphate, NovoSeven
®
, FEIBA
®
 and fresh 
frozen plasma (FFP) (Gatt et al., 2008), providing more potential uses for thrombin 
generation assays in the clinical setting.  
 
Since thrombin generation assays are sensitive to the majority of anticoagulation agents 
it follows that they could be useful in determining the efficacy of new treatments in ex-
vivo models. Indeed thrombin generation has been shown to have an advantage over 
clotting based assays in determining the effects of 6 different thrombin or factor Xa 
inhibitors specifically when regarding the total amount of thrombin generated and the 
time course of the generation as well as providing insights into the mechanisms of 
action of such compounds (Robert et al., 2009). Thrombin generation assays have also 
been used to evaluate the efficacy of new direct thrombin inhibitor drugs such as 
dabigatran etexilate (Wienen et al., 2007). 
 
The above evidence shows multiple potential clinical roles for thrombin generation 
assays; from the development of new anticoagulant agents to patient specific monitoring 
of anticoagulant therapy, making it a valuable addition to existing laboratory tests.  
 
1.5 The Use of Thrombin Generation in Hypercoagulable States 
 
The measurement of ETP should be as sensitive to hypercoagulant states as it is to 
hypocoagulant states. Since there are a large number of conditions which can cause a 
pro-thrombotic state in a patient a high ETP can not be used to diagnose specific 
disorders but should give an indication as to the risks/likelihood of a patient developing 
a thrombosis in the future. Although the current laboratory investigations for 
thrombophilia are for specific disorders including Antithrombin, protein C and protein S 
deficiencies, APC resistance, factor V Leiden and prothrombin variant mutations and 
Lupus anticoagulant, the majority of patients screened have normal results, or transient 
abnormal results due to acute phase reactions or anticoagulation therapy. One of the 
largest risk factors involved in inherited thrombophilia is a family history; this indicates 
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that there are a number of predisposing factors which remain undiscovered; by the 
measurement of ETP in these patients it may be possible to elucidate an inherent risk, 
even if the cause remains to be found. There have been a number of recent arguments 
questioning the validity of ‘traditional’ thrombophilia screening (Dalen 2008). 
Thrombophilia screening is not usually performed to elucidate the risk of an initial 
episode of venous thromboembolism (VTE) but rather is primarily performed to 
determine the risk of recurrent events in patients with a history of VTE. However a meta 
analysis of studies found that only elevated levels of factor VIII, the presence of anti-
phospholipid antibodies and the presence of multiple thrombophilic defects lead to a 
significant increase in the risk of recurrence of VTE. It also showed that there was a 
large cohort of patients with idiopathic VTE in which no heritable thrombophilia was 
found. These findings led the author to query whether thrombophilia screening was cost 
effective. It may be that screening thrombophilia patients via thrombin generation 
assays provides a more cost effective means of assessing risk. 
 
Elevated levels of ETP are not associated with some pro-thrombotic states such as 
exhaustive exercise (Hilberg et al., 2002) (which causes activation of blood 
coagulation), hyperhomocysteinemia (Bos 1999) and pregnancy (Eichinger et al., 1999). 
It has also been reported that there was no difference in the ETP between pregnant 
women with and without the factor V Leiden mutation, despite their being a higher 
incidence of thrombotic events in pregnant women with factor V Leiden than in those 
without (Eichinger et al., 1999). This finding may be due to the set up of the assay 
however (see APC below). Interestingly none of the women in this study developed a 
thromboembolic event despite having levels of D-dimer, Thrombin- antithrombin 
(TAT) and F1+F2 comparable to those seen in DVT, PE and myocardial infarction. 
Thus the ETP in this cohort of patients may be of a diagnostic benefit, since all of them 
demonstrated normal ETP and no thrombotic events were recorded.  ETP was also 
found to be insensitive when used in the diagnosis of DVT (Bucek et al., 2003) but has 
been previously reported to be elevated in patients with active deep vein thrombosis 
(Wielders et al., 1997). Thrombin generation has also been shown to be elevated 
following acute DVT (Ten Cate-Hoek et al., 2008), with a cohort of patients showing 
increased ETP and peak heights when compared to a normal population. This difference 
was shown to become more pronounced over the course of a year before stabilising in 
the patient population. The observed differences became more pronounced if 1pM tissue 
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factor was used as a reaction trigger rather than 5pM tissue factor. The authors also 
discovered that the addition of thrombomodulin to the patients’ plasma caused less 
inhibition of thrombin generation in the patient group than in the normal controls. 
Whether this apparent resistance to activated protein C was causative of the VTE in the 
patients demographic was not discussed. The mechanism for this APC resistance was 
thought to be partially explained by a negative correlation between levels of factor VIII 
and the thrombomodulin dependent thrombin generation reduction in the patient group. 
Elevated levels of factor VIII would lead to an enhanced feedback of thrombin mediated 
factor VIII activation which could counter-act the thrombomodulin mediated inhibition 
of factor VIII by APC. 
 
A number of studies have also demonstrated a link between thrombin generation and the 
risk of recurrent VTE. Besser et al. (2008) showed in a prospective cohort of 188 
patients with either unprovoked VTE or provoked VTE of a non-surgical nature that the 
patients with a high ETP had a significantly higher risk of an unprovoked recurrence 
than those with a low ETP. They also showed that individuals with an unprovoked VTE 
had a significantly higher risk of a subsequent unprovoked VTE than those who had an 
initial provoked VTE and that in this cohort an elevated ETP was associated with an 
increased risk of recurrent thrombosis. A similar experiment using a larger cohort of 
861 patients found a similar result (Eichinger et al., 2008) i.e. an elevated ETP was 
associated with an increased risk of recurrent thrombosis. Interestingly this study also 
showed that an elevated D-dimer was also associated with recurrent risk of thrombosis 
and that there was a degree of synergy between the two parameters. 
 
1.5.1 ETP and Prothrombin Variant 
 
Elevated ETP has been demonstrated in association with the prothrombin variant (Kyrle 
et al., 1998). The prothrombin variant mutation is caused by a single G to A transition at 
position 20210 in the prothrombin gene. This causes carriers of the mutation to have an 
increased level of circulating prothrombin compared to normal individuals. The ETP of 
prothrombin variant heterozygotes is significantly elevated in comparison to normal 
individuals; prothrombin variant homozygotes were shown to have an ETP of almost 
twice that of a normal control. These results correlate well with the findings of Dieri et 
al. (2002)
 
that there is a linear association between prothrombin concentration and the 
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magnitude of ETP. The carriers of this variant allele have an increased risk of venous 
thrombosis presumably due to over production of thrombin once the cascade is 
triggered.  
 
1.5.2 ETP and APC Resistance 
 
Extensive investigation has been performed into the capacity of ETP to elucidate a 
patient’s resistance to APC. An individual with APC resistance will not show an 
increased ETP per se. The defect does not cause pathogenesis via an overproduction of 
thrombin, as is the case for the prothrombin variant allele, but rather by a resistance to 
the negative regulation leading to prolonged thrombin production. The reason this is not 
reflected in the ETP assay is due to the mechanisms of protein C activation. Activation 
of protein C requires thrombin binding to thrombomodulin; a membrane bound protein 
that is therefore not present in the patients’ plasma. APC resistance can therefore be 
investigated using an ETP based assay by the addition of either activated protein C or 
recombinant thrombomodulin to the patient’s plasma.  
 
The APC resistance is usually measured by a normalized APC ratio this is calculated by 
dividing the ETP of a patient following the addition of APC by the patients ETP without 
the addition of APC and further dividing this by the same ratio derived from a pool of 
normal plasma. See below.     
Normalised APC Ratio =  (Patient ETP with APC/ Patient ETP)  
   (Normal Plasma Pool ETP with APC/  Normal Plasma Pool ETP) 
 
An increased normalised ratio when determined by ETP is indicative of APC resistance. 
The most common cause for APC resistance is the presence of the factor V Leiden 
allele. The allele is caused by a missense mutation at position 506 in the amino acid 
sequence of the factor V protein. This mutation removes one of the three specific 
arginine residues at which factor Va is cleaved by APC, thereby rendering the factor V 
Leiden protein more resistant to proteolytic cleavage than wild type factor V. APC 
resistance can also be acquired, this is most common in patients who are either 
undergoing hormone therapy (including oral contraceptives) or who are pregnant 
(Curvers et al., 1999). It has been shown that the APC ratio (and therefore the incidence 
of APC resistance) when measured using the ETP is greater in women who take oral 
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contraceptives than in those who do not (Curvers et al., 1999). This has also been 
shown to be the case when the APC ratio was determined using the standard APTT 
based technique. It was however demonstrated that the ETP based method could 
distinguish a significant difference in the APC ratio between women on different types 
of oral contraception i.e. there is a significant difference between the APC ratio of those 
women taking second generation oral contraceptives and those taking third generation 
oral contraceptives. This difference was undetectable using the APTT based technique, 
implying that the ETP based method is more sensitive in detecting differences in the 
APC ratio. Retrospective studies however found no correlation between an increased 
APC ratio, measured via the ETP, caused by acquired APC resistance and an increased 
risk of venous thromboembolism in pregnancy (Zotz et al., 2004). This is in contrast to 
APC resistance caused by factor V Leiden, which was shown to correlate with the 
incidence of thrombotic events during pregnancy. The same results were shown for a 
second cohort of women who had a previous venous thromboembolism (Heinemann et 
al., 1998). Other studies however provide conflicting evidence and suggest that elevated 
APC ratios as determined via ETP do predict the risk of venous thrombosis in both male 
and female patients (Tans et al., 1999).  
 
It has also been reported that the ETP based APC resistance test is sensitive to the 
prothrombin variant allele, hormone replacement therapy and protein S deficiency and 
insensitive to antithrombin and protein C deficiency (Curvers et al., 2002a). The 
sensitivity of this assay to the prothrombin variant allele is probably due to the 
inhibitory effect of prothrombin on APC dependent factor Va inactivation. The 
sensitivity of this assay to protein S is not unanticipated since free protein S is a 
cofactor for protein C. A deficiency of protein S would therefore reduce the 
effectiveness of any activated protein C used in the assay, whether endogenous or 
exogenous and therefore mimic APC resistance. The affects of protein S deficiency in 
this assay may explain the elevated APC ratios seen in patients who are pregnant and 
who are talking oral contraceptives since the protein S levels in these patients are 
reduced. The insensitivity of the assay to protein C deficiency is unsurprising only if 
exogenous APC is added in the assay. If the assay relies on activation of the patients 
own protein C a deficiency should again mimic APC resistance. 
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It was also shown that the effects of these variables on the APC ratio of a patient are 
additive, for example patients with factor V Leiden who take oral contraceptives have a 
higher APC ratio than those who are factor V Leiden carriers. The ETP based method of 
monitoring APC resistance is therefore a potentially powerful tool since despite its non-
specific nature it can give a global assessment as to a patient’s risk of developing a 
venous thrombosis.  
 
Some of the variation that is seen in the conflicting APC ratio results can potentially be 
explained by the protocols used in the different studies. It has been shown that there are 
a large numbers of pre-analytical variables that can affect the outcome of the assay. 
These include the concentration of the tissue factor, Calcium ions, and phospholipids as 
well as the concentration of anti-coagulant used in the vacutainer (Curvers et al., 
2002b). The assay is unaffected by storage temperature, repeated thawing and 
centrifugation speed. It was shown that the majority of these variables could be 
overcome by using sufficient concentration of tissue factor, Calcium ions, and 
phospholipids since the effects of minor concentration changes on the assay were 
reduced when higher concentrations were used. The single largest factor which 
influenced the results was the concentration of the anti-coagulant used. Samples taken 
into 0.109M tri-sodium citrate showed higher APC sensitivity ratios than those samples 
taken into 0.130M tri-sodium citrate. There is also the possibility that the choice of 
method used can affect the result, although this variability can be overcome via the use 
of automated techniques (Lawrie et al., 2003). 
 
ETP has also been shown to be sensitive to the level of antithrombin and the level of 
protein C assuming recombinant thrombomodulin is used in the assay
`
. Measurement of 
the ETP shows a reduced sensitivity when investigating the patient for lupus 
anticoagulant, although the lag time of thrombin generation is characteristically 
increased (Regnault et al., 2004). The measurement of ETP is therefore sensitive to all 
of the conditions that are screened for in a patient that is investigated for a 
thrombophilic tendency, although it cannot replace the existing assays due to the fact it 
is unable to determine the exact nature of the patients condition. It has the advantage 
however, that it can give a global estimation of a patient’s risk of developing a venous 
thrombosis. This global estimation of risk can be even more potent when considering 
the fact that thrombin generation assays have been shown to be sensitive to some of the 
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more esoteric risk factors of thrombosis such as obesity (Cimenti et al., 2006) where the 
thrombin generation profile of a cohort of obese children, average body mass index 
(BMI) 33 had a higher ETP, peak height, lag time and time to peak than a cohort of 
children with a normal BMI (average 19). The elevated ETP and peak height is 
consistent with an increase thrombotic risk and gives support to the findings that some 
clotting factors such as factors VII and VIII are frequently raised in obesity (Rosito et 
al., 2004). The elevated lag time was more surprising but it was postulated by the 
authors that this is due to an elevation in the concentration of negative regulators of 
thrombosis, such as TFPI, which has been shown to correlate with increasing BMI 
(Vambergue et al., 2001). Thrombin generation assays have also been shown to 
correlate with smoking (Hioki et al., 2001) (Hjemdahl 2001) where it was demonstrated 
that platelet dependent thrombin generation is increased in smokers compared to non 
smokers and also increases immediately after smoking. Ex-vivo spiking of non smokers 
plasma with nicotine and cotinine was also found to increase levels of platelet 
dependent thrombin generation. 
 
1.6 Project Aims 
 
Since the measurement of thrombin generation has potentially great benefits when used 
clinically, it is necessary to evaluate the assay to determine if it is suitable for use in the 
routine diagnostic setting. This is of interest primarily in the detection of patients with 
thrombophilic disorders since the current screening methods are relatively expensive 
and do not always detect abnormalities in the patients that are tested. The measurement 
of thrombin generation in these patients who are apparently ‘normal’ may provide an 
indicator that they do have a thrombotic tendency even if the precise reason for this has 
yet to be elucidated. Success in the introduction of the thrombin generation assay for 
thrombophilia patients would lead to the introduction of the assay in the haemophilia 
setting; although this is slightly more problematic since the assay is sensitive to contact 
activation (auto activation of factor XII) when the capacity of a patients plasma to 
generate thrombin is low and a low concentration of tissue factor is used to initiate the 
reaction. The use of corn trypsin inhibitor can overcome this effect by inhibiting auto 
activation of factor XII (Luddington and Baglin 2004) but creates further problems in 
that it potentially increases the cost of the assay, ultimately making it less desirable for 
routine use.  
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The aim of this project was therefore to evaluate the clinical utility of the thrombin 
generation assay. In order to be effective when used in the diagnostic setting the assay 
should be relatively simple, quick and be cost effective. The assay should also produce 
reliable results, i.e. the assay should have a good level of reproducibility with low levels 
of both inter and intra assay variability. If it is to be used routinely in the diagnostic 
laboratory of a hospital the effects of sample handling, preparation and storage on the 
assay must also be ascertained. The assay must also have a normal range established as 
well as determining how this normal range is affected by both age and sex and how the 
results from an individual may vary over time. It is also necessary to ascertain the limits 
of detection for the assay. Above all the assay should produce results which are 
clinically useful. 
 
1.7 The Calibrated Automated Thrombogram 
 
The use of a primarily automated assay with commercially produced reagents should in 
theory overcome many of the issues encountered with the thrombin generation assay, 
especially those associated with varying levels of tissue factor, phospholipid and 
calcium ion concentration since these factors are known to affect the results generated 
by the assay (Regnault et al., 2004). To this end it was decided to use the Calibrated 
Automated Thrombogram (CAT) assay employing the reagents commercially produced 
by Diagnostic Stago. The CAT assay is essentially the same assay as described by 
Hemker et al. (1993) but relies on commercially produced reagents and a higher degree 
of automation.  
 
The CAT assay functions by initiating the clotting cascade via the extrinsic pathway. 
This is achieved by the addition of patients plasma to a reagent which contains both 
tissue factor and phospholipids with a final concentration of 5pM and 4μM respectively 
(PPP reagent), followed by the addition of FluCa solution which contains a final 
concentration of 20mM calcium ions. This mixture is then incubated at 37°C. The 
initiation of the clotting cascade ultimately leads to the production of thrombin and the 
formation of a fibrin clot. The FluCa solution added to the patients’ plasma contains the 
fluorophore amino-methyl-coumarin (AMC). This is cleaved by the thrombin produced, 
and generates a fluorescent signal which can be measured at 390/460nm. In accordance 
with the specifications laid out above the AMC fluorophore is cleaved specifically by 
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thrombin and is cleaved at a rate which allows for the cessation of thrombin production 
before the consumption of the substrate. Importantly the use of a fluorogenic signal 
means the assay is unaffected by the production of a fibrin clot, this is not true of earlier 
methods which relied on chromogenic signals, which are susceptible to changes in 
plasma turbidity and therefore had to be performed on defibrinated plasma. The 
fluorescent signal generated in the assay is measured at regular intervals over a set time 
course; the data produced is displayed as a graph of fluorescent units against time. The 
curve produced by this measurement is not accurate however, there is variation due to 
the consumption of substrate, the inner filter effect (IFE) and even the colour of the 
patients plasma. To correct for this variation a calibrator is used.  
 
1.7.1 The Use of a Calibrator 
 
The calibrator used in the CAT assay from Diagnostica Stago is a compound with 
thrombin like activity but which is not inhibited by any of the plasma inhibitors of 
thrombin. Since the calibrator has a fixed level of amidolytic activity and is not 
inhibited by proteins in the patients plasma, when a graph of fluorogenic units against 
time is plotted it should be a straight line. This however is not the case, the graph begins 
to plateau to the right as the level of fluorescence increases (see figure 1.2A). This 
pattern is observed primarily due to the IFE and the effects of decreasing substrate 
concentration.  
 
The inner filter effect essentially describes the non linear relationship between the level 
of fluorophore present and the degree of fluorescence produced by that fluorophore. At 
high concentrations of AMC (the fluorophore) not all of the fluorescence is detected by 
the analyser since some of the signal generated is absorbed inside the sample itself. This 
causes an underestimation of the amount of fluorescence generated at high 
concentrations of AMC and therefore ultimately leads to an underestimation of the 
amount of thrombin produced. The consumption of the fluorophore has a similar effect 
on the results as the IFE, i.e. an underestimation of the amount of thrombin as the levels 
of thrombin increase. This phenomenon is due to the kinetics of the enzymatic reaction. 
Even though the level of fluorogenic substrate is in excess, as the reaction progresses 
the rate of enzymatic conversion of fluorogenic substrate to AMC decreases due to a 
reduced rate of collision between the thrombin and the substrate. The correction 
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performed on the patients’ results is based on the assumption that the calibrator graph 
should be a straight line.  
 
The analysis software transforms the curved calibrator graph to give a straight line and 
applies the calculations needed to achieve this to the patients results thereby correcting 
the patients results for both IFE and substrate consumption. This gives the graph seen in 
figure 1.2B, before the correction the graph would begin to plateau earlier. It is 
important to note that unlike the calibrator the patients graph should not be a straight 
line, this is due to the fact that the thrombin produced by the patient is inhibited by 
negative regulators such as Antithrombin. The graph shown in figure 1.2B is expressed 
as fluorescent units against time; in order to convert this to nanomolar (nM) thrombin 
the initial slope of the calibrator is used.  The initial slope of the calibrator fluorescent 
units against time graph corresponds directly to the activity of the calibrator, i.e. the 
higher the activity the steeper the slope. An estimate can then be made as to the activity 
of the patients plasma by comparing the initial slope of the patients corrected 
fluorescent units/ time graph to that of the calibrator.  
 
Importantly the initial slope of the calibrator is highly sensitive to the effects of donor to 
donor variability, such as the colour of the patient’s plasma, which can have an impact 
on the absorbance of fluorescent signal by the plasma. A calibrator is therefore run with 
each patient. So each patient that has their thrombin generation measured has a separate 
calibrator well where the fluorescent signal generated by the calibrator in their plasma is 
measured. Once the units are converted to nanomolar thrombin the first derivative of the 
curve is plotted, this converts the graph from showing the cumulative level of thrombin 
produced over time to showing the amount of thrombin produced at every time point. 
This produces a bell shaped curve shown in figure 1.2C. This curve represents the 
initiation of thrombin generation, followed by a peak of thrombin production and then a 
decrease in thrombin production over time due to inhibition.  
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Figure 1.2 
A.      B. 
  
C.      D.                 
  
Figure 1.2. A, Graph of fluorescent units against time (minutes) for thrombin calibrator performed on the 
plasma of a normal patient. B, Graph of fluorescent units against time (minutes) for PPP reagent 
performed on the same patient corrected for IEF and substrate consumption. C, First derivative of B, note 
graph axes are now fluorescent units/min against time. D, Graph C corrected for the activity of thrombin 
bound to α2 macroglobulin. Note the units are now nM thrombin against time. 
 
1.7.2 α2 Macroglobulin 
 
In a physiological setting the thrombin production would decrease to zero following 
inhibition, the graph in figure 1.2C shows that this is not true of the CAT assay. A low 
level of thrombin production continues at a fixed rate after the initial burst of 
productivity, this is also true of the fluorogenic units against time graph shown in figure 
1.2B. If thrombin production had ceased the graph would reach a plateau instead the 
level of thrombin increases in a linear fashion. This phenomenon is observed due to the 
action of thrombin bound to α2 macroglobulin. α2 macroglobulin is a plasma inhibitor of 
thrombin and therefore plasma bound to α2 macroglobulin has no activity in vivo but 
does have an in vitro effect on the CAT assay, i.e. thrombin bound to α2 macroglobulin 
can still cleave the fluorogenic substrate to release AMC. This can lead to a large 
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overestimate in the level of thrombin produced, especially if the thrombin generation is 
measured over a long time course.  
 
The amidolytic activity of the α2 macroglobulin thrombin complex must therefore be 
excluded in order to give a true value for the patient’s thrombin generation. This 
exclusion is performed by the analysis software, which uses a mathematical model to 
separate the part of the curve generated by free thrombin and the part due to the α2 
macroglobulin thrombin complex. The basis of the mathematical model is the 
identification of when the production of free thrombin is finished in the sample and the 
thrombin generation seen is due solely to the action of thrombin bound to α2 
macroglobulin. This is indicated by the persistent low level thrombin production seen 
after approximately 20 minutes in figure 1.2C. The analysis software can use this level 
to estimate the effect which thrombin bound to α2 macroglobulin has on every time 
point of the curve and ultimately exclude that activity. This gives the final curve which 
is seen in figure 1.2D. Note the level of thrombin production does now return to zero. 
The four primary data points which can be obtained from the graph are shown in figure 
1.3 below. 
 
Figure 1.3 
A.  B. 
       
Figure 1.3 Diagrammatic representation of measured thrombin generation parameters. A: Peak Height 
and time to peak. B: Lag time and ETP. Note ETP is the area under the curve. 
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1.7.3 The CAT Assay and Phospholipid Concentration 
 
The CAT assay can be performed using a number of different reagents which will have 
different effects on the results. Using reagents with varying concentrations of 
phospholipids will impact upon the results generated by the CAT assay. Since the 
coagulation cascade is dependent on the presence of phospholipids low concentrations 
would act to increase the lag time and potentially decrease the ETP. The use of a 
reagent with a low phospholipid concentration also has the potential to make the assay 
more sensitive to the presence of lupus anticoagulant and other antiphospholipid 
antibodies, since these antibodies will sequester the phospholipids in the reagent further 
decreasing the concentration and ultimately having a marked effect on the assay. 
Increasing the concentration of phospholipids will have the reverse effect; making the 
assay insensitive to the presence of lupus anticoagulant and decreasing the lag time as 
well as potentially increasing the ETP.  
 
1.7.4 The CAT Assay and Platelet Rich Plasma 
 
The CAT assay can also be performed using a platelet rich plasma (PRP) reagent. This 
reagent contains no phospholipids and the thrombin generation which occurs takes place 
on the surface of the patient’s platelets which remain in the plasma. This assay is 
therefore of greater relevance physiologically than the PPP reagent assay as in theory it 
is sensitive to defects in platelet function as well as those in the formal clotting cascade, 
although it will not be possible to ascertain the exact nature of the defect from the assay 
results. The PRP reagent assay is however more time consuming and more expensive 
than the PPP reagent assay, the difference in cost arises due to the fact that assays 
performed on platelet rich plasma must be performed within hours of the patient’s 
sample being taken. In a hospital setting this is undesirable as it means that patients 
must be analysed in a large number of small batches rather than smaller number of large 
batches. The time and labour involved in processing the patient’s plasma and running 
the assay a larger number of times will also ultimately increase the cost. The PPP 
reagent assay should prove more cost effective as the patients plasma can be frozen and 
stored thereby increasing the efficiency of the assay and ultimately lowering the cost. 
For these reasons in this project it was chosen to utilise the standard PPP reagent with a 
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final concentration of 4μM phospholipids to give an excellent indication of how robust 
and clinically useful the ‘basic’ CAT assay is in a hospital laboratory setting. 
 
1.7.5 Tissue Factor Concentration 
 
It was decided to use a tissue factor concentration of 5pM to initiate the coagulation 
cascade in this study. One of the deciding factors was that this was the only 
concentration commercially available at the start of the experiments and it was felt that 
the use of lower concentrations, which would be made ‘in house’, would introduce 
potential variables without adding much benefit. This was because any patient 
demographics used would be prothrombotic not haemophiliacs. A secondary 
consideration was that the use of 5pM tissue factor as a reaction trigger meant that it 
should not be necessary to use CTI, although this is discussed in more detail in chapter 
2.  
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Chapter 2 
 
 
Assay Validation 
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2.1 Introduction 
 
The first stage of this project was the validation of the CAT assay for use in the routine 
diagnostic setting. The investigations which are the focus of this chapter include the 
determination of both the intra and inter assay variability, the effects of sample handling 
on the assay including the time taken between sample collection and sample processing 
and the temperature at which samples can be stored. This chapter also determines the 
assay limits of detection, the variability of a patient’s results over time and the normal 
range for the assay, including ascertaining the effects of age and sex on the results. This 
chapter also contains a comparison of thrombin generation data when patients were 
analysed with and without the use of CTI in order to establish whether or not there was 
a difference in the results produced when a 5 pM tissue factor trigger was used to 
initiate thrombin generation. 
 
It is necessary that any parameters measured from a specific sample should be 
comparable if that sample is measured again using the same method at a different time 
(inter assay variation) or if the sample is analysed multiple times on the same run (intra 
assay variation). If an assay which is used to monitor patient results over time 
demonstrates high inter or intra assay variation the results generated are of little use 
clinically as it is uncertain as to whether any differences observed are due to variation 
caused by the assay or to physiological changes in the patient. In a similar fashion 
assays that are used in diagnosis which have high levels of inter and intra assay 
variability will be prone to the production of false positive and negative results; 
especially in those patients who have borderline results in reality.  
 
To maximise the clinical utility of the assay it would be desirable if the results 
generated by the CAT assay were unaffected by the time between sample collection and 
the time the sample was received and processed by the laboratory. If the age of the 
sample did have an effect on the thrombin generation then it may dictate how the assay 
could be requested i.e. if it was found that samples must be separated and frozen within 
an hour of being taken then the patients who required the assay would have to make 
clinic appointments to have blood taken. This would have financial implications for the 
department. It would therefore be desirable if samples taken for thrombin generation 
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studies had a similar shelf life to those which are required for other haemostatic 
investigations, i.e. four hours. 
 
Sample storage has important implications in laboratory diagnosis in terms of both the 
cost of the assay and the patient diagnosis. To minimise the cost it is preferable that 
samples can be stored in order that they can be analysed in batches, but it is important to 
ascertain that sample storage does not impact on the results generated by the assay, i.e. 
the results generated do not differ if a patients sample is analysed after storage for one 
day or analysed after storage for one week. Samples sent to the haemostasis laboratory 
for investigations are analysed within two weeks of receipt and are stored at -40°C for 
the duration of this time. It would therefore be beneficial if samples requiring analysis 
by the CAT assay could be treated in the same manner. 
 
The limits of detection are necessary in order to determine whether an obtained result is 
valid or not. The limits of detection are defined as the upper and lower limits that an 
assay can produce an accurate answer. If for example the assay is inaccurate below a 
certain level all assay results which fall below that level are reported as lower than the 
cut off, rather than giving an actual numerical value. This is of importance since the 
assay may show an increased variability below the cut off which makes the monitoring 
of patients results unreliable. 
 
The variability of a patient’s results over time can have a significant impact on the 
interpretation of any given result. This is similar to the inter assay variability but instead 
of variation in patients results being caused by the assay, the results are affected by 
physiological changes in the patients themselves. The effects however remain the same; 
a high variability across time will mean the assay is less useful in terms of both 
diagnosis and therapeutic monitoring. This chapter investigates the variation of results 
over time in a cohort of normal individuals. 
 
The normal range of the assay is obviously essential in determining whether an obtained 
result is normal or abnormal. It is usually presented as a minimum and maximum level 
between which ~95% of all normal individuals fall. Patients with results which are 
outside the normal range are defined as abnormal. It is therefore extremely important 
that the normal range is accurately defined since it will be used diagnostically. In the 
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case of the CAT thrombin generation assay, levels of ETP and Peak height below the 
normal range will be indicative of a potential bleeding disorder whereas those above 
will be indicative of a potential prothrombotic condition. The reverse is true of the lag 
time and the time to peak parameters where a result above the normal range is indicative 
of a bleeding disorder and a result below the normal range potentially implies a 
tendency towards thrombosis. The normal range is often adjusted depending on a 
variety of different factors, most commonly age and sex. The experiments in this 
chapter are focused on establishing a normal range for the CAT assay and examining 
the effects of both age and sex when determining a normal thrombin generation. 
 
2.2 Materials and Methods 
 
2.2.1 PT/INR 
 
The measurement of the PT/INR was an automated assay performed on the Ca-7000 
analyser manufactured by Sysmex. Innovin (100µl) was added to 50μl of patient’s 
plasma in a plastic cuvette. This initiated the clotting cascade via the extrinsic pathway. 
The cuvette was then incubated at 37ºC. During the incubation the scattered light 
intensity of the sample was measured by a red light with a wavelength of 600nm. The 
conversion of fibrinogen to fibrin increases the turbidity of the sample and hence 
increases the scattered light intensity. The time in seconds at which the scattered light 
intensity changes is the prothrombin time. The PT is routinely converted to an INR. The 
INR is a calculated parameter and is derived using the formula below. 
 
INR= (Patient PT/mean normal PT)
ISI 
 
The mean normal PT is determined by the geometric mean of the PT of 21 normal 
individuals who are representative of the local population. The ISI is effectively a 
calibrator value which indicates how tissue factors produced by different manufacturers 
compare to an internationally standardised sample (human brain thromboplastin held by 
the world health organisation). 
The assay was controlled using Citrol 1 and Citrol 2 which have target values that are 
within the normal and therapeutic ranges respectively. 
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Innovin, Citrol 1 and Citrol 2 are lyophilised reagents and require reconstitution before 
use. 20ml of sterile distilled water was added to Innovin and 1ml of sterile distilled 
water was added to both Citrol 1 and 2. The reagents were then held at room 
temperature for 15 minutes before use. 
 
 
2.2.2 APTT 
 
The measurement of the APTT was an automated assay performed on the Ca-7000 
analyser manufactured by Sysmex.  Actin FS (100µl) was added to 50μ of patient’s 
plasma in a plastic cuvette. The cuvette was then incubated at 37ºC for one minute. 
Following this time 50μl of 0.025M Calcium Chloride solution was added to the 
cuvette; this initiated the clotting cascade via the intrinsic pathway. The scattered light 
intensity of the sample was then measured using a red light with a wavelength of 
600nm. The conversion of fibrinogen to fibrin increases the turbidity of the sample and 
hence increases the scattered light intensity. The time in seconds at which the scattered 
light intensity changes is the activated partial thromboplastin time. 
The assay was controlled using Citrol 1 and Citrol 2 which have target values that are 
within the normal and therapeutic ranges respectively. 
Citrol 1 and Citrol 2 are lyophilised reagents and require reconstitution before use. 1ml 
of sterile distilled water was added to both Citrol 1 and 2. The reagents were then held 
at room temperature for 15 minutes before use. 
 
2.2.3 Thrombin Time 
 
The measurement of the thrombin time was an automated assay performed on the Ca-
7000 analyser manufactured by Sysmex. Thromboclotin reagent (100µl) was added to 
50μl of patient plasma in a plastic cuvette. The cuvette was then incubated at 37ºC. The 
scattered light intensity of the sample was measured using a red light with a wavelength 
of 600nm. The thromboclotin reagent contains activated factor II, which converts the 
fibrinogen in the patients sample into fibrin thereby increasing the turbidity of the 
sample and ultimately causing an increase in the scattered light intensity. The time in 
seconds at which the scattered light intensity changes is the thrombin time. 
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The assay was controlled using Citrol 1 and Citrol 2 which both have target values that 
are within the normal range. 
Thromboclotin, Citrol 1 and Citrol 2 are lyophilised reagents and require reconstitution 
before use. 5ml of sterile distilled water was added to Thromboclotin and 1ml of sterile 
distilled water was added to both Citrol 1 and 2. The reagents were then held at room 
temperature for 15 minutes before use. 
 
2.2.4 Preparation of Samples 
 
Blood was collected into 0.109M tri-sodium citrate vacutainers. Samples were 
centrifuged at 1500 g for 10 minutes. Following this time the top two thirds of the 
patient’s plasma were removed and aliquoted into LP4 tubes. These aliquots were then 
centrifuged for a further 10 minutes at 1500 g. The top two thirds of the double spun 
plasma was then removed, placed in a corning tube and frozen. 
 
2.2.5 Thrombin Generation 
 
Thrombin generation was performed using the Fluoroscan FL plate reader manufactured 
by Thermoelectron. PPP and thrombin calibrator reagents were reconstituted with 1ml 
of sterile distilled water and left to equilibrate for 5 minutes at room temperature. 
During this time 10ml of sterile distilled water and an aliquot of fluoro buffer (120l is 
required for each patient) were preheated to 37°C in a water bath. Following the 5 
minute equilibration the PPP and thrombin calibrator reagents were shaken gently to 
ensure they were fully reconstituted. Each patient sample that was analysed required 6 
wells on a 96 well 2HB Immulon round bottom plate. Into three of the wells 20l of 
PPP reagent was added, 20l of thrombin calibrator was added to the remaining three 
wells. Patient plasma (80µl) was then added to each of the six wells. The plate was then 
placed in the Fluoroscan FL plate reader to equilibrate to 37°C. The dispenser on the 
Fluoroscan FL was then cleaned and primed using the preheated sterile distilled water. 
The Fluca solution was then prepared by adding fluorochrome solution to the preheated 
fluoro buffer. The final ratio of fluorochrome solution to fluoro buffer was 1:40. The 
addition of the fluorochrome solution to the fluoro buffer caused the solution to become 
cloudy, the solution was then vortex mixed to yield a clear, colourless Fluca solution. 
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This solution was then primed into the dispenser and 20l was automatically dispensed 
into each well in use on the plate. The plate was then agitated for 10 seconds. The 
measurement of thrombin generation commenced following the agitation. Fluorescence 
was measured at 390/460nm every 30 seconds for up to one hour depending on the 
experimental procedure.  
 
2.2.6 Reconstitution of Control Plasma P 
 
1ml of sterile distilled water was added to each vial. The vials were then held for 15 
minutes at room temperature. Following this time they were gently mixed. 
 
2.2.7 Reconstitution of Standard Human Plasma 
 
1ml of sterile distilled water was added to each vial. The vials were then held for 15 
minutes at room temperature. Following this time they were gently mixed. 
 
2.2.8 Heat Inactivation of Plasma 
 
Blood was collected into 0.109M tri-sodium citrate vacutainers. Samples were 
centrifuged at 1500 g for 10 minutes. Following this time the patients’ plasma was 
removed and pooled. The pooled plasma was then aliquoted into LP4 tubes and placed 
in a water bath pre-heated to 58°C for 90 minutes. Following this incubation the plasma 
aliquots were again centrifuged at 1500 g for 10 minutes. This centrifugation separates 
any proteins precipitated during the heat inactivation from the plasma. Following the 
centrifugation the patients’ plasma was removed from the precipitated plasma proteins 
and pooled. The heat inactivated plasma was then separated into 5ml aliquots and frozen 
at -70°C. 
 
2.2.9 Statistical Analysis 
 
Statistical analyses were performed using Microsoft excel and PASW statistics 18. 
Comparisons between data sets were performed using either the student’s t-test 
(parametric data) or the Mann Whitney U test (non parametric data). Statistical 
significance was defined as a p value of ≤0.05. Normal distribution was determined 
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using the Kolmogorov-Smirnov test, where a p value of ≥0.05 was indicative of a 
normal distribution. 
 
2.2.10 Reagents 
 
Product Manufacturer 
Actin FS Dade Behring 
Calcium Chloride solution (0.025M) Dade Behring 
Citrol 1 Dade Behring 
Citrol 2 Dade Behring 
Control P Dade Behring 
Corn Trypsin Inhibitor Cambridge Bioscience 
FluCa Kit Diagnostica Stago 
Innovin Dade Behring 
PPP Reagent Diagnostica Stago 
Standard Human Plasma Dade Behring 
Sterile Distilled Water Baxter 
Thrombin Calibrator Diagnostica Stago 
Thromboclotin Dade Behring 
 
2.3 Results 
 
2.3.1 Inter and Intra Assay Variation 
 
2.3.1.1 Experimental Procedure  
 
Using the thrombin generation method described in section 2.2.5 (materials and 
methods) 16 patients could be analysed on a single run. Due to potential problems with 
dead volume of reagents it was decided to run only a maximum of 15 patients per plate 
as this would mean any discrepancies in the results would be due solely to the workings 
of the assay and not any inconsistencies in the volumes of reagents used. To ascertain 
the intra and inter assay variability of the CAT assay the same plasma sample was run 
15 times on each of 10 plates. Since this experiment required a large volume of plasma 
it was decided to use a lyophilised plasma product as it was easily obtainable. The 
plasma used in this experiment was Control plasma P produced by Dade Behring. A 
total of 80ml of the plasma was prepared; this plasma was then pooled and frozen at -
70°C in 10 separate 8ml aliquots. The pooling of the plasma ensured that any 
differences observed were entirely due the technique and not due to the effects of using 
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plasma reconstituted at different times. It was decided that the aliquots of plasma should 
be frozen for a number of reasons. The first of which was to compensate for the time 
needed to analyse the plasma, since the thrombin generation was measured for 1 hour in 
this experiment, if the plasma was left at room temperature the aliquot which was 
analysed last would be at least 9 hours old. Since the half lives of some of the clotting 
factors in the coagulation cascade are shorter than 9 hours, indeed factor VII has a half 
life of only 4 hours, leaving the plasma at room temperature could have a huge impact 
on the thrombin production and ultimately the results generated by this analysis. It was 
decided to freeze the aliquots at the lowest temperature available in order to freeze the 
samples in the quickest time and thereby decrease the potential for any degradation of 
the plasma. The second reason for freezing the plasma was to follow the preparation of 
patient samples which are processed for thrombophilia investigations, these are frozen 
upon receipt. The aliquots of Control plasma P were defrosted by submersion in a 37°C 
water bath, again following the preparation of thrombophilia samples, and analysed 
using the CAT thrombin generation assay. The results for the intra assay variation are 
shown in tables 2.1-2.4 below.   
 
 
2.3.1.2 Intra Assay Variation 
 
When examining the results for intra assay variation each plate was considered 
separately for each of the four thrombin generation parameters. To be considered 
suitable for routine use the assay should have a coefficient of variation (CV) of 
approximately 10% or below and the closer this is the zero the lower the variation 
shown by the assay. All of the plates analysed demonstrate CV’s of below 10% for each 
of the four parameters. Some of the parameters seem to demonstrate more variation than 
others however. Both the peak height and the time to peak had CV’s below 5% for all 
the 10 plates analysed. The CV’s for the ETP were more widely spread ranging from 
2.52% to 8.21%, the greatest difference was demonstrated by the lag time with values 
ranging from 0.00% to 7.5%. All these values did lie within the range of acceptability. 
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Table 2.1 
 
ETP (nM Thrombin) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 2542.0 687.5 2571.9 162.4 6.31 
2 2652.0 807.7 2581.1 199.7 7.73 
3 2955.0 682.0 2922.3 170.6 5.84 
4 2610.0 526.3 2594.7 154.2 5.94 
5 2900.3 256.0 2920.8 73.6 2.52 
6 2622.0 454.8 2671.2 144.7 5.42 
7 2479.5 482.7 2453.4 160.5 6.54 
8 2854.0 382.7 2853.9 121.1 4.24 
9 2671.3 806.5 2672.4 219.6 8.21 
10 2708.0 638.67 2717.4 165.6 6.09 
 
Table 2.1 showing the median, range, mean, standard deviation and coefficient of variation of the ETP of 
Control plasma P for each of the 10 plates analysed 
 
Table 2.2 
 
Lag Time (Minutes) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 2.12 0.42 2.23 0.15 6.91 
2 2.50 0.14 2.51 0.04 1.44 
3 2.92 0.00 2.92 0.00 0.00 
4 2.78 0.42 2.77 0.15 5.59 
5 2.92 0.21 2.91 0.05 1.87 
6 2.26 0.42 2.33 0.17 7.50 
7 2.50 0.00 2.50 0.00 0.00 
8 2.78 0.42 2.78 0.13 4.61 
9 2.50 0.42 2.41 0.13 5.42 
10 2.08 0.21 2.11 0.07 3.28 
 
Table 2.2 showing the median, range, mean, standard deviation and coefficient of variation of the Lag 
time of Control plasma P for each of the 10 plates analysed. 
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Table 2.3 
 
Peak Height (nM Thrombin) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 211.78 28.87 210.01 7.64 3.63 
2 215.89 33.30 213.96 8.30 3.88 
3 223.59 36.12 222.74 8.43 3.78 
4 215.02 22.72 214.59 6.02 2.80 
5 224.69 16.69 224.57 4.77 2.12 
6 216.08 13.93 215.31 4.39 2.03 
7 214.25 22.92 212.45 7.69 3.62 
8 210.95 27.53 211.50 7.58 3.69 
9 203.67 22.53 204.62 6.75 3.30 
10 206.82 25.69 205.67 7.25 3.52 
 
Table 2.3 showing the median, range, mean, standard deviation and coefficient of variation of the peak 
height of Control plasma P for each of the 10 plates analysed 
 
Table 2.4 
Time to Peak (Minutes) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 5.04 0.42 4.90 0.17 3.54 
2 5.00 0.56 4.97 0.12 2.43 
3 5.42 0.83 5.53 0.21 2.86 
4 5.00 0.42 5.06 0.13 2.61 
5 5.42 0.83 5.49 0.20 3.62 
6 4.62 0.42 4.70 0.13 2.80 
7 5.00 0.42 4.90 0.13 2.69 
8 5.28 0.62 5.29 0.16 3.02 
9 5.00 0.70 4.94 0.21 4.31 
10 4.58 0.56 4.68 0.16 3.33 
 
Table 2.4 showing the mean, standard deviation and coefficient of variation of the time to peak of Control 
plasma P for each of the 10 plates analysed. 
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2.3.1.3 Inter Assay Variation  
 
Tables 2.1-2.4 also show data relating to the inter assay variability, the means and the 
standard deviations from the 10 plates were expected to show similar values for each of 
the parameters if the inter assay variation was low. This information is displayed 
graphically in figure 2.1 below. The data shown in figure 2.1 shows that there was a 
marked difference between the assays for some of the parameters. Some fluctuation was 
expected but with the exception of the peak height (Fig 2.1C) where all the boxplots 
showed a degree of overlap there were distinct cases in each of the other graphs 
(Figures 2.1 A, B and D) where at least two of the boxplots showed no overlap at all 
implying that they were statistically distinct populations. E.g. Plates 3 and 10 on figure 
2.1A.  Indeed when analysed using the students t-test/Mann Whitney U test some of 
these comparisons did yield a p value of <0.05 proving this to be the case (Data not 
shown). This suggested a high inter assay variability making the assay unsuitable for 
routine use. However, when all 150 data points (15 replicates on each of the 10 plates) 
for each parameter were compared directly and the mean, standard deviation and CV 
were calculated the differences became less pronounced. The results of this analysis can 
be seen in table 2.5. 
 
Figure 2.1 
 
A.             B. 
  
 
 
 
- 53 - 
 
C.              D. 
  
 
Figure 2.1. Boxplots showing the distribution of the 15 values for each parameter of each of the 10 
analysed plates. Analysis performed using Control plasma P. Boxes show 25
th
 to the 75
th
 percentile of the 
data with the median shown as a horizontal black line. Whiskers show minimum/maximum values. 
Population outliers defined as values deviating by greater than 1.5 times box height are shown by . A: 
Lag time, B: ETP, C: Peak height, D: Time to peak. 
 
Table 2.5 
Parameter Mean SD CV (%) 
ETP (nM Thrombin) 2695.91 217.55 8.07 
Lag Time (Minutes) 2.54 0.29 11.44 
Peak Height (nM Thrombin) 213.54 9.13 4.28 
Time to Peak (Minutes) 5.05 0.33 6.49 
Table 2.5. Meta analysis of all 150 Control plasma P data points. 
 
The results from table 2.5 showed that as predicted the peak height had the lowest CV 
of the four parameters but the CV of the ETP and the time to peak also fell in the range 
of acceptability (<10%). The CV of the lag time however remained unacceptable. In 
summary the initial analysis of the assay produced results which were mixed; the assay 
showed reasonably low levels of intra assay variability but high levels of inter assay 
variation. 
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2.3.1.4 Intra Assay Trends 
 
Although the levels of intra assay variation appeared low it was also important that the 
results across the plate did not show any trends, i.e. the results of the sample should not 
have been higher/lower at the 15
th 
position on the plate than they are at position 1. This 
was of importance in the CAT assay as the bulk of the work was done manually and 
therefore relatively slowly. The PPP and the thrombin calibrator reagents were added to 
the plate first then the patients’ samples were added one at a time. The problem which 
arose from this was that by the time the 15
th
 patient sample was added the first patients 
sample has been incubated in the reagent for a short while and although no thrombin 
generation can occur in this time (owing to lack of calcium ions) this incubation could 
lead to differences in the results. To investigate whether or not this sort of trend did 
occur in the assay it was decided to calculate the mean of each of the 15 possible patient 
positions across the 10 plates, and plot them on a scatter graph. The line of best fit and 
the R
2 
value was then calculated using Microsoft excel.  From the R
2 
parameter a value 
of t was obtained using the formula below. 
 t= r (n-2/1-r2) 
The value of t obtained was used to calculate a p value using the distribution of t table 
shown in the appendix (7.1), n-2 degrees of freedom was used. A p value of 0.05 was 
considered evidence of a significant trend. The results of this analysis are shown in 
figure 2.2 below. Figure 2.2 A, B and D all show relatively flat trend lines and values 
for R
2
 which are comparatively low. An R
2
 value approaching zero indicates that no 
trend is apparent whereas an R
2
 value approaching one is a strong indication of the 
presence of a trend. The p values calculated for the ETP, lag time and time to peak are 
all >0.05 implying there is no trend across the plate; this however is not the case for the 
peak height (figure 2.2C). The peak height graph shows a slight decrease across the 
plate positions i.e. the peak height at position one is higher than that of position 15. This 
trend has an R
2
 value of 0.5434 which gives a highly significant p value of <0.01. This 
is an undesirable result as it implies that the position a patient occupies on a plate can 
have an effect on the result generated. Interestingly although the trend appears highly 
significant the actual decrease in the peak height across the plate is only 13 nM 
thrombin (from 217nM thrombin at position 1 to 204nM thrombin at position 15), this is 
a difference of less that 10% which has already been predefined as acceptable when 
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considering the CV. It is also uncertain as to whether a difference of this magnitude is 
clinically significant or not. Regardless of these points a statistically significant trend 
across the plate is still highly undesirable. The reason for the difference can only be 
hypothesised; any degradation of the reagents or patients sample would have been likely 
to cause the opposite trend i.e. an increase in peak height across the plate. The increased 
incubation time of plasma with the reagents seems to be able to increase the maximum 
rate of thrombin generation possibly because of any calcium independent reactions have 
had more time to occur in the sample wells which are aliquoted first. 
 
Figure 2.2 
A.              B. 
  
C.              D. 
  
Figure 2.2. Graphs showing mean values for plate position across the 10 analysed plates, complete with 
trend lines and R
2
 as an indication of correlation. A: ETP, B: Lag time, C: Peak height, D: Time to peak. 
 
2.3.1.5 Initial Conclusions 
 
The initial experimentation revealed some disappointing results. Although the intra 
assay variation was good, the assay did show a decreasing trend for one of the four 
parameters across the plate. The inter assay variation was poor with the lag time 
showing an unacceptable CV and some of the other parameters demonstrating marked 
differences between runs. One of the potential problems with these experiments may 
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have been the time differential of the addition of reagents and the patients plasma to the 
plate. In order to determine whether or not this was the case it was decided to use an 
automatic pipette to dispense the reagents and the patients plasma as this would be 
quicker and ultimately lead to lower CVs and eliminate any trends if they were indeed 
caused by the length of time taken to set up the plate. 
 
2.3.1.6 Assay Reproducibility Using Electronic Pipetting 
 
This experiment was set up in the same way as above, although only 5 plates were 
analysed as apposed to 10 in the original experiment. 40ml of Control P plasma was 
prepared and frozen at -70°C in five 8ml aliquots. These were defrosted in a 37°C water 
bath and analysed one by one. The intra assay variation results are shown in tables 2.6-
2.9 below. 
 
Table 2.6 
ETP (nM Thrombin) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 2611.67 438.67 2649.07 126.32 4.77 
2 2743 649.33 2708.29 170.53 6.30 
3 2770 489.33 2788.46 141.07 5.06 
4 2869.67 602.5 2825.28 164.50 5.82 
5 2773.67 446.33 2742.28 126.61 4.62 
Table 2.6 showing the median, range, mean, standard deviation and coefficient of variation of the ETP of 
Control plasma P for each of the 5 plates analysed. Each assay was set up using an electronic pipette. 
 
Table 2.7 
Lag Time (Minutes) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 2.08 0.42 2.21 0.16 7.21 
2 2.29 0.42 2.31 0.20 8.46 
3 2.22 0.42 2.25 0.18 8.21 
4 1.87 0.41 1.87 0.18 9.43 
5 2.22 0.42 2.27 0.19 8.28 
Table 2.7 showing the median, range, mean, standard deviation and coefficient of variation of the lag time 
of Control plasma P for each of the 5 plates analysed. Each assay was set up using an electronic pipette. 
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Table 2.8 
Peak Height (nM Thrombin) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 218.10 9.03 217.88 2.72 1.25 
2 215.03 20.14 215.93 6.08 2.82 
3 217.51 20.76 217.09 5.68 2.62 
4 218.74 18.27 219.87 4.72 2.15 
5 221.63 20.01 221.13 5.11 2.31 
Table 2.8 showing the median, range, mean, standard deviation and coefficient of variation of the peak 
height of Control plasma P for each of the 5 plates analysed. Each assay was set up using an electronic 
pipette. 
 
Table 2.9 
Time to peak (Minutes) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 4.68 0.28 4.68 0.11 2.25 
2 4.89 0.42 4.89 0.12 2.47 
3 4.72 0.42 4.86 0.14 2.88 
4 4.44 041 4.39 0.09 2.11 
5 4.58 042 4.82 0.13 2.73 
Table 2.9 showing the median, range, mean, standard deviation and coefficient of variation of the time to 
peak of Control plasma P for each of the 5 plates analysed. Each assay was set up using an electronic 
pipette. 
 
2.3.1.7 Electronic Pipetting and Intra Assay Variation 
 
The results in tables 2.6-2.9 were very similar to those obtained without the use of an 
electronic pipette. The CVs for each of the parameters on all of the plates are below the 
10% cut off of acceptability. The best CVs were seen in the peak height and the time to 
peak parameters with the ETP and the lag time showing elevated CVs in comparison. 
Indeed the lag time still showed the highest degree of variation with CVs ranging 
between 7.21% and 9.43%. 
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2.3.1.8 Electronic Pipetting and Inter Assay Variation 
 
The inter assay variation data is shown graphically in figure 2.3 below. The results for 
inter assay variation were also similar to those previously achieved without the use of 
electronic pipetting, although now it was the ETP and the peak height which 
demonstrated a high degree of overlap  instead of the peak height alone. The lag time 
and the time to peak still showed a marked variation between runs some of which had a 
statistically significant p value when analysed by the student’s t-test (data not shown). 
Although the majority of the variation in these parameters seemed to come from a 
single run, that of plate 4.  The meta analysis of the results obtained using electronic 
pipetting is shown in table 2.10 below. The CVs of all the parameters except that of the 
lag time fell below the 10% cut off and indeed all of them showed a degree of 
improvement when compared to the results obtained without the electronic pipette, 
although not by the magnitude that was anticipated. The assay still ultimately showed 
an unacceptably high level of inter assay variation. 
 
Figure 2.3 
 
A.              B. 
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C.              D. 
  
Figure 2.3. Boxplots showing the distribution of the 15 values for each parameter of each of the 5 
analysed plates, each of which was set up using an electronic pipette. Analysis performed using Control 
plasma P. Boxes show 25
th
 to the 75
th
 percentile of the data with the median shown as a horizontal black 
line. Whiskers show minimum/maximum values. Population outliers defined as values deviating by 
greater than 1.5 times box height are shown by . A: ETP, B: Lag Time, C: Peak height, D: Time to 
peak. 
 
Table 2.10 
Parameter Mean SD CV (%) 
ETP (nM Thrombin) 2742.68 155.76 5.68 
Lag Time (Minutes) 2.18 0.24 10.86 
Peak Height (nM Thrombin) 218.22 5.22 2.40 
Time to Peak (Minutes) 4.73 0.22 4.64 
Table 2.10. Meta analysis of all 75 Control P data points, each set up using an electronic pipette. 
 
2.3.1.9 Electronic Pipetting and Intra Assay Trends 
 
The use of the electronic pipette also failed to correct the intra assay trends that were 
found in the initial experiment. The results of the trend analysis are shown in figure 2.4 
below. Both the ETP and the time to peak showed no significant trends across the plate 
with non significant p values. The lag time and peak height both showed significant 
trends across the plate with p values of <0.01.  The trends themselves were in opposite 
directions with the lag time increasing and the peak height decreasing with plate 
position. The magnitude of these trends was also different, with the changes in peak 
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height relatively small (<10%) and the changes in lag time much more pronounced, 
reaching approximately 20% across the plate. 
 
Figure 2.4 
 
A.              B. 
  
 
C.              D. 
  
Figure 2.4. Graphs showing mean values for plate position across the 5 analysed plates each set up using 
an electronic pipette, complete with trend lines and R
2
 as an indication of correlation. A: ETP, B: Lag 
time, C: Peak height, D: Time to peak. 
 
The increasing lag time across the plate fitted well with the increased incubation time of 
plasma and reagents hypothesis, but this was highly unlikely since the same effects 
were not seen in the original experiment where the time differential in setting up the 
plate was larger.  
 
The use of an electronic pipette therefore failed to correct any of the problems seen in 
the assay in the initial experiment, implying the underlying cause for the trends and 
poor inter assay variability observed were not due to the speed that the plate is set up. A 
potential reason for the differences is the lyophilised plasma itself. Upon analysis it 
became clear that the use of this plasma was associated with a high degree of ‘noise’ in 
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the assay i.e. the thrombin generation curve was not as smooth as was anticipated. An 
example of this is shown below in figure 2.5. The effects of this ‘noise’ can be most 
appreciated when considering the ETP. Since this is a parameter derived by calculating 
the area under the curve, the erratic curves obtained using Control plasma P may have 
interfered with the analysis software producing results which were ultimately less 
reliable. The background ‘noise’ may also have effects on the other parameters. It is 
therefore possible that the Control plasma P itself was not suitable for use in the CAT 
thrombin generation assay. The exact reason as to why Control P produces erroneous 
results was initially thought to be due to its composition, this however seems unlikely 
since the only chemical additive is Hepes buffer which is unlikely to have any effect on 
the generation of a fluorescent signal. It is likely that the disruption of the fluorescent 
signal could instead be due to the presence of particulate matter in the Control P plasma, 
possibly as a result of incomplete reconstitution of the reagent. To test this hypothesis 
this experiment was performed again using fresh plasma from volunteers. 
 
Figure 2.5 
 
Figure 2.5. An example thrombin generation curve produced by analysing Control plasma P.  
 
2.3.1.10 Assay Reproducibility Using Fresh Plasma 
 
This experiment was performed in the same manner as those above but used plasma 
taken from healthy volunteers instead of a lyophilised plasma product. The electronic 
pipette was not used in this analysis. Since the concentration of the anti-coagulant used 
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can have large effects on the results of thrombin generation assays
 
(Gatt et al., 2008) all 
blood was taken into 0.109M tri-sodium citrate vacutainers. Blood samples were taken 
and prepared as described in section 2.2.4 preparation of samples (materials and 
methods). This method of sample preparation was chosen as it was the method 
employed by the haemostasis laboratory for the preparation of samples for 
thrombophilia investigation. This method of separation should effectively remove 
platelets from the patient’s plasma and therefore limit the level of endogenous 
phospholipids in the patient’s sample. Since the double spinning procedure described 
yielded approximately 1ml of plasma from each vacutainer of whole blood, four 4.5ml 
vacutainers of whole blood were collect from 10 healthy volunteers. The criteria for 
selection of the volunteers were that they were consenting adults over 18 years of age 
with no current medical conditions who had no history of either bleeding disorders or 
thrombosis. A clotting screen including PT/INR, APTT and thrombin time was 
performed on the plasma collected from each volunteer to determine any unknown 
haemostatic disorders and to ascertain whether or not they were undergoing 
anticoagulation therapy. All volunteers screened for this experiment had normal results 
(data not shown). The plasma prepared from the 40 vacutainers was then pooled and 
frozen at -70°C in five 8ml aliquots. Each aliquot was defrosted by submersion in a 
37°C waterbath and analysed separately. Thrombin generation was measured as 
described in section 2.2.5 for a total of 45 minutes in this experiment. The results for the 
intra assay variation are shown in tables 2.11-2.14 below. 
 
 
Table 2.11 
ETP (nM Thrombin) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 2123.00 256.67 2140.88 79.22 3.70 
2 2028.33 239.66 2049.47 64.79 3.16 
3 1973.67 274.67 1958.07 70.83 3.62 
4 2072.00 341.33 2053.05 84.71 4.12 
5 2103.67 329.00 2114.04 95.44 4.51 
Table 2.11 showing the median, range, mean, standard deviation and coefficient of variation of the ETP 
of a pool of fresh human plasma for each of the 5 plates analysed.  
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Table 2.12 
Lag Time (Minutes) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 3.33 0.28 3.45 0.14 4.01 
2 3.33 0.41 3.23 0.14 4.38 
3 3.06 0.41 3.11 0.18 5.93 
4 3.75 0.42 3.83 0.16 4.09 
5 3.30 0.41 3.43 0.19 5.53 
Table 2.12 showing the median, range, mean, standard deviation and coefficient of variation of the lag 
time of a pool of fresh human plasma for each of the 5 plates analysed.  
 
Table 2.13 
Peak Height (nM Thrombin) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 384.19 43.05 383.64 12.53 3.26 
2 368.66 35.07 367.49 9.04 2.46 
3 354.93 43.33 354.59 11.45 3.23 
4 357.07 48.88 357.10 14.12 3.95 
5 355.38 23.67 356.87 7.54 2.11 
Table 2.13 showing the median, range, mean, standard deviation and coefficient of variation of the peak 
height of a pool of fresh human plasma for each of the 5 plates analysed.  
 
Table 2.14 
Time to peak (Minutes) 
Plate  
Number 
Median Range Mean SD CV (%) 
1 5.97 0.28 5.97 0.12 1.98 
2 5.83 0.41 5.73 0.14 2.00 
3 5.69 0.41 5.63 0.18 3.29 
4 6.39 0.42 6.44 0.18 1.68 
5 6.07 0.42 6.05 0.16 2.61 
Table 2.14 showing the median, range, mean, standard deviation and coefficient of variation of the time 
to peak of a pool of fresh human plasma for each of the 5 plates analysed.  
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2.3.1.11 Fresh Plasma and Intra Assay Variation 
 
The results in tables 2.11-2.14 show good levels of intra assay variation with the CVs of 
each of the four parameters on all of the 5 plates below 6%. This was an improvement 
on those obtained using Control plasma P. The reason for this apparent improvement 
can be elucidated by examining the thrombin generation curve obtained using the fresh 
pooled plasma seen in figure 2.6 below. The curve produced is much smoother than that 
obtained in analysis of Control plasma P eluding to a reduction of background ‘noise’ in 
the assay, implying that the ‘noise’ produced when analysing Control plasma P was 
responsible for some of the variation seen previously. 
 
Figure 2.6  
 
Figure 2.6. An example of a thrombin generation curve produced by analysing a pool of fresh plasma 
 
2.3.1.12 Fresh Plasma and Inter Assay Variation 
 
The inter assay variation data is shown graphically in figure 2.7 below. The levels of 
inter assay variation showed a similar result to those achieved using Control plasma P. 
The results for ETP and peak height show a reasonable degree of overlap implying no 
statistical significance between the results which when analysed using the students t-test 
proved to the be the case p= >0.05 (data not shown). The lag time and the time to peak 
however again showed marked variation between runs with statistically significant 
results when analysed using the students t-test p= <0.05 (data not shown).  When a meta 
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analysis was performed using all 75 available data points the results showed a degree of 
improvement. See table 2.15. The CVs obtained on all four parameters fell below the 
10% cut off of acceptability and were all better than those obtained using Control 
plasma P without electronic pipetting (table 2.5). The results obtained again 
demonstrate that the use of fresh pooled plasma decreased the level of variability in the 
assay compared to the use of lyophilised Control plasma P. The degree of inter assay 
variation was still a cause for concern however since there were still statistically 
significant differences between the plates when measuring the lag time and the time to 
peak. The magnitude of the observed difference was less than 10%, therefore the assay 
was technically suitable for routine analysis. 
 
Figure 2.7 
 
A.              B. 
  
 
C.              D. 
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Figure 2.7. Boxplots showing the distribution of the 15 values for each parameter of each of the 5 
analysed plates. Analysis performed using a pool of fresh human plasma. Boxes show 25
th
 to the 75
th
 
percentile of the data with the median shown as a horizontal black line. Whiskers show 
minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 times box 
height are shown by . A: ETP, B: Lag time, C: Peak height, D: Time to peak. 
 
Table 2.15 
Parameter Mean SD CV (%) 
ETP (nM Thrombin) 2063.27 100.28 4.86 
Lag Time (Minutes) 3.41 0.29 8.64 
Peak Height (nM Thrombin) 363.93 15.40 4.23 
Time to Peak (Minutes) 5.96 0.32 5.42 
 
Table 2.15. Meta analysis of all 75 fresh pooled plasma data points. 
 
2.3.1.13 Fresh Plasma and Intra Assay Trends 
 
The use of fresh pooled plasma also eliminated the intra assay trends which were seen 
in the analysis of Control plasma P. The results are shown in figure 2.8 below. It can be 
seen that all of the R
2
 values fell below 0.16 and therefore all yielded non significant p 
values of between 0.1-0.5 for ETP and the lag time and >0.5 for both peak height and 
time to peak. 
 
Figure 2.8 
A.               B. 
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C.              D. 
  
Figure 2.8. Graphs showing mean values for plate position across the 5 analysed plates, complete with 
trend lines and R
2
 as an indication of correlation. Analysis performed on fresh pooled plasma. A: ETP, B: 
Lag time, C: Peak height, D: Time to peak. 
 
2.3.2 Sample Stability and Storage Assessment 
 
2.3.2.1 Sample Stability and Thrombin Generation 
 
To test the effects of sample age on the results produced by the CAT thrombin 
generation assay four 4.5ml 0.109M tri-sodium citrate samples were taken from a group 
of 10 volunteers. All of the volunteer samples had normal clotting screen results as 
determined by PT/INR, APTT and thrombin time (data not shown). The samples were 
then divided into four groups of 10 samples (consisting of one sample from each of the 
10 volunteers). The first group of samples were prepared as described in section 2.2.4 
and frozen immediately; the other 3 groups were then left at room temperature (22-
24°C) for a predefined time course. The second group was processed after 4 hours, the 
third after 8 hours and the fourth after 24 hours. During the incubation the samples were 
left on their side to maximise the contact between the blood sample and the air in the 
vacutainer mimicking a worse case sample storage scenario. Each of the groups were 
left frozen at -70°C overnight in order to standardise any potential confounding 
variables. Each group of samples was then defrosted in a 37°C water bath and analysed 
on a separate plate. The results obtained from this analysis for each of the four thrombin 
generation parameters for each of the groups of samples can be seen graphically in 
figure 2.9 below. 
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Figure 2.9 
 
A.             B. 
  
 
C.             D. 
  
Figure 2.9.  Boxplots showing time between sample collection and storage and the distribution of the 
results obtained from a group of 10 volunteers for each of the four thrombin generation parameters. Boxes 
show 25
th
 to the 75
th
 percentile of the data with the median shown as a horizontal black line. Whiskers 
show minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 
times box height are shown by . A: ETP, B: Lag time, C: Peak height, D: Time to peak.  
 
If the assay was unaffected by the time between sample collection and processing the 
boxplots would show a high degree of homology. Figures 2.9 A-D show that this was 
the case, with the populations for each of the four groups for each of the four thrombin 
generation parameters showing a high degree of overlap. Statistical comparisons of the 
populations using the student’s t-test confirmed this result. The p values obtained from 
this analysis are shown in tables 2.16-2.19 below. None of the groups showed any 
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statistical significant difference from the group separated at time zero or indeed each 
other, implying that the samples were stable for at least 24 hours between collection and 
storage. 
 
Table 2.16 
Time to Separation 
(Hours) and ETP 
 
0 
 
4 
 
8 
 
24 
0 N/A 0.64 0.67 0.64 
4 - N/A 0.95 1.00 
8 - - N/A 0.95 
24 - - - N/A 
Table 2.16. Matrix of p values comparing each of the times before sample separation and the values of 
ETP produced following analysis.  
 
Table 2.17 
Time to Separation 
(Hours) and Lag Time 
 
0 
 
4 
 
8 
 
24 
0 N/A 0.87 0.90 0.66 
4 - N/A 0.77 0.55 
8 - - N/A 0.74 
24 - - - N/A 
Table 2.17.  Matrix of p values comparing each of the times before sample separation and the lag time 
produced following analysis.  
 
Table 2.18 
Time to Separation 
(Hours) and Peak Height 
 
0 
 
4 
 
8 
 
24 
0 N/A 0.77 0.65 0.95 
4 - N/A 0.86 0.58 
8 - - N/A 0.58 
24 - - - N/A 
Table 2.18. Matrix of p values comparing each of the times before sample separation and the values of 
peak height produced following analysis.  
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Table 2.19 
Time to Separation 
(Hours) and Time to Peak 
 
0 
 
4 
 
8 
 
24 
0 N/A 0.83 0.90 0.95 
4 - N/A 0.73 0.86 
8 - - N/A 0.85 
24 - - - N/A 
Table 2.19. Matrix of p values comparing each of the times before sample separation and the time to peak 
produced following analysis.  
 
2.3.2.2 Sample Stability and Assay Trends 
 
Although there were no statistical differences detected using the student’s t-test, the 
results were then analysed to confirm that there were no obvious trends across the four 
groups. This was performed by drawing a linear regression trendline across all of the 
values obtained for each of the four groups and calculating a value for R
2
 for that trend 
using Microsoft excel. The results of this analysis are shown in figure 2.10 below. 
 
Figure 2.10 
A.            B. 
  
C.               D. 
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Figure 2.10 Graphs showing time between sample collection and storage and the results obtained from a 
group of 10 volunteers for each of the four thrombin generation parameters. Graphs show a trendline and 
a value for R
2 
as an indicator of correlation. A: ETP, B: Lag Time, C: Peak Height and D: Time to Peak 
 
The p values obtained using the distribution of t table shown in 7.1 (appendix) were 
>0.5 for all the of the four thrombin generation parameters, showing that there was no 
trend across the groups for any of the four parameters. This result confirms the fact that 
the storage of samples at room temperature for up to 24 hours did not have an effect on 
the thrombin generation as measured by the CAT assay. An example of the thrombin 
generation curves of one of the volunteers across the four groups is shown in figure 
2.11.  This gives a visual indication of what the above data shows. The four curves 
show a high degree of overlap, with no obvious shift between any of the time points. 
 
Figure 2.11 
 
Figure 2.11. Thrombin generation curves produced from four different samples taken from the same 
donor and stored at room temperature for varying lengths of time. 
 
2.3.2.3 Storage Temperature and Thrombin Generation 
 
In order to ascertain the effects of storage temperature on the results produced by the 
CAT thrombin generation assay four 4.5ml 0.109M tri-sodium citrate samples were 
taken from a group of 10 volunteers. All of the volunteers’ samples had normal clotting 
screen results as determined by PT/INR, APTT and thrombin time (data not shown). 
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These samples were prepared as detailed in section 2.2.4 and separated into four groups 
of 10 (consisting of one sample from each of the 10 volunteers). Each of the groups 
were then placed at a different storage temperature, one  at 4°C, one at -20°C, one at -
40°C and one at -70°C. Following 24 hours storage one of the aliquots from each 
volunteer stored in the -70°C freezer was thawed in a 37°C water bath and analysed 
using the CAT assay. This group was designated as ‘fresh’ and was used as a base line 
to which the other groups would be compared. It was decided to freeze and thaw the 
fresh group to eliminate any confounding variables which may arise from the 
freeze/thawing process.  
 
Following four weeks incubation (longer than the required turn-around time for routine 
haemostatic investigations) at the various storage temperatures the four remaining 
groups were defrosted one at a time in a 37°C water bath and analysed on separate 
plates. Following the analysis the means and standard deviations of the four groups and 
the fresh group were calculated and plotted on the graphs shown in figure 2.12 below. If 
the four week storage at the varying temperatures had no effect on the results the 
median values and the distribution of data of the various groups should be analogous to 
that of the fresh group. It was anticipated that the storage of samples at 4°C would have 
a detrimental effect on the results since the levels of clotting factors would begin to 
decrease. It was also anticipated that the samples frozen at lower temperatures (-70°C) 
would show a greater degree of stability than those frozen at higher temperatures (-
20°C). From the graphs it can be seen that the groups stored at -20°C, -40°C and -70°C 
show similar results to the fresh groups for each of the different parameters. The 
samples stored at 4°C however did show marked differences to the fresh groups for all 
four of the measured parameters and also showed a difference to the groups stored at -
20°C, -40°C and -70°C. Statistical analysis of these results using the student’s t-test is 
shown in tables 2.20-2.23 below. 
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Figure 2.12 
 
A.             B. 
  
 
C.             D. 
  
Figure 2.12.  Boxplots showing storage temperature of samples and the distribution of the results obtained 
from a group of 10 volunteers for each of the four thrombin generation parameters following a four week 
incubation at that temperature. The fresh group was stored at -70°C for 24 hours before analysis. Boxes 
show 25
th
 to the 75
th
 percentile of the data with the median shown as a horizontal black line. Whiskers 
show minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 
times box height are shown by . A: ETP, B: Lag time, C: Peak height, D: Time to peak.  
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Table 2.20 
Sample Storage and ETP 
 Fresh 4°C -20°C -40°C -70°C 
Fresh N/A 0.12 0.50 0.34 0.35 
4°C - N/A 0.04 1.2x10
-4 
0.02 
-20°C - - N/A 0.78 0.80 
-40°C - - - N/A 0.98 
-70°C - - - - N/A 
Table 2.20. Matrix of p values comparing each of the storage temperatures and the value of ETP produced 
following analysis. Results highlighted in red are statistically significant. 
 
 
Table 2.21 
Sample Storage and Lag Time 
 Fresh 4°C -20°C -40°C -70°C 
Fresh N/A 6.6x10
-6 
0.82 0.66 0.40 
4°C - N/A 2.1x10
-6 
1.1x10
-5 
4.3x10
5 
-20°C - - N/A 0.81 0.49 
-40°C - - - N/A 0.66 
-70°C - - - - N/A 
Table 2.21. Matrix of p values comparing each of the storage temperatures and the lag time produced 
following analysis. Results highlighted in red are statistically significant. 
 
Table 2.22 
Sample Storage and Peak Height 
 Fresh 4°C -20°C -40°C -70°C 
Fresh N/A 1.7x10
-3 
0.99 0.85 0.75 
4°C - N/A 1.3x10
-3 
8.6x10
-4 
7.4x10
-4 
-20°C - - N/A 0.85 0.75 
-40°C - - - N/A 0.89 
-70°C - - - - N/A 
Table 2.22. Matrix of p values comparing each of the storage temperatures and the peak height produced 
following analysis. Results highlighted in red are statistically significant. 
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Table 2.23 
Sample Storage and Time to Peak 
 Fresh 4°C -20°C -40°C -70°C 
Fresh N/A 4.1x10
-6 
0.66 0.63 0.52 
4°C - N/A 3.9x10
-6 
5.2x10
-6 
1.8x10
-5 
-20°C - - N/A 0.95 0.79 
-40°C - - - N/A 0.84 
-70°C - - - - N/A 
Table 2.23. Matrix of p values comparing each of the storage temperatures and the time to peak produced 
following analysis. Results highlighted in red are statistically significant. 
 
The results in tables 2.20-2.23 show that there is no difference in the results generated 
for any of the four thrombin generation parameters by the CAT assay in samples that 
have been frozen at -20°C, -40°C and -70°C for four weeks compared to samples taken 
from the same pool of donors which have been frozen overnight at -70°C. Samples 
which are stored at 4°C for the same time period show marked differences in the results 
however, with statistically significant differences between the lag time, peak height and 
time to peak when compared to the fresh group and in all four parameters when 
compared to the groups frozen at -20°C, -40°C and -70°C. This result implies that 
samples for thrombin generation can be stored at any temperature between -20°C and -
70°C for longer than the required turn-around time for other routine diagnostic test 
samples. Since there is no stability advantage to be gained by storing the samples at -
70°C rather than -40°C patients requiring both thrombin generation and other 
haemostatic investigations could have their samples stored together. Samples stored at 
4°C produce results which are statistically significantly different when compared to 
those of samples which have been frozen, indicating samples stored in this manner 
cannot be analysed using the CAT assay. The impact of 4°C storage on a patients results 
can be seen in the thrombin generation curves of one of the volunteers across each of 
the five groups in figure 2.13 below.   
 
 
 
 
 
- 76 - 
 
Figure 2.13 
 
Figure 2.13. Thrombin generation curves produced from five different sample aliquots taken from the 
same donor and stored at varying temperatures for 4 weeks. The fresh group was stored at -70°C for 24 
hours. 
 
2.3.3 Limits of Detection 
 
When considering the upper and lower limits of detection for the thrombin generation 
assay it is important to note that there are four parameters which are measured: the ETP, 
the peak height, the lag time and the time to peak. The lag time and the time to peak are 
the time taken for the initiation of thrombin generation and the time until the maximum 
rate of thrombin generation is achieved, since these parameters are both times in 
minutes it is feasible that they may take any value (within reason) from 0 onwards. The 
lower limit of detection is therefore 0 and the upper limit of detection for any given run 
is the pre-specified time course for the assay. In order to calculate the results of a 
thrombin generation assay the computer software detects an initial thrombin burst, 
followed by a cessation of thrombin production and then a consistent low level of 
thrombin production which characterises the activity of thrombin bound to α II 
macroglobulin. The point at which this commences is defined as the ‘start tail’ by the 
software. If the measurement time is reached before the thrombin curve is complete or 
the ‘start tail’ is found the software will not calculate the results. A reaction time which 
is too short will therefore yield no results. Since the lag time and the time to peak have 
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clearly defined upper and lower limits of detection this section focuses on the 
determination of the limits of detection for both ETP and peak height. 
 
The upper and lower limits of detection for assays in the haemostasis department are 
frequently determined via different methods. The lower limit of detection is often 
defined as the mean of a cohort of 10 ‘blank’ samples plus three standard deviations of 
the results of that cohort. This is the minimum result that the assay in question can 
reliably detect. The upper limit can be difficult to determine, this is because many 
assays are dependent on the action of an enzyme (which is being measured) on a 
substrate which is in excess over a given time course. The actual limit of detection is 
therefore the amount of enzyme which can diminish the substrate quicker than the 
specified time course of the assay. This is unlikely to be a value obtainable in human 
plasma, pathological or otherwise, since the substrate is in excess. A large number of 
assays have results which are interpolated from stored standard curves or at the 
extremes derived from extrapolated standard curves. The limit at which it is deemed the 
extrapolation is no longer valid is the upper limit at which results are no longer 
reported. Most curves in the laboratory are extrapolated 1.5 times their original length. 
This is more correctly an upper limit of quantification rather than detection. The CAT 
assay poses difficulties when considering the upper limit of either quantification or 
detection. The results are not derived from stored standard curves making defining an 
upper limit of quantification via the above method impossible. An upper limit of 
detection is challenging since it requires a plasma sample which has a thrombin 
generation capacity so high as to consume the substrate before the computer software is 
capable of calculating the results. A titration of this sample until a valid result is 
achieved would give a respectable upper limit of detection. Unfortunately obtaining 
such a plasma sample is difficult. van Veen et al. (2009b), managed to achieve substrate 
depletion by spiking plasma with >0.5U/ml FEIBA
®
, but obtaining samples of FEIBA
®
 
was not possible in this study. The upper limit of detection for the CAT assay was not 
therefore determined in this study.  
 
The lower limit of detection for both the ETP and the peak height could be determined 
by the above method if a suitable blank could be found. Finding a ‘true’ blank can be 
challenging, since materials known to have a thrombin generation of zero, such as saline 
or water have a different matrix to that of plasma and therefore introduce other 
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confounding variables. Suitable blanks for the thrombin generation assay could either 
be serum or heat inactivated plasma. It was chosen to use heat inactivated plasma in this 
experiment since it was felt that the use of serum could still yield a low thrombin 
generation if all the clotting factors were not adequately consumed. Plasma subjected to 
heat inactivation as described in section 2.2.8 should have all plasma proteins denatured 
and therefore provide a true blank. 
 
Samples for heat inactivation were obtained from patients at the Royal London 
Hospital, who had normal clotting screens as defined by PT/INR, APTT and thrombin 
time and were therefore not undergoing any anti-coagulant therapy which could 
interfere with the analysis. The heat inactivated plasma was then analysed 10 times on a 
single plate using the CAT assay as described in section 2.2.5. The measurement time 
was set for 1 hour. Although inspection of the thrombin generation curves as the 
analysis was progressing revealed no obvious thrombin generation, the computer 
software was unable to interpret the results and instead flagged the 10 groups with a 
‘flat curve’ error. This was an undesirable result as it implies that the CAT assay cannot 
be used to measure a true blank sample i.e. the CAT analysis software cannot interpret a 
flat generation curve as a zero result. This meant that the lower limit of detection could 
not be determined in the normal manner.  
 
2.3.3.1 Standard Human Plasma Dilutions 
 
In order to discern what level of result could be accurately calculated by the CAT 
analysis software it was decided to dilute a normal human plasma with heat inactivated 
plasma to see what levels of clotting factors the CAT assay could accurately measure. 
The lowest dilution with an accurate result could then be used as a ‘blank’ for the lower 
limit of detection. These dilution experiments would also provide an insight into what 
effects decreasing the levels of clotting factors in a patients sample has on the assay 
results. 
 
The normal human plasma that was chosen to form the basis of the dilutions was 
standard human plasma (SHP) produced by Dade Behring. This was chosen because it 
was known to contain normal levels of each clotting factor and naturally occurring 
anticoagulants. SHP is a lyophilised plasma product and was chosen despite the 
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observed difficulties in the measurement of lyophilised plasma by the CAT assay 
because it was felt that dilution of SHP in heat inactivated plasma would also dilute out 
the particulate matter, which was thought to cause the observed variation.  
 
The first stage in this experiment was to produce a series of 11 different dilutions of 
SHP in heat inactivated plasma. These initial dilutions varied from 100% SHP to 5% 
SHP. Each dilution was analysed once on a single plate as described in section 2.2.5. 
The thrombin generation curves for each of the dilutions are shown in figure 2.14 
below. 
 
Figure 2.14 
 
Figure 2.14. A graph showing the thrombin generation curves of a series of dilutions of SHP in heat 
inactivated plasma. 
 
From figure 2.14 it can be seen that as anticipated the lower the concentration of SHP 
the smaller the thrombin generation curves become. This correlates with a decreasing 
ETP and peak height. From the shape of the curves it also appears that the lag time and 
time to peak parameters are increasing as the concentration of SHP is decreasing.  In 
order to better determine the relationship between the concentration of SHP and the 
individual assay parameters the results of the above experiment were plotted on separate 
graphs as shown in figure 2.15 below. 
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Figure 2.15 
 
A.             B. 
  
 
C.             D. 
  
Figure 2.15 Graphs showing the results for each of the thrombin generation parameters against the 
concentration of SHP for a series of dilutions of SHP in heat inactivated plasma, complete with trend 
lines and R
2
 value as an indication of correlation. A: ETP, B: Peak Height, C: Lag Time, D: Time to Peak 
 
From figure 2.15 A and B it can be seen that the ETP and peak height demonstrate a 
striking linear relationship between the result and the concentration of SHP (and 
therefore the levels of clotting factor present) with R
2
 values exceeding 0.95 in both 
cases, indicating statistically significant trends as calculated in section 2.3.1.4 (p = 
<0.001).  This pattern holds best with clotting factors levels between ~10% and ~90%. 
It would appear that the results for both peak height and ETP begin to plateau when the 
clotting factor concentration reaches ≥90% of normal. Levels of clotting factor below 
10% of normal are suggestive of a hyperbolic trend, although it can only be 
hypothesised from the above graphs. The linear relationship demonstrated here is 
similar to that shown by Al Dieri et al. (2002),
 
who showed a linear relationship 
between the levels of prothrombin and the ETP. Although that experiment used a 
plasma containing normal levels of other clotting factors and a varying level of factor II. 
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Deficiencies of other clotting factors showed a hyperbolic relationship with ETP when 
varied individually. SHP contains ~100 U/dL of all clotting factors, it is interesting 
therefore that the relationship continues to be linear and not hyperbolic, which was the 
result most commonly observed by Dieri et al, when all of the clotting factors are 
reduced simultaneously. This implies that deficiency of factor II is a rate limiting step in 
the CAT assay. This is not an unanticipated result since a normal level of thrombin 
generation cannot occur if there is not a normal level of prothrombin present. 
 
Figure 2.15 C and D show that the relationship between clotting factor concentration 
and the lag time and time to peak is different to that of ETP and the peak height which 
both show a proportional increase as the concentration of clotting factors increase. The 
relationship between the lag time and the time to peak with the concentration of clotting 
factors is less dramatic as indicated by the R
2
 values, which are lower than both the ETP 
and peak height but the p values still indicate statistically significant trends (p= <0.01). 
Demonstrating that there is an inversely proportional relationship between both the lag 
time and time to peak and the concentration of clotting factors, i.e. the lag time and time 
to peak increase as the levels of clotting factor decrease. This relationship however is 
non linear with near normal clotting times once the concentration of clotting factors 
reaches 30% of normal. This result implies that plasma with only 30% levels of all 
clotting factors can produce clotting times which are ~90% of normal. Due to the 
exponential shape of the curves in figure 2.15 it was decided to plot the graphs again on 
a logarithmic scale in order to better establish the relationships between the 
concentration of clotting factors in a sample and the thrombin generation capacity of 
that sample. The results of this are shown in figure 2.16 below. 
 
Figure 2.16 
A.             B. 
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C.              D. 
  
Figure 2.16 Graphs showing the results for each of the thrombin generation parameters against the 
concentration of SHP for a series of dilutions of SHP in heat inactivated plasma, complete with trend 
lines and R
2
 value as an indication of correlation. Plotted on a log-log scale. A: ETP, B: Peak Height, C: 
Lag Time, D: Time to Peak 
 
From figure 2.16 it can be seen that plotting the data on a logarithmic scale enhances the 
correlation between clotting factor concentration (percentage SHP) and all four of the 
thrombin generation parameters. In the case of the ETP and peak height parameters this 
change is relatively modest, whereas for the lag time and time to peak parameters the 
increase is profound rising to 0.96 and 0.95 respectively from 0.61 and 0.63. This 
change increases the significance of the correlation to a p value of <0.001 for both 
parameters. 
 
Importantly it can be observed that all of the 11 dilutions of SHP have produced valid 
results by the CAT assay. In order to ascertain the limits of detection it is necessary to 
continue the titration of SHP until the assay fails to produce a valid result. In the next 
step of the experiment dilutions of between 1% and 4% of SHP in heat inactivated 
plasma were made. These dilutions were measured in duplicate on a single plate as 
described in section 2.2.5. The thrombin generation curves of one of each of the 
dilutions from this analysis are shown in figure 2.17 below. The CAT assay produced 
valid curves for the dilutions between 2-4% of SHP in heat inactivated plasma, but was 
unable to find an appropriate start tail for the curve of the 1% SHP dilution. This can be 
set manually and the curve is therefore shown on figure 2.17 for comparative purposes. 
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Figure 2.17 
 
Figure 2.17. A graph showing the thrombin generation curves of a series of dilutions of SHP in heat 
inactivated plasma. 
 
It can be seen from figure 2.17 that the trends described above still hold for the low 
dilutions of SHP. Although the curves appear to show high levels of ‘noise’ this is more 
an artefact of the magnitude of the graph axes than any increased variability. As noted 
above the CAT assay was unable to calculate any results for the 1% SHP dilution and 
although the start tail can be set manually to produce results this is subjective, and can 
lead to an increased level of variation especially when the levels of thrombin generation 
are low. For this reason it was chosen to use a dilution of 2 % SHP to represent the limit 
of detection. The above analysis was performed for 50 Minutes. In order to ascertain 
whether the failure of the software to detect a start tail was due to the analysis time, the 
experiment was repeated with an analysis time of 70 minutes with identical results (data 
not shown). 
 
The lower limit of detection for the peak height and the endogenous thrombin potential 
was therefore determined by analysing a 2% dilution of SHP in heat inactivated plasma 
10 times on a single plate as described in section 2.2.5 with a measurement time of 70 
minutes. The results are shown in table 2.24 below. From the results it can seen that the 
CVs of the 10 replicates for the four parameters were all good ranging from 1.59-
5.62%, well below the 10% target as discussed previously. This is a good demonstration 
of precision, proving that the CAT assay has a low level of variability even at the lower 
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limit of detection. The lower limit of detection itself was calculated by the mean +3SD. 
This is used in laboratory terms as a cut off, below which it is assumed that any results 
generated are inaccurate. In this respect it is more correctly a lower limit of 
quantification, although the lower limit of detection and quantification are effectively 
the same in this assay. Any numerical result for the CAT assay falling below 325 nM 
thrombin for ETP and below 18.6 nM Thrombin for peak height will be reported as 
<325 nM thrombin and <18.6 nM thrombin respectively. 
 
Table 2.24 
Parameter Mean SD CV (%) Lower Limit 
of Detection 
ETP 
(nM Thrombin) 
278.23 
 
15.65 5.62 325.18 
Peak Height 
(nM Thrombin) 
16.99 0.54 3.16 18.60 
Lag Time 
(Minutes) 
12.58 0.36 2.85 N/A 
Time to Peak 
(Minutes) 
17.94 0.28 1.59 N/A 
 
Table 2.24 A Table showing the mean, standard deviation, coefficient of variation and lower limit of 
detection of each of the four thrombin generation parameters calculated from the analysis of 10 replicates 
of a 2% dilution of SHP  in heat inactivated plasma. 
 
2.3.4 Variation Across Time 
 
In order to investigate the variation of a patient’s capacity to generate thrombin over 
time it was decided to take blood samples from a cohort of healthy individuals across a 
predefined time course, to establish whether or not there was any significant change in 
the results generated by the CAT thrombin generation assay.  
 
A cohort of 10 healthy volunteers (5 male and 5 female) were chosen for this 
experiment, all of these individuals had no prior history of bleeding or thrombosis and 
had normal clotting screens as defined by PT/INR, APTT and thrombin time. Blood 
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samples were collected from each individual every week for four weeks (giving a total 
of four samples for each participant). These samples were prepared as described in 
section 2.2.4 and frozen at -70°C. Once all four samples were collected on a single 
individual and the final sample had been frozen for 24 hours, all four stored samples 
were defrosted in a 37°C waterbath and analysed via the CAT thrombin generation 
assay as described in section 2.2.5. The analysis time for these experiments was 45 
minutes. The analysis of samples was performed in this manner to ensure that no 
patients sample was stored for longer than the maximum four week storage time that 
was validated in section 2.3.3.3. This procedure also ensured that all of the samples 
obtained on a single patient were analysed on a single run, thereby minimising any 
confounding variables associated with inter assay variation.  
 
Following the analysis the results obtained from the cohort for each of the thrombin 
generation parameters across the four weeks were compared using a paired student’s t-
test. The results of this statistical analysis are shown in tables 2.25-2.28 below. A p 
value of <0.05 was considered statistically significant. It can be seen from the tables 
that there were no statistically significant differences between the results obtained from 
the cohort from any of the four weeks. This result implies that there was no statistically 
significant difference between the thrombin generation results of the individuals in the 
cohort across a four week time course. 
 
 
Table 2.25 
Variation Across Time: Lag Time 
 Week 1 Week 2 Week 3 Week 4 
Week 1 N/A 0.18 0.60 0.54 
Week 2 - N/A 0.09 0.08 
Week 3 - - N/A 0.67 
Week 4 - - - N/A 
Table 2.25. Matrix of p-values comparing the lag time results of a cohort of individuals across a four 
week time course 
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Table 2.26 
Variation Across Time: ETP 
 Week 1 Week 2 Week 3 Week 4 
Week 1 N/A 0.12 0.47 0.11 
Week 2 - N/A 0.50 0.69 
Week 3 - - N/A 0.88 
Week 4 - - - N/A 
Table 2.26. Matrix of p-values comparing the ETP results of a cohort of individuals across a four week 
time course 
 
Table 2.27 
Variation Across Time: Peak Height 
 Week 1 Week 2 Week 3 Week 4 
Week 1 N/A 0.90 0.93 0.18 
Week 2 - N/A 0.96 0.68 
Week 3 - - N/A 0.63 
Week 4 - - - N/A 
Table 2.27. Matrix of p-values comparing the peak height results of a cohort of individuals across a four 
week time course 
 
Table 2.28 
Variation Across Time: Time to Peak 
 Week 1 Week 2 Week 3 Week 4 
Week 1 N/A 0.62 0.40 0.76 
Week 2 - N/A 0.42 0.73 
Week 3 - - N/A 0.33 
Week 4 - - - N/A 
Table 2.28. Matrix of p-values comparing the time to peak results of a cohort of individuals across a four 
week time course 
 
In order to try and accurately assess the level of variation seen between the results of 
each patient over the four weeks the CVs were determined for each of the thrombin 
generation parameters for each of the 10 patients. The median CV and the range of 
results obtained for each parameter are shown in table 2.29 below. 
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Table 2.29 
Thrombin Generation 
Parameter 
Range of CVs Obtained 
(%) 
Median CV 
 (%) 
Lag Time 0.0 - 12.7 6.3 
ETP 1.0 - 6.5 3.5 
Peak Height 1.4 - 6.1 3.4 
Time to Peak 0.0 - 5.4 2.0 
Table 2.29. Range and median CVs obtained for each thrombin generation parameter following the 
analysis of samples taken weekly for four weeks from a cohort of 10 individuals.  
 
It can be seen from table 2.29 that the CVs obtained from the analysis of the individual 
patient’s results were relatively low. Only 2 of the 40 calculated values exceeded the 
10% cut-off for acceptable variation discussed in previously. These values were both 
12.7% and were both obtained from measurement of the lag time, which was previously 
highlighted as the parameter with the highest levels of variation. The median CVs 
obtained from this analysis are of similar magnitude to those obtained when measuring 
the intra assay variability of pooled fresh plasma (tables 2.11-2.14). This implies that 
the variation seen between the results of the individuals in the cohort across the four 
week time course is consistent with intra assay variation and is probably not a result of 
physiological changes in the patients themselves. Importantly this finding is consistent 
with the analysis of the results using the student’s t-test (above). Together these 
analyses are suggestive of minimum variation in the thrombin generation potential of an 
individual across time. An example of the thrombin generation curves produced from 
one of the individuals in the cohort over the four week time course is shown in figure 
2.18 below. 
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Figure 2.18 
 
 Figure 2.18. Graph showing the thrombin generation curves produced following the analysis of samples 
taken weekly from the same individual over a period of four weeks.  
 
2.3.5 Normal Range 
 
In order to establish a normal range for the CAT assay it was necessary to take blood 
samples from a cohort of individuals who had no history of bleeding or thrombosis and 
who were healthy at the time of sampling. The normal control cohort was composed of 
40 males and 40 females of between 20 and 60 years of age. Both the male and female 
cohort were composed of 10 individuals aged between 20-29, 10 aged between 30-39, 
10 aged between 40-49 and 10 aged between 50-59. The individuals chosen were 
composed of healthy volunteers and outpatients samples from individuals attending 
surgical clinics (such as potential kidney donors). All volunteers had normal clotting 
screen results as determined by PT/INR, APTT and thrombin time, thus ensuring the 
patients were not undergoing any anticoagulant therapy, which may affect the results. A 
normal clotting screen should also exclude most inherited bleeding disorders, which 
may have been previously undiagnosed. An even distribution of age and sex was chosen 
to ensure any differences due to these variables could be detected.  
 
Although it would have been interesting to also determine a paediatric normal range it 
was decided, due to a lack of suitable patients and ethical concerns over consent, that it 
would not be attempted in this study. All samples were prepared as described in section 
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2.2.4. The samples were analysed as described in section 2.2.5. The measurement time 
was 45 minutes. 
 
Ideally to facilitate the ease of use in the laboratory the CAT assay would have a single 
normal range, although this is by no means essential, as it is not uncommon to have 
different normal ranges depending on factors such as age, sex or ethnicity. Before any 
meta analysis of all of the 8 groups could be performed it was necessary to determine 
whether there were any differences between any of the groups for any of the four 
parameters analysed. This was important as it was unknown whether age, sex or both 
were confounding variables. Initially a comparison of the differences due to age in both 
the male and female groups was performed. Comparisons were performed using the 
student’s t-test and the results of the analysis are shown in tables 2.30-2.37 below. A p 
value of ≤0.05 was considered significant. From the results it can be seen that there are 
no significant differences between any of the comparisons performed. This implies that 
age has no effect on any of the thrombin generation parameters when males and females 
are considered separately. 
 
Table 2.30 
Male: ETP    
Age Group 20-29 30-39 40-49 50-59 
20-29 N/A 0.91 0.54 0.54 
30-39 . N/A 0.60 0.40 
40-49 . . N/A 0.73 
50-59 . . . N/A 
Table 2.30. Matrix of p values comparing the ETP results of each of the 4 age groups in the male cohort. 
 
Table 2.31 
Male: Lag Time    
Age Group 20-29 30-39 40-49 50-59 
20-29 N/A 0.82 0.63 0.86 
30-39 . N/A 0.72 0.98 
40-49 . . N/A 0.78 
50-59 . . . N/A 
Table 2.31. Matrix of p values comparing the Lag Time results of each of the 4 age groups in the male 
cohort.  
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Table 2.32 
Male: Peak Height   
Age Group 20-29 30-39 40-49 50-59 
20-29 N/A 0.65 0.76 0.75 
30-39 . N/A 0.47 0.88 
40-49 . . N/A 0.55 
50-59 . . . N/A 
Table 2.32. Matrix of p values comparing the Peak Height results of each of the 4 age groups in the male 
cohort. 
 
Table 2.33 
Male: Time to Peak    
Age Group 20-29 30-39 40-49 50-59 
20-29 N/A 0.87 0.58 0.46 
30-39 . N/A 0.67 0.53 
40-49 . . N/A 0.87 
50-59 . . . N/A 
Table 2.33. Matrix of p values comparing the Time to Peak results of each of the 4 age groups in the male 
cohort.  
 
Table 2.34 
Female: ETP    
Age Group 20-29 30-39 40-49 50-59 
20-29 N/A 0.73 0.70 0.71 
30-39 . N/A 0.48 0.97 
40-49 . . N/A 0.43 
50-59 . . . N/A 
Table 2.34. Matrix of p values comparing the ETP results of each of the 4 age groups in the female 
cohort. 
 
Table 2.35 
Female: Lag Time    
Age Group 20-29 30-39 40-49 50-59 
20-29 N/A 0.26 0.09 0.06 
30-39 . N/A 0.57 0.71 
40-49 . . N/A 0.73 
50-59 . . . N/A 
Table 2.35. Matrix of p values comparing the Lag Time results of each of the 4 age groups in the female 
cohort.  
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Table 2.36 
Female: Peak Height   
Age Group 20-29 30-39 40-49 50-59 
20-29 N/A 0.65 0.91 0.53 
30-39 . N/A 0.74 0.93 
40-49 . . N/A 0.63 
50-59 . . . N/A 
Table 2.36. Matrix of p values comparing the Peak Height results of each of the 4 age groups in the 
female cohort. 
 
Table 2.37 
Female: Time to Peak   
Age Group 20-29 30-39 40-49 50-59 
20-29 N/A 0.36 0.23 0.14 
30-39 . N/A 0.64 0.68 
40-49 . . N/A 0.85 
50-59 . . . N/A 
Table 2.37. Matrix of p values comparing the Time to Peak results of each of the 4 age groups in the 
female cohort.  
 
The next stage of the analysis was to compare the results of each of the four thrombin 
generation parameters for each of the four age groups from the male and female cohorts 
with each other. Comparisons were again made using the student’s t-test. A p value of ≤ 
0.05 was considered a statistically significant result. The results of the comparisons are 
shown in tables 2.38-2.41 below. 
 
 
Table 2.38 
ETP  Female  
Male 20-29 30-39 40-49 50-59 
20-29 0.29 0.16 0.53 0.11 
30-39 0.32 0.18 0.59 0.11 
40-49 0.66 0.44 0.97 0.38 
50-59 0.95 0.71 0.76 0.70 
Table 2.38. Matrix of p values comparing the ETP results for each of the four age groups of the male and 
female cohorts. 
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Table 2.39 
Lag Time Female 
Male 20-29 30-39 40-49 50-59 
20-29 0.28 0.97 0.56 0.68 
30-39 0.09 0.85 0.62 0.80 
40-49 0.07 0.65 0.85 0.88 
50-59 0.21 0.89 0.68 0.85 
Table 2.39. Matrix of p values comparing the Lag Time results for each of the four age groups of the male 
and female cohorts. 
 
Table 2.40 
Peak Height  Female  
Male 20-29 30-39 40-49 50-59 
20-29 0.67 0.41 0.61 0.32 
30-39 0.31 0.13 0.27 0.06 
40-49 0.98 0.72 0.91 0.66 
50-59 0.40 0.18 0.35 0.10 
Table 2.40. Matrix of p values comparing the Peak Height results for each of the four age groups of the 
male and female cohorts. 
 
Table 2.41 
Time to Peak  Female  
Male 20-29 30-39 40-49 50-59 
20-29 0.76 0.65 0.42 0.40 
30-39 0.60 0.76 0.49 0.47 
40-49 0.34 0.87 0.77 0.87 
50-59 0.23 0.72 0.88 0.98 
Table 2.41. Matrix of p values comparing the Time to Peak results for each of the four age groups of the 
male and female cohorts. 
 
From the results it can be seen that there were no statistically significant differences 
between any of the four age groups in the male and female cohorts for any of the four 
parameters analysed. This result suggests that age does not affect the results for any of 
the thrombin generation parameters when grouped as shown above. This comparison 
also alludes to the fact there is potentially no differences between the male and female 
cohorts. To confirm this finding a further analysis was performed. Since there were no 
differences between any of the age groups in either of the two cohorts a t-test 
comparison was performed between all 40 of the data points for each parameter in the 
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male cohort and all 40 data points for each parameter in the female cohort. This would 
distinguish definitively whether or not there were any differences in any of the four 
thrombin generation parameters between the two cohorts. The p values for the 
comparisons ranged between 0.10 and 0.87 indicating that there were no statistically 
significant differences due to sex in any of the thrombin generation parameters 
analysed. This result was desirable since it meant that a single normal range could be 
derived from the available data for both male and female patients. Before that analysis 
was performed a final comparison was made to definitively exclude any effect of age on 
any of the thrombin generation parameters. Although the t-test comparisons performed 
above showed no differences between the different age groups both within and between 
the different sexes, it is possible that the results could be skewed due to the effects of 
grouping the data rather than considering age as a continuous variable. To properly 
ascertain the impact of age on thrombin generation a correlation was performed for each 
parameter using all 80 of the available data points. The graphs depicting these analyses 
are shown in figure 2.19 below. 
 
 
Figure 2.19 
 
A.             B. 
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C.             D. 
  
Figure 2.19. Graphs showing the results of the four thrombin generation parameters against age, complete 
with trend lines and R
2
 values as indicators of correlation. A: ETP, B: Lag Time, C: Peak Height, D Time 
to Peak. 
 
From the graphs it can be seen that there was no clear correlation of age with any of the 
four thrombin generation parameters, this was also indicated in the low values for R
2
. 
Calculation of the p value using the distribution of t as described in section 2.3.1.4 
confirmed that there was no general trend between any of the thrombin generation 
parameters and age (p values >0.05 for all 4 parameters). 
 
Since neither age nor sex had any statistically significant effect on any of the parameters 
analysed, a single normal range could be defined for all patients analysed via the CAT 
assay using the 80 available data points for each parameter. Frequency charts for each 
parameter were then drawn to determine the distribution of the population, as this would 
determine how the normal range was calculated. The frequency charts are shown in 
figure 2.20 below.  
 
The frequency charts in figure 2.20 imply that the data for the ETP, peak height and 
time to peak parameters are normally distributed and that the data for the lag time may 
be skewed. Analysis using the Kolmogorov-Smirnov test revealed this was indeed the 
case. For each of the normally distributed parameters the normal range was defined by 
the mean ±1.96 Standard deviations. This provides a range into which 95% of all 
normal individuals should fall. The normal range for the lag time was determined by 
calculating the 2.5 and 97.5 percentiles of the data as this provides the equivalent 
normal range. The results of this analysis are shown in table 2.42 
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Figure 2.20 
A.             B. 
  
 
C.             D. 
  
Figure 2.20. Frequency charts showing the distribution of the four thrombin generation parameters of the 
80 normal individuals analysed. A: Lag Time, B: ETP, C: Peak Height, D: Time to Peak. 
 
 
 
Table 2.42 
Parameter Normal Range 
ETP (nM Thrombin) 1336 - 2886 
Lag Time (Minutes) 2.00 - 4.01 
Peak Height (nM Thrombin) 258 - 454 
Time to Peak (Minutes) 4.38 - 7.65 
Table 2.42. Table showing the derived normal range for the four thrombin generation parameters. ETP 
and Peak Height shown to 4 and 3 significant figures respectively. Lag Time and Time to Peak shown to 
2 decimal places. 
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2.3.6 Thrombin Generation and CTI 
 
The final stage of the evaluation was to ascertain the effects of the addition of CTI on 
the CAT thrombin generation assay. CTI inhibits contact activation in thrombin 
generation assays and therefore prevents an overestimation of a patient’s thrombin 
generation capacity. There is evidence in the literature to suggest that the addition of 
CTI is not required when a 5pM concentration of tissue factor is used as a reaction 
trigger, as in this study (van Veen et al., 2008). To ascertain whether or not this was the 
case blood samples were taken from a cohort of 6 healthy volunteers. Two samples 
were taken from each individual, one sample was taken into a standard 4.5ml 0.109M 
tri-sodium citrate sample, the second was taken into a 4.5ml 0.109M tri-sodium citrate 
sample containing 77µl of 1.3mg/ml CTI. This gave a final concentration of 20µg/ml 
CTI, which is similar to the concentration employed in a paper by van Veen et. al., 
(2009a), who used a final concentration of 18.3µg/ml. The CTI was added to the 
vacutainer before the blood sample was collected as described previously (van Veen et. 
al., 2009a). The samples were processed as described in section 2.2.4 and then frozen at 
-70°C overnight. The samples were thawed in a 37°C waterbath before being analysed 
on a single plate as described in section 2.2.5. The analysis time for this experiment was 
45 minutes. The results obtained from the samples with and without CTI were then 
compared using a paired t-test. The data obtained from this experiment as well as the 
results of the paired t-tests are shown in figure 2.21 below. 
 
From the figure it is clear that the addition of CTI to an individual’s blood sample has 
no effect on the lag time, ETP or time to peak parameters as evidenced by the non-
significant t-test results (p ≤0.05 was considered significant). This was not true however 
for the peak height results which show a statistically significant reduction (p= 0.007) in 
the samples to which CTI was added when compared to those without the addition of 
CTI. This suggests that the addition of CTI can lead to a reduction in the maximum rate 
of thrombin production and that contact activation may play a part in the maximum rate 
of thrombin generation when CTI is not added into the blood sample. It may be noted 
that although there is a statistically significant decrease in the peak height of a sample 
when CTI is added the magnitude of this difference is relatively small, with the mean 
decrease across the cohort being ~20nM Thrombin. This equates to a decrease of  6% 
which is inside the 10% for variation deemed acceptable earlier in this chapter.  
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Figure 2.21 
A.               B. 
  
C.               D. 
  
Figure 2.21. Boxplots showing the effect of the addition of CTI to the samples of a cohort of 6 healthy 
individuals when compared to samples without the addition of CTI. Boxes show 25
th
 to the 75
th
 percentile 
of the data with the median shown as a horizontal black line. Whiskers show minimum/maximum values. 
Population outliers defined as values deviating by greater than 1.5 times box height are shown by . A: 
Lag Time, B: ETP, C: Peak height, D: Time to peak. P values calculated using a paired t-test. 
 
2.4 Discussion 
 
The overall aim of this project was to introduce the CAT thrombin generation assay into 
routine use in the haemostasis laboratory and ascertain the clinical utility of the results 
which the assay generates. The primary starting point was to determine how reliable the 
results generated by the CAT thrombin generation assay are in terms of both the inter 
and intra assay variation. If the assay demonstrated poor levels of variability its clinical 
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utility would be questioned as the results produced would be of little use in either a 
diagnostic or therapeutic monitoring scenario.  
 
The initial experimentation for the assay variability yielded poor results, with levels of 
inter assay variability exceeding the 10% cut off of acceptability of the coefficient of 
variation. All other diagnostic assays currently in use in the haemostasis laboratory 
demonstrate a lower level of inter assay variability than this. The assay also revealed a 
trend of decreasing peak height across the plate. Although initially it was felt that these 
results could be due to the effects of the time taken to prepare the plate for analysis, 
decreasing the preparation time by using an electronic pipette did not eliminate these 
effects. Although the intra and inter assay variability did decrease, the levels of inter 
assay variability remained unacceptably high. The intra assay trends were also 
unaffected by the use of the electronic pipette indeed the problem was accentuated with 
an increase in lag time across the plate in combination with the decreasing peak height. 
Since it seemed preparation time was not responsible for these effects, assuming the 
assay itself was not at fault the only other constant across the experiments was the use 
of the lyophilised Control plasma P.  
 
The Control plasma P was chosen for use in this assay for a number of reasons; the most 
obvious of which was that it was available in large enough quantities to enable the 
generation of a large number of results. The second reason it was chosen was down to 
the unavailability of control plasma for the CAT thrombin generation assay. Control 
plasma P is used as an abnormal control in a large number of routine assays in the 
haemostasis laboratory including a number of thrombophilia investigations. It contains 
‘pathologically’ low levels of most of the proteins involved in the coagulation process. 
It was felt that if the plasma yielded acceptable results it could potentially be used as an 
abnormal control in the CAT assay. The results from this analysis revealed that Control 
plasma P would make a poor abnormal (low) control for the CAT assay due in part to its 
elevated ETP, decreased lag time and time to peak in comparison with a pool of fresh 
human plasma. The assay also produced a high level of background noise when 
analysing Control plasma P. The level of interference in the assay was unprecedented 
and is most likely to be caused by particular matter in the reconstituted plasma which 
could interfere with the generation of the fluorescent signal. This particular matter could 
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be generated by inefficient reconstitution of the reagent. This hypothesis is given weight 
by the elimination of the assay ‘noise’ when a fresh pool of plasma was analysed.  
 
The analysis of the pooled plasma eliminated the intra assay trends and decreased the 
inter and intra assay variability to acceptable levels. The CAT thrombin generation 
assay therefore is suitable for routine diagnostic use in the haemostasis laboratory. It is 
worth noting that the repeatability of both the lag time and the time to peak parameters 
were still subject to a high variation between runs. The reasons for this may have been 
due to sample preparation. The time to peak measurement was highly dependent on the 
lag time since the maximal rate of thrombin production cannot occur until thrombin 
generation has begun, therefore the variability in the time to peak measurement may 
have been exclusively due to the variation in the lag time. The lag time itself is 
dependent on the phospholipid concentration in the sample, although the concentration 
of phospholipids in the reagent is standardised the concentration of phospholipid 
particles in the patient’s plasma may be subject to high variability. The double spinning 
preparation of patient’s plasma is designed to remove endogenous phospholipids in the 
form of platelets but does not remove platelet microparticles. These can only be 
removed by filtration of the patients plasma and may be the cause of some of the inter 
assay variation witnessed in the assay. 
 
The sample handling and storage experiments were highly successful with the sample 
stability proving surprisingly robust. It was hoped that the time between collection and 
storage would have no impact on the results up until at least four hours; it was actually 
proved that the samples could be left at room temperature for up to 24 hours before they 
were separated and frozen without any effect on any of the four thrombin generation 
parameters. This result is perhaps less surprising when considering that the levels of 
clotting factors can be markedly decreased and still produce near normal levels of ETP 
(Al Dieri et al., 2002). Factor VII has the shortest half life of all the clotting factors, 
with a half life of just four hours. It is quoted that a level of 2% factor VII can produce 
an ETP approaching normality. Since the normal range of factor VII extends from 50-
150% a patient with a factor VII level at the top end of this range who has their plasma 
stored at room temperature for 24 hours (6 half lives) would have a factor VII level of 
2.3% after this time. It was anticipated that decreasing clotting factor concentration 
would have a more pronounced effect on the lag time and peak height. This trend was 
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not observed in the course of this experiment. This was possibly due to the fact that the 
decrease of clotting factors may not have been as dramatic as demonstrated above. This 
is due to the incubation temperature; factor VII has a half life of 4 hours at 37°C, which 
may well be prolonged at room temperature, yielding higher levels of clotting factor 
following a 24 incubation and ultimately a reduced effect on the thrombin generation 
parameters. Indeed the in vitro half life of factor VII (and other clotting factors) may 
well be elevated in comparison to that observed in vivo since they are unlikely to be 
consumed due to physiological processes. 
 
The sample storage experiment yielded the anticipated results with a good level of 
stability following 4 weeks storage provided the samples remained frozen. Storage at 
4°C was unsuitable due to a statistically significant decrease in ETP and peak height 
and a statistically significant increase in lag time and time to peak when compared to 
the other storage temperatures. This pattern i.e. decreased total thrombin generation and 
maximum rate of production coupled with prolonged time to initiation of thrombin 
generation and time to maximum rate of generation is consistent with a decrease in the 
levels of clotting factors associated with sample degradation as described above. This 
shows that at an incubation temperature of 4°C the levels of clotting factors are 
diminished markedly after 4 weeks.  
 
These results indicate that the CAT thrombin generation assay sample handling 
requirements are suitable for routine laboratory use, with the samples stable for up to 24 
hours post collection (longer than any sample should realistically be in transit) and once 
frozen the samples remained stable longer than the required turn-around time of any 
routine haemostatic investigation. The fact that the samples can be stored at any 
temperature -20°C means that there is also a great flexibility of where the samples can 
be kept. 
 
The limit of detection experiments initially produced undesirable results, with the 
analysis software unable to produce valid thrombin generation curves on a ‘true blank’ 
sample, indicating that a flat generation curve cannot be interpreted as a zero result. 
This is a potential limitation of the assay since it is unlikely that the CAT analysis 
software will produce valid results on patients with an extremely low thrombin 
generation. Patients with a flat curve error therefore will have their results reported as 
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below the lower limit of quantification. It is worth noting however, that patients with 
thrombin generation levels below the limit of detection will have an extremely 
pathological condition, if not undergoing anticoagulation therapy, since the lower limit 
of detection was defined using a concentration of ~2% for all clotting factors. This 
limitation is also unlikely to have any effect on this study since it is primarily focused 
on patients with thrombotic tendencies rather than haemophilia and therefore the 
thrombin generation parameters are likely to be elevated rather than decreased.  
Unfortunately, for the above reason, it would be desirable therefore to also establish an 
upper limit of detection, which proved impossible in this study. Although no formal 
limit was established, no patient in this study had a level of thrombin generation so 
great as to cause substrate depletion over the time course of the reaction. Therefore the 
upper limit of detection is obviously a value of ETP and Peak Height that are highly 
pathological since they must be in excess of 3965 and 611 respectively (the highest 
values seen in this study), which are 37% and 34% above the upper limit of the normal 
range. 
 
Although the initial experiments to define the lower limit of detection using a thrombin 
generation blank were unsuccessful the titration experiments performed with SHP in 
heat inactivated plasma provided an adequate substitute, proving that the analysis 
software cannot produce valid answers when the clotting factor levels in a patient’s 
plasma are below ~2 u/dL. A 2% dilution of SHP in heat inactivated plasma was used to 
successfully define the lower limit of detection for both the ETP and the Peak Height. 
The CVs generated in these analyses were also surprisingly good, suggesting that the 
assay is capable of good precision even at very low levels of thrombin generation. 
 
The SHP titration experiments also provided a valuable insight into the effects of 
decreasing clotting factor concentration on the results generated, with statistically 
significant linear correlations between clotting factor concentration and both ETP and 
peak height. The majority of which was probably caused by the concentration of 
prothrombin in the sample. Interestingly the effect was not so dramatic when 
considering the impact of clotting factor concentration on both the lag time and the time 
to peak parameters. Although there was a significant negative correlation (decreasing 
times with increasing clotting factor concentration) which could be significantly 
increased in magnitude when plotting the data on a logarithmic scale, most of the 
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variation was caused when the clotting factor levels are <30% of normal. This means 
that when the clotting factor concentration levels are greater than this there are 
sufficient levels of prothrombin and other factors to initiate thrombin generation and 
reach the maximum rate of thrombin generation in a time that is approximately 90% of 
normal. This is the case even if the subsequent level of thrombin generation and the rate 
of maximum thrombin generation are markedly reduced. The discovery that a clotting 
factor concentration exceeding 30% of normal (>30 u/dL) can lead to relatively normal 
clotting times as defined by the lag time and time to peak parameters in the thrombin 
generation assay fits neatly with the levels of clotting factors needed to prevent bleeding 
episodes in patients with factor deficiencies. Patients with mild haemophilia are 
classified as those who have factor levels of between 5-30 u/dL. Those with levels 
between 30-50 u/dL are technically deficient but are rarely symptomatic. 
 
The measurement of a patient’s thrombin generation over time yielded positive results. 
When performing an assay for routine diagnostic testing it is important to be confident 
that the result generated reflects the pathological condition of the patient i.e. a decreased 
thrombin generation is indicative of a bleeding tendency. If there was a high level of 
variance in a patients thrombin generation from one day to the next this would reduce 
the diagnostic power of the assay. Although it would be fair to suggest the variation 
would have to be large in order to misdiagnose a patient with a severe bleeding 
tendency or predisposition to thrombosis, this would not be the case for patients with 
mild disorders. If the level of variation was high then it would be likely patients with 
borderline results would have to be repeated several times in order to be confident of a 
correct diagnosis. A similar scenario is adopted in the screening of patients for von 
Willebrand disease as the level of vWF can vary quite markedly due to stress and acute 
phase. Repeat testing of patients is ultimately undesirable since it has negative 
implications for assay cost and places additional pressures on the clinics to which the 
patients are referred. A high level of assay variation in individual patients across time 
would also impact upon the use of the assay for therapeutic monitoring as it would be 
difficult to discern whether any changes observed in a patient’s thrombin generation 
profile were due to variation in the patients themselves or a physiological response to 
the patient’s therapy.  
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The levels of variation observed in the cohort of normal individuals in this study over 
the four week time course were consistent with those achieved in the intra assay 
variability experiments. The majority of the participants displayed levels of variation 
below the 10% cut-off previously discussed and the differences observed between the 
weeks were non-significant as defined by a paired t-test. This result implies that a 
patient’s baseline level of thrombin generation is relatively stable and therefore 
abnormal results obtained via the CAT thrombin generation assay can be interpreted 
with a degree of confidence. This result also suggests that the CAT assay is suitable for 
use in the monitoring of patients undergoing treatment. 
 
Although the results in this experiment are suggestive of minimal variance in thrombin 
generation capacity over time, this experiment was only carried out over the course of 
four weeks. It would be beneficial to perform this experiment over a longer time course 
in order to more accurately determine the variability of an individual’s thrombin 
generation capacity. It would also be of interest to study the degree of variance in 
thrombin generation over several years in order to ascertain the effects of aging on 
thrombin generation although such an experiment is outside the scope of this study. It 
may be noted that although the variance observed in this experiment was low and 
therefore suggestive of the fact that the assay should be sensitive to the diagnosis of 
congenital conditions, the individuals measured in this study were all healthy. One 
would expect the thrombin generation profile of an individual, with an acquired 
condition (acquired haemophilia or DIC for example), to show marked variation from 
their resting thrombin generation profile. Variation in patients results over and above 
that which is seen in normal inter assay variation may therefore be consistent with a 
pathological change in the patient.  
 
The experiments to define a normal range for the thrombin generation assay provided 
good results, with no statistically significant differences between any of the groups 
analysed, suggesting that neither age nor sex have any effect on the thrombin generation 
of an individual. The fact that no significant differences were found meant that a single 
normal range could be calculated for use in all patients. This was a desirable result since 
it simplifies assay interpretation, and therefore makes routine use of the thrombin 
generation assay easier. The fact that all of the available data could be pooled to 
establish the normal range also means that any other potential confounding factors are 
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likely to have a smaller impact. The greater the level of subdivision of the available data 
the greater the impact that anomalous results can have on the normal range. Although 
every effort has been made to choose individuals who should have ‘normal’ levels of 
thrombin generation it is impossible to exclude patients who have underlying but 
currently asymptomatic clotting disorders. The impact that such an individual has on the 
overall normal range is reduced if the total number of patients in the cohort is larger. 
 
There were no statistically significant differences between any of the groups for either 
age or sex however some of the p values displayed in tables 2.30 to 2.37 were 
approaching significance. In particular the comparison between the lag times of the 20-
29 year old women and the 50-59 year old women (p= 0.06) and to a lesser extent the 
comparison of the time to peak parameter between the same cohorts (p= 0.14). The 
mean lag time and time to peak of the 50-59 year old women was elevated in 
comparison to the mean times of the 20-29 year old women. Although the magnitude of 
these differences were not statistically significant it is  suggestive of an increase in lag 
time and time to peak parameters with age in female patients. Interestingly the age of 
the cohorts would imply that any potential trend may be due to changes in hormonal 
expression associated with the menopause. If this were to be the case it would imply 
that post menopausal women exhibit changes in hormonal expression which directly 
impact upon their levels of thrombin generation. It is possible that if cohorts of 60-69 
year olds were compared with 20-29 year old women there would be a significant 
difference between them. Alternatively it may be that the sample size of the groups in 
this study were too small to adequately detect the differences between the two cohorts. 
It is also possible that due to the relatively small sample size of the cohorts the 
statistical analysis is suggestive of a difference between the two groups when in fact 
there is no difference between them. It is clear that further analysis is required to 
ascertain whether or not there is a difference between the two cohorts or indeed between 
older cohorts of women. 
 
The normal range defined in this study is not without limitations however, since 
technically it is only valid for patients between the ages of 20-60. Although the analyses 
revealed no variation in the thrombin generation parameters with age it is potentially 
unsafe to assume that this is the case for patients outside the age range analysed. This is 
especially true with paediatric patients who are known to have reduced levels of clotting 
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factors and therefore potentially reduced levels of thrombin generation. The use of the 
assay is therefore limited to adult patients and any analysis performed on paediatric 
patients must be interpreted with caution. It would have been desirable to include 
patients over the age of 60 in the normal range but finding appropriate patients was 
difficult since very few individuals who work in the laboratory are above 60 years of 
age and the number of patients available without medical conditions which might affect 
the results was also very small. It was therefore decided to exclude any patients above 
60 from the normal range experiments. 
 
The addition of CTI to samples prior to analysis by the CAT thrombin generation assay 
showed a statistically significant decrease in the peak height compared to samples 
without the addition of CTI. This conflicts with a report in the literature which states 
that the use of CTI is not required when a 5pM tissue factor reaction trigger  is used to 
initiate thrombin generation (van Veen et al., 2008). There was no statistically 
significant difference in any of the other thrombin generation parameters analysed 
following the addition of CTI. A potential explanation for this result could be the 
concentration of tissue factor in the PPP reagent manufactured by Diagnostica Stago. 
No attempt was made in this study to verify the manufacturers claim that the reagent 
contained 5pM tissue factor (or indeed 4µM phospholipid). Variations in the 
concentration of tissue factor (specifically reductions) in the PPP reagent could, 
potentially, make the assay more sensitive to contact activation. Whether this was the 
case is unknown. There is evidence to the contrary. The manufacturer’s data was used 
(ie concentration of tissue factor, phospholipid and composition of phospholipids in the 
PPP reagent) in all studies. If there were fluctuations in the concentration of the PPP 
reagent this would have resulted in fluctuations of the results across the course of this 
study. This means that samples taken from the same individuals that were analysed in 
several different experiments using different batches of PPP reagent would show 
discordant results. The same would be true of the experiments using Control Plasma P. 
This was not the case.  It may be concluded that the composition of the PPP reagent did 
not have significant batch to batch variation. 
 
The change in peak height following the addition of CTI was small, with an average 
decrease of ~6%, which was within the 10% cut off as previously discussed. Indeed, the 
difference is similar to the average intra assay variation for peak height attained 
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following the analysis of a pool of fresh human plasma, which was 3% (table 2.13).  
The decrease in peak height may also be due to a dilution effect of the blood samples to 
which CTI was added, since the volume of liquid in the vacutainer was increased from 
500µl to 577µl. This equated to a decrease of ~1.5%, so that the actual average decrease 
was ~4.5% (6-1.5). The change in peak height following the addition of CTI is not 
likely to be of clinical significance in the demographic of patients analysed in this study 
(patients with elevated thrombin generation), because a small variation in a sample with 
an elevated peak height would have a minimal impact on the result generated compared 
to the same change seen in a patient with a relatively low peak height. A final 
consideration is the cost implication to the study. If CTI was used at the concentration 
specified above the cost of the assay would rise from ~£3 to ~£13 per sample. An 
increase of 433%.  In conclusion, it was decided to forgo the addition of CTI in this 
study as it would not increase the clinical utility of the experiments performed but 
would substantially increase the cost. 
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3.1 Introduction 
 
With the completion of the validation experiments covered in chapter 2, it was decided 
that the CAT thrombin generation assay was suitable for routine diagnostic use in the 
haemostasis laboratory. The first group that was analysed by the new technique was a 
cohort of pregnant women with and without pre-eclampsia. 
 
3.1.1 Thrombophilia and Pregnancy 
 
Pregnancy itself is associated with marked changes in haemostasis that lead to a 
prothrombotic state in the mother. These changes include elevated levels of factor VII, 
factor VIII, von Willebrand factor and fibrinogen, combined with decreased levels of 
natural anticoagulants such as free Protein S and an increased incidence of resistance to 
activated protein C (Stirling et al., 1984), (Clark et al., 1998). These changes are 
thought to have arisen at an evolutionary level in order to provide potential protection 
again post partum haemorrhage and thereby confer a selective advantage. These natural 
physiological changes may be aggravated by either acquired or inherited thrombophilia 
however, giving rise to a number of serious obstetric complications such as recurrent 
pregnancy loss, intrauterine growth retardation (IUGR), placental abruption, pre-
eclampsia and recurrent thromboembolism (Pabinger 2009).  
 
Evidence linking recurrent pregnancy loss, as defined as three consecutive pregnancy 
losses before the 20
th
 week of gestation, and inherited thrombophilia is often conflicting 
although some meta-analyses have shown a correlation; most notably Rey et al. (2003) 
who showed factor V Leiden, APC resistance, Prothrombin variant and free protein S 
deficiency were all associated with early recurrent pregnancy loss with odds ratios 
ranging from 2.01 to 14.72. The meta analysis demonstrated no correlation between 
Antithrombin and protein C deficiencies as well as the Methlylenetetrahydrofolate 
reductase (MTHFR) enzyme mutation and recurrent foetal loss. The evidence linking 
acquired thrombophilia and foetal loss is more striking with an estimated 7-25% of all 
recurrent spontaneous abortions having antiphospholipid syndrome (APS) as the main 
risk factor (Vinatier et al., 2001).  
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The association between thrombophilia and pre-eclampsia is also not clearly defined 
with a number of studies providing conflicting evidence. A meta-analysis by Kosmas et 
al. (2003) examined the incidence of the factor V Leiden allele in women with 
pregnancy related hypertension and a cohort of normotensive controls and found an 
odds ratio of 2.3 (95% CI: 1.5-3.4). Interestingly not all of the studies examined in the 
analysis demonstrated an association between factor V Leiden and hypertension. A 
further meta-analysis by the same authors (Kosmas et al., 2004) showed a weak 
correlation between the MTHFR gene mutation and pre-eclampsia but other studies 
have shown no link between hyperhomocysteinemia and pre-eclampsia (Pabinger 
2009).  
 
Some studies such as that by van Pampus et al. (1999) have shown a striking 
relationship between pre-eclampsia and thrombophilia, with 40% of a cohort of women 
with severe pre-eclampsia having a diagnosed thrombophilia, approximately four times 
the incidence compared to a cohort of normotensive pregnant women. Although this 
study included a broader range of tests including APC resistance, 
hyperhomocysteinemia, anticardiolipin antibodies as well as a genetic test for factor V 
Leiden. The incidence of thrombophilic conditions also showed an increase of between 
1.5-2 times more in the women who delivered before 28 weeks gestation when 
compared to those who delivered after 28 weeks gestation.  
 
The apparent conflicting evidence in the literature linking thrombophilia with pregnancy 
loss and pre-eclampsia may be partially explained by the focused nature of some of the 
studies. Most papers focus on a single test for thrombophilia whereas there are several 
known causes and therefore multiple assays to be performed to get an accurate idea of 
any association. It is no surprise therefore that the study by Pampus et al. (1999) 
showed the greatest level of correlation since their diagnosis of thrombophilia was the 
most broad i.e. they performed the highest number of analyses. However as discussed in 
section 1.5 a large number of patients who come to the Royal London Hospital for 
thrombophilia screening have normal results for the tests performed. This does not 
mean that they do not have an inherited thrombophilia however, but merely confirms 
that they do not have one of the conditions for which they were screened. The use of a 
global method such as the CAT thrombin generation assay may therefore be a powerful 
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tool in detecting the true association between any prothrombotic conditions and 
pregnancy loss/pre-eclampsia.  
 
3.1.2 Pre-eclampsia  
 
Pre-eclampsia is a complication of pregnancy, which is characterised as proteinuria (the 
presence of protein in urine) and new-onset gestational hypertension. It is important to 
distinguish between pre-eclampsia and other hypertensive disorders of pregnancy since 
pre-eclampsia carries the greatest risk to both mother and foetus. The hypertensive 
disorders of pregnancy include hypertension which pre-dates pregnancy (either acute or 
chronic) and transient gestational hypertension. Women who have chronic hypertension 
who develop proteinuria during pregnancy are said to have chronic hypertension with 
superimposed pre-eclampsia. (Roberts et al., 2005). Pre-eclampsia is a disorder which 
has a large impact on both mother and foetus and is one of the major causes of 
maternal/foetal morbidity and mortality worldwide. Hypertensive diseases of pregnancy 
were the second leading cause of direct maternal death in the UK in 2001 and 
hypertension and/or proteinuria are associated with 20% of all still births, of which 7% 
are directly caused by Pre-eclampsia (PRECOG 2004).  
 
Once diagnosed pre-eclampsia can only be cured by delivery, in the developed world 
where antenatal care is readily available this is the most frequent intervention, indeed it 
is estimated that 15% of all preterm births are due to delivery of women in order to halt 
the progression of pre-eclampsia to eclampsia (convulsions often followed by the onset 
of coma) which can be fatal. In the third world where antenatal care is less prevalent 
progression of pre-eclampsia accounts for approximately 50000 deaths per year (Duley 
1992).  
 
Although the diagnosis of pre-eclampsia is primarily based around the development of 
proteinuria and gestational hypertension, the condition itself is far more wide ranging 
causing multiple systemic changes in patients. These include endothelial dysfunction, 
activation of the clotting cascade, an increased inflammatory response, vasoconstriction 
and numerous changes to metabolic pathways (Roberts et al., 2005). Models detailing 
the natural history of pre-eclampsia commonly describe a two stage process, the first 
stage of which is reduced placental perfusion (reduction of blood flow in the placenta). 
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This then leads to the second stage which is multisystemic pre-eclampsia in the mother. 
It is important to note that although there is a myriad of evidence for such a model, 
much still remains to be discovered. For example although it is clear that reduced 
placental perfusion is prevalent in women with pre-eclampsia it is by no means certain 
that reduced perfusion will lead to the development of the condition itself. The 
molecular mechanism of the progression from stage one to stage two also remains to be 
elucidated, although this is discussed in more depth below. 
 
3.1.3 Stage 1: Reduced Placental Perfusion 
 
The first links between pre-eclampsia and reduced placental perfusion were based on 
clinical findings and epidemiological evidence which linked pre-eclampsia to disorders 
where the placenta was enlarged. Such conditions include molar pregnancies (a tumour 
arising from the abnormal development of the embryo) and multiple pregnancies where 
it was postulated that the enlarged placenta could not be adequately perfused given its 
size. Striking evidence for reduced placental perfusion in pre-eclampsia was provided 
by Starzyk et al. (1999) who demonstrated that the uterine spiral arteries of women with 
pre-eclampsia either failed to undergo the vascular remodelling process which is 
characteristic of normal pregnancy or the vascular remodelling was only partially 
complete. The uterine spiral arteries would normally be remodelled in order to offer less 
resistance to blood flow to the placenta. This remodelling typically includes an increase 
of vessel diameter, the loss of smooth muscle surrounding the vessel, as well as a loss of 
the internal elastic lamina. Importantly the loss of the internal lamina and therefore the 
loss of many endothelial receptors renders the vessels immune to vasoactive stimuli. 
These observations are confirmed by Doppler velocimetry of uterine vessels in women 
with pre-eclampsia which show increased resistance to blood flow in those vessels 
which supply the intravillous space. Interestingly this increased resistance can also be 
detected in women early in gestation who subsequently go on to develop pre-eclampsia 
(Papageorghiou et al., 2002). 
 
In normal pregnancy embryo implantation is mediated via the eroding of the uterine 
surface endothelium by embryonic trophoblastic cells. Trophoblasts can either retain 
their cellularity (cytotrophoblasts) or fuse with other trophoblasts to form 
syncytiotrophoblasts. The cytotrophoblasts proliferate and are responsible for invasion 
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into the maternal decidual tissue. The decidual tissue into which the embryo invades is 
effectively ‘digested’ to form a yolk reservoir.  Remodelling of the uterine spiral arteries 
is thought to be a result of trophoblast invasion; this invasion is mediated by both 
changes in the local oxygen concentration and via various immune mechanisms. The 
oxygen tension of the intervillous space remains relatively low for the first 12 weeks of 
pregnancy, following this time perfusion of the intervillous space begins to increase and 
as a result the oxygen tension rises. This conversion from anaerobic to aerobic 
metabolism is accompanied by a dramatic rise in the formation of reactive oxygen 
species such as free radicals. Such free radicals can rapidly cause indiscriminate damage 
to cellular proteins, lipids and DNA. This cellular damage is limited by various 
antioxidant defences. Syncytiotrophoblasts are particularly vulnerable to free radical 
damage since they exist adjacent to the intervillous space and therefore undergo the 
conversion to aerobic metabolism early but also because they have reduced levels of 
antioxidant enzymes when compared to other villous tissues early in pregnancy 
(Jauniaux et al., 2000). It is hypothesised that this burst of oxidative stress is required 
for normal placental development, such as the initiation of a variety of differentiation 
pathways. This potentially includes the conversion of cytotrophoblasts from a 
proliferative phenotype to an invasive phenotype. Endovascular invasion of the 
cytotrophoblasts leads to invasion of the endometrial arteries and therefore allows 
adequate perfusion of the intervillous space and subsequently adequate placental 
exchange. 
 
A potential cause of pre-eclampsia could therefore be a disruption of the normal 
interaction between the maternal and foetal antioxidants leading to inefficient 
endovascular invasion of cytotrophoblasts and therefore a failure of the uterine spiral 
arteries to undergo vascular remodelling. A second school of thought is associated with 
increased damage to the syncytiotrophoblast layer due to inadequate antioxidant 
defences leading to apoptosis in these cells. Syncytiotrophoblast fragments can then 
pass directly into the maternal circulation and can lead to the activation of peripheral 
maternal endothelial cells and hence the second stage of pre-eclampsia (Hung et al., 
2002). 
 
Invasion by cytotrophoblasts into the uterine decidual tissue is also mediated via 
immune interactions. The most important of which is thought to be between the MCH 
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class I molecule HLA-C present on the cytotrophoblasts and the killer inhibitory 
receptors (KIR) found on uterine natural killer cells. Uterine natural killer cells are 
thought to be functionally and phenotypically distinct from the natural killer cells found 
in peripheral blood. Once activated they release cytokines and chemokines which are 
thought to play a role in remodelling the uterine spiral arteries (Hiby et al., 2004). It was 
hypothesised by the authors that certain combinations of KIR and HLA-C result in an 
increased risk of pre-eclampsia. Specifically the combinations responsible were uterine 
killer cells with KIR AA haplotypes (which lack functional activator receptors but have 
functional inhibitory receptors) and trophoblasts displaying HLA-C2. It is thought that 
this combination leads to increased suppression of uterine killer cell activity and 
ultimately a suppression of cytotrophoblast invasion and vascular remodelling. 
 
3.1.4 Stage 2: The Maternal Syndrome 
 
Although pre-eclampsia is thought to arise from reduced placental perfusion, reduced 
perfusion is by no means limited to the uterus in women with the systemic condition. 
Indeed evidence of decreased perfusion is present in virtually all organs in a woman 
with pre-eclampsia. The reduced perfusion is thought in part to be due to increased 
vasoconstriction caused by an increased sensitivity of vascular endothelial cells to 
vasopressors (Roberts et al., 2002). Reduced perfusion can ultimately lead to both 
infarction and necrosis of affected tissues. Reduction in blood flow can further reduce 
the level of placental perfusion leading to an exacerbation of the condition via a positive 
feedback mechanism, which can only be cured by delivery. Systemic vasoconstriction is 
accompanied in women with pre-eclampsia by an activation of the clotting cascade and 
subsequently the formation of occlusive microthrombi (with can lead to further 
infarction) as well as a decrease in the volume of fluid in the intravascular space. Since 
endothelial function is linked with all the pathological changes described above it is no 
surprise that studying endothelial changes has become a central focus of research into 
pre-eclampsia. This research has yielded a great deal of results showing increased levels 
of circulating markers of endothelial activation such as von Willebrand factor, cellular 
fibronectin, thrombomodulin and endothelin as well as an increased level of 
thromboxane released from platelets in the blood of women with pre-eclampsia 
(Roberts et al., 2002). It has also been shown that many of these endothelial markers are 
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elevated before the clinical symptoms are manifest which implies a causal role for these 
markers in disease development (Roberts et al., 2005).  
 
Many of the above markers of endothelial activation are associated with haemostasis; it 
is thought that elevated levels of thrombomodulin, tissue factor activity and circulating 
procoagulant phospholipids may reflect the level of vascular endothelial damage in 
patients with pre-eclampsia. These parameters were all significantly elevated in women 
with pre-eclampsia compared to normotensive pregnant women and non-pregnant 
women (Rousseau et al., 2009). Elevated levels of von Willebrand factor, fibrinogen, D-
dimer and thrombomodulin were also reported in the circulation of women with severe 
pre-eclampsia by Heilmann et al. (2007), who also reported a decreased platelet count 
in the same cohort. These findings are consistent with activated coagulation in women 
with pre-eclampsia. Further evidence of the activation of the haemostatic system was 
provided by Peracoli et al. (2008) who reported reduced platelet function and reduced 
numbers of platelets in conjunction with increased levels of transforming growth factor 
β (TGF-β) in the circulation of women with pre-eclampsia. These findings were 
consistent with platelet activation in vivo since the reduced number of platelets was 
likely to be caused by consumption and the reduced function was likely to be the result 
of partial granule release in the platelets which remained. The high circulating levels of 
TGF-β were also consistent with platelet granule release since TGF-β is stored in the 
alpha granules of platelets. These studies provide compelling evidence for a significant 
shift towards a prothrombotic state in women with pre-eclampsia. 
 
There is also evidence to implicate other metabolic changes with having a role in the 
genesis of pre-eclampsia. These include elevated levels of uric acid, triglycerides, free 
fatty acids and LDL cholesterol, insulin resistance and reduced levels of HDL 
cholesterol. Interestingly elevated levels of uric acid have been shown to be evident 
early in pregnancy in women who develop pre-eclampsia. Elevated levels of uric acid 
have also been shown to cause increased blood pressure in a rat model. Subsequent 
reduction in uric acid levels in the rat model alleviated the hypertension (Mazzali et al., 
2001). Despite this evidence the mechanism for a causal role in pre-eclampsia remains 
to be elucidated. 
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3.1.5 What Links Stage 1 and Stage 2? 
 
The link between the initial reduction of placental perfusion and the subsequent 
systemic condition of pre-eclampsia is not clear cut. In an ideal scenario the reduced 
perfusion would lead to the production of a unique substance by the placenta which 
would enter the maternal circulation and trigger the maternal condition, in reality the 
link is much more subtle. Increased apoptosis of syncytiotrophoblasts due to oxidative 
stress as described above can lead to an increased level of microvillus particles in the 
blood of women with pre-eclampsia. It is hypothesised that these fragments can interact 
with and activate circulating inflammatory cells or even directly activate the vascular 
endothelium leading to the maternal condition (Redman and Sargent, 2000). Although 
this theory fits neatly with the ideal scenario outlined above it is not the only suggested 
hypothesis. 
 
3.1.5.1 Angiogenic Factors and Pre-eclampsia 
 
A large body of evidence links the levels of a number of angiogenic factors to the 
pathogenesis of pre-eclampsia. Specifically patients with pre-eclampsia demonstrate an 
imbalance of circulating angiogenic factors, with reduced levels of the pro-angiogenic 
factors placenta-derived growth factor (PLGR) and vascular endothelial growth factor 
(VEGF) and elevated levels of the anti-angiogenic factors soluble Fms like tyrosine 
kinase 1 (sFlt1) and soluble endoglin (sEng). This imbalance in angiogenic factors 
which results in a primarily anti-angiogenic phenotype is thought to trigger vascular 
endothelial cell injury in multiple organs including the placenta, liver, kidney and brain. 
This systemic vascular injury then results in the systemic maternal syndrome (Steinberg 
et al., 2009). sFlt1 is a splice variant of Flt-1 which lacks both the transmembrane and 
cytoplasmic domain of the Flt-1 protein. Flt-1 is the receptor for VEGF and ordinarily 
the binding of VEGF to Flt-1 would result in activation of intracellular signalling 
pathways yielding a pro-angiogenic response. sFlt1 is an antagonist of both VEGF and 
PLGF and acts by binding to these proteins in the circulation. Once sequestered by sFlt1 
VEGF and PLGF cannot bind to Flt-1 and therefore their pro-angiogenic action is 
inhibited. sFlt1 is synthesised in elevated amounts in the placentas of women with pre-
eclampsia where it is subsequently exported into maternal circulation. The levels of 
sFlt1 have been reported to be elevated in pregnant women who subsequently develop 
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pre-eclampsia compared with those who remain normotensive (Levine et al., 2004) and 
have also been shown to correlate with the severity of the condition where patients with 
severe pre-eclampsia had statistically higher levels of sFlt1 than those patients who had 
mild pre-eclampsia (Chaiworapongsa et al., 2004). Although this evidence suggests that 
sFlt1 is increased in pre-eclampsia it is not evidence that this increase can lead to the 
condition itself. Evidence is however provided in rat models, where pregnant rats given 
exogenous sFlt1 developed hypertension, proteinuria and other symptoms found in pre-
eclampsia in humans (Maynard et al., 2003). Similar findings have also been reported in 
non pregnant mice treated with antibodies against VEGF (Sugimoto et al., 2003) as well 
as in oncology patients treated with VEGF antagonists (Patel et al., 2008). 
 
Multiple isoforms of the sFlt1 protein have been reported. One of these isoforms has a 
unique C-terminus structure when compared to sFlt 1 and is referred to as sFlt1-14 (by 
virtue of the fact it is composed of the first 14 N-terminal exons of the Flt 1 receptor 
rather than the first 13 like sFlt 1). This difference in structure between sFlt 1 and sFlt1-
14 is due to the utilisation of a previously unknown slice acceptor site present in intron 
14 to produce the extended sFlt1-14 mRNA.  Despite the differences in structure sFlt1-
14 still functions as a potent inhibitor of VEGF and the authors propose its function is to 
protect vascular smooth muscle cells (where it is primarily expressed) from the pro-
angiogenic signals of VEGF (Sela et al., 2008). Interestingly the authors also proposed 
a role for sFlt1-14 in the development of pre-eclampsia, they suggest that the increased 
expression of soluble VEGF receptors seen in pregnancy is entirely due to increased 
expression of sFlt1-14 after the first trimester and that expression of sFlt1-14 is 
increased in women with pre-eclampsia. It was demonstrated that sFlt1-14 is the 
primary isoform produced by the placenta in women with pre-eclampsia and that the 
majority of this expression was found in the syncytial knots of the placenta. Synctial 
knots are localized aggregations of syncytiotrophoblastic nuclei in the villi of the 
placenta, these structures are thought to be induced by placental hypoxia and are a 
histological hallmark of pre-eclampsia. More anecdotal evidence linking sFlt1-14 to 
pre-eclampsia comes from the fact that the C-terminus structure of sFlt1 which is 
replaced in sFlt1-14 is conserved on an evolutionary level and the sFlt1-14 isoform is 
only found in humans and primates which are also the only species to exhibit pre-
eclampsia. 
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The fact that sFlt1-14 expression is primarily found in syncytial knots which themselves 
are produced in response to hypoxia provides further evidence linking reduced oxygen 
tension and pre-eclampsia. This is given further weight by the fact that VEGF and Flt1 
(and by extension sFlt 1) gene expression are controlled by the transcription factor 
hypoxia-inducible factor 1α (HIF-1α) (Gerber et al., 1997) and that HIF-1α levels are 
significantly elevated in the placentas of women with pre-eclampsia (Rajakumar et al., 
2003). 
 
Despite the compelling evidence for the involvement of sFlt 1 in pre-eclampsia it has 
been observed that animals treated with sFlt 1 in order to provoke pre-eclampsia do not 
develop symptoms associated with complications of severe pre-eclampsia such as the 
HELLP syndrome (Haemolysis, elevated liver enzymes and low platelets). It was 
therefore hypothesised that other soluble placenta derived factors may act in synergy 
with sFlt 1 to cause sufficient endothelial dysfunction and result in severe pre-
eclampsia. It was hypothesised by Venkatesha et al. (2006) that sEng, a truncated form 
of the cell surface co-receptor for TGF-β, was responsible. Endoglin (CD105) is a co 
receptor for TGF-β. Binding of TGF-β to Endoglin results in intracellular signalling 
which influences the activity of endothelial nitric oxide synthase (eNOS). Endothelium-
derived nitric oxide (NO) is a potent vasorelaxant that contributes to the regulation of 
systemic blood pressure, vascular permeability and angiogenesis. sEng can sequester 
TGF-β in a similar way to the interaction of sFlt 1 and VEGF resulting in an 
amelioration of the vasorelaxant effect of TGF-β. Expression of sEng was shown to be 
increased four-fold in the placentas of women with pre-eclampsia compared to 
normotensive pregnant women. sEng was also shown to inhibit capillary tube formation 
in vitro and induce vascular permeability and hypertension in vivo. In rat models co-
administration of both sFlt 1 and sEng exacerbated the effects seen with sEng alone and 
led to severe pre-eclamptic like symptoms including the HELLP syndrome and 
restricted foetal growth (Venkatesha et al., 2006). 
 
Despite all the evidence linking an over-expression of sFlt 1 with pre-eclampsia, there 
still remains a sub set of pre-eclampsia cases including some women with severe pre-
eclampsia where the patients demonstrate low levels of sFlt 1 and high levels of PLGF 
(Levine et al., 2004). Anti angiogenic action of a different mechanism cannot be 
excluded however. In studies of pregnant rats treated with the angiogenesis inhibitor 
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Suramin (which can bind to basic fibroblast growth factor, platelet derived growth 
factor, VEGF receptor 2 and fibroblast growth factor receptors) the animals displayed 
symptoms of pre-eclampsia including a failure of vascular remodelling, but the serum 
levels of sFlt are known to decrease in Suramin treated rats (Jankowski 2009). It is 
possible in this study that the Suramin used initiated the pre-eclamptic symptoms via 
inhibition of the synthesis or release of vasodilators such as nitric oxide, in a similar 
way to the over-expression of sEng. This potentially highlights a role for the over-
expression of sEng as causative of pre-eclampsia in those women with low levels of 
circulating sFlt 1. 
 
3.1.5.2 The Renin-Angiotensin System and Pre-eclampsia 
 
Other biological systems have also been implicated in the natural history of pre-
eclampsia. One of these is the renin-angiotensin system, which is a signalling cascade 
responsible for the regulation of blood pressure and the balance of electrolytes. The 
renin-angiotensin system is regulated by proteins made in multiple organs around the 
body but is primarily controlled by the production of the enzyme renin which is 
synthesised by the juxtaglomerular cells of the kidney. Renin release is stimulated by 
either a decrease in blood pressure or low circulating levels of sodium chloride. The 
primary function of renin is to cleave the functionally inactive protein angiotensinogen, 
which is produced in the liver, to produce angiotensin-I. Angiotesin-I is still 
biologically inactive however and requires further enzymatic cleavage by angiotensin 
converting enzyme (ACE), which is primarily synthesised in the lung endothelium, in 
order to produce the functionally active angiotensin-II. This conversion is mediated via 
proteolytic cleavage to convert angiotensin-I from a 10 amino acid protein to the 8 
amino acid protein angiotensin-II (Irani and Xia 2008).  
 
There are two primary receptors for angiotensin-II these are AT1 and AT2. The two 
receptors share 34% sequence homology and have similar affinities for the binding of 
angiotensin-II. The biological effects that the differential binding mediates are markedly 
different however. Activation of AT1 results in the activation of signalling pathways 
which lead to elevated levels of intracellular calcium, which ultimately leads to 
vasoconstriction, sympathetic activity and aldosterone release (aldosterone increases the 
reabsorption of sodium and water and the release of potassium in the kidneys 
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subsequently increasing blood volume and pressure). Activation of AT2 results in an 
inhibition of cell growth, an increase in the level of apoptosis and causes vasodilation. 
The AT1 receptor is primarily expressed on the surface of vascular smooth muscle cells 
and the adrenal glands where as the AT2 receptor is highly expressed in the foetal 
kidney and its expression decreases after birth. AT1 receptor expression is more 
prevalent in the adult kidney than the AT2 receptor (Irani and Xia 2008). 
 
The renin angiotensin system which is classically described in the kidneys has been 
increasingly shown to be present in other tissues; most notably components of the renin 
angiotensin system including angiotensinogen, renin, ACE and the AT1 receptor have 
been described in both the foetal placental tissues (Irani and Xia 2008) and the maternal 
decidua (Morgan et al., 1998). As these findings would suggest, the regulation of the 
renin-angiotensin system is altered in normal pregnancy. The primary changes are 
increased levels of renin, angiotensin-I and angiotensin-II (and therefore increased 
levels of aldosterone) and decreased levels of ACE (Langer et al., 1998). Intuitively 
these changes would facilitate an increase in blood pressure in pregnant women; this 
potential effect is however repressed by a decrease in sensitivity of pregnant women to 
angiotensin-II (Gant et al., 1980). Since the maternal sensitivity to angiotensin-II is 
decreased it is thought that the ‘intended target’ of the increased levels of angiotensin-II 
is foetal tissue and that of the placenta. This theory is given weight by the fact that 
trophoblastic cells are rich in AT1 receptors. It is thought that the renin-angiotensin 
system is responsible for the regulation of foetal-placental circulation and ultimately 
ensuring there is adequate blood blow for both nutrient supply and oxygen exchange 
(Irani and Xia 2008). 
 
Interestingly the changes observed in the renin-angiotensin system during normal 
pregnancy are subverted in patients with pre-eclampsia to give a new phenotype. The 
circulating maternal levels of renin, angiotensin-I, angiotensin-II and aldosterone in a 
patient with pre-eclampsia are all significantly lower than those of a normotensive 
pregnant woman, although they are all increased when compared to a non pregnant 
woman. The levels of ACE in the circulation of women with pre-eclampsia can be 
equivalent to a non pregnant woman and therefore can be elevated when compared to a 
normotensive pregnant woman (Langer et al., 1998). The most striking difference 
however is that pre-eclampsia patients typically do not demonstrate the reduced 
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sensitivity to angiotensin-II that is the norm in pregnancy. This reduction in sensitivity 
is thought to be due to the structure of the AT1 receptors in the two groups. In 
normotensive pregnant women the AT1 receptors are primarily monomers. These 
receptors are sensitive to inactivation by reactive oxygen species. In patients with pre-
eclampsia however the AT1 receptor is often present in a heterodimer with the 
bradykinin receptor, these heterodimers show increased resistance to deactivation by 
reactive oxygen species (AbdAlla et al., 2001) and therefore predispose women with 
pre-eclampsia to increased blood pressure when compared to normotensive pregnant 
women and especially when compared to non pregnant women since they have elevated 
levels of angiotensin-II. Another possible route to subvert the normal pregnancy related 
insensitivity to angiotensin II is thought to be associated with the expression of 
haemopexin.  Plasma haemopexin activity is increased in normal pregnancy in contrast 
to pre-eclampsia and increased haemopexin activity has been shown to down-regulate 
expression of the AT1 receptor (Bakker et al., 2009).  Therefore decreased haemopexin 
activity in pre-eclamptic patients leads to increased levels of AT1 receptor expression 
when compared to normotensive pregnant women and ultimately an increase in blood 
pressure. 
 
The elevated sensitivity of pre-eclamptic women to angiotensin-II when compared to 
normotensive women is further exacerbated by the fact that the expression of the AT1 
receptor itself is upregulated in the maternal decidua of women with pre-eclampsia 
(Herse et al., 2007). In addition to this the placentas of women with pre-eclampsia 
demonstrate increased levels of chymase when compared with the placentas of 
normotensive pregnant women (Wang et al., 2007). Chymase is a serine protease 
enzyme released by mast and smooth muscle cells which is capable of producing 
angiotensin-II in a similar way to ACE. Transgenic mice engineered to over express 
human chymase have been shown to demonstrate several symptoms of pre-eclampsia 
including hypertension and vasoconstriction (Ju et al., 2001).  
 
Despite the changes in the renin-angiotensin system seen in pre-eclampsia described 
above, one of the most profound findings was the discovery that women with pre-
eclampsia produced an agonistic AT1 receptor autoantibody. This antibody has been 
shown to bind to a seven amino acid sequence present on the extracellular loop of the 
AT1 receptor and ultimately cause the activation of the associated cell signalling 
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pathways resulting in vasoconstriction and elevated blood pressure (Wallukat et al., 
1999). Interestingly one of the regulatory genes controlled by the AT1 receptor is that of 
sFlt1. The production of a AT1 receptor activating autoantibody coupled with a loss of 
sensitivity of the receptor to deactivation via reactive oxygen species would therefore 
provide a secondary mechanism for the over expression of sFlt1. This is significant as it 
indicates that hypoxia and hence activation of the transcription factor HIF-1α is not the 
only route to high circulating levels of sFlt1. Indeed it is possible that over expression 
of sFlt1 via the production of an agonistic AT1 receptor autoantibody or in combination 
with hypoxia in the placenta could lead to a positive feedback loop where increased 
levels of sFlt1 lead to decreased angiogenesis and therefore increase the severity of the 
hypoxia. This pattern is indicative of pre-eclampsia progression where the symptoms 
only show an increase in severity until such time as the foetus is delivered. 
 
Aside from its role in enhancing the expression of sFlt1 the AT1 auto antibody found in 
the circulation of pregnant women with pre-eclampsia has been implicated in disease 
progression in a number of other ways. The first of these is the fact that the AT1 receptor 
autoantibody can lead to the production of free radicals and other reactive oxygen 
species in placental trophoblastic cells and smooth muscle cells. This reaction was 
mediated by activation of NADPH oxidase (Dechend et al., 2003). This finding 
provides a direct link with the experiments of Hung et al. (2002) discussed above, who 
hypothesised that a link between placental disease and the maternal pre-eclampsia 
syndrome may be caused by syncytiotrophoblast fragments passing into maternal 
circulation following excessive free radical damage. These fragments can then 
systemically activate the maternal endothelium. 
 
The AT1 autoantibody has also been shown to regulate the levels of plasminogen 
activating inhibitor 1 (PAI-1). PAI-1 has a role in the regulation of fibrinolysis (the 
breakdown of fibrin clots). It mediates this effect by the inactivation of urokinase-like 
plasminogen activator and tissue plasminogen activator. Urokinase-like/tissue 
plasminogen activators convert the zymogen plasminogen to the biologically active 
plasmin, which is directly involved in the breakdown of fibrin. Elevated levels of PAI-1 
therefore result in a decreased level of fibrinolysis. PAI-1 can also indirectly inhibit 
extracellular matrix degradation via matrix metalloproteinases. This impacts on pre-
eclampsia progression in two ways, the first of which is an impairment of trophoblast 
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invasion in the developing placenta. Effective fibrinolysis and extracellular matrix 
digestion is thought to be necessary in efficient trophoblast invasion. AT1 receptor 
activation via the AT1 receptor autoantibody has been shown to both increase PAI-1 
expression in trophoblasts and ultimately decrease trophoblastic invasion (Bobst et al., 
2005). This shows a potential role for the AT1 receptor autoantibody in the development 
of pre-eclampsia via decreased placental perfusion. Over expression of PAI-1 is also 
thought to contribute to some of the symptoms of the maternal condition, particularly 
those involving renal impairment. It is thought that an excess of fibrin deposits in the 
kidney could lead to increased tissue damage and that fibrin deposits in the glomeruli 
may decrease renal filtration rates and therefore contribute to proteinuria (Irani and Xia 
2008).  
 
Expression of the AT1 receptor autoantibody may also cause further disruption in the 
haemostatic pathways since activation of the AT1 receptor causes an over expression of 
tissue factor in both vascular smooth muscle cells (Dechend et al., 2000) and monocytes 
(Dorffel et al., 2003). Since tissue factor is a potent stimulator of coagulation these 
findings may explain the hypercoagulability seen in patients with pre-eclampsia. Indeed 
this prothrombotic state in patients with pre-eclampsia is only likely to be exacerbated 
by the dysregulation of the fibrinolytic system caused by the over expression of PAI-1. 
This imbalance of haemostasis is likely to result in the formation of systemic 
microthrombai and ultimately further organ damage. 
 
The above evidence shows that the AT1 receptor autoantibody can produce a wide 
variety of pathological effects. Evidence that the antibody alone can induce pre-
eclampsia is provided by animal models where Zhou et al. (2008) injected pregnant 
mice with the autoantibody obtained from pregnant women with pre-eclampsia. The 
mice subsequently demonstrated pre-eclamptic symptoms including hypertension, 
proteinuria and elevated levels of sFlt-1. Importantly the use of an antibody neutralising 
peptide ameliorated these effects proving the autoantibody played a part in disease 
development. The origin of the pre-eclamptic AT1 receptor agonistic antibody remains 
unclear however. The fact that the Antibody retains homology in terms of the 7 amino 
acid peptide to which it binds across patients with pre-eclampsia implies a common 
immunological origin (Irani and Xia 2008). Whether or not this ‘antigen’ is found in the 
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placenta due to vascular damage associated with reduced perfusion remains to be 
elucidated. 
 
3.1.5.3 Other Possible Links 
 
Numerous other molecules and biological systems have also been proposed as either 
being possible causes of or contributing factors to pre-eclampsia. The first of these is 
the expression of the tumour necrosis factor (TNF) gene variant 308A. This is a 
polymorphism of the wild type TNF gene where there is a G to A transition at position 
308. This results in a mutated promoter region which leads to elevated levels of 
transcription of the TNF gene. TNF is a pro-inflammatory cytokine which is thought to 
be involved with endothelial activation associated with systemic pre-eclampsia. The 
TNF 308A variant is therefore thought to contribute to disease progression via increased 
levels of TNF. Studies investigating the association were however conflicting. In a large 
meta analysis involving 1919 patients with pre-eclampsia and eclampsia the expression 
of TNF 308A was found to have a pooled relative risk of 1.02 (95% CI 0.86-1.20). This 
indicates that there was no correlation between the TNF 308A isoform and pre-
eclampsia (Bombell and McGuire 2008).  
 
Other studies have attempted to characterise genetic changes in pre-eclampsia using 
microRNA analysis. MicroRNAs are short (21-24 nucleotides in length) non-coding 
RNAs which function as negative regulators of gene expression via binding to specific 
mRNAs and therefore preventing translation. A study by Zhu et al. (2009) showed 
differential expression of 34 microRNAs in the placentas of women with pre-eclampsia 
when compared with a control group. They found 11 of the microRNAs were over-
expressed in the patient group and 24 were under-expressed. Although this study 
provides clear evidence for changes in gene expression in pre-eclampsia the targets for 
the differentially expressed microRNAs were not clearly defined. 
 
Immunological activation is also thought to play a part in the development of pre-
eclampsia and is also a possible route to explain the systemic maternal condition. 
Specifically the up regulation of CD40 and the CD40 ligand have been described in pre-
eclampsia (Alacacioglu et al., 2007), (Lukanov et al., 2009). CD40 is a member of the 
TNF receptor family and is primarily expressed on the surface of antigen presenting 
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cells such as macrophages. CD40 ligand was first described on T-cells and has since 
been found to be expressed on other leukocytes as well as platelets, smooth muscle 
cells, endothelial cells and epithelial cells. The binding of CD40 ligand to CD40 causes 
activation of macrophages and the release of pro-inflammatory cytokines as well as 
reactive oxygen species. Alacacioglu et al. (2007) reported a significant increase in the 
level of soluble CD40 ligand, thought to be released by activated platelets, in the blood 
of pre-eclamptic women when compared to healthy pregnant women. Lukanov et al. 
(2009) reported elevated surface expression of CD40 ligand on platelets and CD40 
expression on the surface of macrophages in women with pre-eclampsia when 
compared to normotensive pregnant women. The authors also reported increased 
platelet expression of P-selectin (CD62P), a cell adhesion molecule, in pre-eclamptic 
women. Elevated numbers of platelet derived microparticles expressing P-selectin were 
also reported in the blood of women with pre-eclampsia compared to that of healthy 
pregnant controls by Lok et al. (2007). Expression of P-selectin on the surface of 
platelets and the production of platelet microparticles are consistent with platelet 
activation in pre-eclampsia. Platelets expressing P-selectin can bind to neutrophils and 
monocytes via leukocyte P-selectin ligand-1 (PSGL-1). The resultant intracellular 
signalling causes leukocyte surface expression of tissue factor (Barnard et al., 2005). 
Tissue factor is a potent trigger of the coagulation cascade and may ultimately yield the 
production of thrombin, which itself is a potent agonist of platelet activation. It is 
possible therefore that platelet activation can lead to a positive feedback mechanism 
where P-selectin expression yields increased levels of tissue factor, and hence thrombin 
production, leading to further platelet activation. Increased platelet activation can lead 
to increased CD40 ligand production (both soluble and surface expressed) which could 
potentially sustain systemic leukocyte activation and ultimately the resultant pro-
inflammatory cytokine response. Although this mechanism fits with the gradual 
exacerbation of the maternal condition it is not known what the initial driving force may 
be. 
 
What is clear when considering the link between the two stages of pre-eclampsia is that 
there are many potential antecedents of the condition and there is conflicting evidence 
in the literature surrounding the subject. One possibility is that there are simply multiple 
ways of getting from reduced placental perfusion to the systemic maternal condition and 
that there is no one causal factor responsible for disease progression. There are a great 
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many molecular pathways reported as disrupted in the development of pre-eclampsia 
some of which can be subverted in numerous ways. For example when considering 
over-expression of sFlt-1, this can be caused via hypoxia or activation of the AT1 
receptor. Activation of the receptor itself can be caused by increased levels of 
angiotensin II coupled with impaired down-regulation of the receptor or via the 
expression of the AT1 receptor agonistic autoantibody. The anti-angiogenic response 
mediated by sFlt-1 may itself be unnecessary in disease development if sEng is 
sufficiently over-expressed. This hypothesis would provide reasons as to why there 
always appears to be a sub group of women with pre-eclampsia who develop the disease 
despite having normal levels of the protein under investigation. 
 
3.1.6 Predicting Pre-eclampsia 
 
Whatever the cause of the condition, predicting the onset of disease and the severity of 
the condition is of direct benefit to both the mother and foetus. Pre-eclampsia can be 
characterised as either mild or severe. Mild pre-eclampsia is most commonly classified 
as blood pressure exceeding 140/90 mmHg with proteinuria of 0.3-3g/24 h. Severe pre-
eclampsia has diagnostic criterion of blood pressure exceeding 160-170/100-110 
mmHg, heavy proteinuria of between 3-5g/24 h or the occurrence of symptoms such as 
headache or visual disturbance. It is of benefit to identify those women with the greatest 
risk (women with severe pre-eclampsia) so as they can be closely monitored and receive 
intervention when necessary, either in the form of premature delivery or the use of 
MgSO4. Interestingly since these interventions are associated with foetal and maternal 
morbidity respectively it is of benefit to identify women who are at low risk of 
developing complications (mild pre-eclampsia) and therefore avoid the use of 
potentially harmful interventions (von Dadelszen et al., 2009). 
 
Numerous studies have tried to either predict the onset of pre-eclampsia or classify the 
disease severity based on the measurement of biological markers. Decreased 24 hour 
urinary calcium and elevated proteinuria between 20-28 weeks gestation were shown to 
be risk factors for the development of pre-eclampsia in one study (Sirohiwal et al., 
2009). Although the study highlighted potential useful markers in the prediction of pre-
eclampsia, in an ideal scenario any potential biological predictors of pre-eclampsia 
would be able to detect the onset of disease early in pregnancy.  
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Measurement of the angiogenic factors sFlt-1 and PLGF was shown to predict the early 
onset of pre-eclampsia with a sensitivity of 83% and specificity of 95% (Stepan and 
Jank 2009). This predictive value was increased to a sensitivity of 100% and specificity 
of 93.3% if the measurement of sEng was also included. Although the predictive values 
of this screening test are impressive it is important to note that these values were 
obtained via the measurement of angiogenic factors in women who had already been 
defined as high risk second trimester pregnancies characterised by abnormal placental 
perfusion. It is unlikely that this measurement will be introduced as a routine screening 
test due to a prohibitive cost. 
 
Since the measurement of proteinuria is diagnostic in pre-eclampsia some effort has 
been made to determine whether the degree of proteinuria correlates with the severity of 
the disease. A meta analysis of 16 articles with a total cohort of 6749 women with pre-
eclampsia found proteinuria to be a poor predictor for either maternal or foetal 
complications in pre-eclamptic women (Thangaratinam et al., 2009) (Hofmeyr and 
Belfort 2009). 
 
It has been suggested that a high dietary intake of antioxidants such as vitamins C and E 
may prove protective against pre-eclampsia, although two trials investigating this 
hypothesis have shown no correlation between the incidence of pre-eclampsia and 
dietary intake of a combination of vitamins C and E (Poston et al., 2006) (Klemmensen 
et al., 2009). Interestingly the trial by Klemmensen et al. did report a statistically 
significant decreasing trend in the numbers of women with severe pre-eclampsia, 
eclampsia or HELLP syndrome with increased vitamin C intake. This suggests that 
antioxidants may be protective against disease progression even if they do not prevent 
the onset of pre-eclampsia itself. 
 
Many predictors of pre-eclampsia rely on epidemiological evidence as a means of 
ascertaining whether or not an individual is at risk of developing pre-eclampsia. 
Conditions which are known to increase the risk of pre-eclampsia include obesity (Sibai 
et al., 1995), hypertension and diabetes (Caritis et al., 1998), hyperhomocysteinemia 
(Powers et al., 2001) and being of Black ethnic origin (Eskenazi et al., 1991), although 
the latter is only a risk in first time pregnancies. There is also compelling evidence for a 
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hereditary predisposition to pre-eclampsia. Familial inheritance studies have shown the 
incidence of pre-eclampsia to be 2-5 times greater in blood relatives in families than 
between genetically unrelated women in the same families (Cooper et al., 1993). Given 
the number of potential molecular causes of pre-eclampsia a genetic link is of no great 
surprise, the pattern of inheritance is however difficult to define. The reasons for this 
stem from the fact that pre-eclampsia is not a condition which is easily observed. It is 
prevalent only in women, even if the condition itself is not sex linked, does not manifest 
until an individual is of reproductive age and then only if the individual actually falls 
pregnant. Since there are no specific genetic tests for pre-eclampsia as the molecular 
cause is unclear, tracking its inheritance through a family is problematical. Despite this, 
efforts have been made to characterise the pattern of inheritance. Data accumulated by 
Arngrimmson et al. (1995) was consistent with a dominant pattern of expression 
coupled with variable penetration. 
 
The pre-eclampsia community guideline (PRECOG) was first published in the UK in 
2004 and includes guidance on how to identify women at risk of developing pre-
eclampsia, so they can receive specialist referral early in pregnancy. The PRECOG 
assessment is based on both epidemiological evidence taken as a history during an 
antenatal visit and physiological measurements taken from the patient, including blood 
pressure and a measure of proteinuria. Patients receive specialist referral early in 
pregnancy if they meet any of the following criteria: 
 
 Multiple Pregnancy 
 Underlying medical conditions 
o Pre-existing hypertension or booking diastolic blood pressure ≥90mmHg 
o Pre-existing renal disease or booking proteinuria (>1+ on more than one 
occasion or quantified at ≥0.3g/ 24 hour) 
o Pre-existing diabetes 
o Presence of antiphospholipid antibodies 
 Pre-eclampsia in any previous pregnancy 
 Any two other factors from: 
o First pregnancy 
o Age 40 years or more 
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o Body Mass Index of  35 or more 
o Family history of pre-eclampsia (in mother or sister) 
o booking diastolic blood pressure ≥80mmHg 
 
It was the aim of this chapter to investigate the thrombin generation profile of women 
with pre-eclampsia with a view to using thrombin generation to enable the detection of 
pre-eclampsia either in conjunction with the PRECOG assessment or as a stand-alone 
test. Little is currently know about the thrombin generation capacity of women with pre-
eclampsia; although it was anticipated that they may show an elevated level of thrombin 
generation due to systemic activation of the coagulation cascade. The thrombin 
generation data of this cohort of women would also be used to try and predict other 
outcomes of pregnancy associated with pre-eclampsia such as birth weight, mode of 
delivery, length of stay in hospital and post partum haemorrhage (PPH). 
 
3.2 Materials and Methods 
 
3.2.1 Selection of Patients and Controls 
 
All patients and controls were recruited from the obstetrics unit at the Royal London 
Hospital, Whitechapel, London. The study was approved by the local research ethics 
committee and all participants gave informed consent. In total 104 participants were 
recruited to the study, 52 patients with pre-eclampsia and 52 controls. All women 
presenting with pre-eclampsia during weekdays were invited to participate. Pre-
eclampsia was defined as new onset hypertension and proteinuria on or after 20 weeks 
gestation. New onset hypertension was defined as a blood pressure of ≥ 140 mm Hg 
(systolic) or ≥ 90 mm Hg (diastolic) on at least two occasions and at least 4-6 hours 
apart at or after the 20th week of pregnancy in women previously shown to be 
normotensive. New proteinuria was defined as protein excretion ≥ 0.3g per 24 h or ≥ 1 + 
on dipstick in at least 2 random urine samples taken at least 4-6 hours apart. Samples for 
thrombin generation analysis were taken when the women presented with pre-
eclampsia.  
 
The control group was chosen from pregnant women attending the same antenatal 
clinics as the women presenting with pre-eclampsia and were women with no reported 
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medical or pregnancy related complications. Any women with known medical or 
pregnancy related complications were excluded from the study. The controls were 
matched to the patient group to try and minimise potential confounding factors 
including age, parity, ethnicity and gestational age. 
 
3.2.2 Defining Disease Severity 
 
Mild pre-eclampsia: greater than 20% increase in blood pressure from booking or a 
diastolic blood pressure of at least 90 mmHg with a trace of protein in urine. Aspartate 
transaminase (AST)/ Alanine transaminase (ALT) may be slightly abnormal with raised 
urate. May require medication. 
Moderate Pre-eclampsia: Diastolic blood pressure of between 90-100mmHg, 
Proteinuria 1+ or +2 on dipstick and abnormal Liver function tests (LFT). Will require 
medication/observation 
Severe Pre-eclampsia: Diastolic blood pressure >100mmHg, proteinuria 2+ or 3+ on 
dipstick with raised LFTs and urate. Patient is symptomatic and requires HDU 
admission and medication/delivery 
 
3.2.3 Preparation of Samples 
Please refer to section 2.2.4 for details 
 
3.2.4 Thrombin Generation 
Please refer to section 2.2.5 for details 
 
3.2.5 Statistical Analysis 
Please refer to section 2.2.9 for details 
 
3.2.6 Reagents 
 
Product Manufacturer 
FluCa Kit Diagnostica Stago 
PPP Reagent Diagnostica Stago 
Sterile Distilled Water Baxter 
Thrombin Calibrator Diagnostica Stago 
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3.3 Results 
 
Following collection of the patient’s samples they were prepared as described in section 
3.2.3 and frozen at -70°C. The samples were stored for no longer than 4 weeks. 
Thrombin generation was performed on the samples as described in section 3.2.4 with a 
measurement time of 60 minutes. Samples were analysed in groups of 15 where 
possible. All analyses were performed blind. A total of 4 samples were unsuitable for 
analysis: 3 samples were underfilled and 1 was clotted. As a result, of the 104 patients 
recruited for the trial thrombin generation data was available on 100 patients (51 
controls and 49 cases).  
 
3.3.1 Pregnancy and Thrombin Generation 
 
The first stage of the analysis was to ascertain the affects of pregnancy on thrombin 
generation. Since pregnancy is known to be associated with a shift towards a pro-
thrombotic state (Stirling et al., 1984) (Clark et al., 1998) it was anticipated that the 
thrombin generation profile of the normotensive pregnant patients in this experiment 
would reflect this. A comparison of the 51 normotensive pregnant women in this 
experiment with the normal range described in chapter 2 using the students t-test shows 
this was indeed the case. The pregnant women showed a statistically significant increase 
of both ETP and peak height and statistically significant decrease of both the lag time 
and time to peak (all P values were <0.01) when compared to normal non-pregnant 
individuals. This reflects the fact that the pregnant women started thrombin production 
earlier than normal individuals, their maximum rate of thrombin generation was higher 
and reached more quickly than the normal individuals and their maximum level of 
thrombin production exceeds that of a normal individual. These results are shown 
graphically in figures 3.1 and 3.2 below. 
 
 
 
 
 
 
 
- 131 - 
 
Figure 3.1 
 
A.             B. 
  
 
C.             D. 
   
Figure 3.1. Boxplots showing a comparison between the four thrombin generation parameters of pregnant 
women and a cohort of normal individuals. Boxes show 25
th
 to the 75
th
 percentile of the data with the 
median shown as a horizontal black line. Whiskers show minimum/maximum values. Population outliers 
defined as values deviating by greater than 1.5 times box height are shown by . P values were 
calculated using the student’s t-test. A: Lag Time, B: ETP, C: Peak Height and D: Time to Peak. 
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Figure 3.2 
 
Figure 3.2. Thrombin generation curves showing one normal control and one pregnant woman who are 
most representative of the average parameters for each of the two groups. 
 
3.3.2 Pre-eclampsia Severity and Thrombin Generation 
 
Since it is clear that the thrombin generation profile of a pregnant woman is markedly 
different from a non-pregnant individual, no further comparisons were made between 
the women with pre-eclampsia and the normal range. This was because it would not be 
possible to ascertain whether any observed difference was due to pre-eclampsia or due 
to pregnancy. The women with pre-eclampsia in this study were further divided into 
women with mild, moderate and severe pre-eclampsia depending on their degree of 
proteinuria and severity of their hypertension as well as the development of further 
symptoms (section 3.2.2). In order to ascertain the effects of pre-eclampsia on thrombin 
generation the results of the three groups of pre-eclampsia patients were compared with 
each other and the normotensive pregnant control group using the student’s t-test. 
Boxplots showing the results for each of the thrombin generation parameters for each 
group can be seen in figure 3.3 below. P values for the comparison between the four 
groups are shown in tables 3.1-3.4 below. A value of ≤0.05 was considered statistically 
significant. 
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Figure 3.3 
 
A.             B. 
  
 
C.             D. 
  
Figure 3.3. Boxplots showing a comparison between the four thrombin generation parameters of women 
with pre-eclampsia of varying severity and normotensive pregnant controls. Boxes show 25
th
 to the 75
th
 
percentile of the data with the median shown as a horizontal black line. Whiskers show 
minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 times box 
height are shown by .  A: Lag Time, B: ETP, C: Peak Height and D: Time to Peak 
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Table 3.1 
Pre-eclampsia Severity and Lag Time 
 Control Mild Moderate Severe 
Control N/A 0.21 0.83 0.66 
Mild - N/A 0.46 0.24 
Moderate - - N/A 0.58 
Severe - - - N/A 
Table 3.1. Matrix of p values comparing the severity of pre-eclampsia and the lag time. Statistically 
significant values are shown in red. 
 
Table 3.2 
Pre-eclampsia Severity and ETP 
 Control Mild Moderate Severe 
Control N/A 0.01 <0.01 <0.01 
Mild - N/A 0.44 0.19 
Moderate - - N/A 0.64 
Severe - - - N/A 
Table 3.2. Matrix of p values comparing the severity of pre-eclampsia and the ETP. Statistically 
significant values are shown in red. 
 
Table 3.3 
Pre-eclampsia Severity and Peak Height 
 Control Mild Moderate Severe 
Control N/A <0.01 0.01 0.06 
Mild - N/A 0.76 0.84 
Moderate - - N/A 0.69 
Severe - - - N/A 
Table 3.3. Matrix of p values comparing the severity of pre-eclampsia and the peak height. Statistically 
significant values are shown in red. 
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Table 3.4 
Pre-eclampsia Severity and Time to Peak 
 Control Mild Moderate Severe 
Control N/A 0.23 0.23 0.27 
Mild - N/A 0.28 0.09 
Moderate - - N/A 0.46 
Severe - - - N/A 
Table 3.4. Matrix of p values comparing the severity of pre-eclampsia and the time to peak. Statistically 
significant values are shown in red. 
 
These results clearly show that there is a difference between the thrombin generation 
profile of a normotensive pregnant woman and a woman with pre-eclampsia. All three 
of the pre-eclampsia groups show a statistically significant elevation in ETP compared 
to the cohort of normotensive controls with P values ≤0.01. Interestingly the mean ETP 
seems to increase in line with severity (figure 3.3 B) although the differences between 
the three pre-eclampsia groups were all non significant. Trend analysis revealed that 
there was no significant correlation between ETP and disease severity (data not shown). 
The women with mild and moderate pre-eclampsia also demonstrate an elevated peak 
height when compared to the normotensive controls with p values of <0.01 and 0.01 
respectively. The difference between the peak height of the women with severe pre-
eclampsia and the normotensive controls is non-significant. This result is marginal 
however and with an increased number of patients may have yielded a positive result. 
From the analysis it can be seen that there are no differences between the three pre-
eclampsia groups and the normotensive pregnant controls when comparing either the 
lag time or the time to peak parameters. It can also be seen from the comparisons that 
there are no significant differences between any of the three pre-eclamptic groups of 
patients for any of the four thrombin generation parameters. This would suggest that 
pre-eclampsia of any severity has the same impact on a patients capacity to generate 
thrombin. The changes seen in pre-eclamptic women seem to be consistent with an 
elevated level of thrombin generation and an increased rate of maximum thrombin 
production with no decrease in the time taken for initiation of thrombin generation or 
time taken to reach the maximum rate of thrombin production. It is worth noting 
however this is a comparison with pregnant controls so the pre-eclamptic women 
demonstrate the same changes as the pregnant women (decreased lag time and time to 
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peak) when compared with normal individuals with a further enhancement of their ETP 
and peak height parameters over and above those levels consistent with normal 
pregnancy. 
 
The subdivision of the pre-eclampsia patients into three groups seemed to be of little 
benefit as there were no differences between them. It should be noted that the 
subdivision of the pre-eclamptic patients also resulted in a decrease in the statistical 
power of the analysis, since the groups were all smaller in number. There were a total of 
24 patients with mild pre-eclampsia, 12 patients with moderate pre-eclampsia and 13 
patients with severe pre-eclampsia. The small sample size could have led to the non 
significant difference between the peak height of the severe pre-eclamptic women and 
the normotensive controls as mentioned above. This is because a small number of 
aberrant results can have a large impact on any comparison if the sample size is small. 
 
3.3.3 Pre-eclampsia Cases Verses Controls 
 
Since there were no differences between the mild, moderate and severe pre-eclamptic 
women it was decided to group them into a single cohort. This group was then 
compared with the normotensive pregnant controls in order to ascertain if the 
differences observed above still held. Since this comparison was between 49 pre-
eclamptic women and 51 normotensive controls the statistical power of the analysis 
should also be increased. The results of this comparison can be seen in figure 3.4 below. 
This analysis clearly shows the same results as the above comparison. The pre-
eclamptic women (cases) show a statistically significant elevation in both the ETP and 
peak height parameters when compared to the normotensive pregnant controls (p= 
0.0007 and 0.0009 respectively). No difference was observed between the two groups 
for either the lag time or time to peak parameters. This finding is consistent with 
elevated thrombin production and increased maximum rate of thrombin generation in 
pre-eclamptic women compared to normotensive pregnant controls as described above. 
Average thrombin generation curves for the two groups as well as a comparison with a 
normal non-pregnant individual are shown in figure 3.5 below. 
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Figure 3.4 
 
A.             B. 
  
 
C.              D. 
  
Figure 3.4. Boxplots showing a comparison between the four thrombin generation parameters of a cohort 
of women with pre-eclampsia and a cohort of normotensive pregnant controls. Boxes show 25
th
 to the 75
th
 
percentile of the data with the median shown as a horizontal black line. Whiskers show 
minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 times box 
height are shown by . P values were calculated using the student’s t-test. A: Lag Time, B: ETP, C: Peak 
Height and D: Time to Peak 
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Figure 3.5 
  
Figure 3.5. Thrombin generation curves showing one pre-eclamptic woman, one normotensive control 
and one normal individual who are most representative of the average parameters for each of the three 
groups. 
 
3.3.4 Confounding Factors 
 
The preliminary analysis seemed to show an apparent difference between the thrombin 
generation profile of pregnant women with and without pre-eclampsia. The next stage 
of the analysis was to examine the effects that any confounding variables may have had 
on the results of this analysis. In order to minimise the effects of confounding variables 
the cases and controls were matched for a number of parameters including age, parity, 
ethnicity and gestational age. A comparison of the two groups is shown in table 3.5 
below. 
 
From the table it appears that the two groups are very closely matched for both age and 
parity and hence these parameters are not likely to influence the results of the above 
comparison. Indeed age was shown to have no effect when considering thrombin 
generation in chapter 2. Both the gestational age and ethnicity were matched less closely 
between the two cohorts.  
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Table 3.5 
Parameter Controls 
N= 51 
Cases 
N=49 
Age (Years) 
Mean 
Range 
 
28.1 
(18 – 42) 
 
28.9 
(19 – 42) 
Parity 
Mean 
Range 
 
1.32 
(0 – 5) 
 
1.43 
(0 – 6) 
Gestational Age (Weeks) 
Median 
Range 
 
38 
(9 - 42) 
 
37.5 
(23 - 40) 
Ethnicity (%) 
Caucasian 
Asian 
Black 
 
62 
45 
44 
 
38 
55 
56 
 Table 3.5. A comparison of the potential confounding factors between the cohort of pre-eclampsia cases 
and the normotensive pregnant controls. 
 
3.3.4.1 Gestational Age 
 
The median gestational ages of the two cohorts match relatively closely but the mean 
gestational ages are 32.8 and 36.1 for the controls and cases respectively. This is 
because the control group contains a number of individuals with a gestational age of 
below 20 weeks. This is not possible in the pre-eclampsia cohort since the diagnosis of 
pre-eclampsia relies on new onset proteinuria and hypertension after 20 weeks 
gestation. It is therefore possible to infer that the reason for the observed difference 
between the ETP and the peak height of the control and case groups is because of 
differences in gestational age and not due to pre-eclampsia. In order to disprove this 
hypothesis all of the data was grouped together and re-analysed to show the effects of 
gestational age on thrombin generation. A clear trend showing an increase in thrombin 
generation throughout pregnancy would be indicative of the differences between the 
two groups being due to gestational age and not pre-eclampsia. The results of this 
analysis are shown in figure 3.6 below. 
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Figure 3.6 
A.              B. 
  
Figure 3.6. Graphs showing the impact of gestational age on thrombin generation in a cohort of pregnant 
women, complete with trend line and R
2
 value as an indication of correlation. A: ETP and B: Peak Height 
 
It is clear from this analysis that there is little evidence for either increasing ETP or peak 
height with increasing gestational age. Using the value of R
2
 to calculate a value for p as 
described in section 2.3.1.4 shows that both trends are non-significant with a p value of 
>0.5 for ETP and a p value of 0.1-0.5 for the peak height. The lack of any significant 
trend throughout pregnancy effectively eliminates gestational age as a confounding 
factor in the above analysis. Indeed if the data is again split into cases and controls and 
the same analysis is performed the result still holds true. See figure 3.7 below. 
 
Figure 3.7 
A.             B. 
  
Figure 3.7. Graphs showing the impact of gestational age on thrombin generation in a cohort of pregnant 
women with pre-eclampsia (cases) and a cohort of normotensive pregnant women (controls), complete 
with trend lines and R
2
 values as an indication of any correlations. A: ETP and B: Peak Height 
 
Calculation of p values as described above reveals that all of the trends shown in figure 
3.7 are non-significant, with p values of 0.1-0.5. Indeed if anything figure 3.7 shows a 
decreasing trend of both ETP and peak height throughout pregnancy in both the cases 
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and controls. This would imply the actual differences between the cases and controls 
may have been even more pronounced if the two cohorts had been more closely 
matched for gestational age. 
 
3.3.4.2 Ethnicity 
 
The ethnicity data presented in table 3.5 shows the distribution of the three ethnic 
groups involved in this study between the cases and controls. An ideal scenario would 
be to have 50% of the total number of each ethnic group in both the case and control 
cohorts. Table 3.5 shows that this is not the case, all three ethnic groups show some 
level of disparity. The biggest difference is seen between the Caucasian patients with 
62% in the control cohort and 38% in the cohort of women with pre-eclampsia. In 
absolute terms this is only a difference of 8 patients between the two groups however. 
The actual numbers of patients in each group is shown in table 3.6 below.  
 
Table 3.6 
Ethnicity Control Case 
Caucasian 20 12 
Asian 25 30 
Black 6 7 
Table 3.6. A table showing the absolute number of patients of each ethnic group in the 
two cohorts. 
 
In order to establish what effect, if any, ethnicity had on the obtained results it was 
decided to compare the case and control data of the three ethnic groups separately. If 
there was no observable difference between them, this would imply that ethnicity had 
no impact on the trends described above. The results of this comparison for the 
endogenous thrombin potential are shown in figure 3.8 and tables 3.7-3.8 below. The 
results for the comparison of peak height are shown in figure 3.9 and tables 3.9-3.10 
below. 
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Figure 3.8 
A.             B. 
  
Figure 3.8. Boxplots showing the ETP for Caucasian, Black and Asian women in a cohort of women with 
pre-eclampsia (A) and in a cohort of normotensive pregnant women (B). Boxes show 25
th
 to the 75
th
 
percentile of the data with the median shown as a horizontal black line. Whiskers show 
minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 times box 
height are shown by . 
 
Table 3.7 
ETP: Cases 
 Caucasian Black Asian 
Caucasian N/A 0.39 0.99 
Black - N/A 0.28 
Asian - - N/A 
Table 3.7. A matrix of p values comparing the ETP and the ethnicity of a group of pregnant women with 
pre-eclampsia. Significant values are shown in red. 
 
Table 3.8 
ETP: Controls 
 Caucasian Black Asian 
Caucasian N/A 0.005 0.49 
Black - N/A 0.008 
Asian - - N/A 
Table 3.8. A matrix of p values comparing the ETP and the ethnicity of a group of normotensive pregnant 
women. Significant values are shown in red. 
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Figure 3.9 
A.              B. 
  
Figure 5.9. Boxplots showing the peak height for Caucasian, Black and Asian women in a cohort of 
women with pre-eclampsia (A) and in a cohort of normotensive pregnant women (B). Boxes show 25
th
 to 
the 75
th
 percentile of the data with the median shown as a horizontal black line. Whiskers show 
minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 times box 
height are shown by . 
 
Table 3.9 
Peak Height: Cases 
 Caucasian Black Asian 
Caucasian N/A 0.63 0.54 
Black - N/A 0.30 
Asian - - N/A 
Table 3.9. A matrix of p values comparing the peak height and the ethnicity of a group of women with 
pre-eclampsia. Significant values are shown in red. 
 
Table 3.10 
Peak Height: Controls 
 Caucasian Black Asian 
Caucasian N/A 0.07 0.87 
Black - N/A 0.002 
Asian - - N/A 
Table 3.10. A matrix of p values comparing the peak height and the ethnicity of a group of normotensive 
pregnant women. Significant values are shown in red. 
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These analyses showed that there were no differences between any of the ethnic groups 
for either the ETP or peak height when considering the cohort of women with pre-
eclampsia. This however was not the case when examining the results for the cohort of 
normotensive women. Whilst there were no observed differences between the 
Caucasian and Asian women in either their ETP or peak height results, the Black 
women showed a significantly higher ETP than both the Asian (P=0.008) and Caucasian 
(P=0.005) groups. The Black women in the control cohort also showed a significantly 
higher peak height when compared to the Asian sub group (P=0.002) and a difference 
approaching statistical significance when compared to the Caucasian group. There were 
no significant differences found between any of the ethnic groups in either cohort for 
either the lag time or time to peak parameters. These findings indicate that normotensive 
pregnant Black women have a level of thrombin generation which is significantly 
elevated when compared to normotensive pregnant Caucasian or Asian women. 
 
To further investigate this finding the case and control data for each ethnic group was 
then compared directly to ascertain whether or not the findings of the preliminary 
analysis still held i.e. there is a difference between the ETP and peak height parameters 
in women with pre-eclampsia when compared with normotensive pregnant women. The 
results of this analysis are shown in figure 3.10 below. 
 
Figure 3.10 
A.             B. 
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C.              D. 
  
E.             F. 
  
Figure 3.10. A series of boxplots showing a comparison between the ETP and peak height for both cases 
and controls for each of the three different ethnic groups in the study. Boxes show 25
th
 to the 75
th
 
percentile of the data with the median shown as a horizontal black line. Whiskers show 
minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 times box 
height are shown by . P values derived via student’s t-test. A and B: Black women, C and D: Caucasian 
women, E and F: Asian women. 
 
This data shows that whilst the Caucasian and Asian women demonstrate a clear 
difference between the controls and cases for both the ETP and peak height parameters, 
the same trend is not present in the Black women, who show strikingly similar results in 
both the control and case groups. This is a highly interesting result as the implications 
are potentially quite large. What the data appears to show is that while Asian and 
Caucasian women show abnormal thrombin generation patterns when they develop pre-
eclampsia, Black women do not. What is most interesting is that the apparent lack of 
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difference between the Black women with and without pre-eclampsia does not manifest 
in the way one might expect (i.e. a failure of the pre-eclamptic patients to demonstrate 
elevated thrombin generation parameters) but rather the opposite way around. The 
normotensive black women demonstrate a level of thrombin generation which is equal 
to the pathological level seen in the Asian and Caucasian women with pre-eclampsia. 
The implications for this unexpected result in terms of a confounding factor for this 
analysis would probably be to reduce the size of the observed difference between the 
cases and controls. This is because the control values of the Black women would skew 
the mean and standard deviation of the control group (making them higher) and 
ultimately increasing the p value of the comparisons. The actual difference however is 
likely to be small given the size of the cohort of Black women in the study is only 13 of 
the 100 patients analysed. The small number of Black women analysed obviously 
increases the likelihood of obtaining a non significant difference between the cases and 
controls by chance. This is because one or two aberrant values can have a large impact 
on the analysis. In some ways this is true of the control group of Black women, which 
contains the woman with the highest value of ETP in this entire study. Excluding this 
individual does not eliminate all the observed differences between the groups however 
(data not shown).  Since both the Asian and Caucasian groups show the same pattern as 
each other and as the preliminary analysis when considering the differences between the 
cases and controls it can be assumed that the imbalance between the number of 
Caucasian and to a lesser extent Asian women between the control and case cohorts did 
not directly impact on the findings of the study. As mentioned above, the impact of the 
Black women is most likely to reduce the statistical significance of the study findings. 
Since this impact is likely to be small, based on the sample size of the Black cohort, the 
Black women were not excluded from further analysis. 
 
3.3.5 Prediction of Pre-eclampsia 
 
As stated the primary aims of this chapter were three fold, the first aim was to 
investigate the thrombin generation profile of women with pre-eclampsia, the second 
was to establish whether or not any observed differences in the thrombin generation 
profile of women with pre-eclampsia could be used in order to potentially predict which 
patients would develop pre-eclampsia. The third aim was to try and correlate the 
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thrombin generation data with some end points of pregnancy associated with pre-
eclampsia 
 
It is clear from the above analysis that there is a significant difference between the 
thrombin generation profiles of women with pre-eclampsia and normotensive pregnant 
women. The next stage of this study was to ascertain whether the observed differences 
were of sufficient magnitude that they could be potentially used as a prospective 
screening test for pre-eclampsia in the future. In an ideal scenario the magnitude of the 
difference between the ETP and peak height of women with pre-eclampsia and 
normotensive pregnant women would be so great that there would be no overlap 
between the two populations. An upper limit of normal could then be established for 
normotensive women and any women presenting with thrombin generation parameters 
over that limit could be flagged as at risk of pre-eclampsia. As mentioned above, any 
measure of thrombin generation could be considered in conjunction with the PRECOG 
score to potentially increase its diagnostic power.  
 
Before any analysis was undertaken to establish how good the thrombin generation 
assay was at discriminating between normotensive women and pre-eclampsia patients, 
the data for the PRECOG score was analysed. This would establish how effective the 
PRECOG screen was at detecting the women at risk of pre-eclampsia as a stand-alone 
assay. Before the women were enrolled on the study each of them was assessed for risk 
using the PRECOG scoring system described in section 3.1.6. This system is designed 
to offer early referral for specialist care to those women who are at risk of pre-
eclampsia. Often such specialist referral includes tests such as uterine Doppler 
investigation to detect the changes (or lack thereof) in the uterine spiral arteries which 
are indicative of pre-eclampsia. Such assays are both time consuming and expensive to 
the NHS and as a result it is important the right patients are referred for screening. 
Having been assessed using the PRECOG scoring system each woman in the study was 
flagged as either high or low risk of developing pre-eclampsia. Since the diagnosis of 
each individual was known it was possible to retrospectively analyse the data to 
establish how good the PRECOG assessment was at detecting the women who went on 
to develop pre-eclampsia. In order to ascertain the effectiveness of the PRECOG score 
the sensitivity, specificity, positive predictive value and negative predictive value were 
established as shown in table 3.11 below. The definitions of these terms are as follows: 
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Sensitivity: The proportion of ‘positive’ patients (pre-eclampsia cases) correctly 
identified as being positive (high risk) 
 
Specificity: The proportion of ‘negative’ patients (normotensive controls) correctly 
identified as being negative (low risk) 
 
Positive predictive value: The proportion of high risk individuals who are correctly 
diagnosed (pre-eclampsia cases) 
 
Negative predictive value: The proportion of low risk individuals who are correctly 
diagnosed (normotensive controls) 
 
Table 3.11 
 Diagnosis  
Prediction Case Control 
 
High Risk 
 
True Positive 
 
False Positive 
Positive Predictive 
Value 
TP/(TP+FP) 
 
Low Risk 
 
False Negative 
 
True Negative 
Negative Predictive 
Value 
TN/(TN+FN) 
 Sensitivity 
TP/ (TP+FN) 
Specificity 
TN/ (TN+FP) 
 
Table 3.11. A table showing the calculation of the sensitivity, specificity, positive predictive value and 
negative predictive value. Derived answers were reported as percentages by multiplying by 100. 
 
Data were available for all 104 women recruited to the trial for both the PRECOG score 
and the diagnosis. The analysis of the predictive power of the PRECOG score provided 
surprisingly low values for both sensitivity and specificity, 58% and 69% respectively, 
with similar values for both the positive predictive value (65%) and negative predictive 
value (62%). Whilst it is common for screening tests to often sacrifice specificity in 
order to enhance their sensitivity or vice versa, this analysis suggests that the PRECOG 
score is neither very effective as detecting the high risk patients or excluding those who 
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are low risk. In absolute terms, from the cohort of women in this study 16 (35% of those 
scored as high risk) were falsely scored as high risk and would therefore go on receive 
unnecessary specialist referral, whereas 22 (38% of those scored as low risk) of those 
women flagged as low risk would receive no early specialist care even though they 
would subsequently develop pre-eclampsia. This shows the PRECOG score is not an 
effective stand alone screening test as it can neither successfully predict which women 
will develop disease nor detect those who are not at risk of developing disease. In real 
terms this means the NHS will suffer from elevated costs due to unnecessary referrals 
and a number of patients will fail to receive the care they actually need. 
 
In order to ascertain whether the measurement of thrombin generation was any more 
effective than the PRECOG score at discriminating between normotensive and pre-
eclamptic women, the women in the trial were flagged as either high or low risk 
depending on their thrombin generation parameters and this risk assessment was 
compared to their actual diagnosis as described for the PRECOG assessment above. 
Before this could be done however it was necessary to determine a cut off for the ETP 
and/or peak height over which an individual would be classified high risk. As stipulated 
above, an ideal scenario would be little or no degree of overlap between the thrombin 
generation parameters of the case and control cohorts. Examining the results as shown 
in figures 3.4 B and C, this does not appear to be the case, despite the highly significant 
p values of the comparisons, since there is a relatively large degree of overlap between 
the two populations. In order to better assess the overlap of the results between the two 
populations, the obtained results for ETP and peak height from each cohort were plotted 
as frequency charts on the same axis. These graphs are shown in figure 3.11 below. It is 
clear from these graphs that although the data appears roughly normal in distribution, 
there is no clear delineation point between the cases and controls for either parameter. 
Selecting an appropriate cut off in order to establish a patient as either high or low risk 
was therefore problematical.  
 
Selecting cut off values for high and low risk using the mean ETP of either the control 
cohort +1 SD or case cohorts -1SD respectively yielded results which were not 
compelling. The selection of these cut-off values immediately poses a problem since 
any population which is normally distributed would by definition have ~16% of values 
above/below 1 standard deviation from the mean. Hence these cut-off values would 
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result in approximately one sixth of the populations being incorrectly assigned as 
high/low risk.  
 
Figure 3.11 
A. 
 
 
 
B. 
 
 
Figure 3.11. Graphs showing the distribution of the ETP (A) and peak height (B) results for both the case 
and control cohorts.  
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Choosing more extreme cut off values for characterising patients as high and low risk 
such as high risk being defined as values of ETP exceeding the mean ETP of the control 
cohort +2 SD or low risk being defined as values of ETP below the mean ETP of the 
case cohort -2SD improved the specificity and sensitivity of the individual screens 
respectively dramatically to values exceeding 90%. These improvements were however 
at the expense of the sensitivity and specificity respectively. This was as a result of 
classifying the vast majority of patients as either low risk or high risk (depending on the 
cut off used). The negative and positive predictive values for these cut off values were 
~50% showing that the use of such cut off values were highly impractical since nearly 
half of the women in this study would have been falsely identified as low or high risk 
respectively using the cut off values described above. In NHS terms this would result in 
either specialist referral of only a handful of women who needed further treatment or the 
referral of virtually every woman screened. 
 
 A number of potential different cut-off values were examined using either the ETP, the 
peak height or both parameters in combination in an attempt to optimise the use of 
thrombin generation as a screening test for pre-eclampsia. The cut off values which 
resulted in the greatest number of correctly categorised patients (64 out of 100 patients) 
of any of the cut-off values or combinations thereof used was the categorisation of 
patients as high risk if they had an ETP and peak height exceeding the mean of the case 
cohort minus one standard deviation (ETP >2263nM Thrombin and a peak height of 
>445nM Thrombin). Patients were categorised as low risk if only one parameter was 
elevated or if both parameters were below the high risk cut-off. This resulted in a 
specificity of 43% and a sensitivity of 86%. The positive predictive value was 59% and 
the negative predictive value was 76%. 
 
It is clear from the above analyses that the use of thrombin generation as a stand-alone 
screening test for the detection of pre-eclampsia is flawed. This is primarily due to the 
high overlap of the thrombin generation parameters between the case and control 
cohorts, which ultimately makes the selection of an appropriate cut-off difficult. The 
next stage of analysis was therefore to use the thrombin generation parameters in 
conjunction with the PRECOG score in order to try and improve its predictive power. In 
order to combine the tests it was necessary to first consider how the women would be 
classified as high risk and which high risk cut-off value for the thrombin generation 
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parameters would be used in the analysis. Since neither the PRECOG score nor the 
thrombin generation results could be relied upon to classify women as high/low risk 
independently it was decided to only classify a woman as high risk when both the 
thrombin generation parameters were elevated and the PRECOG score also suggested 
they were high risk. If only one of the screening tests suggested the women were high 
risk they were classified as low risk. The thrombin generation cut-off used in this 
analysis to classify an individual as potentially high risk, was the one which had 
produced the most promising results so far, namely an ETP and peak height exceeding 
one standard deviation below the mean ETP and peak height of the case cohort.  
 
The results of the predictive power of this combination of screening tests did not 
initially appear positive. The sensitivity and specificity were 37% and 75% respectively 
with a positive predictive value of 58% and a negative predictive value of 55%. The real 
power of this combination of tests however lies in those individuals who had both low 
risk thrombin generation parameters (ETP ≤ 2263nM Thrombin and a peak height of ≤ 
445nM Thrombin) and a low risk result via the PRECOG risk assessment. The negative 
predictive value of these individuals was 94%. This result was of great interest since it 
meant that in combination thrombin generation analysis and the PRECOG score could 
be used to successfully detect a subgroup of women in whom pre-eclampsia was highly 
unlikely to occur.  When considering this subgroup of women the negative predictive 
value of the two assays in combination exceeds that of either assay in isolation, (62% 
and 76% for PRECOG and thrombin generation respectively).  
 
Whilst this finding was encouraging it would have been better if the positive predictive 
value or sensitivity was also elevated when the screening tests were combined, as this 
would increase the clinical utility of the screen. One of the primary reasons for the poor 
sensitivity of the combined screen was the high number of false negative patients. It was 
felt that classifying women as high risk only when they were designated high risk by 
both screening tests was excluding too many positives. Classifying women as high risk 
when either screen was positive was likely to make the assay too sensitive however. As 
a compromise it was decided to give one screening test more weight in the classification 
of risk than the other. In the following analysis an individuals risk was decided using 
the rules below: 
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Women with high risk PRECOG score and elevated thrombin generation parameters 
(ETP >2263nM Thrombin and a peak height of >445nM Thrombin) = HIGH RISK 
Women with high risk PRECOG score and low risk thrombin generation parameters 
(ETP ≤2263nM Thrombin and a peak height of ≤445nM Thrombin) = HIGH RISK 
Women with low risk PRECOG score and elevated thrombin generation parameters 
(ETP >2263nM Thrombin and a peak height of >445nM Thrombin) = LOW RISK 
Women with low risk PRECOG score and low risk thrombin generation parameters 
(ETP ≤2263nM Thrombin and a peak height of ≤445nM Thrombin) = LOW RISK 
 
This analysis seemed to provide no additional benefit over the original screen, although 
the ‘double negatives’ retained their screening power, the sensitivity and specificity 
results for the screen as a whole were poor (49% and 61% respectively). The positive 
and negative predictive values were 55%. 
 
Subsequent to this analysis the process was repeated again, this time giving more 
weight to the thrombin generation results rather than the PRECOG score, so patients 
with a low risk PRECOG score and elevated thrombin generation parameters were 
categorised as high risk and patients with a high risk PRECOG score and low risk 
thrombin generation parameters were categorised as low risk. Again this analysis 
conserved the predictive power of the low risk patients but also reduced the number of 
false negative patients, increasing the sensitivity to 86%. The specificity (43%) was 
decreased when compared to the original combination analysis however. The positive 
and negative predictive values of this analysis were 59% and 76%. On the whole this 
combination of tests was the most clinically effective described to this point. This is due 
to the fact that it is able to detect the majority of cases in a population and therefore 
allows effective referral and treatment but also can effectively exclude a subgroup of 
patients from referral testing. This is not true of some of the other methods examined 
which demonstrate improved sensitivity when compared to this screen.  
 
If this screen is modified so that women are classified as high risk if either the 
PRECOG score or thrombin generation parameters are high risk, the sensitivity is 
increased from 86% to 98%, but the specificity is reduced to 29%. The positive 
predictive value is similar at 57% and the negative predictive value rises to 94% (since 
the only negative patients are those who are low risk via both screening tests).  
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These predictive algorithms are not without flaws however, in that there are a relatively 
large number of false positives. In order to combat this, it was decided to investigate the 
possibility of introducing a more effective ‘double positive’ screening result i.e. looking 
for a higher cut-off above which the positive predictive value would be enhanced. To 
investigate the feasibility of this a separate comparison was performed using a 
combination of the PRECOG score and a thrombin generation cut-off of greater than 
one standard deviation above the mean of the control cohort. This cut off was chosen 
since it had subsequently shown an elevated positive predictive value when compared to 
the other cut-off values (72%). In this analysis a patient was categorised as high risk 
only if they had a high risk PRECOG assessment and high risk thrombin generation 
parameters (ETP >2920 nM Thrombin and peak height >519 nM Thrombin). This 
combination of cut-off values with the PRECOG score did not enhance the positive 
predictive value however. Indeed the positive predictive value fell to 60%, this 
comparison highlights that although low risk thrombin generation and PRECOG scores 
might be used to exclude pre-eclampsia, these tests cannot be used in unity to predict 
pre-eclampsia with the same degree of success.  
 
In a final attempt to choose a cut-off for the thrombin generation parameters which 
would enhance the predictive value of thrombin generation in the detection of pre-
eclampsia it was decided to use a cut-off value for the ETP that was mid way between 
the two values employed most successfully so far i.e. between one standard deviation 
below the mean of the case cohort (2263 nM Thrombin) and one standard deviation 
above the mean of the control cohort (2920 nM Thrombin). The mid way point between 
the two values is 2591 nM Thrombin. Classifying patients with ETP values >2591 nM 
Thrombin as high risk yielded sensitivity and specificity values of 71% and 61% 
respectively and positive and negative predictive values of 64% and 69% respectively. 
In retrospect these values could have been predicted, since the cut-off is mid range the 
sensitivity and specificity values fall between those of the higher and lower cut-off 
values. The use of the lower cut-off increases the sensitivity, whereas the use of the high 
cut-off increases the specificity. The use of a mid range cut-off for the peak height (482 
nM Thrombin) in conjunction with the mid range cut-off for ETP, with high risk 
patients defined as those who show both elevated ETP and peak height, does little to 
improve the predictive values with a sensitivity of 59% and a specificity of 71%.  
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Interestingly when the mid range ETP cut-off is used in conjunction with the PRECOG 
score, with high risk individuals defined as those with either a high risk PRECOG score, 
elevated ETP (>2591 nm thrombin) or both, the predictive values of the screen are very 
similar to those of the modified combination of thrombin generation (low cut-off) and 
PRECOG described above. The sensitivity and specificity values were 84% and 43% 
respectively. A major disadvantage of this screen however is that the ‘double negative’ 
result using the mid range cut-off has a lower negative predictive value of 73% when 
compared to the 94% of the lower cut-off (1SD below the mean case value). 
 
Although the methods employed above demonstrate that the measurement of thrombin 
generation could be potentially used as a predictor of pre-eclampsia or used to 
effectively characterise a subgroup of women who will not develop pre-eclampsia when 
used in conjunction with the PRECOG score, the selection of appropriate cut off values 
proved problematical due to the high degree of overlap between the case and control 
cohorts. To  further characterise the predictive value of the measurement of thrombin 
generation in pre-eclampsia it was decided to plot receiver operating characteristic 
(ROC) curves of both ETP and peak height in relation to disease state (case or control). 
A ROC curve is effectively a graphical plot of the sensitivity (true positives), against 1 
– specificity (false positives). The area under the curve is used to determine the 
effectiveness of a parameter as a predictive characteristic. A value of 1 is indicative of a 
perfect screening test whereas values approaching 0.5 indicate poor predictive 
parameters. The ROC curves for both ETP and peak height are shown in figure 3.12 
below. 
 
Figure 3.12 shows that both ETP and peak height have very similar areas under the 
curve of ~0.7, indicating that the two parameters have very similar predictive values in 
determining whether a patient has pre-eclampsia or not. A value of 0.7 suggests that if a 
random individual was selected from both the case and control cohorts the individual 
from the case cohort would have a higher ETP/peak height in 70% of cases. This 
finding is supportive of the analysis above, that the measurement of thrombin 
generation is potentially of moderate predictive value in pre-eclampsia. 
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Figure 3.12 
A. 
 
B. 
 
Figure 3.12. ROC curves of ETP (A) and Peak Height (B) against disease status. The blue line indicates 
the ROC curve of the parameter. The green line indicates an area under the curve of 0.5. Area under the 
curve is shown as an indicator of the predictive value of the parameter. 
 
Area under curve: 0.702 
Area under curve: 0.691 
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Further to the analysis discussed in this project, samples were taken from all the 
subjects enrolled on this study for analysis by flow cytometry. The parameters 
investigated included, platelets expressing P-selectin, P-selectin expressing 
microparticles, platelet-monocyte aggregates and platelet-neutrophil aggregates. In 
comparison to the normotensive pregnant women the women with pre-eclampsia 
demonstrated significantly elevated levels of P-selectin expressing platelets and platelet 
microparticles as well as platelet-monocyte aggregates (p= <0.05) (Macey et al., 2010a) 
(Paper in the appendix, section 7.2). These parameters were then used in conjunction 
with the ETP to try and distinguish between the cases and the controls. Women were 
classified as high risk if they had an elevated level of one or more of the selected 
parameters. The cut-off for high risk patients was defined as greater than two standard 
deviations above the mean of a cohort of normal non-pregnant controls. The ETP value 
used to define high risk in this study was >2579 nM Thrombin, which is roughly 
analogous to the mid range cut-off employed above. The sensitivity and specificity 
values for this analysis were 83% and 80% respectively. The positive and negative 
predictive values were 81% and 82% respectively.   
 
3.3.6 Thrombin Generation and Pregnancy Endpoints 
 
It is clear from the above analyses that both the peak height and ETP are elevated in a 
cohort of women with pre-eclampsia when compared to a cohort of normotensive 
pregnant women and that these parameters can potentially be used as predictive 
indicators in pre-eclampsia,  however this study was a retrospective analysis. To further 
elucidate the clinical utility of the CAT thrombin generation assay it was decided to use 
the thrombin generation data obtained in this investigation in a small number of 
prospective studies. The parameters measured in these studies were either associated 
with pre-eclampsia or linked to a patient’s capacity to generate thrombin. Importantly 
they were all events which were recorded following the measurement of the patients’ 
thrombin generation capacity. These parameters were birth weight, length of stay in 
hospital, mode of delivery and post partum haemorrhage (PPH) 
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3.3.6.1 Thrombin Generation and Birth Weight 
 
The birth weights of the control cohort were significantly higher than those of the case 
cohort (Macey et al., 2010a), this was not an unexpected finding since patients with pre-
eclampsia often have pre-term deliveries in order to prevent the progression of pre-
eclampsia to eclampsia and as a result the babies of pre-eclamptic women have lower 
birth weights. The data in this study is supportive of this theory. The birth weights of 
the babies from the women enrolled on this study were correlated with both the ETP 
and peak height. Data was available for 42 of the pre-eclamptic women and 44 of the 
normotensive pregnant women for this analysis. The results of this correlation are 
shown in figure 3.13 below. 
 
Figure 3.13 
A.              B. 
  
 
C.              D. 
  
Figure 3.13. A series of graphs showing the correlation between birth weight and ETP in the control (A) 
and case (B) cohorts and the correlation between birth weight and peak height in the control (C) and case 
(D) cohorts. Trend lines and R
2 
are shown as an indication of correlation. 
  
Since the ETP and peak heights were significantly elevated in the case cohort in 
comparison to the normotensive control cohort and the birth weights were significantly 
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lower in the case cohort when compared to the controls, it was hypothesised that there 
would be a significant correlation between the two parameters. This was especially true 
of the ETP which seems to show a stepwise increase with disease severity in figure 
3.3B (although this is not statistically significant) and it was felt that those patients with 
the most severe disease would have the infants with the lowest birth weight. Figure 3.13 
however does not support this hypothesis for any of the correlations shown. All the 
correlations were non-significant (p= >0.05). Figure 3.13 B, C and D show that the 
modest correlations present were in accord with the hypothesis as indicated by the trend 
lines (decreasing birth weight with increasing ETP/peak height). To increase the 
statistical power of the analysis the case and control cohorts were combined into a 
single group and the correlations performed again. The results of this analysis are 
shown in figure 3.14. 
 
Figure 3.14 
A.              B. 
  
Figure 3.14. Graphs showing the correlation between birth weight and ETP (A) and peak height (B) in a 
cohort of pregnant women. Trend lines and R
2 
are shown as an indication of correlation. 
 
Although the correlations initially do not appear enhanced when comparing the values 
of R
2
 in figures 3.14 A and B with those in figure 3.13, the p values are significant 
(p=<0.05) for both ETP and peak height. This is probably as a result of the initial 
correlations having insufficient numbers of data points to detect what is a weak 
statistical trend (R values of 0.26 and 0.27 for ETP and peak height respectively). In 
conclusion there is a weak association between decreasing birth weight and both an 
increasing ETP and peak height. 
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3.3.6.2 Thrombin Generation and Length of Stay in Hospital 
 
The association between thrombin generation parameters and the length of stay in 
hospital were also investigated for similar reasons to those outlined above. Women with 
the most severe cases of pre-eclampsia may be expected to be the ones who had the 
longest stays in hospital at the time of delivery. Data for this comparison was available 
for 46 of the women in the control cohort and 47 of those in the case cohort. A 
comparison of the length of stay in hospital can be seen in figure 3.15 below. From the 
figure it may be seen that the women in the case cohort had a longer stay in hospital at 
delivery when compared to the women in the control cohort. When comparing the two 
populations using a Mann Whitney U test this is proved to be statistically significant 
(p=<0.001). 
 
Figure 3.15 
 
Figure 3.15. Boxplots showing the length of time spent in hospital at the time of delivery in a cohort of 
normotensive pregnant women (Controls) and a cohort of women with pre-eclampsia (cases). Boxes show 
25
th
 to the 75
th
 percentile of the data with the median shown as a horizontal black line. Whiskers show 
minimum/maximum values. Population outliers defined as values deviating by greater than 1.5 times box 
height are shown by . P value derived using the Mann Whitney U test. 
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Correlations of ETP/ peak height with the length of stay in hospital for the case and 
control groups respectively are shown in figure 3.16. 
 
Figure 3.16 
 
A.              B. 
  
C.              D. 
  
Figure 3.16. A series of graphs showing the correlation between length of stay in hospital at delivery and 
ETP in the control (A) and case (B) cohorts and the correlation between length of stay in hospital at 
delivery and peak height in the control (C) and case (D) cohorts. Trend lines and R
2 
are shown as an 
indication of correlation. 
 
Figure 3.16 shows that the length of stay in hospital does correlate with the 
measurement of ETP but not with the peak height. There was a significant p value of 
<0.02 for the correlations of length of stay with ETP in both the case and control 
cohorts and non significant p values of between 0.1 and 0.5 for the two peak height 
correlations. It appears from figure 3.16 B that the statistically significant correlation 
between the length of stay and the ETP in the case cohort is largely due to the outlying 
data point at 24 days. Excluding this point from the analysis causes the R
2
 value to 
decrease to 0.06 which in turn increases the p value of the correlation to between 0.05 
and 0.1. The case and control cohorts were then combined to increase the statistical 
power of the correlations. The results of this analysis are shown in figure 3.17. 
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Figure 3.17  
A.              B. 
  
Figure 3.17. Graphs showing the correlation between length of stay in hospital at the time of delivery and 
ETP (A) and peak height (B) in a cohort of pregnant women. Trend lines and R
2 
are shown as an 
indication of correlation. 
 
Combining the case and control cohorts increases the degree of correlation, as indicated 
by R
2
, compared to analysing the two groups separately.  The p value of the correlation 
with the length of stay decreased to <0.001 and <0.01 for the ETP and peak height 
parameters respectively. This implies that an increased ETP/ peak height correlates with 
an increased length of stay in hospital at the time of delivery in this cohort of women. 
As described above a large part of these correlations is possibly due to the outlying 
point at 24 days, without data points between this outlier and the rest of the cohort it is 
perhaps ‘unsafe’ to include this point in the analysis. Excluding this point does reduce 
the R
2 
values of the correlations to 0.157 and 0.065 for ETP and peak height 
respectively. This in turn increases the derived p value of the peak height correlation to 
between 0.01 and 0.02. The p value of the ETP correlation remains <0.001. Despite 
removing the outlier from the analysis there are still statistically significant correlations 
between both the ETP and peak height and the length of stay in hospital. 
 
3.3.6.3 Thrombin Generation and Mode of Delivery 
 
In this section it was decided to examine whether or not the measurement of thrombin 
generation could be used to potentially predict the mode of delivery in the cohort of 
women analysed in this study. Data were available on the mode of delivery for 85 of the 
women enrolled on the study, 43 in the control cohort and 42 in the case cohort. To 
simplify the analysis it was decided to try to ascertain whether or not the measurement 
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of either the ETP or peak height could be used to predict whether or not the women in 
the study would have a lower segment caesarean section (LSCS) instead of a standard 
vaginal delivery. Women who had other methods of delivery were excluded from the 
analysis; this included 2 women who had forceps deliveries and one woman who had a 
ventouse delivery. Data was available on 41 women in each of the control and case 
cohorts. The incidence of LSCS in the two cohorts was very similar (13/41 in the 
control cohort and 16/41 in the case cohort). It was anticipated that the incidence of 
LSCS would be higher in the pre-eclamptic women since premature delivery is often 
necessary in these women to prevent progression to eclampsia. Figure 3.18 shows ROC 
curves of ETP/peak height predicting the incidence of LSCS in the control and case 
cohorts respectively. 
 
From figure 3.18 it can be seen that the ETP and peak height are poor indicators of the 
mode of delivery in this cohort of women, this is especially true in the case cohort as the 
area under the curve is 0.502 for both parameters. The ETP and peak height have 
slightly more predictive value in the control cohort with areas of 0.629 and 0.566 for the 
ETP and peak height parameters respectively, although these values are far from 
compelling. Combining the two cohorts and re-plotting the curves does not enhance the 
predictive value with areas of 0.571 and 0.554 for the ETP and peak height respectively. 
This analysis is shown in figure 3.19 and is consistent with the fact that   the 
measurement of thrombin generation cannot be used to accurately determine the mode 
of delivery in this cohort of women. 
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Figure 3.18 
 
A.               B. 
 
   
C.               D. 
 
  
 
Figure 3.18. A series of ROC curves showing the predictive value of the ETP in determining whether or 
not women have LSCS deliveries in the control (A) and case (B) cohorts and the predictive value of the 
peak height  in determining whether or not women have LSCS deliveries in the control (C) and case (D) 
cohorts . The blue line indicates the ROC curve of the parameter. The green line indicates an area under 
the curve of 0.5. Area under the curve (AUC) is shown as an indicator of the predictive value of the 
parameter. 
 
 
 
 
 
AUC = 0.629 AUC = 0.502 
AUC = 0.502 AUC = 0.566 
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Figure 3.19 
A.               B. 
  
Figure 3.19. ROC curves showing the predictive value of the ETP (A) and peak height (B) in determining 
whether or not women have LSCS deliveries in a cohort of pregnant women. The blue line indicates the 
ROC curve of the parameter. The green line indicates an area under the curve of 0.5. Area under the curve 
(AUC) is shown as an indicator of the predictive value of the parameter. 
 
3.3.6.4 Thrombin Generation and Post Partum Haemorrhage 
 
This section focuses on the use of the measurement of the ETP and the peak height to 
predict whether or not women are at risk of PPH. In order to establish the degree of 
blood loss during delivery the change in haemoglobin of each of the women was 
calculated by subtracting the haemoglobin measurement pre delivery from that obtained 
post delivery. Women who had a loss of ≥2.0g/dL haemoglobin during delivery were 
assumed to have had a PPH. Those women who did not have their haemoglobin 
measured post delivery were assumed not to have had a PPH (Definitions devised 
following discussion with an obstetric consultant at The Royal London Hospital). 
 
Although PPH is not associated with pre-eclampsia it was thought that there may be an 
association between an individual’s capacity to generate thrombin and their risk of 
bleeding at delivery. It was thought that the individuals with the highest ETP and peak 
height parameters would be those with the lowest risk of having a PPH. If this 
hypothesis was correct it would be reasonable to assume that the incidence of PPH 
would be reduced in the case cohort when compared to the controls since women with 
pre-eclampsia have a higher ETP and peak height when compared to normotensive 
AUC = 0.571 AUC = 0.554 
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pregnant women as discussed above. Interestingly this does not appear to be the case; 
data were available on 46 women in the control cohort and 47 women in the case cohort 
and of these 10 in the control cohort and 9 in the case cohort were classified as having 
had a PPH using the definition above. Figure 3.20 shows ROC curves of ETP/peak 
height predicting the incidence of PPH in the control and case cohorts respectively. 
 
Figure 3.20 
 
A.               B. 
  
 
C.               D. 
  
 
Figure 3.20. A series of ROC curves showing the predictive value of the ETP in determining whether or 
not women have a PPH in the control (A) and case (B) cohorts and the predictive value of the peak height  
in determining whether or not women have a PPH in the control (C) and case (D) cohorts . The blue line 
indicates the ROC curve of the parameter. The green line indicates an area under the curve of 0.5. Area 
under the curve (AUC) is shown as an indicator of the predictive value of the parameter. 
 
AUC = 0.567 AUC = 0.450 
AUC = 0.567 AUC = 0.471 
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Figure 3.20 clearly shows that the ROC curves for the case and control cohorts appear 
contradictory. The curves for the control cohort show a modest predictive value in using 
ETP and peak height in the prediction of PPH (AUC values are 0.567 for both the ETP 
and peak height). This association is contrary to the above hypothesis in which higher 
ETP and peak height values are protective against PPH and implies a relationship 
between increasing ETP and peak height and increasing risk of PPH. The AUC values 
for the case cohort are in support of the initial hypothesis (values below 0.5 are 
indicative of an association in opposition to that entered into the analysis program) 
indeed the attained values are equivalent to AUC values of 0.55 (1-0.45) and 0.529 (1-
0.471) for increasing values of ETP and peak height being associated with not having a 
PPH.  These findings and the relatively low AUC values suggest that the measurement 
of thrombin generation is not a good predictive parameter for the detection of PPH in 
this cohort of women. Combining the two cohorts into a single group and recalculating 
the curves yields unsurprising results, as the two contradictory results effectively cancel 
each other out, yielding AUC values close to 0.5 as shown in figure 3.21 below. In 
conclusion the measurement of thrombin generation is a poor predictor of the incidence 
of PPH in this cohort of women. 
 
Figure 3.21 
A.               B. 
  
Figure 3.21. ROC curves showing the predictive value of the ETP (A) and peak height (B) in determining 
whether or not women have a PPH in a cohort of pregnant women. The blue line indicates the ROC curve 
of the parameter. The green line indicates an area under the curve of 0.5. Area under the curve (AUC) is 
shown as an indicator of the predictive value of the parameter. 
 
AUC = 0.482 AUC = 0.514 
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To ascertain whether there was any association between the measurement of thrombin 
generation and the degree of blood loss at delivery, the change in haemoglobin 
following delivery was correlated with both the ETP and peak height. All of the 
correlations yielded non significant p values regardless of whether the case and control 
groups were analysed separately or combined into a single cohort. Data not shown. 
 
3.4 Discussion 
 
The primary aims of this chapter were to investigate the effects of pre-eclampsia on 
thrombin generation and attempt to utilise any observed differences to devise a 
predictive screen for pre-eclampsia. The measurement of thrombin generation was also 
correlated with several end points of pregnancy in order to better assess its clinical 
utility in a prospective study. 
 
The initial investigation of the normotensive pregnant women yielded the anticipated 
results, in that the thrombin generation profile of the cohort of normotensive pregnant 
women was profoundly altered when compared to the normal range described in chapter 
2. The normotensive pregnant women demonstrated a significantly elevated ETP and 
peak height and a significantly reduced lag time and time to peak when compared to 
non-pregnant individuals. This result is consistent with a shift towards a pro-thrombotic 
state during pregnancy, as characterised by an increase in several clotting factors 
throughout pregnancy and a decrease in the levels of or sensitivity towards some of the 
negative regulators of haemostasis (Stirling et al., 1984), (Clark et al., 1998). Although 
this result was unsurprising, elevated levels of ETP were not described as characteristic 
of pregnancy by Eichinger et al. (1999). 
 
The next stage of the analysis provided  compelling evidence for further pro-thrombotic 
changes in women with pre-eclampsia when compared to the cohort of normotensive 
pregnant women. The thrombin generation profile of women with pre-eclampsia of 
varying severity showed a statistically significant increase in both ETP and peak height 
when compared to the cohort of normotensive pregnant women. Whist the changes in 
the ETP were conserved regardless of the severity of a patients pre-eclampsia the 
observed differences for peak height were only seen between the  normotensive controls 
and the women with either mild or moderate the pre-eclampsia. The difference between 
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the peak height of the normotensive cohort of pregnant women and the women with 
severe pre-eclampsia was non-significant, although the small number of patients in this 
group (n = 13) could have contributed to the lack of a significant difference between the 
two groups. What was disappointing concerning this analysis was that there were no 
differences in any of the four thrombin generation parameters between any of the three 
classes of pre-eclampsia severity. As highlighted by von Dadelszen et al. (2009), it 
would be beneficial to diagnose those most in need of intervention (those with severe 
pre-eclampsia) and also to avoid potentially harmful interventions in those patients who 
are unlikely to develop further complications (those with mild pre-eclampsia). The data 
available in this study however does not support the use of any of the thrombin 
generation parameters in the diagnosis of pre-eclampsia severity. It is quite likely 
however that due to the small sample size used in this analysis the comparisons were of 
insufficient power to distinguish between the different levels of pre-eclampsia severity. 
It would be beneficial to investigate the differences regarding the thrombin generation 
profiles of women with differing severity levels of pre-eclampsia in a separate study in 
order to establish whether or not there is actually a difference between the disease 
states. This is especially true of the ETP since it seems to show an increasing trend with 
disease severity in figure 3.3B. 
 
What is clear from the data is that when combined into a single cohort the pre-eclampsia 
cases show the same pattern when compared to the normotensive pregnant controls as 
when they were considered as three distinct groups i.e. a significantly elevated ETP (p = 
0.0007) and peak height (p = 0.0009). This difference is consistent with the further 
activation of the haemostatic system, over and above that which is expected in normal 
pregnancy, as reported in patients with pre-eclampsia (Roberts et al., 2005) (Roberts et 
al., 2002) (Heilmann et al., 2007). The discovery of this difference is profound, since it 
potentially highlights a role for the use of thrombin generation in the diagnosis of pre-
eclampsia.  
 
The analysis of the data for potential confounding factors revealed that it was unlikely 
that any of the parameters for which the case and control groups were matched (age, 
parity, gestational age and ethnicity) impacted on the observed difference between the 
two cohorts. This analysis did flag up an interesting result however. The Black women 
recruited to the study seemed to demonstrate no difference in any of the thrombin 
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generation parameters between those in the case and control cohorts. The same is not 
true of the Caucasian and Asian women who demonstrate the same pattern between the 
case and control cohorts as that which is described above. Interestingly the source of 
this difference is that the normotensive Black controls seem to have a level of thrombin 
generation which is consistent with the pathological level seen in the Caucasian and 
Asian pre-eclampsia cohorts. This result would imply that the baseline level of thrombin 
generation in a normotensive pregnant black woman is higher than that of a Caucasian 
or Asian woman. Assuming that this finding is correct it highlights several potential 
implications, not least of which is the implication for the thrombin generation profile of 
non-pregnant Black individuals. The normal range as described in chapter 2 did not 
make any concession towards the ethnicity of any of the individuals used in the 
analysis. In the light of the potential difference exhibited by the normotensive Black 
controls in this study, this may have been an oversight. It would be worthwhile 
comparing the thrombin generation profile of normal non-pregnant individuals of 
different ethnicities to see if the observed differences between Black and 
Caucasian/Asian normotensive controls still holds true. If this was to be the case a 
separate normal range would have to be established for individuals of Black ethnic 
origin. 
 
The reason as to why the thrombin generation profile of a Black individual should be 
different to that of an individual of a different ethnic origin remains unclear. None of the 
thrombophilia parameters to which thrombin generation assays have been shown to be 
sensitive have separate normal ranges for different ethnic groups when analysed at the 
Royal London Hospital. Indeed the primary difference between individuals of Black 
ethnic origin and other ethnic backgrounds is if anything likely to result in an individual 
of Black ethnic origin having a thrombin generation which is lower than that of a 
Caucasian or Asian individual, the incidence of factor V Leiden is practically zero in 
Black populations in comparison to the incidence of ~6% in Caucasian populations. The 
incidence of factor V Leiden had no impact upon the results produced in this study 
however since the thrombin generation assay was not specifically set up to be sensitive 
to its presence.  
 
It was reported by Eskenazi et al. (1991), that being of Black ethnic origin was a risk 
factor for pre-eclampsia. It is possible that part of the reason for this is that Black 
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women have higher baseline levels of thrombin generation than women of other ethnic 
backgrounds and are therefore naturally more pro-thrombotic. This theory is given 
weight by the findings of Montagnana et al. (2009) who reported that the global 
incidence of venous thromboembolism is highest in individuals of Black origin. It is 
possible that this ethnic predisposition to thrombosis contributes to the development of 
pre-eclampsia, for example by increasing the level of microthrombi formation and 
exacerbating placental infarction following disease onset. A natural prothrombotic 
tendency may also lead to an increase of disease severity; a study by Mulla et al. (2007) 
found that being of Black race was a risk factor for prolonged length of stay in hospital 
among patients with pre-eclampsia. 
 
It is worth considering that the overall number of Black women in this study is quite 
low, which pre-disposes the statistical analysis to errors. This study was not specifically 
set up to analyse the differences in thrombin generation between patients of different 
ethnic groups and as such any conclusions drawn from the data should be subject to 
intense scrutiny. It is possible that the lack of difference between the Black case and 
control cohorts in this study is entirely down to a play of chance during the selection of 
patients. Although all of the individuals in the control cohorts were women with 
uncomplicated pregnancies, it is worth noting that pre-eclampsia is not the only factor 
which can impact upon the thrombin generation capacity of a patient. It is perfectly 
possible that some of women in the Black control cohort have underlying and to this 
point non-symptomatic pro-thrombotic mutations, which have led to higher than 
expected thrombin generation parameters. Since the sample size is small a small number 
of patients of this type would be sufficient to skew the analysis. It is also worthy of note 
that since the control patients were not followed up after the samples were taken there is 
the possibility that some of these women may have subsequently developed pre-
eclampsia later in pregnancy. This is especially true of the small number of women who 
were recruited before 20 weeks gestational age as the diagnosis of pre-eclampsia is not 
possible until this point. It may be that some of the women in the black control cohort 
were therefore classified as controls when they should have been cases thereby reducing 
the statistical difference between the case and control cohorts. This is also theoretically 
possible of the Asian and Caucasian groups although this scenario is likely to impact 
most upon the cohort of Black women due to the relatively small sample size in this 
cohort. The elevated parameters in the Black control cohort are by no means down to a 
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single patient however, the entire cohort have ETP and peak height values in excess of 
the mean of the Caucasian and Asian control groups. It is unlikely (but not impossible) 
that the entire cohort have an undiscovered pro-thrombotic tendency/went on to develop 
pre-eclampsia but since none of the women were screened for thrombophilia before 
analysis or followed up subsequent to analysis this possibility cannot be excluded. 
Further studies therefore must be carried out to elucidate the reasons for the differences 
between the thrombin generation profiles of the different ethnic groups observed in this 
study. 
 
The discovery of a difference in the thrombin generation capacity between women with 
pre-eclampsia and normotensive pregnant women (at least in Caucasian and Asian 
women) led to the possibility of the CAT thrombin generation assay being used to 
predict the onset of pre-eclampsia. In order to ascertain whether this would be possible 
the data in this study was extensively analysed to try and choose an appropriate cut-off 
for the thrombin generation parameters to enable the detection of those patients with 
pre-eclampsia.  
 
What was surprising in this analysis was the relatively low predictive value of the 
PRECOG screen (sensitivity and specificity 58% and 69% respectively). The 
advantages that this screen offers are that it is relatively quick and obviously has a low 
cost to the NHS. It can also be performed in the community, effectively a point of care 
pre-eclampsia screen. What is obvious is that although cheap and convenient, it is not 
particularly effective at excluding low risk patients or accurately defining which 
patients are high risk.  
 
It is debateable what predictive power a ‘good’ screening test for pre-eclampsia should 
have. Obviously in an ideal world any screening tests would have sensitivities and 
specificities of 100%, this is often not the case. In terms of pre-eclampsia a test of high 
sensitivity is likely to result in a higher degree of false positives ultimately leading to 
the specialist referral of a number of patients who do not require further treatment and 
therefore using valuable NHS resources. A high sensitivity assay would however result 
in the specialist referral of those patients who do require further treatment and specialist 
care. A high sensitivity assay is most useful in cases where intervention can have a 
positive effect on the outcome i.e. a curative treatment. This is not always the case for 
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pre-eclampsia where there is no cure available and early intervention may have no 
impact on the clinical outcome. The most effective treatment is premature delivery and 
that is not always desirable.  
 
An assay with high specificity would in the case of pre-eclampsia result in the referral 
of a low number of patients for specialist care, ultimately saving money, but would 
result in a large number of false negatives and may impact on the morbidity and 
mortality of those patients who were not referred for specialist care early in pregnancy. 
The difficulty of devising a ‘good’ screening assay is therefore tempered by trying to 
balance the necessity of saving money verses the clinical impact of failing to refer the 
patients who may develop pre-eclampsia. 
 
The choice of a suitable cut-off for the thrombin generation parameters proved 
problematical in this analysis. Despite the magnitude of the statistical difference 
between the control and case cohorts the two populations showed a high degree of 
overlap as shown in figures 3.11 A and B, with a number of the control patients 
showing very high levels of thrombin generation and some of the pre-eclamptic patients 
demonstrating low levels of thrombin generation. Indeed the highest ETP value found in 
both cohorts was one of the normotensive controls and the lowest value for ETP in 
either cohort was found to be one the severe pre-eclampsia cases. The reason for this 
overlap can only be postulated, it is possible that a number of women in the control 
cohort had underlying pro-thrombotic conditions/or were misclassified as controls (as 
discussed above), this is a likely scenario for those women in the normotensive control 
group who showed extreme values for both ETP and peak height. It may also be the 
case that the pro-thrombotic shift seen in normal pregnancy is more pronounced in some 
women when compared to others. This is reflected in the fact that some normotensive 
pregnancies are associated with thrombosis where as others have post partum 
haemorrhage. The pre-eclampsia patients also showed a high level of variation and this 
is consistent with the heterogeneous nature of the disease state itself. As discussed 
above it is possible that there are many pathways all leading to the same net result of the 
systemic pre-eclampsia condition. Some but by no means all of these involve activation 
of the coagulation cascade, which results in the elevated thrombin generation 
parameters seen in this analysis. It may be that the measurement of thrombin generation 
may be more sensitive to the development of some ‘types’ of pre-eclampsia rather than 
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others. It is also worth noting that this is not a longitudinal study and that the subjects in 
this analysis were analysed only once. It may be that the pre-eclamptic patients with low 
thrombin generation parameters have naturally low levels all of the time and that the 
level of thrombin generation demonstrated in this analysis represents a significant jump 
from their base line levels before the start of their pregnancy, and therefore the onset of 
the disease. It may be that the most effective screen for pre-eclampsia is the monitoring 
of an individuals thrombin generation before and during pregnancy and that the 
magnitude of any change is the best indicator of disease onset. It is impossible to either 
prove or disprove this theory using the data obtained in this study, further 
experimentation is necessary in order to prove whether or not this is indeed the case. 
 
Based on the available information, the choice of cut-off for ETP and peak height in 
order to establish whether an individual is high risk or not can greatly affect the 
sensitivity and specificity of the assay. Choosing a low cut-off value (such as 1SD 
below the mean of the case cohort) increases the sensitivity of the assay, whereas 
increasing the cut-off value leads to an increase of the specificity of the assay (at the 
expense of the sensitivity). Using extreme cut-off values, such as ±2 SD from the mean 
of either the case or control cohorts can result in very high sensitivity or specificity 
values but this is achieved by characterising practically all women as high risk or low 
risk and is therefore unpractical. The measurement of thrombin generation is 
unnecessary when the cut off will classify all women as high risk. The use of a cut-off 
which is ±1SD from the mean of either group appears therefore to be more clinically 
relevant.  
 
The combined use of both ETP and peak height in the same analysis (where both 
parameters must be elevated in order for an individual to be classified as high risk) 
appears more effective than using just the ETP alone as the small loss in sensitivity 
(from 92% to 86%) is more than compensated for by the increase in specificity (22% to 
43%). These statistics refer to the use of a cut-off of 1SD below the mean values of the 
case cohort. When considering the cut-off of 1SD above the mean values of the control 
cohort the impact of using both parameters together is much less pronounced. What is 
clear from these analyses is that the measurement of thrombin generation is far from 
perfect as a stand-alone assay for the detection of pre-eclampsia in this cohort of 
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women. Evidence in support of this can also be seen in the modest area under the curve 
values (~0.70) calculated from the ROC curves in figure 3.12. 
 
Since it is clear that the use of thrombin generation cannot adequately separate those 
women who have pre-eclampsia from those who have not, it is perhaps better to focus 
on cut-off values that will result in higher sensitivity values. This remains the case even 
if the positive predictive value is low (high degree of false positives) since this will 
result in the separation of a cohort without disease from a cohort who may have disease. 
Specialist referral of those women will then reveal which have disease. If a high 
specificity cut-off was chosen there would be a high number of false negatives with no 
means of picking out the women at risk until the onset of pre-eclampsia. 
 
 When considering the above statement the use of both thrombin generation and the 
PRECOG score in tandem can provide more useful clinical information than either 
screening test can on its own (thrombin generation parameter cut-off greater than 1SD 
below the mean of the case cohort). The primary clinical utility of combining the two 
assays is to enhance the negative predictive value of the screens. From this study 94% 
of the women classified as low risk by both thrombin generation and the PRECOG 
score did not have pre-eclampsia. The use of this ‘double negative’ approach is 
analogous to the use of a low risk clinical score in conjunction with a normal D-dimer 
in the exclusion of DVT (Wells et al., 2003).  The assays can be combined in a number 
of ways in order to classify women as high risk or not, which can progressively increase 
the sensitivity of the assay but decrease the specificity as a result. This is shown in table 
3.12 below.  
 
All of the combinations in the table retain the 94% negative predictive value for the 
‘double negative’ results. Which combination is judged ‘best’ is a difficult decision. 
Based on the earlier assumptions classifying patients as high risk if they have either 
high risk thrombin generation parameters (ETP > 2263nM Thrombin and a peak height 
of >445nM Thrombin) or a high risk PRECOG score (or both), gives the highest 
sensitivity value. This would ensure that 98% of women with pre-eclampsia received 
specialist referral, although it would mean that 71% of women who did not have pre-
eclampsia would also receive further specialist testing. Since the incidence of pre-
eclampsia in the UK is approximately 2-7%, this would mean specialist referral for 
- 176 - 
 
about two thirds of all normotensive pregnancies. So although this is the most effective 
screen for the detection of pre-eclampsia which can be devised using a combination of 
thrombin generation and the PRECOG screen, it is not the most cost effective. It is 
perhaps better to give the thrombin generation results more weight than the PRECOG 
score in determining high risk status, whilst it is true that this reduces the sensitivity it 
would in absolute terms reduce the number of specialist referrals considerably. Whether 
this cost benefit outweighs the cost in terms of morbidity in the cohort of women who 
would not receive specialist care as a result is another question. Whichever 
classification is used, the women characterised as low risk by both assays can be 94% 
certain that they will not develop disease. Practically the measurement of thrombin 
generation combined with the PRECOG score would not be too difficult, even if the 
patient was assessed in the community. The sample handling procedures for the 
measurement of thrombin generation are not too stringent as discussed in chapter 2, 
indeed as long as the sample reaches the referral laboratory in less than 24 hours the 
analysis should not be affected. The thrombin generation assay is also relatively cheap 
with a cost of approximately £3 per assay. 
 
Table 3.12 
High Risk Classification Sensitivity (%) Specificity (%) 
Elevated Thrombin generation and high 
risk PRECOG only. 
37 75 
High risk PRECOG and Thrombin 
generation and high risk PRECOG only 
49 61 
High Risk PRECOG and Thrombin 
generation and Thrombin generation only 
86 43 
High Risk PRECOG or High risk 
Thrombin generation 
98 29 
Table 3.12. Sensitivity and specificity values obtained when different strategies are employed in order to 
determine whether an individual is high risk of developing pre-eclampsia, using a combination of the 
PRECOG score and a cut off for thrombin generation of greater than 1SD below the mean values of the 
case cohort. 
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A final consideration as to the classification of women as either high or low risk is 
whether the Black women should be excluded from the analysis. In actual fact when 
considering the scoring system for high risk as described above the exclusion of the 
Black women makes very little difference to the figures obtained. This is due to the fact 
that the cohort of Black individuals is evenly distributed between the cases and the 
controls and removing them from the analysis removes as many actual positives as it 
does false positives. 
 
Overall this study has shown that the thrombin generation profile of a woman with pre-
eclampsia is distinct from that of a normotensive pregnant woman (in the Caucasian and 
Asian cohorts) and that this difference when used in conjunction with the PRECOG 
score can be used to effectively distinguish a cohort of women from this study who do 
not have disease from a cohort of women in which pre-eclampsia is prevalent. This 
potentially highlights a new clinical application of the CAT thrombin generation assay. 
 
One of the most profound findings of this study as a whole is the successful 
combination of the thrombin generation analysis (the ETP in particular) with the other 
parameters analysed by flow cytometry in the same cohort of patients. These include 
platelets expressing P-selectin, P-selectin expressing microparticles, platelet-monocyte 
aggregates and platelet-neutrophil aggregates. Although combined data was only 
available in 92 of the 104 women recruited to the study the predictive values far outstrip 
any of those obtained when either considering thrombin generation alone or in 
combination with the PRECOG score. The sensitivities and specificities of the analysis 
were 83% and 80% respectively. The positive and negative predictive values were 81% 
and 82% respectively (Macey et al., 2010a). As a screening test the cost of performing 
the combined analysis would exceed the cost of just thrombin generation and the 
PRECOG screen but the benefits of reduced specialist referral rates would more than 
compensate for this.  What was interesting regarding this analysis was the comparison 
between healthy normal controls, normotensive pregnant women and women with pre-
eclampsia when considering the different parameters. The ETP and peak height showed 
a step wise progression throughout those three groups. The normotensive pregnant 
women showed significantly elevated ETP and peak height values when compared to 
the normal range and the pre-eclamptic women had significantly higher values still. 
This pattern however was not conserved when considering the parameters measured by 
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flow cytometry. There were no differences in the levels of platelets expressing P-
selectin, P-selectin expressing microparticles and platelet-monocyte aggregates between 
the normotensive pregnant women and a cohort of healthy normal individuals. The 
women with pre-eclampsia however demonstrated significantly elevated levels of all 
three of these parameters when compared to the normotensive pregnant women (p= 
<0.03 in all cases). What this result could imply is that whereas the difference in 
thrombin generation seen between the normal range and the normotensive pregnant 
women could be due to changes in the plasma levels of some clotting factors. The 
further elevation in both peak height and ETP seen in women with pre-eclampsia over 
and above that which is normal in pregnancy may be due to the elevated levels of 
platelets expressing P-selectin, P-selectin expressing microparticles and platelet-
monocyte aggregates. To be more precise the changes could be due to the elevated 
levels of microparticles found in the blood of patients with pre-eclampsia. The 
preparation of patient’s plasma for thrombin generation should both exclude platelets 
and platelet monocyte aggregates but is unlikely to remove the microparticles. 
 
The presence of P-selectin expressing microparticles could impact upon thrombin 
generation in a number of ways. This is because the measurement of thrombin 
generation relies on the addition of a fixed quantity of both tissue factor and 
phospholipid. Microparticles themselves are effectively phospholipid vesicles and can 
induce the expression of tissue factor from leukocytes (Barnard et al., 2005); it is quite 
likely therefore that they can elevate the level of thrombin generation in a patient’s 
plasma by elevating the level of tissue factor and or phospholipids in the reaction. This 
possibility is discussed in more depth in chapter 4. It is important to note that this is 
another potential explanation as to why all of the women with pre-eclampsia did not 
demonstrate an elevated level of thrombin generation. Although elevated levels of 
platelets expressing P-selectin, P-selectin expressing microparticles and platelet 
monocyte aggregates are elevated in pre-eclampsia (Lukanov et al., 2009) (Lok et al., 
2007) (Macey et al., 2010a) they are by no means elevated or elevated to the same 
extent in all the patients analysed.  
 
A further point of note is that the parameters analysed via flow cytometry described 
above are also elevated in association with cardiovascular disease. Indeed there is a 
great deal of evidence showing a link between pre-eclampsia and subsequent risk of 
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cardiovascular disease in later life, with pre-eclamptic women approximately twice as 
likely to develop cardiovascular disease when compared to normotensive pregnant 
women (Craici et al., 2008). Assuming the CAT thrombin generation assay is sensitive 
to the presence of microparticles in the blood of women with pre-eclampsia it may also 
be sensitive to the changes in microparticle number seen in patients with cardiovascular 
disease. If this is the case then perhaps thrombin generation analysis may also be of use 
in the detection of cardiovascular disease. 
 
Despite the many compelling findings of this investigation, it is apparent that as 
mentioned above, this study is not longitudinal i.e. the individuals recruited to the study, 
whether cases or controls, were only analysed once. In some cases the analysis occurred 
quite late in pregnancy and although this helped in determining the effect of gestational 
age on the parameters analysed, it does mean that it is unknown when during pregnancy 
the parameters investigated begin to manifest their increased magnitude in pre-
eclampsia. In other words it is currently unknown whether the parameters flagged as 
raised in this study in the pre-eclamptic patients are precursors to disease onset or are 
manifested only in late stage disease. The most effective screening test would involve 
the use of those parameters which demonstrated the pathological changes associated 
with pre-eclampsia earliest in pregnancy. Without analysis of these parameters in a 
prospective manner it will be impossible to determine whether the measurement of 
these parameters will make an effective screen for the detection of pre-eclampsia or not.  
 
What this study was intended to show then, is that these parameters are elevated in 
association with pre-eclampsia and that suitable cut-off values can be determined for 
these parameters which enable the case and control cohorts to be distinguished. It was 
necessary to perform this study retrospectively in order to ensure that a sufficient 
number of cases were present to allow a more accurate determination of any cut-off 
values. If this were attempted as a prospective study upwards of 700 patients would 
need to be recruited to obtain the same number of cases. 
 
A further point to note in this study is that these experiments were intended to highlight 
the clinical utility of what could be considered the ‘basic’ thrombin generation assay i.e. 
the use of commercially produced reagents apparently containing known levels of tissue 
factor and phospholipids (5pM and 4µM respectively). No attempt was made to 
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optimise the sensitivity of this assay for the detection of disease in pre-eclamptic 
women. It is possible that adjusting the concentration of tissue factor and/or the 
concentration of phospholipids in the reagents may make the assay more sensitive in the 
detection of pre-eclampsia. One area that this may be of use is in determining whether 
or not there is a difference in thrombin generation with disease severity. As highlighted 
above there was no difference between any of the four thrombin generation parameters 
in any of the levels of disease severity in this study using reagents with 5pM tissue 
factor and 4µM phospholipids, although figure 3.3B is suggestive of the fact that the 
ETP is increasing in-line with disease severity. It is possible that the relatively high 
concentrations of tissue factor and phospholipids used in this study are creating an 
artificial plateau for the results (although they are not leading to substrate depletion) and 
that this is restricting the magnitude of difference that can be measured between patients 
with mild, moderate and severe pre-eclampsia. It may be that the use of a reagent with 
lower levels of tissue factor or indeed phospholipids may remove this plateau and 
therefore allow the determination of disease severity in women with pre-eclampsia 
using the thrombin generation assay. If the elevated level of thrombin generation in 
women with pre-eclampsia is indeed due to elevated levels of circulating microparticles 
(which are effectively phospholipid vesicles) then the use of a reagent with a lower 
concentration of phospholipids would certainly make the assay more sensitive to the 
detection of pre-eclampsia. Optimisation of the thrombin generation assay in this 
manner may also allow for a much more effective cut-off to be calculated in order to 
predict disease onset in pregnant women. Further work is required to elucidate whether 
or not this is the case. 
 
Although assay optimisation may improve the results presented it is important to note 
that at the time this study was undertaken the only commercial reagents available were 
those which contained 5pM tissue factor and 4µM phospholipids, reagents of different 
strengths would have had to have been manufactured in-house, leading to potential 
problems with batch to batch variation. 
 
In order to better highlight the clinical utility of the commercially produced reagents it 
was decided to correlate the thrombin generation data measured in the case and control 
cohorts with some end points of pregnancy in order to elucidate the effectiveness of the 
measurement of thrombin generation in a true prospective study. 
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The measurement of thrombin generation as characterised by the ETP and peak height 
parameters was shown to have little predictive value in determining either the mode of 
delivery or the risk of PPH in this cohort of women. The failure of the measurement of 
thrombin generation to correlate with either blood loss during delivery defined as a 
continuous variable or the incidence of PPH defined as a discreet variable was 
unanticipated. Intuitively blood loss and thrombogenicity seem intrinsically linked 
although the poor AUC values attained when the case and control cohorts are combined 
(0.482 and 0.514 for the ETP and peak height respectively) shown in figure 3.21 imply 
this is not the case. On reflection this result is not surprising as blood loss during 
pregnancy is not always spontaneous and can be due to a number of medical/surgical 
complications and is not therefore solely dependent on an individual’s capacity to 
generate thrombin. There is also the potential for a large number of confounding 
variables in this analysis, not least of which is the incidence of LSCS and other surgical 
procedures which may exacerbate blood loss in patients. There is also the possibility 
that some of the patients in this study may have had red cell transfusions which could 
have masked the magnitude of blood loss and therefore skewed the results of this 
analysis. In real terms the impact of this is likely to be small as the number of patients 
requiring a transfusion would be low and haemoglobin levels are frequently monitored 
before transfusing patients. In order to better gauge the relationship between thrombin 
generation and blood loss during delivery a much larger study must be undertaken as 
this will reduce the impact which confounding variables can have on the analysis and 
also allow the determination of relationships between thrombin generation and much 
rarer outcomes of delivery such as fatal PPH. 
 
The apparent lack of correlation between the ETP or peak height with the mode of 
delivery as evidenced by the low AUC values, especially in the case cohort (0.502 for 
both ETP and peak height) was also perhaps unsurprising. Initially it was felt that the 
incidence of LSCS would be higher in the case cohort when compared to the 
normotensive controls because women with pre-eclampsia often have emergency 
deliveries to prevent disease progression. Since the peak height and ETP are typically 
raised in the case cohort when compared to the controls it was felt that the two 
parameters might correlate quite well. This was not the case; and is probably because 
the incidence of LSCS was quite similar in both the case and control cohorts 
highlighting that pre-eclampsia is not the only reason for women to undergo LSCS. 
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What is interesting regarding this analysis is that the predictive value of the ETP in  
whether or not a pregnant woman will have an LSCS is higher in the control cohort 
when compared to the case cohort (figure 3.18), although the AUC is far from 
compelling at only 0.629. 
 
The measurement of both the ETP and peak height were found to have statistically 
significant correlations with both the birth weight of the baby and the length of time 
spent in hospital at delivery. The correlation between birth weight and thrombin 
generation was also a parameter in which an association was thought to be likely, since 
those women with pre-eclampsia often have pre-term babies (which have a lower birth 
weight) in order to prevent disease progression. The correlations between ETP/ peak 
height and birth weight were only apparent when the data from the case and control 
cohorts were combined. This is probably an artefact of the relatively weak statistical 
trend (R values of 0.26 and 0.27 for ETP and peak height respectively) but nevertheless 
this finding highlights a statistically significant association between both increasing 
ETP and peak height with decreasing birth weight in this cohort of women. This finding 
is pleasing since it suggests a new clinical application of the measurement of thrombin 
generation, since it may be able to highlight which pregnancies may be at risk at 
delivery. 
 
The correlation between ETP and peak height with the length of stay in hospital at 
delivery was even more compelling with R values of 0.44 and 0.29 for the ETP and 
peak height respectively. Although these values did decrease when the outlying data 
was removed, this did not markedly reduce the statistical significance of the correlation 
(p=<0.001 and <0.02 for the ETP and peak height respectively).  One of the most 
interesting findings in this analysis is that the correlation of the ETP with the length of 
stay in hospital was the only correlation from this phase of analysis which demonstrated 
a statistically significant trend in both the case and control cohorts prior to them being 
combined. This implies that this trend may be independent of pre-eclampsia. 
 
This analysis would benefit from the recruitment of more pregnant women in order to 
fill in the gap between the outlying value (seen in figure 3.17 A and B) and the rest of 
the cohort of women. If this further analysis confirms the trend suggested here then it 
provides a very useful clinical application of the measurement of thrombin generation in 
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pregnancy, since the magnitude of the ETP can potentially highlight which women will 
need the most post natal care. 
 
In conclusion this phase of analysis has yielded some very promising results, since it 
highlights two new potential roles for the measurement of thrombin generation using 
the ‘basic’ CAT assay during pregnancy; including whether or not the baby will have a 
low birth weight and providing an indication of the level of maternal care required post 
delivery. It may be possible to optimise the CAT assay as discussed above to enhance 
the correlations described and therefore further enhance the clinical utility of the 
measurement of thrombin generation. 
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4.1 Introduction 
 
Following the discovery that there were no differences in the levels of P-selectin 
expressing microparticles between normotensive pregnant women and a cohort of non-
pregnant individuals and that the numbers of P-selectin expressing microparticles were 
significantly elevated in a cohort of women with pre-eclampsia in comparison (Macey 
et al., 2010a), it was hypothesised that the increase in thrombin generation observed 
between a cohort of women with pre-eclampsia and a cohort of normotensive pregnant 
women was due, in part, to the increase in the number of circulating microparticles. The 
primary aim of this chapter was to investigate the impact of microparticles on thrombin 
generation. 
 
4.1.1 Microparticles 
 
Microparticles are vesicles derived from the budding of cell membranes of multiple cell 
types including: platelets, endothelial cells, monocytes, granulocytes and erythrocytes. 
Typically they range in size between 0.2-2µm in diameter, although those derived from 
erythrocytes are generally smaller, being approximately 0.15 µm in diameter (Piccin et 
al., 2007). Platelet derived microparticles are by far the most abundant in the 
circulation, constituting between 70-90% of the total number of microparticles 
(Flaumenhaft, 2006). Indeed these were the first to be described, experiments dating as 
far back as 1949 were able to identify a precipitable factor which could be isolated from 
platelet free plasma and was capable of inducing thrombin generation (Chargaff and 
West, 1949). Further experimentation (Wolf, 1967) revealed that there was a linear 
correlation between the platelet count of an individual and the level of ‘Platelet dust’ 
(platelet microparticles) in a sample of platelet free plasma from the same individual. 
The use of electron microscopy conclusively proved that the microparticles originated 
from the surface of activated platelets. It was not until more recently that microparticles 
of different cellular origins such as monocytes (Satta et al., 1994) and endothelial cells 
(Combes et al., 1999) were described. Typically the different microparticle subtypes can 
be differentiated via flow cytometry due to the differential expression of surface 
proteins. Platelet microparticles express CD42b (GpIb), GpIIb-IIIa, CD62P (P-selectin), 
CD31, CD63, CD41a and CD61 whereas endothelial microparticles express CD31, 
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CD34, CD51, CD52, CD62E (E-selectin), CD62P P-selectin, CD105 (endoglin) and 
CD146 (Piccin et al., 2007). Although these lists are by no means exhaustive.  
 
4.1.2 Formation of Microparticles 
 
Regardless of their cellular origin it is believed that microparticle formation is 
dependent on the disruption of the asymmetric distribution of phospholipids in the cell 
membrane. The expression of phospholipids is conserved and maintained throughout all 
cell types. Phosphatidylcholine and sphinomyelin are expressed externally whereas 
phosphatidylserine and phosphatidyl-ethanolamine are found on the internal cell 
membrane. This asymmetrical distribution is maintained by a number of cellular 
proteins including Aminophosholipid translocase, floppase, scramblase, calpain and 
gelsolin, although the latter is only found in platelets. 
 
Aminophospholipid translocase is an enzyme whose activity is dependent on the 
presence of ATP. Its function is specific for the transport of aminophospholipids 
(phosphatidylserine and phosphatidyl-ethanolamine) from the outer layer of the cell 
membrane to the inner layer.  Floppase is similar to aminophospholipid translocase in 
that it too is dependent on ATP for its activity but its function is to export lipids from 
inside of the cell to the outside of the cell. Interestingly its function is not limited to 
specific lipids. Scramblase is usually inactive, but when activated facilitates the passage 
of lipids across the cell membrane. Whereas aminophospholipid translocase, floppase 
and scramblase are all cell membrane bound proteins both calpain and gelsolin are 
cytoplasmic enzymes. Typically microparticle formation is triggered by cellular 
activation, apoptosis or necrosis; these events are generally accompanied by an influx of 
calcium ions released by the endoplasmic reticulum. The influx of calcium ions leads to 
the inhibition of aminophospholipid translocase activity and the activation of 
scramblase. This ultimately leads to the loss of lipid asymmetry across the cell 
membrane, with the expression of phosphatidylserine on the external membrane. 
Calpain is also activated in the presence of calcium ions. Calpain is a cysteine 
proteinase of the papainase family and can cleave long actin filaments thereby 
disrupting the cytoskeleton (Piccin et al., 2007). It has also been shown that calpain can 
cleave both type I and type II phosphatidylinositol phosphate (PIP) kinases (O’Connell 
et al., 2005). PIP kinases mediate the conversion of PIP to phosphatidylinositol 4,5-
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biphosphate (PIP2). Enrichment of PIP2 in cell membranes increases the membrane-
cytoskeleton adhesion energy (Raucher et al., 2000) and incubation of platelets with 
PIP2 inhibits microparticle formation when stimulated by agonists such as thrombin and 
collagen (O’Connell et al., 2005). The action of calpain is therefore two fold in that it 
can both destabilise the cellular cytoskeleton directly and prevent its reinforcement via 
the inhibition of PIP2 formation. In platelets actin microfilaments are further protected 
by proteins such as Adductin and Cap Z which cap the actin filaments and prevent the 
interaction of actin with other proteins and ultimately therefore maintain the structure of 
the cellular cytoskeleton. These capping proteins are themselves the target of proteolytic 
cleaveage mediated by the enzyme gelsolin. Gelsolin is activated by calcium ion influx 
following platelet activation (Piccin et al., 2007). The disruption of the cytoskeleton 
mediated by calpain and gelsolin (in platelets) is central to microparticle formation. 
With the cell membrane no longer anchored to the cytoskeleton it begins to bud from 
the cell surface, eventually leading to detachment of the bud from the cell and to the 
production of a microparticle which has exposed phosphatidylserine on its external 
surface. 
 
It is known that individuals maintain a constant baseline level of microparticle 
expression (Brogan et al., 2004) but given that platelet microparticles are cleared 
rapidly from the circulation following infusion into mice (Flaumenhaft, 2006) it is 
uncertain whether the level of platelet activation seen in healthy individuals is sufficient 
to maintain these levels of microparticles. This would imply that platelet activation is 
not the only mechanism by which platelet microparticles are produced. Other potential 
routes of production include the shedding of microparticles directly by megakaryocytes 
or production of microparticles from ‘resting’ platelets. Evidence that both of these 
routes of microparticle production are possible has been shown by in vitro 
experimentation. Megakaryocytes cultured for 11-14 days show evidence of 
microparticle production (Rozmyslowicz et al., 2003) and platelet concentrates also 
exhibit vesiculation without any decrease in the number of platelets (Bode and Miller, 
1986). The generation of microparticles from stored platelets is only partially blocked 
by inhibitors of platelet activation (Bode et al., 1991). The exact contribution that these 
processes make towards the number of platelet microparticles in vivo remains to be 
elucidated.  
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4.1.3 The Function of Microparticles 
 
The fact that the baseline levels of microparticles are maintained in a healthy individual 
and that the majority of microparticles in circulation are derived from platelets (or 
megakaryocytes) would imply a role for microparticles in the maintenance of 
haemostasis. Evidence that this is indeed the case is provided by individuals with Scott 
syndrome, a rare autosomal recessive disorder. Individuals with this condition have 
mutations which impact upon the function of the scramblase protein and as a direct 
result of this the numbers of microparticles in these patients are reduced, as is the 
expression of phosphatidylserine on the surface of the microparticles which are present. 
This leads to a severe bleeding phenotype in these patients despite apparently normal 
platelet function (Zwaal et al., 2004).  
 
The presence of phosphatidylserine on the surface of microparticles provides binding 
sites for a number of activated clotting factors including those associated with both the 
tenase and prothrombinase complexes (Berckmans et al., 2001)(Sims et al., 1989). 
Indeed the expression of phosphatidylserine by microparticles allows the concentration 
of clotting factors to reach the levels necessary to achieve optimum kinetics for the 
generation of thrombin (Morel et al., 2006). The shielding of phosphatidylserine results 
in a decrease in the enzymatic activity of the tenase and prothrombinase complexes by a 
factor of 200 and 1000 respectively (del Conde et al., 2005a). This then is the likely 
physiological cause of the bleeding seen in patients with Scott syndrome. A similar yet 
distinct disorder characterised by a deficiency in microparticle generation termed 
Castamans defect has also been described (Castaman et al., 1996). Patients with this 
condition present with a bleeding tendency and have a prolonged bleeding time. These 
conditions provide compelling evidence that microparticles play a crucial role in 
coagulation.  
 
Their role in haemostasis is not limited to providing a surface for the assembly of the 
tenase and prothrombinase complexes however. There is evidence to show that 
endothelial derived microparticles can bind high molecular weight multimers of von 
Willebrand factor (vWF) and enhance their stability. It has also been shown that vWF 
bound in this manner has a higher affinity for platelet binding than soluble vWF (Jy et 
al., 2005). There is also a large body of evidence that microparticles express tissue 
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factor, a potent activator of the coagulation cascade. The exact cellular origin of tissue 
factor expressing microparticles is the subject of some debate, whilst it is clear that 
monocytes can produce microparticles enriched with tissue factor (del Conde et al., 
2005b), it was shown that 90% of tissue factor expressing microparticles in the 
circulation of healthy volunteers originated in equal shares from microparticles derived 
from platelets and monocytes. Interestingly in relative terms this equates to 91% of all 
monocyte derived microparticles expressing tissue factor in contrast to only 6% of 
platelet derived microparticles (Hron et al., 2007).  
 
Initially the tissue factor expressed by platelet derived microparticles was thought to be 
produced by other cells since tissue factor could not be isolated from megakaryocytes 
(Muller et al., 2003). It was thought that tissue factor was transferred to platelets 
following an interaction with tissue factor expressing microparticles derived from 
leukocytes mediated via the binding of CD15 to P-selectin on the surface of platelets 
(Rauch et al., 2000). Although it was demonstrated subsequently that platelets can 
synthesise and translocate biologically active tissue factor to their cell membranes 
(Panes et al., 2007). The role that these tissue factor expressing microparticles play in 
vivo is unclear, in vitro experimentation using human blood and in vivo experiments 
using murine models have postulated a role in the recruitment of these microparticles to 
the sites of vascular injury where presumably they act as a trigger for fibrin production 
(Giesen et al., 1999)(Falati et al., 2002). The recruitment of these microparticles was 
shown to be mediated by the interaction of PSGL-1 on the microparticle surface and P-
selectin on the surface of platelets at the site of injury (Falati et al., 2003). Other studies 
have suggested that the concentration of tissue factor on the surface of microparticles in 
the circulation of a healthy patient whose blood remains unstimulated with cytokines is 
below the threshold needed to initiate in vivo thrombin generation (Butenas et al., 
2005). Intuitively this result would be anticipated as if the levels of tissue factor were 
sufficient to induce thrombin generation prior to activation the individuals in this cohort 
would demonstrate a predisposition towards thrombus formation. Subsequent activation 
of platelets in these patients did not result in a significant increase in the level of tissue 
factor expression however. It is worth noting that the binding of P-selectin expressed by 
platelets or microparticles can induce tissue factor expression in monocytes via binding 
of PSGL-1 (Barnard et al., 2005) and that this induction of tissue factor may cause the 
local concentration of tissue factor to rise to a level capable of triggering the formation 
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of fibrin. It may be the case that tissue factor expressing microparticles are recruited to 
the sites of vascular injury not to initiate clot formation but to stabilise the thrombus by 
inducing further fibrin production (Wagner, 2005). The recruitment of endothelial cell 
derived microparticles bound to vWF would also help maintain clot stability by 
enhancing platelet aggregate formation. 
 
The involvement of microparticles in haemostasis may also not be limited to thrombus 
formation, as microparticles have also been shown to express negative regulators of 
thrombosis such as thrombomodulin, TFPI (Steppich et al., 2005) and Protein C (Satta 
et al., 1997). It is therefore likely that the development of a thrombus is dependent on 
the relative signal strengths of the pro-coagulant and anti-coagulant factors. 
 
Although there is significant evidence regarding the role which microparticles play in 
haemostasis, this is by no means the only function of microparticles in vivo. There is 
evidence to suggest that microparticles effectively act as long range signalling 
molecules which can act on cells other than those from which they are derived and that 
the function of these microparticles is dependent on the molecules they express on their 
cell membranes (Martínez et al., 2005). Microparticles can interact with endothelial 
cells to affect both vasoreactivity and angiogenesis. Platelet microparticles can both 
activate the endothelium and cause vasoconstriction via the modification of arachidonic 
acid metabolism in the target cells, leading to the generation of thromboxane A2. It has 
been shown that platelet microparticles can enhance arachidonic acid mediated 
contractions of the aorta in a rabbit model (Pfister, 2004). Endothelial cell derived 
microparticles can also impact on the regulation of vascular tone by inhibiting 
vasodilation. This effect is mediated by the inhibition of NO and was demonstrated in 
vitro in a rat model (Brodsky et al., 2004).  
 
Microparticles of platelet and endothelial origin can also induce angiogenesis but the 
mechanisms by which this effect is mediated differs between them. Platelet 
microparticles isolated from normal individuals have been shown to promote 
proliferation, migration and tube formation in cultured endothelial cells by the 
activation of the mitogen-activated protein kinase (MAPK) pathway (stimulation of 
EGFR)(Kim et al., 2004). In contrast endothelial cell microparticles have been shown to 
induce angiogenesis facilitated by the binding of metalloproteinases which are 
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necessary in order to induce proteolytic breakdown essential for vascular invasion 
(Taraboletti et al., 2002). 
 
The microparticles produced via cellular activation are known to differ from those 
produced via apoptosis in terms of both size and lipid/protein composition (Martínez et 
al., 2005) the surface markers have also been shown to be distinct when endothelial 
microparticles are produced by either activation or apoptosis (Jimenez et al., 2003). 
Whether the function of these microparticles differs distinctly in line with these 
observations is unclear, but it has been postulated that microparticle generation may 
form part of a cellular response to sub-lethal complement attack, since cells can shed 
complement components from their surface in this manner (Piccin et al., 2007). It has 
also been suggested that the expression of phosphatidylserine on the surface of 
apoptotic cells and microparticles might act as a signal for the removal of these 
cells/microparticles from the circulation via macrophages, since activated macrophages 
express specific phosphatidylserine receptors (Comfurius et al., 1995). 
 
4.1.4 Microparticles and Disease 
 
Whilst it is known that microparticles play important roles in normal physiology, such 
as in the maintenance of haemostasis as well as being involved in both 
vasoconstriction/dilation and angiogenesis, a large number of investigations have 
studied how microparticle function is subverted in disease. 
 
Given that one of the primary roles of microparticles is the regulation of haemostasis it 
is perhaps no surprise that elevated levels of microparticles have been reported in a 
number of thrombotic conditions such as heparin induced thrombocytopenia (HIT), 
where platelets are activated in an autoimmune reaction, Sepsis, in which bacterial 
lipopolysaccharide can activate monocytes resulting in tissue factor expression (Satta et 
al., 1994), Thrombotic Thrombocytopenic Purpura (TTP) (Galli et al., 1996), 
Paroxysmal Nocturnal Haemoglobinuria (PNH)(Hugel et al., 1999) and Sickle cell 
disease (Tomer et al., 2001). Interestingly the endothelial microparticles expressed in 
PNH and sickle cell disease express CD144 and CD105 both of which have relatively 
short half-lives in the circulation, implying that both disorders are characterised by 
chronic endothelial damage/activation (Piccin et al., 2007). Elevated numbers of 
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endothelial and platelet derived microparticles have also been demonstrated in patients 
with active venous thromboembolism (Heresi et al., 2003). It was also shown that the 
numbers of platelet microparticles can be combined with the measurement of both P-
selectin expression and D-dimer to predict DVT diagnosis with a sensitivity and 
specificity of 73% and 81% respectively (Rectenwald et al., 2005). An increase in 
circulating microparticles has been linked with other thrombotic disorders such as 
ischemic cerebrovascular accidents, transient ischemic attacks (Doeuvre et al., 2009) 
and multi-infarct dementia (Lee et al., 1993). Interestingly microparticles have also 
been linked to the pathology of cerebral malaria. The circulating levels of microparticles 
were only shown to be elevated in patients with severe malaria complicated by coma. It 
was also shown using a knockout mouse model, in which normal microparticle 
production was impaired, that the presence of microparticles may be necessary for 
disease progression to cerebral malaria. The knockout mice showed a complete 
resistance to cerebral malaria following infection with the parasite (Combes et al., 
2006). 
 
There is also evidence of elevated microparticle expression in a number of systemic and 
chronic conditions such as diabetes mellitus (Diamant et al., 2002), renal failure (Faure 
et al., 2006) and coronary artery disease, where the levels of circulating endothelial 
derived microparticles were shown to correlate with the degree of stenosis in a cohort of 
84 patients (Bernal- Mizrachi et al., 2003). It was also demonstrated that the number of 
tissue factor expressing microparticles was two-fold higher in a cohort of 20 patients 
with colorectal cancer in comparison with a cohort of healthy normal individuals (Hron 
et al., 2007), thus suggesting a possible mechanism as to the cause of thrombosis in 
oncology patients. The authors postulated that the circulating levels of microparticles 
may explain why the location of vascular thrombosis in oncology patients if often distal 
to the site of the tumour. Another study showed enhanced microparticle tissue factor 
activity in 50 patients with either pancreatic or breast adenocarcinoma and that 
increasing activity correlated with disease severity. Interestingly the patients in the 
cohort with a venous thromboembolic event all had microparticle tissue factor activity 
in excess of the 99
th
 percentile of the activity demonstrated by a cohort of normal 
individuals (Tesselar et al., 2007). 
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It is worthy of note that an elevated level of microparticles is not always associated with 
a detrimental effect, indeed the elevation in the numbers of platelet microparticles 
reported in autoimmune thrombocytopenias may well be protective against bleeding and 
are postulated to be the reason why such patients can show relatively mild symptoms 
despite profound thrombocytopenia (Jy et al., 1992).  
 
There is also evidence to suggest that the primary cellular origin from which the 
circulating microparticles are derived may differ between pathological conditions. 
Platelet microparticles appear to be the most prevalent in Hypertension, Myocardial 
infarction, cancer and PNH, whereas microparticles of endothelial origin are associated 
with acute coronary syndromes, type I diabetes mellitus and Lupus anticoagulant. 
Microparticles derived from leukocytes have been associated with HIV, severe trauma, 
sepsis and type II diabetes mellitus (Martínez et al., 2005). It is worthy of consideration 
that an elevation in the numbers of circulating microparticles is by no means causative 
of disease in all cases and that the disease state itself may give rise to the increased 
production of microparticles. Elevated levels of microparticles may well be implicated 
in the exacerbation of disease severity however. 
 
4.1.5 Microparticles in Pregnancy 
 
Since increased microparticle expression is associated with systemic inflammatory 
responses it is perhaps of no great surprise that that the numbers of both platelet and 
endothelial derived microparticles have been shown to be elevated in normal pregnancy 
in comparison to non-pregnant healthy women (Bretelle et al., 2003). There is a degree 
of conflict in the literature however with some groups reporting an initial decrease in the 
numbers of microparticles during pregnancy followed by a return to normal levels (Lok 
et al., 2008). As uteroplacental thrombosis is a frequently proposed mechanism for 
pregnancy loss and since microparticles have been shown to be elevated in a number of 
pro-thrombotic conditions, there has been some study into the role in which elevated 
numbers of microparticles may play in pregnancy loss. A study comparing the levels of 
pro-coagulant microparticles found in a cohort of women with a history of unexplained 
pregnancy loss with a cohort of women with no history of pregnancy loss found that the 
circulating levels of procoagulant microparticles were significantly elevated in those 
women with a history of pregnancy loss (Laude et al., 2001). This result provides 
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evidence to explain why many women with recurrent pregnancy loss are found to be 
‘normal’ when screened for thrombophilia using traditional assays yet still manifest a 
clinical history of thrombosis. An interesting finding of this study is the fact that the 
blood samples were analysed a minimum of 2 months after the last reported obstetric 
event, thus implying that the circulating levels of pro-coagulant microparticles could be 
a chronic phenomenon in these patients and that this is only clinically ‘unmasked’ in 
pregnancy (Greer, 2001). Proof that microparticles can precipitate placental thrombosis 
was provided by studies in a murine model, where phosphatidylserine expressing 
phospholipid vesicles were injected into pregnant mice and subsequently induced 
thrombosis in the placental bed and ultimately resulted in reduced birth weight 
(Sugimura et al., 1999). The addition of Annexin V which binds with high affinity to 
phosphatidylserine ameliorated this effect, implying that the presence of 
phosphatidylserine is necessary to induce thrombosis. Indeed it was postulated by Greer 
(2001) that the binding of phosphatidylserine expressing microparticles to the 
trophoblast layer on which annexin V is exposed inhibits the anticoagulant effect of 
annexin V thereby predisposing the placenta to thrombosis. 
 
4.1.5.1 Microparticles in Pre-eclampsia  
 
The numbers and types of microparticles have been the source of a number of 
investigations in the field of pre-eclampsia. It is generally shown in the literature that 
the circulating levels of microparticles in patients with pre-eclampsia are elevated over 
and above what is seen in association with normotensive pregnancy (Redman and 
Sargent, 2008). Indeed patients with pre-eclampsia have been shown to have elevated 
levels of microparticles derived from multiple cellular origins including endothelial 
cells (Gonzalez-Quintero et al., 2004), leukocytes, platelets (Meziani et al., 2006), T-
cells and granulocytes (Van Wijk et al., 2002a) in comparison to normotensive pregnant 
women. Although as is the case in normal pregnancy, a number of studies have shown 
discrepant findings, with some reporting decreased levels of platelet derived 
microparticles in pre-eclamptic patients (Lok et al., 2008). It was postulated by the 
authors that this may be due to the decreased platelet counts in patients with pre-
eclampsia. It is also a possibility that the differing results between studies may be 
indicative of the different methodologies employed by the various laboratories or even 
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in the definitions used to define the pre-eclamptic patients themselves (Aharon and 
Brenner, 2009). 
 
The study of microparticles in pre-eclampsia is an interesting field since placenta 
derived microparticles potentially provide a neat link between the two stages of disease 
onset. Indeed this theory is discussed in chapter 3, where Redman and Sargent (2000) 
proposed a mechanism whereby reduced placental perfusion leading to oxidative stress 
caused increased levels of syncytiotrophoblast apoptosis. This in turn would lead to 
increased microparticle production and the long range signalling capacity of the 
microparticles could result in the systemic maternal syndrome. Increased levels of 
microparticles would obviously also contribute to the pro-coagulant nature of the 
condition. Placental microparticles are present in normal pregnancy and are derived 
from the syncytiotrophoblast layer. These syncytiotrophoblast microparticles have been 
detected in normal pregnancies by the second trimester and are shown to increase in 
number significantly into the third trimester. In pre-eclamptic patients the number of 
these syncytiotrophoblast derived microparticles has been shown to be significantly 
elevated when compared to normotensive pregnancies (Knight et al., 1998). Further to 
this, syncytiotrophoblast derived microparticles have been shown to be able to bind to 
monocytes and stimulate the production of inflammatory cytokines such as TNFα, IL-
12, IL-18 and Interferon γ (Germain et al., 2007).  
 
Although these experiments do not offer conclusive proof of a placental derived 
population of microparticles causing the maternal pre-eclamptic syndrome they are 
certainly suggestive of a role for these microparticles in systemic endothelial 
inflammation and perhaps further microparticle production as a result. It is worthy of 
note that other species of microparticles known to be elevated in pre-eclampsia are also 
likely to contribute to disease severity regardless of whether their production is initially 
triggered via placental microparticles or not. Since platelet microparticles can initiate 
vasoconstriction via the modification of arachidonic acid metabolism (Pfister, 2004), an 
overexpression of platelet microparticles could in theory exacerbate the hypertension 
seen in patients with pre-eclampsia. When taken into account with an elevated level of 
endothelial derived microparticles, also described in pre-eclampsia, which can inhibit 
vasodilation via inhibition of NO (Brodsky et al., 2004) the evidence for microparticle 
involvement in the pathology of pre-eclampsia is quite compelling. Indeed 
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microparticles produced following chronic endothelial damage in disorders such as 
sickle cell anaemia have been shown to express CD105 (Endoglin) and could sequester 
TGF-β in a similar manner to sEng, thus providing a secondary mechanism by which 
vasorelaxation could be inhibited in pre-eclampsia. Evidence in support of these 
theories was shown using an in vitro model where microparticles isolated from patients 
with pre-eclampsia significantly inhibited bradykinin-mediated vasorelaxation in 
myometrial arteries taken from healthy pregnant women in comparison to 
microparticles isolated from normotensive pregnant controls (Van Wijk et al., 2002b). 
 
Vascular dysfunction mediated by microparticles is not limited to vasoconstriction 
however, Meziani et al (2006) described that microparticles isolated from pre-eclamptic 
patients were able to induce vascular hyporeactivity in an ex vivo model using human 
omental arteries and mouse aortas. This effect was not observed using microparticles 
isolated from normotensive pregnant controls and could be reversed using an inhibitor 
of NO. This observation suggests the hyporeactivity was due to increased production of 
NO. Interestingly the authors also described that the platelet derived microparticles 
found in the circulation were primarily associated with NO production, whereas those 
microparticles of leukocyte origin could induce both vasorelaxation via induction of NO 
production and a vasoconstriction response due to the induction of cellular COX-2 
expression. The authors postulated that the platelet derived microparticles may therefore 
be protective in pre-eclampsia since enhanced expression of NO could counteract the 
vasocontrictive signal mediated by the leukocyte derived microparticles. It may be that 
the impact which microparticles have on hypertension in pre-eclamptic patients depends 
on the relative balance of signal strength between vasoconstriction and vasodilation. It 
is of note therefore that leukocytes are highlighted as a primary cellular origin of 
microparticles in patients with pre-eclampsia (Martínez et al., 2005). It has also been 
shown that leukocyte derived microparticles can further inhibit vasodilation via the 
induction of increased levels of caveolin-1 which acts to decrease cellular levels of 
endothelial NO synthase. 
 
Although the physiological role which microparticles play in pre-eclampsia is not yet 
fully understood it is clear from the literature that their role is far from benign and that 
there is a myriad of ways in which they can subvert normal endothelial function and 
therefore contribute to pathogenesis.  
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4.1.6 Microparticles as a Therapeutic Target 
 
Since elevated numbers of microparticles are found in a myriad of different pathological 
conditions and there is a strong evidence base to suggest that microparticles themselves 
may be implicated in the pathology of some if not all of these conditions it is no surprise 
that microparticles are coming under scrutiny as potential targets for disease 
monitoring/treatments. In conditions where there is systemic chronic endothelial 
damage, such as sickle cell disease and PNH, the monitoring of microparticle levels 
may provide insights to the efficacy of available treatments (Piccin et al., 2007). 
Following on from this the identification of microparticles from specific cellular origins 
such as neurovascular microparticles in CSF or even tears, may provide a valuable tool 
as biomarkers for disease onset, diagnosis or prognosis (Doeuvre et al., 2009).     
 
Although there are currently no therapies which intentionally target microparticles as a 
mode of action, a number of therapies already available may mediate some of their 
beneficiary effects by decreasing the numbers of microparticles or by inhibiting their 
function. The use of anti-platelet drugs such as clopidogrel and aspirin can lead to 
decreased levels of both platelet and leukocyte derived microparticles (Serebruany et 
al., 2003) and therefore reduce the risk of thrombotic events in patients with cardiac 
disorders. Similarly the use of the statin fluvastatin was shown to reduce the production 
of endothelial microparticles from human coronary artery endothelial cells in an in vitro 
model (Tramontano et al., 2004), thereby reducing the potential for microparticle 
mediated vascular dysfunction in hypertension. It has also been suggested that one of 
the reasons why plasmapheresis is a superior treatment when compared to plasma 
infusion in the treatment of TTP is that it results in the removal of circulating 
microparticles (Piccin et al., 2007). Despite these observations, there is little evidence to 
suggest any clinical trials have been performed using these agents to ameliorate the 
pathological effects of microparticles in any other conditions aside from those which the 
drugs were initially formulated to treat. 
 
There is evidence in the literature however concerning the rationale of using 
microparticles in the treatment of bleeding disorders. Pro-coagulant leukocyte derived 
microparticles stimulated by the infusion of soluble P-selectin were shown to be able to 
correct haemostatic balance in a murine model of haemophilia A (Hrachovinova et al., 
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2003). There is also a suggestion that the transfusion of older stored platelets may offer 
a haemostatic advantage to the patients in which they are administered due to the 
formation of microparticles during storage (Piccin et al., 2007).  
 
The physiological roles of microparticles are varied, but since they are known to be 
implicated in thrombosis, this intuitively suggests that they probably have an effect on a 
patient’s capacity to generate thrombin. The aim of this chapter therefore is to determine 
the impact that microparticles have on thrombin generation as measured by the CAT 
thrombin generation assay.  
 
4.2 Materials and Methods 
 
4.2.1 PT/INR 
Please refer to section 2.2.1 for details 
 
4.2.2 APTT 
Please refer to section 2.2.2 for details 
 
4.2.3 Thrombin Time 
Please refer to section 2.2.3 for details 
 
4.2.4 Preparation of Samples: Single Spun Plasma 
Blood was collected into 0.109M tri-sodium citrate vacutainers. Samples were 
centrifuged at 1500 g for 10 minutes. Following this time the plasma was then removed, 
placed in a corning tube and frozen. 
 
4.2.5 Preparation of Samples: Double Spun Plasma 
Blood was collected into 0.109M tri-sodium citrate vacutainers. Samples were 
centrifuged at 1500 g for 10 minutes. Following this time the top two thirds of the 
patient’s plasma were removed and aliquoted into LP4 tubes. These aliquots were then 
centrifuged for a further 10 minutes at 1500 g. The top two thirds of the double spun 
plasma was then removed, placed in a corning tube and frozen. 
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4.2.6 Preparation of Samples: Filtration of Patient Plasma 
Plasma was filtered using a Ceveron microparticle filtration unit (MFU) 500. Plasma for 
filtration was first prepared by centrifugation as described in either section 6.2.1 or 6.2.2 
above. Centrifuged plasma was then loaded into the 96 well 0.2µm filtration plates, no 
more than 200µl of sample was placed into each well. The number of wells used was 
dictated by the size of the plasma sample being filtered.  The filter plate was then 
covered using plate sealer foil. The instrument was then activated, producing a vacuum 
of ~70kPa. The vacuum sucks the plasma through the filter plate into the pre-loaded 96 
well receiver plate. Plasma samples were then aspirated from the receiver plate using a 
Pasteur pipette and pooled.   
 
4.2.7 Reconstitution of Control Plasma P 
Please refer to section 2.2.6 for details 
 
4.2.8 Filtration of Control Plasma P 
Following reconstitution as described above the plasma was aspirated into a 5ml plastic 
syringe driver. A 0.2µm filter was fitted to the end of the syringe and the plasma forced 
through the filter into a plastic 25ml universal container. 
 
4.2.9 Thrombin Generation 
Please refer to section 2.2.5 for details 
 
4.2.10 Protein C Activity 
The measurement of the Protein C activity was an automated assay performed on the 
CS2100i analyser manufactured by Sysmex. Patient’s plasma (12μl) was added to an 
equal volume of CA System Buffer in a plastic cuvette. To this 120μl of Berichrom 
Protein C Activator reagent was added after a 60 second incubation at 37ºC. The 
Berichrom Protein C Activator reagent contains a snake venom extract which activates 
the protein C in the patient’s sample. Following a further 290 second incubation at 37ºC 
24μl of Berichrom Protein C Substrate reagent was added. The substrate reagent 
contains a chromogenic substrate consisting of a peptide bound to methoxy-nitroanilide. 
The action of activated Protein C cleaves the peptide and releases the methoxy-
nitroanilide. This can be measured at 405nm. The reaction was allowed to proceed for 
100 seconds, after this time the absorbance of the cuvette at 405nm was measured. The 
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absorbance at 405nm is proportional to the level of Protein C activity in the sample. The 
absorbance of the cuvette is converted to an activity via interpolation from a stored 
standard curve produced by measuring in duplicate 5 dilutions of SHP (which has a 
known protein C activity) and plotting the mean OD result against activity. 
The assay was controlled using Coagulation Control N and Coagulation Control A 
which have target values that are within the normal and abnormal ranges respectively. 
Berichrom Protein C Activator reagent, Berichrom Protein C Substrate reagent, 
Coagulation Control N and Coagulation Control A are lyophilised reagents and require 
reconstitution before use. 10ml of Berichrom Protein C Activator Diluent was added to 
the Berichrom Protein C Activator reagent. 3ml of distilled water was added to the 
Berichrom Protein C Substrate reagent and 1ml of distilled water was added to each of 
the control plasmas. The reagents were then held at room temperature for 15 minutes 
before use. 
 
4.2.11 Antithrombin Activity 
The measurement of the Antithrombin activity was an automated assay performed on 
the CS2100i analyser manufactured by Sysmex. Patient’s plasma (21μl) was added to 
147μl of CA System Buffer in a plastic cuvette, 24μl of this dilution was subsequently 
transferred to a different cuvette. To this 175μl of Berichrom ATIII reagent THR was 
added after a 40 second incubation at 37ºC. The Berichrom ATIII reagent THR contains 
an excess of thrombin to which the antithrombin in the patients plasma binds. Thrombin 
bound to antithrombin is inactive; the amount of unbound active thrombin remaining 
following this reaction is therefore inversely proportional to the amount of antithrombin 
in the patient’s plasma. Following a further 190 second incubation at 37ºC 33μl of 
Berichrom ATIII Substrate reagent was added. The substrate reagent contains a 
chromogenic substrate consisting of a peptide bound to acid isopropylamide. The action 
of the unbound thrombin cleaves the peptide and releases the acid isopropylamide. This 
can be measured at 405nm. The reaction was allowed to proceed for 60 seconds, after 
this time the absorbance of the cuvette at 405nm was measured. The absorbance at 
405nm is inversely proportional to the level of Antithrombin activity in the sample. The 
absorbance of the cuvette is converted to an activity via interpolation from a stored 
standard curve produced by measuring in duplicate 5 dilutions of SHP (which has a 
known antithrombin activity) and plotting the mean OD result against activity. 
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The assay was controlled using Coagulation Control N and Coagulation Control A 
which have target values that are within the normal and abnormal ranges respectively. 
Berichrom ATIII reagent THR, Berichrom ATIII Substrate reagent, Coagulation 
Control N and Coagulation Control A are lyophilised reagents and require reconstitution 
before use. 15ml of Berichrom ATIII reagent THR Diluent was added to the Berichrom 
ATIII reagent THR. 3ml of distilled water was added to the Berichrom ATIII Substrate 
reagent and 1ml of distilled water was added to each of the control plasmas. The 
reagents were then held at room temperature for 15 minutes before use. 
 
4.2.12 Clotting Factor Activity 
The measurement of clotting factor activities (FII, FV, FVII, FVIII, FIX, FX, FXI and 
FXII) were automated assays performed on the CS2100i analyser manufactured by 
Sysmex. Patient’s plasma (5μl) was added to 45μl of CA System Buffer in a plastic 
cuvette. To this an equal volume of Coagulation Factor Deficient plasma was added, the 
Coagulation Factor Deficient plasma used was dependent on the assay being performed; 
a factor II assay utilises coagulation factor II deficient plasma. Then either following a 
190 second incubation at 37ºC 100μl of Innovin was added to the reaction mixture (FII, 
FV, FVII and FX) or following a 60 second incubation 50μl of Actin FS followed by 
50μl of Calcium Chloride after a further 190 second incubation (FVIII, FIX, FXI and 
FXII) was added to the reaction mixture. This was then incubated at 37ºC for a further 
180 seconds. During the incubation the transmission of light through the sample was 
measured at wavelength of 660nm. The conversion of fibrinogen to fibrin increases the 
turbidity of the sample and hence decreases the light transmission. Clot detection is 
defined as the time taken to reach the midway point in terms of light transmittance 
between the baseline and final transmission values. The clotting time is converted to a 
clotting factor activity via interpolation from a stored standard curve produced by 
measuring in duplicate 5 dilutions of SHP (which has a known factor activity) and 
plotting the mean clotting time in seconds against clotting factor activity. The analysis 
outlined above is repeated twice more with further dilutions of the patients plasma in 
CA System Buffer. The analysis described above is classed as a 1:1 dilution; the 
subsequent dilutions are 1:2 and 1:4. The three dilutions should yield the same level of 
clotting factor activity (when corrected for dilution) and should yield a line that runs 
parallel to the standard curve when plotted. The mean of the three dilutions is the 
reported value. 
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The assay was controlled using Coagulation Control N and Coagulation Control A 
which have target values that are within the normal and abnormal ranges respectively. 
The Coagulation Deficient plasmas, Coagulation Control N and Coagulation Control A 
are lyophilised reagents and require reconstitution before use. 1ml of distilled water was 
added to each of the reagents. The reagents were then held at room temperature for 15 
minutes before use. 
 
4.2.13 Free Protein S Antigen 
The measurement of the Free Protein S antigen was an automated assay performed on 
the CS2100i analyser manufactured by Sysmex. Patient’s plasma (10μl) was added to 
20μl of CA System Buffer in a plastic cuvette. To this 60μl of LIATEST® Free Protein 
S Buffer was added after a 40 second incubation at 37ºC. Following a further 230 
second incubation at 37ºC 90μl of LIATEST® Free Protein S Latex was added. The 
latex reagent contains latex beads coated in antibodies against Free Protein S. The 
binding of the beads to Free Protein S in the patient’s plasma causes agglutination of the 
beads and subsequently leads to an increased absorbance of light by the cuvette which 
can be measured at 575nm. The reaction was allowed to proceed for 200 seconds, after 
this time the absorbance of the cuvette at 575nm was measured. The absorbance at 
575nm is proportional to the level of Free Protein S Antigen in the sample. The 
absorbance of the cuvette is converted to a concentration via interpolation from a stored 
standard curve produced by measuring in duplicate 5 dilutions of Coagulation 
Reference Plasma (which has a known Free Protein S Antigen) and plotting the mean 
OD result against concentration. 
The assay was controlled using Coagulation Control N and Coagulation Control A 
which have target values that are within the normal and abnormal ranges respectively. 
Coagulation Control N and Coagulation Control A are lyophilised reagents and require 
reconstitution before use. 1ml of distilled water was added to each of the control 
plasmas. The reagents were then held at room temperature for 15 minutes before use. 
 
4.2.14 von Willebrand Factor Antigen 
The measurement of the von Willebrand factor antigen was an automated assay 
performed on the CS2100i analyser manufactured by Sysmex. Patient’s plasma (15μl) 
was added to an equal volume of CA System Buffer in a plastic cuvette. To this 60μl of 
vWAg Reagent was added after a 20 second incubation at 37ºC. Following a further 250 
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second incubation at 37ºC 90μl of vWAg Buffer was added. The vWAg Reagent 
contains polystyrene beads coated in antibodies against von Willebrand factor. The 
binding of the beads to von Willebrand factor in the patient’s plasma causes 
agglutination of the beads and subsequently leads to an increased absorbance of light by 
the cuvette which can be measured at 575nm. The reaction was allowed to proceed for 
170 seconds, after this time the absorbance of the cuvette at 575nm was measured. The 
absorbance at 575nm is proportional to the level of von Willebrand factor antigen in the 
sample. The absorbance of the cuvette is converted to a concentration via interpolation 
from a stored standard curve produced by measuring in duplicate 5 dilutions of SHP 
(which has a known von Willebrand factor Antigen) and plotting the mean OD result 
against concentration. 
The assay was controlled using Coagulation Control N and Coagulation Control A 
which have target values that are within the normal and abnormal ranges respectively. 
Coagulation Control N and Coagulation Control A are lyophilised reagents and require 
reconstitution before use. 1ml of distilled water was added to each of the control 
plasmas. vWAg Reagent requires the addition of 4ml of vWAg Reagent Buffer. The 
reagents were then held at room temperature for 15 minutes before use. 
 
4.2.15 Flow Cytometry 
Analysis was performed on the BD FACS Canto II with a standard set up using 
FACSDiva software version 6.1.2. 5µl of the appropriate antibodies were added to 50µl 
of patient’s plasma. This mixture was placed in the dark for 15 minutes at room 
temperature. Following this time the sample was diluted with the addition of 450µl of 
Tyrodes salt solution, which was previously filtered using a 0.2µm filter attached to a 
syringe. 10µl of Sphero AccuCount fluorescent particles were then added to the mixture 
followed by 1µl of 1.1µm beads. The sample was then gently agitated to ensure 
sufficient mixing prior to analysis. The sample was aspirated at a low flow rate. The 
cellular material was gated using forward and side scatter. Separate gates were 
established for both the 1.1µm beads and the Sphero AccuCount fluorescent particles. 
The sample was analysed until a total of 400 Sphero AccuCount fluorescent particles 
were acquired. 
 
4.2.16 Statistical Analysis 
Please refer to section 2.2.9 for details 
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4.2.17 Reagents 
 
Product Manufacturer 
Actin FS Dade Behring 
Annexin V FITC Beckman Coulter 
Berichrom ATIII reagent THR Siemens 
Berichrom ATIII reagent THR Diluent Siemens 
Berichrom ATIII Substrate reagent Siemens 
Berichrom Protein C Activator Diluent Siemens 
Berichrom Protein C Activator reagent Siemens 
Berichrom Protein C Substrate reagent Siemens 
Calcium Chloride Solution (0.025M) Dade Behring 
CA System Buffer Siemens 
CD15 FITC Antibody BD 
CD42b PE Antibody Immunotech 
CD45 Pacific Blue Antibody Caltag 
Citrol 1 Dade Behring 
Citrol 2 Dade Behring 
Coagulation Control A Technoclone 
Coagulation Control N Technoclone 
Coagulation Factor II Deficient Plasma Siemens 
Coagulation Factor IX Deficient Plasma Siemens 
Coagulation Factor V Deficient Plasma Siemens 
Coagulation Factor VII Deficient Plasma Siemens 
Coagulation Factor VIII Deficient Plasma Siemens 
Coagulation Factor X Deficient Plasma Siemens 
Coagulation Factor XI Deficient Plasma Siemens 
Coagulation Factor XII Deficient Plasma Siemens 
Coagulation Reference Plasma Technoclone 
Control Plasma P Dade Behring 
Corn Trypsin Inhibitor Cambridge Bioscience 
FluCa Kit Diagnostica Stago 
Glycophorin A FITC Antibody Dako 
Innovin Dade Behring 
LIATEST
®
 Free Protein S Buffer Diagnostica Stago 
LIATEST
®
 Free Protein S Latex Diagnostica Stago 
PPP Reagent Diagnostica Stago 
Sphero AccuCount Fluorescent particles Spherotech 
Standard Human Plasma Siemens 
Sterile Distilled Water Baxter 
Thrombin Calibrator Diagnostica Stago 
Thromboclotin Dade Behring 
Tyrodes Salt Solution Sigma 
vWAg Buffer Siemens 
vWAg Reagent Siemens 
vWAg Reagent Buffer Siemens 
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4.3 Results 
 
4.3.1 Filtration of Control Plasma P 
 
The first stage of analysis in this chapter is concerned with the filtration of control 
plasma P. This control plasma was used in the inter and intra assay variability 
experiments described in chapter 2 and yielded unacceptably poor results, in terms of 
both intra assay trends and high levels of inter assay variability. It was hypothesised that 
these results were possibly due to the presence of particulate matter in the reconstituted 
plasma. It is possible that the particulate matter implicated in this analysis includes the 
presence of microparticles which may have been unevenly reconstituted or distributed 
throughout the plasma and may have ultimately led to the high variation in the results.  
 
Since microparticles cannot be removed via centrifugation at the forces generated by 
any of the centrifuges available in the haemostasis laboratory at the Royal London 
Hospital, it was decided to pass the plasma through a filter with apertures small enough 
to remove most of the microparticles in the plasma. Since microparticles typically range 
from 0.2-2µm in diameter (Piccin et al., 2007), a 0.2µm filter was chosen. In order to 
ascertain the effects of plasma filtration on the thrombin generation of Control plasma 
P, 48ml of Control plasma P was reconstituted and pooled. Half of this plasma was 
aliquoted into three 8ml aliquots and frozen at -70°C. The remainder was filtered as 
described in section 4.2.8 above with a view to freezing in three further 8ml aliquots. 
Due to the nature of the filters employed, which retained some of the sample volume 
and the magnitude of the particulate matter, which required the use of multiple filters, a 
large volume of sample was lost. Indeed the entire filtration process only yielded 
approximately 13ml of plasma. This was frozen at -70°C in two 6.5ml aliquots. It was 
decided to freeze the plasma in order to mimic the conditions of the earlier 
experimentation and to minimise the degeneration of the plasma between the runs. The 
aliquots of Control plasma P were defrosted one at a time by submersion in a 37°C 
water bath before analysis via the CAT thrombin generation assay as described in 
section 4.2.9 above. The analysis time for these experiments was 45 minutes. The non 
filtered plasma was analysed on three separate plates with 15 replicates on each plate, 
thus providing 45 data points. The filtered plasma was analysed on two separate plates 
with 13 replicates on each plate, providing a total of 26 data points. A comparison of the 
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thrombin generation parameters for the filtered and non filtered Control plasma P 
samples is shown in figure 4.1 below. 
 
Figure 4.1 
  
A.              B. 
  
C.             D. 
  
Figure 4.1. Boxplots showing a comparison of the results of the four thrombin generation parameters for 
both non filtered and filtered Control plasma P. Boxes show 25
th
 to the 75
th
 percentile of the data with the 
median shown as a horizontal black line. Whiskers show minimum/maximum values. Population outliers 
defined as values deviating by greater than 1.5 times box height are shown by . A: Lag time, B: ETP, C: 
Peak height, D: Time to peak. P values derived using the student’s t-test or Mann Whitney U test as 
appropriate. 
 
It is clear from figure 4.1 that filtration of Control plasma P had a significant impact on 
the results of the thrombin generation assay. There is a statistically significant reduction 
(p= <0.001) in all 4 of the thrombin generation parameters following filtration. 
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Filtration also reduced the CV of all four of the assayed parameters implying a 
reduction of variability following filtration. See table 4.1 below. It is of interest 
however that the CVs for the non filtered plasma are elevated when compared to the 
same experiment in chapter 2 (table 2.5). This effect may be due to the reduced number 
of data points in this experiment (45 verses 150). 
 
 
Table 4.1 
Parameter Non Filtered CV (%) Filtered CV (%) 
Lag Time 21.1 16.3 
ETP 10.2 5.4 
Peak Height 6.2 3.4 
Time to Peak 9.3 5.6 
Table 4.1. CV values for each of the four thrombin generation parameters for both non filtered and 
filtered Control plasma P. 
 
 
The reduction of variability seen post filtration would suggest that there is a decreased 
level of assay ‘noise’ when the filtered plasma is analysed, although this is a subjective 
parameter to quantify, it would appear to be the case. Figure 4.2 shows a comparison of 
typical thrombin generation curves taken from each population. The curves demonstrate 
the observed findings of plasma filtration for Control plasma P, with the filtered plasma 
showing a decrease in peak height, ETP, lag time and time to peak when compared to 
the non filtered plasma. The thrombin generation curve of the filtered plasma also 
appears smoother than that of the non filtered plasma implying a reduction of assay 
‘noise’. 
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Figure 4.2 
 
 
Figure 4.2. Examples of thrombin generation curves produced following the analysis of non filtered and 
filtered Control plasma P. 
 
The results from the non filtered Control Plasma P were then analysed to see if there 
were any significant intra assay trends which were evident in the initial experiments 
carried out in chapter 2. Whilst there was no evidence of any trends for both the lag time 
and the time to peak parameters (data not shown) both the ETP and peak height 
parameters showed a significant trend of decreasing value with the order in which they 
were pipetted on to the plate (p=<0.001). The results of these analyses are shown in 
figure 4.3 below. Following these findings the filtered plasma was subsequently 
analysed in the same manner. The results of this analysis are shown in figure 4.4 below. 
Interestingly the filtered plasma despite an apparent decrease in variability still showed 
evidence of identical intra assay trends for both peak height and ETP (p= <0.01 and 
<0.001 respectively), implying that the decrease in assay noise does not ameliorate the 
intra assay trends as hypothesised in chapter 2 and that this observed phenomenon is an 
artefact of Control plasma P itself. 
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Figure 4.3 
 
A.             B. 
  
Figure 4.3. Graphs showing the values obtained from the analysis of 45 replicates of non filtered Control 
plasma P relative to the order in which they were added to the plate, complete with trend lines and R
2
 as 
an indication of correlation. A: Peak Height, B: ETP 
 
Figure 4.4 
A.             B. 
  
Figure 4.4. Graphs showing the values obtained from the analysis of 26 replicates of filtered Control 
plasma P relative to the order in which they were added to the plate, complete with trend lines and R
2
 as 
an indication of correlation. A: Peak Height, B: ETP 
 
An interesting finding regarding the above filtration experiments is the apparent 
changes which are observed in the thrombin generation analysis post filtration. The 
filtration step was introduced as an attempt to remove potentially pro-coagulant 
microparticles from the plasma, which may be influencing the results generated. Since it 
is possible any microparticles present have phosphatidylserine rich phospholipid 
membranes which may increase the rate and magnitude of thrombin generation as well 
as possibly expressing tissue factor which may also act to enhance thrombin generation, 
the removal of these microparticles would in theory be accompanied by a decrease in 
the thrombin generation potential of the sample. This hypothesis fits well with both the 
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reduction in peak height and ETP seen following the filtration of Control plasma P but 
not with the reduction of the lag time and time to peak parameters. The removal of pro-
coagulant material from the sample would intuitively be accompanied by a prolongation 
of these times, not the observed reduction. A potential explanation for this is the 
possibility of mechanical contact activation of the plasma during the filtration process. 
Sample activation is typically accompanied by a reduction of clotting time (APTT) 
when measured in the laboratory and can be achieved via the taking of a blood sample 
with a syringe and the subsequent transferral of the blood sample into a vacutainer. 
 
4.3.2 Filtration of Pooled Fresh Plasma 
 
Following the filtration of the pool of Control plasma P it was decided to determine 
whether or not the effects observed post filtration were artefacts of the filtration of 
Control plasma P itself or whether a similar pattern is observed following the filtration 
of a pool of fresh patient plasma.  
 
The plasma pool was obtained via the mixing of plasma from the samples of 80 patients 
in the Royal London hospital. All patients samples selected had normal clotting screens 
as determined by the INR, APTT and Thrombin time, therefore excluding any patients 
known to be undergoing anticoagulant therapy. The patients’ samples had initially been 
centrifuged at 1500g for 10 minutes. The top two thirds of the plasma from each of the 
samples was then removed and pooled. The plasma pool was subsequently aliquoted 
into LP4 tubes and centrifuged at 1500g for 10 minutes. Following this time the top two 
thirds of the plasma was removed from the LP4 tubes and pooled. This process yielded 
approximately 80ml of plasma. Half of this plasma pool was then separated into five 
8ml aliquots and frozen at -70°C. The remaining half of the plasma was filtered as 
described in section 4.2.6. This filtration process resulted in a reduction in the volume 
of sample lost during filtration, when compared with the method described in section 
4.2.8, and yielded four 8ml plasma aliquots which were subsequently frozen at -70°C. 
The pooled plasma aliquots were then thawed in a 37°C water bath and analysed 
separately using the CAT thrombin generation assay as described in section 4.2.9. A 
comparison of the thrombin generation parameters for the filtered and non filtered 
pooled plasma is shown in figure 4.5 below. 
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Figure 4.5 
A.              B. 
  
C.             D. 
  
Figure 4.5. Boxplots showing a comparison of the results of the four thrombin generation parameters for 
both non filtered and filtered pooled fresh plasma. Boxes show 25
th
 to the 75
th
 percentile of the data with 
the median shown as a horizontal black line. Whiskers show minimum/maximum values. Population 
outliers defined as values deviating by greater than 1.5 times box height are shown by . A: Lag time, B: 
ETP, C: Peak height, D: Time to peak. P values derived using the student’s t-test or Mann Whitney U test 
as appropriate. 
 
It is clear from the graphs that the results for the filtration of the fresh plasma pool are 
consistent with those found following the filtration of Control plasma P, i.e. there is a 
statistically significant decrease of all four thrombin generation parameters following 
filtration. Examples of the thrombin generation curves produced can be seen in figure 
4.6. The curves for both the non-filtered and filtered plasma are typically smoother than 
those produced via the analysis of Control plasma P, again highlighting the increased 
assay ‘noise’ evident in Control plasma P analysis.  
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Figure 4.6 
 
 
Figure 4.6. Examples of thrombin generation curves produced following the analysis of non filtered and 
filtered pooled fresh plasma. 
 
Interestingly the filtration of the pooled fresh plasma did not impact on the CVs of the 
thrombin generation parameters in the same manner as the filtration of Control plasma 
P, which all showed a reduction post filtration. The results of this analysis are shown in 
table 4.2. Whilst the CVs for both the ETP and peak height parameters are reduced 
following filtration of the fresh plasma pool, the CVs for the lag time and the time to 
peak parameters both show an increase post filtration. Neither the results from the 
filtered or non filtered plasma show much variation from the analysis of the fresh 
plasma pool discussed in chapter 2 (table 2.15). This implies that the differences in the 
variation of results following filtration are probably due to chance rather than any effect 
caused by the filtration process itself. When taken in comparison with the effect of 
filtration on Control plasma P, which appears to show a decrease in result variation post 
filtration (although this is by no means proof positive) these results imply that 
something further is removed from the Control plasma P during the filtration process, 
which is both different from that responsible for the observed changes in the thrombin 
generation parameters and absent from the fresh pooled plasma. It is most likely 
filtration removes particular matter in the Control plasma P reagent, possibly present via 
inefficient reconstitution of the reagent, which probably disrupts the fluorescent signal 
in thrombin generation analysis resulting in a reduction in variation post filtration.  
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Table 4.2 
Parameter Non Filtered CV (%) Filtered CV (%) 
Lag Time 5.6 8.2 
ETP 6.4 5.0 
Peak Height 5.8 4.4 
Time to Peak 3.8 4.2 
Table 4.2. CV values for each of the four thrombin generation parameters for both non filtered and 
filtered pooled fresh plasma. 
 
4.3.3 Filtration of Non-Pooled Samples 
 
Following the results obtained using both pools of commercially produced plasma and 
fresh patient plasma; it was decided to examine the effects of plasma filtration on 
individual patients in order to ascertain whether the patterns observed in the 
experiments described above still held. Although the findings of the first two 
experiments were both significant and consistent with one another, the fact remained 
that only two different plasma samples were tested (albeit a number of times each). In 
order to investigate whether the changes in thrombin generation parameters observed 
above were conserved in all individuals 19 samples from patients at the Royal London 
Hospital were analysed. The patients’ samples were prepared as described in section 
4.2.5 above, although prior to freezing the plasma was divided into two equal sized 
aliquots one of which was filtered as described in section 4.2.6.  This resulted in one 
filtered and one non filtered aliquot for each of the 19 patients. The samples were then 
frozen at -70°C. The patients’ samples were thawed in a 37°C water bath and the 
thrombin generation of the filtered/non filtered aliquots was subsequently measured as 
described in section 4.2.9. In order to reduce the impact of inter assay variation on the 
results both of a patients aliquots were analysed on the same run. The results of this 
analysis are shown in figure 4.7 below. These graphs show the correlation of the results 
for the 19 patients analysed for each of the four thrombin generation parameters. Each 
graph also shows a dashed line corresponding to X=Y, showing what the correlation 
would resemble if plasma filtration had no impact on the results. The position of the 
patients trendline relative to the X=Y line is indicative of the average change of the 
results post filtration. Since the filtered plasma results are shown on the Y axis the 
presence of the trendline above X=Y is suggestive of an increase of the results post 
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filtration, if the trendline is below X=Y it suggests the results are lower post filtration. 
From the graphs it appears that post filtration the majority of the 19 patients processed 
show a decreased ETP and peak height and an increase in both the lag time and the time 
to peak parameters. The average change in each of the parameters can be calculated by 
calculating the equation of the trendline; the intercept of the y axis is indicative of the 
magnitude of the change. A negative value is indicative of a decrease in the parameter 
post filtration where as a positive value indicates an increase post filtration. The y 
intercept of the trend line, the median change of the cohort of 19 individuals and range 
of the observed changes are shown for each of the four thrombin generation parameters 
in table 4.3 below. To calculate the median change, first the magnitude of the difference 
between a patient’s results pre and post filtration was derived by subtracting the result 
obtained pre filtration from the value obtained post filtration. The median was then 
calculated. 
 
Figure 4.7 
A.             B. 
  
C.             D. 
  
Figure 4.7 A series of graphs showing the correlation of the results of the CAT thrombin generation assay 
pre and post plasma filtration in a cohort of 19 individuals. The solid line is the trendline for the 
correlation of the results of the 19 patients, with R
2
 shown as an indication of correlation.  The dashed 
line shows how the patients trend line would look if plasma filtration had no effect on the results. I.e. X 
=Y. A: Lag Time, B: ETP, C: Peak Height and D: Time to Peak 
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Table 4.3 
Parameter Range of 
Change 
Median 
Change 
Y Intercept 
Lag Time  (Minutes) -0.33 – 0.83 0.17 0.145 
ETP (nM Thrombin) -341 – 148 -81 -48 
Peak Height (nM Thrombin) -42.8 – 28.0 -12.4 17.4 
Time to Peak (Minutes) -0.33 – 1.16 0.17 0.14 
Table 4.3 A table detailing the range of change obtained in a cohort of 19 individuals for each of the four 
thrombin generation parameters pre and post plasma filtration. The table also shows the median change of 
the cohort and the y intercept of the trendlines drawn in figure 4.7 as a further indication of average 
change. 
 
The average changes observed for the lag time, ETP and time to peak parameters, as 
defined by the median change and the y intercept, appear consistent in both trend and 
magnitude, this is not the case for the peak height where the average observed change as 
defined by the two methods appears contradictory. The median change appears to show 
a decrease in peak height post filtration and the y intercept implies an increase in peak 
height post filtration. The reason for this conflict is probably a result of the 
extrapolation of the trendline in order to calculate the intercept, since the trend line is 
not parallel to the X=Y line. This result implies that filtration has a greater impact on 
the reduction of the peak height parameter with increasing peak height. The patients’ 
trend line is indicative of the fact that any patients with peak height parameters 
below~140nM Thrombin are likely to demonstrate an increase post filtration. It is 
worthy of note however that a peak height of <140 nM Thrombin is a highly abnormal 
result (normal range 258-454 nM thrombin) and corresponds to the peak height 
generated by spiking heat inactivated plasma with 30% SHP (figure 2.15 B). The 
majority of patients would therefore demonstrate a decrease in peak height post 
filtration.  
 
This experiment is suggestive of an average decrease in both ETP and peak height 
parameters as well as an average increase in both lag time and time to peak parameters 
post filtration. Using a paired t-test to compare the patients results pre and post filtration 
revealed that all of these trends were statistically significant (p= <0.01 for all 
comparisons). What is striking about this result is that whilst the observed post filtration 
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trends for both ETP and peak height are consistent with those observed in the pooled 
plasma experiments above, the trends for the lag time and time to peak parameters are 
not. The pooled plasma experiments above revealed decreasing lag time and time to 
peak parameters whilst the paired comparison of 19 patients reveals the average change 
as an increase in these parameters post filtration. The reason for this conflict is probably 
due to the fact that the paired comparison is based on an average change and although 
the majority of the patients analysed did follow the observed pattern, this was by no 
means true of all of the patients analysed. It is worthy of note that this is not just the 
case for the time to peak and lag time parameters but also the ETP and peak height 
measurements as well. That is some of the patients analysed in the paired comparison 
had elevated ETP and peak height parameters post filtration. Figure 4.8 shows Bland 
Altman plots (mean result of the pre and post filtration result for each patient plotted 
against magnitude of change) of the results for each of the thrombin generation 
parameters for the 19 patients analysed. 
 
Figure 4.8 
 
A.              B. 
  
C.              D. 
  
Figure 4.8 A series of Bland Altman plots showing the mean result for each of the four thrombin 
generation parameters obtained pre and post filtration against the change post filtration for a cohort of 19 
patients. A: Lag time, B: ETP, C: Peak Height, D: Time to Peak. 
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From figure 4.8 it is clear that although the majority of the patients analysed 
demonstrate the same pattern of change post filtration a handful of the patients analysed 
follow the opposite pattern. It is interesting that the pooled plasmas analysed in the 
above experiments demonstrate the post filtration pattern exhibited by the minority of 
individuals. The magnitude of any observed changes are also not consistent, this result 
is perhaps seen more clearly in figure 4.8 rather than in the trendlines of figure 4.7, 
which seem to show a high level of correlation consistent with a constant change in the 
results. It is important to note that the average post filtration changes observed in the 
paired comparison are consistent with the removal of pro-coagulant material (probably 
microparticles) following the filtration process, since the patients total capacity and 
maximum rate of thrombin production are reduced in conjunction with an increase in 
the time taken to initiate thrombin generation and the time to reach the maximum rate of 
thrombin generation. The fact that neither the magnitude of these changes or indeed the 
pattern of these changes is conserved implies that the material removed in the filtration 
process is not conserved from patient to patient. For example it may be the case that 
those patients who show the largest decreases in ETP following filtration are those who 
have the highest levels of tissue factor expressing microparticles, those patients who 
demonstrate decreased lag time and time to peak parameters may well have higher 
circulating levels of microparticles expressing negative regulators of haemostasis such 
as TFPI and Protein C. 
 
One hypothesis which seems to be disproved by the paired comparison is the fact that 
the decreased lag time and time to peak parameters seen following plasma filtration in 
the pooled plasma experiments are due to plasma activation during the filtration 
process. Since this trend is not conserved in the 19 patients in the paired comparison 
this hypothesis does not seem likely. Indeed an analysis performed using a separate 
cohort of 20 individuals where the PT and APTT of the 20 plasma samples was 
measured pre and post filtration revealed no significant differences when compared 
using a paired t-test (data not shown). 
 
4.3.4 Analysis of Plasma Pre and Post Filtration by Flow Cytometry 
 
The next stage of the analysis was to examine the plasma of a cohort of patients pre and 
post filtration, with a view to discovering the changes in the number and type of 
- 218 - 
 
microparticles present following the filtration process. The ultimate aim was to correlate 
the microparticle changes in the patients’ plasma with the changes observed in their 
thrombin generation profiles following filtration. In order to ascertain the effectiveness 
of flow cytometry as a tool for measuring changes in microparticle numbers plasma 
samples from two patients were analysed pre and post filtration. The patients’ samples 
were prepared as described in section 4.2.5 above, although prior to freezing the plasma 
was divided into two equal sized aliquots one of which was filtered as described in 
section 4.2.6. The analysis was performed as described in section 4.2.15. Four different 
antibodies were used in this analysis: 
Anti-CD15 FITC, used to detect microparticles of monocyte origin 
Anti-CD42b (Glycoprotein 1b) PE, used to detect microparticles of platelet origin 
Anti-CD45 Pacific Blue, used to detect microparticles of Leukocyte origin 
Anti-Glycophorin A FITC, used to detect microparticles of erythroid origin 
Since two of the antibodies utilise the fluorochrome FITC the plasma samples were 
measured in two separate tubes each containing a pair of antibodies. Anti CD42b and 
Glycophorin A were used in one tube and Anti-CD15 and CD45 in the other.  
 
The use of the 1.1µm beads allowed the size of the particles present in the patients’ 
plasma to be determined. The initial gates were placed around the particulate material in 
the patients’ plasma, the 1.1µm beads and the sphero AccuCount Fluorescent particles. 
Since the 1.1µm beads form a discreet cloud in the analysis, the position of the beads 
could be use to position two further gates around the particular matter present.  These 
gates were used to divide the cellular material present into two distinct groups with the 
gates bisecting the 1.1µm beads. These gates are P4 and P5 shown in figure 4.9 below. 
The material in gate P4 is smaller than 1.1µm in diameter whereas the material gated by 
P5 is greater that 1.1µm in diameter. The material gated by P4 is therefore more likely 
to contain exclusively microparticles; the material gated in P5 will contain some 
microparticles (up to 2µm in diameter) but may also contain some larger cell fragments 
or intact platelets. 
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Figure 4.9 
 
Figure 4.9. Gating strategy for the flow cytometry analysis. P1: All microparticle events. P2: 1.1µm 
beads. P4: Microparticle events <1.1µm. P5: Microparticle events >1.1µm. P7: Sphero AccuCount 
Fluorescent particles 
 
It can be seen from figure 4.9 that a distinct population of particulate matter was 
excluded from the P1 gate and therefore from further analysis.  It was felt that this 
population was likely to be contamination as a result of incomplete removal of 
particulate matter from the tyrodes salt solution. The material present in gates P4 and P5 
was then analysed to in order to ascertain how many of the events were positive for the 
different antibodies. Example plots are shown in figures 4.10 and 4.11 below.  
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Figure 4.10 
 
A.     B.  
   
 
  
 
Figure 4.10. Comparison of flow cytometry results for a patient’s plasma pre and post filtration. Blue 
plots represent material in gate P4. Orange plots represent material in gate P5. Material in gates Q1-2 and 
Q1-3 is positive for CD42b expression. Material in gates Q4-2 and Q4-3 is positive for glycophorin A 
expression. Material in Q3-2 and Q3-3 is negative for both CD42b and Glycophorin A. Material in gates 
Q2-2 and Q2-3 express both CD42b and Glycophorin A. A: Plasma pre filtration. B: plasma post 
filtration. 
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Figure 4.11 
 
A.      B. 
   
  
 
Figure 4.11. Comparison of flow cytometry results for a patient’s plasma pre and post filtration. Blue 
plots represent material in gate P4. Orange plots represent material in gate P5. Material in gates Q1-1 and 
Q1-3 is positive for CD45 expression. Material in gates Q4-1 and Q4-3 is positive for CD15 expression. 
Material in Q3-1 and Q3-3 is negative for both CD15 and CD45. Material in gates Q2-1 and Q2-3 
expresses both CD15 and CD45. A: Plasma pre filtration. B: plasma post filtration. 
 
 
It can be clearly seen from figure 4.10 that filtration of a patients plasma results in a 
dramatic decrease in the number of both CD42b and Glycophorin A positive events. 
This implies a reduction in the number of both platelet and erythroid derived 
microparticles. The results in figure 4.11 are much less dramatic with the number of 
CD15 positive events showing little change post filtration and the number of CD45 
positive events increasing slightly. This result is unexpected as it implies the filtration 
process has little or no effect on the number of monocyte derived microparticles and 
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may act to enhance the numbers of leukocyte derived microparticles. It is important to 
note that figures 4.10 and 4.11 are a visual means of assessing the results of filtration on 
microparticle numbers and are therefore subjective. The actual number of microparticles 
were calculated using Sphero
TM
 AccuCount Fluorescent particles produced by 
Spherotech. 10µl of Sphero
TM
 AccuCount Fluorescent particles were added to each of 
the samples to be analysed by flow cytometry. Since the beads were of a known size 
(10µm) and therefore appear as a discreet cloud when analysed, they can be gated and 
counted accurately (gate P7 in figure 4.9). The numbers of microparticles can be 
calculated using the following equation:  
Number of cells per µl of test sample = (A/B)x(C/D) 
Where: 
A= number of events in the test sample 
B= number of events for AccuCount Fluorescent particles 
C= number of AccuCount Fluorescent particles per 10µl (10015) 
D= volume of test sample initially used 
 
Tables 4.4 and 4.5 show the numbers of microparticles of each origin pre and post 
filtration for the sample analysed above for the material gated in P4 and P5 respectively. 
 
Table 4.4 
Microparticle Origin Number per µl 
Pre Filtration 
Number per µl 
Post Filtration 
Platelet 2640 15 
Erythroid 745 28 
Leukocyte (All types) 37 92 
Monocyte 27 30 
 
Table 4.4. Number of microparticles per µl from gate P4 (<1.1µm in diameter) of each cellular origin in 
the plasma of a patient pre and post filtration. 
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Table 4.5 
Microparticle Origin Number per µl 
Pre Filtration 
Number per µl 
Post Filtration 
Platelet 493 4 
Erythroid 157 7 
Leukocyte (All types) 21 41 
Monocyte 1 4 
Table 4.5. Number of microparticles per µl from gate P5 (>1.1µm in diameter) of each cellular origin in 
the plasma of a patient pre and post filtration. 
 
The data analysis presented in tables 4.4 and 4.5 is consistent with the flow cytometry 
plots in figures 4.10 and 4.11 above, with the number of platelet and erythroid derived 
microparticles showing a large reduction post filtration whereas microparticles of 
monocyte origin seem to be unaffected following the filtration process. The most 
surprising result is the fact that the number of leukocyte derived microparticles seems to 
show an increase post filtration. The pattern of change is also conserved between the 
material gated in P4 and P5. It was a concern that the P5 gate may contain a large 
number of cellular fragments which were not ‘true’ microparticles and that these could 
not be excluded in this analysis and would impact upon the results. The conservation of 
results between the groups would imply this is not the case, although it is by no means 
proof positive.  
 
Another concern was that the filtration process itself would result in the shearing of the 
cellular material in the sample and lead to a large increase in the level of cellular 
material in gate P4 post filtration. This however seems not to be the case in this pilot 
study as the percentage of events in gate P4 appears conserved post filtration in both 
tubes analysed (data not shown). The results observed in this study also confirm those 
published in the literature. Flaumenhaft (2006) reported that platelet derived 
microparticles are the most abundant in circulation and constitute 70-90% of the total 
number. In the example shown above platelet derived microparticles constitute 77% and 
73% of the total number in gates P4 and P5 respectively.  
 
A number of interesting and unanticipated results were found in this pilot study 
however. The first of these was the presence of microparticles greater than 0.2µm in 
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diameter post filtration. The filters used in this experiment were 0.2µm in diameter and 
therefore should have removed all material greater in diameter than this. This is clearly 
not the case as there are number of events in gate P5 post filtration which are positive 
for the cellular antigens used in this assay in both of the tubes analysed. The fact that 
they are positive for these antigens implies that they are not simply a result of particular 
contamination from the buffer used in this experiment. This is suggestive of the fact that 
microparticles demonstrate an ability to alter their shape and pass through the filter 
apertures without an apparent loss of surface antigen expression. This goes some way to 
explaining one of the other aberrant findings of this experiment which is the increase in 
the number of leukocyte microparticles and the conservation of the number of 
microparticles of monocyte origin post filtration. These results are consistent with the 
hypothesis that these microparticles can alter their shape to pass through the filter 
unhindered. What is interesting regarding this study is that there are very few events 
which are dual positives for CD15 and CD45 implying that the monocyte derived 
microparticles are a distinct population compared to those of other leukocyte origins.  
 
A further point of note is the change in the number of erythroid microparticles post 
filtration. Piccin et al. (2007) reported the average size of erythroid microparticles as 
0.15µm in diameter. The results in this study do not support these findings. If this were 
the case, the red cell derived microparticles would pass through the filter unhindered 
leading to a conservation of the numbers of erythroid microparticles pre and post 
filtration. The results presented above show a marked decrease in erythroid 
microparticle numbers post filtration eluding to the fact that they must be large enough 
to be removed by the filtration process (>0.2µm in diameter).The samples used in this 
experimentation showed no evidence of haemolysis therefore suggesting that the result 
obtained in this study was not simply an artefact of filtering red cell fragments from the 
patients plasma.  
 
It is of importance to note that the discussion presented above is based on a very small 
sample size (n=2) and may therefore not be representative of the results of a larger 
cohort. What this study has revealed is that the analysis of microparticles by flow 
cytometry can accurately determine the numbers of microparticles pre and post filtration 
and therefore can be used to examine a larger cohort of patients. 
 
- 225 - 
 
4.3.5 Correlation of Thrombin Generation and Microparticle Numbers 
 
The next stage of experimentation was to compare the changes observed in the thrombin 
generation profile of a cohort of individuals’ pre and post filtration with the change in 
the numbers of microparticles present in the same samples pre and post filtration. This 
would allow us to determine whether or not it is the removal of microparticles from the 
patients plasma during the filtration process which causes the changes observed in the 
thrombin generation profile of patients. This experiment would also determine whether 
microparticles of different cellular origins have a larger impact on thrombin generation 
than others.  
 
A cohort of 35 patients was used in this experiment. The patients’ samples were 
prepared as described in section 4.2.5 above, although prior to freezing the plasma was 
divided into two equal sized aliquots one of which was filtered as described in section 
4.2.6. Samples were defrosted in a 37°C water bath prior to analysis. Thrombin 
generation was performed as described in section 4.2.9. The pre and post samples of 
each individual were analysed on the same plate in order to ameliorate any effects of 
inter assay variation on the results generated. Microparticle analysis was performed by 
flow cytometry as described in section 4.2.15, with the exceptions that the volume of 
patients plasma used in the analysis was decreased to 10µl and the volume of Sphero 
AccuCount fluorescent particles was increased to 25µl. The antibodies used included 
those described above and Annexin V FITC. Annexin V has high affinity for binding to 
phosphatidylserine and therefore the degree of Annexin V binding should correlate with 
total microparticle numbers. The data from this study is shown in Macey et al., 2010b 
 
The median change in the thrombin generation parameters of this cohort post filtration 
were analogous to those described in table 4.3 above with the vast majority of the 
cohort manifesting a decrease in both the ETP and peak height parameters of similar 
magnitudes to those described above. The majority of the cohort also demonstrated 
either an increase or no change in the lag time and time to peak parameters. Although as 
detailed above not all patients followed these patterns closely, with some displaying 
decreasing lag time and time to peak parameters and others increasing ETP and peak 
heights post filtration.  
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The variation in the change of microparticle numbers following filtration was marked. 
All patients showed a decrease in the numbers of both platelet derived (CD42b positive) 
microparticles and total number of microparticles (Annexin V binding) although the 
magnitude of these decreases varied dramatically between individuals. One patient 
demonstrated a modest decrease of 188 CD42b positive events per µl of plasma post 
filtration whereas the highest change was a decrease of 32320 per µl of plasma. Almost 
all of the patients analysed (33/35) showed a decrease in the number of microparticles 
of erythroid origin following filtration, interestingly this was also the case for the CD15 
positive microparticles with 30 of the 35 individuals analysed showing a decrease in 
numbers following filtration. This is in contrast to the pilot study above where the 
numbers of CD15 positive microparticles were conserved following filtration. The 
change in the number of microparticles of leukocyte origin (CD45 positive) showed the 
most variation between individuals in terms of the pattern of change (although not the 
magnitude of change) post filtration, with 40% of individuals showing an increase in 
numbers following the filtration process and the remainder showing a decrease in 
number. The largest increase was 255 CD45 positive microparticles per µl of plasma 
whereas the biggest decrease was 1122 per µl of plasma. The median change was a 
decrease of 40 CD45 positive events per µl of plasma. 
 
The most important findings of this analysis were the correlations between the changes 
in the thrombin generation parameters and the changes in the number of microparticles 
of different cellular origins. The change in ETP following filtration showed no 
statistically significant correlations with the changes in the number of microparticles of 
any origin with the exception of monocyte derived (CD15 positive) microparticles, with 
which there was a highly significant correlation (p= <0.001) of decreasing ETP with  
decreasing numbers of CD15 positive events. 
 
The change in peak height post filtration showed a number of statistically significant 
correlations with changes in microparticle numbers following filtration, with decreasing 
peak height showing significant correlations with decreasing CD42b positive events 
(p=<0.05), Annexin V positive events (p=<0.01) and CD15 positive events (p=<0.01). 
The strongest correlation was however that between decreasing peak height and 
decreasing numbers of CD15 positive events, which had an R
2
 value of 0.28. 
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Interestingly both the change in the lag time and time to peak parameters post filtration 
showed statistically significant correlations with the same microparticle measurements, 
namely the numbers of CD42b positive and Annexin V positive events (p= <0.05 for 
both lag time correlations and p= <0.01 for both correlations with time to peak). The 
pattern of these changes was also conserved with decreasing thrombin generation 
parameters correlating with decreasing numbers of microparticle events. 
 
The results of this experimentation are promising since they are suggestive of the fact 
that the measurement of thrombin generation using the CAT assay is sensitive to the 
presence of microparticles in a patients plasma and that microparticles of different 
cellular origins have a greater impact on some thrombin generation parameters than they 
do on others. It is evident from the analysis that the number of CD15 positive 
(monocyte derived) microparticles has the biggest impact on both the ETP and peak 
height parameters, whereas the lag time and time to peak parameters are primarily 
affected by the number of CD42b positive and Annexin V positive events. 
 
4.3.6 The Effects of Plasma Filtration 
 
Although the previous experiment suggests a good correlation between the changes in 
thrombin generation and the change in the numbers of microparticles post filtration it is 
conceivable that the correlation is incidental and not causative i.e. something other than 
the change in microparticle numbers is responsible for the change in an individual’s 
capacity to generate thrombin following plasma filtration. This was hypothesised since 
it was unknown whether it was realistically possible to expect the removal of 
microparticles to have such a large impact in terms of the change in thrombin generation 
given the relatively high concentrations of tissue factor and phospholipids employed in 
the reaction. One possibility is that the filtration process may change some of the 
plasma levels of clotting factors or negative regulators of haemostasis either by 
mechanical filtration or by adsorbing these clotting factors onto the filter itself. 
 
In order to test this hypothesis 10 plasma pools were prepared. Each pool consisted of 
four samples taken from patients at The Royal London Hospital. All patients samples 
selected had normal clotting screens as determined by the INR, APTT and Thrombin 
time, therefore excluding any patients known to be undergoing anticoagulant therapy. 
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The samples were spun at 1500g for 10 minutes and the top two thirds of the plasma 
from each of the four samples were subsequently pooled. Following this the pooled 
plasma was spun for a further 10 minutes at 1500g. The top two thirds of this double 
spun plasma were divided into two aliquots one of which was filtered as described in 
section 4.2.6. The two aliquots were then frozen at -70°C. This process yielded 20 
different plasma samples: one filtered and one non-filtered aliquot from each of the ten 
pools. The samples were subsequently thawed by immersion in a 37°C water bath and 
analysed for Antithrombin activity, Protein C activity, Free Protein S antigen, von 
Willebrand Factor antigen and clotting factor activities for factors II, V, VII, VIII, IX, 
X, XI and XII as described in sections 4.2.10 - 4.2.14. All 20 plasma samples were 
analysed using the same reagents in order to reduce the effects of inter assay variation 
on the results. The results obtained pre and post filtration from each of these analyses 
were compared using a paired t-test. Boxplots showing the results generated from these 
analyses as well as the p values obtained from the paired t-test comparisons are shown 
in figure 4.12 below. 
 
Figure 4.12 
 
A.               B. 
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C.               D. 
  
 
E.               F. 
  
 
G.               H. 
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I.               J. 
  
 
K.               L. 
  
Figure 4.12. Boxplots showing the effects of plasma filtration on the levels of plasma clotting factors in a 
cohort of 10 plasma pools.  Boxes show 25
th
 to the 75
th
 percentile of the data with the median shown as a 
horizontal black line. Whiskers show minimum/maximum values. Population outliers defined as values 
deviating by greater than 1.5 times box height are shown by . A: Antithrombin activity, B: Protein C 
activity, C: Free Protein S antigen, D: von Willebrand Factor antigen, E: Factor II activity, F: Factor V 
activity, G: Factor VII activity, H: Factor VIII activity, I: Factor IX activity, J: Factor X activity, K: 
Factor XI activity, L: Factor XII activity. P values derived using the paired t-test. 
 
It is clear from figure 4.12 that the filtration of plasma as described in section 4.2.6 has 
no statistically significant effect on the Antithrombin Activity, Protein C activity, Free 
Protein S antigen, von Willebrand factor antigen, factor II activity, factor V activity, 
factor VII activity, factor IX activity and factor X activity in this cohort of plasma 
samples. There was however statistically significant trends in the factor VIII activity, 
factor XI activity and the factor XII activity post filtration. The changes in the levels of 
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factors XI and XII post filtration, despite being statistically significant, are unlikely to 
be responsible for the apparent change in the thrombin generation following filtration, 
due to the small magnitude of difference in the results pre and post filtration (a mean 
increase of 1.36 iu/dL for factor XI and an increase of 1.74 iu/dL for factor XII). It is 
also worthy of note that an increase in the levels of clotting factors post filtration would 
not be associated with decreasing ETP and peak height parameters or indeed increasing 
lag time and time to peak parameters following filtration. Intuitively these changes 
would be caused due to decreasing levels of clotting factors following the filtration 
process or indeed an increase of the negative regulators of haemostasis (Antithrombin 
activity, Protein C activity or Free Protein S antigen). The change in the Factor VIII 
activity following filtration (a mean decrease of 9.02 iu/dL) is consistent with the 
changes in the thrombin generation parameters most commonly seen following the 
filtration process. The most likely cause for this decrease is the removal of vWF (a 
plasma carrier of factor VIII) from the samples following filtration. Although there was 
no statistically significant difference in the plasma levels of vWF following filtration 
there is a mean decrease post filtration and the difference is approaching significance. 
vWF is a large multimeric protein and could be of sufficient size to be affected by the 
filtration process. What is uncertain in this analysis is whether or not the change in the 
level of factor VIII activity post filtration is of sufficient magnitude to cause the change 
in the levels of thrombin generation seen in the prior experimentation. It is interesting to 
note that the plasma pools prepared in this experiment all have very high levels of factor 
VIII activity (possibly due to acute phase reactions), indeed the mean factor VIII 
activity in the cohort prior to filtration was 225.9 iu/dL, with normal levels typically 
between 50-150 iu/dL. The mean change is therefore a decrease of ~4% which is 
actually consistent with the intra assay variation of the assay. The fact that the majority 
of the samples show a decrease of factor VIII activity post filtration is probably 
indicative that this is more than just an artefact of intra assay variation. Evidence 
provided in the literature (Al Dieri et al., 2002) shows that there is a hyperbolic 
relationship between the levels of clotting factor activity and the ETP, therefore 
suggesting that a difference of 4% in the level of factor VIII activity should have little 
impact on the level of thrombin generation, especially when the plasma level of factor 
VIII activity is so great. Indeed further evidence for this hypothesis is provided in 
chapter 2 where there is little difference in the plasma generating capacity of SHP when 
the clotting factor levels reached >90% of normal. In order to ascertain whether or not 
- 232 - 
 
the change in the levels of factor VIII activity seen post filtration in this experiment 
could be responsible for the changes in the thrombin generation parameters seen 
following filtration described previously in this chapter  it was decided to measure the 
thrombin generation of the 10 plasma pools pre and post filtration. The changes in 
thrombin generation would then be correlated with the changes in the factor VIII 
activity and examined to see if there was any evidence of statistically significant trends. 
The measurement of thrombin generation was performed as described in section 4.2.9. 
The change in each parameter following filtration was calculated by subtracting the 
result obtained prior to filtration from that obtained post filtration. The results of the 
correlation analysis are shown in figure 4.13 below. 
 
Figure 4.13 
A.              B. 
  
C.               D. 
  
Figure 4.13. A series of graphs showing the correlation between the change in each of the four thrombin 
generation parameters post filtration with the change in factor VIII activity post filtration in a cohort of 10 
plasma pools. Trend lines and R
2
 are shown as an indication of correlation. A: Lag Time, B: ETP, C: Peak 
Height, D: Time to Peak 
 
Although it is clear from figure 4.13 that there appears to be a degree of correlation 
between the change in factor VIII activity post filtration with the change in the ETP, 
peak height and time to peak parameters post filtration, none of these trends is 
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statistically significant when the p values of the correlations are determined as described 
in section 2.3.1.4. It is worthy of note that the number of samples in these correlations is 
quite small and therefore there may not be sufficient power to establish whether these 
trends are indeed significant. Even if a larger number of samples could prove a 
statistically significant correlation it is apparent that the ‘direction’ of the correlations as 
shown by the trend lines are not supportive of the change in factor VIII activity being 
causative of a decrease in either the ETP or peak height or indeed an increase in lag 
time and time to peak post filtration, since the correlations imply the opposite trend i.e. 
the samples with the biggest decrease in factor VIII are those with the smallest change 
in ETP/ peak height and the largest decrease in lag time and time to peak parameters. 
These correlations therefore provide good evidence that the apparent change in factor 
VIII activity post filtration is not causative of the changes seen in an individual’s 
thrombin generation following filtration. 
 
4.3.7 The Thrombogenicity of Microparticles 
 
Since the experiments performed in the previous section are suggestive of the fact that 
the filtration process does not cause changes in the plasma levels of clotting factors 
which are responsible for the changes apparent in the thrombin generation parameters 
post filtration, it is increasingly likely that the original hypothesis that these changes are 
caused via the removal of microparticles is correct. To provide further evidence for this 
hypothesis it was decided to try and determine whether or not microparticles could 
initiate thrombin generation and therefore provide proof that the presence or absence of 
microparticles could impact upon the thrombin generation capacity of a patient’s 
plasma. 
 
In order to establish the impact which microparticles could have on thrombin generation 
in the CAT assay it was decided to see if concentrated microparticles could be used to 
initiate thrombin generation in a patients plasma in the absence of PPP reagent (without 
the addition of either exogenous tissue factor or phospholipids). This analysis would 
also therefore establish beyond doubt whether or not microparticles express tissue 
factor. For this experiment two 4.5ml 0.109M tri-sodium citrate samples spiked with 
77µl of 1.3mg/ml CTI were taken from a cohort of 6 healthy volunteers. The use of CTI 
is essential in these experiments given that the concentration of tissue factor and 
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phospholipids is very low, the assay would be exceedingly sensitive to contact 
activation. The samples were then double spun as described in section 4.2.5 although 
the samples were not subsequently frozen.  The plasma collected was then ultra 
centrifuged at 14000rpm in order to pellet the microparticles and therefore produce 
microparticle free plasma. The microparticle free plasma was removed from the pellet 
using a Pasteur pipette, leaving a residual volume of approximately ~100µl of plasma. 
The microparticle pellet was then re-suspended via the addition of a further 400µl of 
microparticle free plasma. This process yielded one aliquot of microparticle free plasma 
and one aliquot of microparticle rich plasma from each of the 6 volunteers. The final 
concentration of microparticles in the microparticle rich plasma was approximately 10 
times that usually found in the patients plasma. The concentration of microparticles was 
necessary since it was reported by Butenas et al. (2005) that the concentration of tissue 
factor on the surface of microparticles in the circulation of a healthy patient whose 
blood remains unstimulated with cytokines is below the threshold needed to initiate in 
vivo thrombin generation. Following the preparation of the plasma samples the 
thrombin generation was measured as described in section 4.2.9 with the exception that 
20µl of CA system buffer was added to the thrombin generation measurement wells 
instead of PPP reagent. The analysis time for this experiment was 120 minutes. All 12 
plasma samples were analysed on a single plate in order to minimise the effects of inter 
assay variation. As the analysis proceeded it was clear that all 6 of the microparticle rich 
plasmas demonstrated thrombin generation curves whereas all 6 of the microparticle 
poor plasma samples failed to generate recognisable thrombin generation curves. An 
example of the curves produced following the analysis of one of the patients is shown in 
figure 4.14 below. 
 
What is apparent from figure 4.14 is that the thrombin generation curve produced 
following the analysis of the microparticle rich plasma is distinctly different from the 
curve produced following the analysis of the microparticle poor plasma. This provides 
compelling evidence for the fact that microparticles can initiate thrombin generation in 
the CAT thrombin generation assay and therefore must express tissue factor. 
Unfortunately none of the curves produced by the measurement of any of the 6 
microparticle rich plasma samples was complete (the level of thrombin generation did 
not return to zero over the time course of the reaction) and therefore it is impossible to 
calculate the ETP and ultimately quantify the impact that the presence of microparticles 
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has on thrombin generation. The cause of this apparent failure is probably an artefact of 
the low levels of thrombin generation in these samples rather than a truncated 
measurement time (personal communication). The median thrombin generation 
parameters as well as the range of results obtained following this analysis are shown in 
table 4.6. It is immediately clear from the results that the microparticle rich plasma 
samples had a higher maximum rate of thrombin generation, a shorter time to the 
initiation of thrombin generation and a shorter time until the maximum rate of thrombin 
generation was achieved when compared to the microparticle poor plasma. Indeed these 
differences are all statistically significant when analysed using the Mann Whitney U test 
(data not shown). The actual differences between the results of the two cohorts may be 
even greater than table 4.6 actually suggests since some of the measurements in the 
microparticle poor plasma cohort are very spurious and are likely caused by 
mathematical quirks in the analysis software rather than any thrombin generation per se.  
 
Figure 4.14 
 
 
Figure 4.14. Example thrombin generation curves produced when measuring microparticle poor plasma 
and microparticle rich plasma using the CAT thrombin generation assay without the addition of 
exogenous tissue factor or phospholipids. 
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An example of this is demonstrated by the lag time of 6.67 minutes in the microparticle 
poor plasma cohort, this result relates to the thrombin generation curve shown in figure 
4.14, which shows little or no thrombin generation at all. Indeed four of the 6 samples in 
the microparticle poor cohort demonstrated flat curves and therefore no thrombin 
generation data due to the ‘flat curve error’ discussed in chapter 2. It is worthy of note 
that some of the values attained in this phase of experimentation do fall below the lower 
limit of quantification as discussed in chapter two. These limits were established using 
different concentrations of tissue factor and phospholipids as reaction triggers and 
without the addition of CTI and are therefore not strictly applicable in this case. 
 
Table 4.6 
Parameter Microparticle Poor Microparticle Rich 
 Median Range Median Range 
Lag Time 
(Minutes) 
>120 6.67 - >120 54.44 30.44 – 60.11 
Peak Height  
(nM Thrombin) 
0 0 – 3.85 14.15 6.44 – 24.13 
Time to Peak 
(Minutes) 
>120 74.67 - >120 91.89 69.33 – 107.78 
Table 4.6. The median and range of results produced for each of the thrombin generation parameters 
following the analysis of microparticle poor plasma and microparticle rich plasma using the CAT 
thrombin generation assay without the addition of exogenous tissue factor or phospholipids. 
 
What is apparent following this phase of experimentation is that microparticles not only 
express tissue factor as evidenced by the initiation of thrombin generation in the above 
experiment but the presence of microparticles in a patients plasma is likely to have an 
impact on a patients capacity to generate thrombin. Taken with the results from the 
previous section the results presented here provide solid evidence that the changes seen 
in thrombin generation following the filtration process are likely to be caused by the 
removal of microparticles during filtration. 
 
 
4.4 Discussion 
- 237 - 
 
 
The initial aim of this chapter was to ascertain the effects of microparticles on thrombin 
generation as measured by the CAT assay. The starting place for this investigation was 
the analysis of Control plasma P, a commercially produced lyophilised plasma product 
initially used to assess both the inter and intra assay variability of the CAT assay (see 
chapter 2). These experiments were unsuccessful due to unacceptably high levels of 
inter assay variability and the presence of intra assay trends (decreasing peak height and 
increasing lag time with plate position). It was thought that the reason for this apparent 
variability was the presence of particular matter in the Control plasma P itself, which 
could include microparticles. Due to their procoagulant nature, inefficient or incomplete 
reconstitution of the plasma leading to uneven distribution of microparticles could be 
responsible for some of the variation seen in the results. The filtration of Control plasma 
P did result in a significant decrease in the variability of the results produced by the 
CAT assay, reducing the CV of the ETP by almost half from 10.2% to 5.4%, with 
similarly profound decreases in the variation of the peak height and time to peak 
parameters (45%  and 40% decreases respectively). The decrease in CV for the lag time 
post filtration was the most modest at 23%. These decreases in variability were 
accompanied by a decrease in assay ‘noise’, with the production of smoother thrombin 
generation curves as shown in figure 4.2. The filtration of the Control plasma P also 
produced a visible effect on the plasma in that it became less opaque, although this was 
not formally quantified. These changes are all consistent with the removal of particulate 
matter from the plasma via the filtration process. Whether the particulate matter 
removed contained microparticles which interfered with the analysis is still unclear. The 
effects of plasma filtration on the results of the thrombin generation assay (statistically 
significant reductions of all parameters) were conserved between the filtration of 
Control plasma P and pooled fresh plasma but the fresh plasma pool showed no 
apparent decrease in variation post filtration. This finding is suggestive of the fact that 
the cause of the changes in the thrombin generation parameters is distinct from the 
cause of the decreased variability seen in the Control plasma P. It is most likely 
therefore that the high degree of variability witnessed in the analysis of Control plasma 
P is caused by disruption of the fluorescent signal generated by the CAT assay by 
particulate matter present in the plasma following incomplete reconstitution. The 
removal of this matter via filtration reduces the assay ‘noise’ and therefore decreases the 
variability seen in the results. What is interesting regarding this analysis is the fact that 
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plasma filtration does not ameliorate the intra assay trends prevalent in the analysis of 
Control plasma P. There was evidence of both decreasing ETP and peak height with 
increasing plate position in both the filtered and non-filtered Control plasma P in the 
experiments described in this chapter. These effects are most likely due to some other 
inherent artefact of the Control plasma P. One potential cause is a predisposition of 
Control plasma P to calcium independent contact activation with increasing incubation 
time. Plasma activation is known to lead to an over estimation of ETP (van Veen et al., 
2009a), although this is most prevalent in the use of a 1 pM concentration of tissue 
factor as a reaction trigger in the absence of CTI. This hypothesis can also potentially 
explain the increase in the lag time with increasing plate position seen in chapter 2. 
What is evident is that this effect cannot be ameliorated by decreasing the incubation 
time by the magnitude achieved using an electronic pipette. 
 
The initial filtration experiments performed on both Control plasma P and pooled fresh 
plasma demonstrated that the filtration of plasma resulted in statistically significant 
changes in the measured thrombin generation parameters, whilst it was assumed that the 
removal of pro-coagulant microparticles was responsible for this change, the observed 
pattern in results did not fit neatly with this hypothesis. Since microparticles have 
membranes rich in phosphatidylserine which has been shown to allow optimisation of 
the reaction kinetics for the generation of thrombin (Morel et al., 2006) and can also 
express tissue factor (del Conde et al., 2005b) (Hron et al., 2007) it was thought that 
microparticle removal following filtration would ultimately reduce an individuals 
capacity to produce thrombin and decrease their maximum rate of thrombin production 
as well as potentially increasing the time taken for the initiation of thrombin generation 
and the time taken to attain the maximum rate of thrombin production. Whilst the first 
part of this hypothesis was consistent with the observed results (decreased ETP and 
peak height following filtration), the observed reduction of both the lag time and time to 
peak parameters post filtration were unexpected. Whilst it was initially hypothesised 
that the reduction of these times following filtration was due to sample activation during 
the filtration process, this theory was discredited by the fact that there were no 
significant differences in either the PT or APTT measured on plasma taken from a 
cohort of individuals pre and post filtration. The most likely cause for the decrease in 
lag time and time to peak parameters post filtration was therefore the removal of 
negative regulators of haemostasis such as TFPI, thrombomodulin and Protein C all of 
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which have been reported to be expressed by microparticles (Steppich et al., 2005) 
(Satta et al., 1997). Intuitively the removal of a negative regulator of haemostasis would 
also lead to an increase in the ETP and peak height parameters rather than the observed 
reduction. This however need not necessarily be the case as TFPI is primarily involved 
in the inhibition of the initiation phase of coagulation, when less than 5% of the total 
thrombin is formed (Hemker and Béguin, 1995). The removal of microparticles 
expressing TFPI may therefore have a much greater impact on the initiation of thrombin 
generation rather than the total level of thrombin produced. 
 
The analysis of non-pooled plasma samples however revealed that whilst the majority 
of individuals did manifest a reduction in both ETP and peak height parameters 
following filtration, consistent with the removal of pro-coagulant material, the changes 
in the lag time and time to peak parameters demonstrated by the two pooled plasma 
experiments displayed a pattern of change (decrease post filtration) which is evident in a 
minority of individuals. The majority of subjects in the non-pooled analysis showed an 
increase in both lag time and time to peak post filtration, which is again consistent with 
the removal of procoagulant material from their plasma during the filtration process. 
This analysis was profound as it revealed that the magnitude of change and even the 
pattern of change in thrombin generation parameters post filtration varied markedly 
between individuals. This variation is suggestive but certainly not proof positive of the 
fact that different individuals not only have varying numbers of circulating 
microparticles but also varying numbers of microparticles of a pro-coagulant nature 
(expressing tissue factor) as well as those expressing negative regulators of haemostasis.  
 
The measurement of microparticle numbers by flow cytometry in the pilot study 
revealed that microparticles could be accurately quantified and that they were removed 
by plasma filtration. This experiment therefore provided circumstantial evidence that 
the changes in the number of microparticles could be responsible for the changes seen in 
the measurement of thrombin generation post filtration. The pilot study also highlighted 
a number of interesting results which were confirmed in the analysis of a larger cohort 
of individuals. The first of these was the apparent increase in the number of CD45 
positive events post filtration. Whilst this finding was by no means the case in all 
individuals it was a pattern observed in 40% of those patients analysed. The reason for 
this phenomenon is unknown, a potential explanation is the shearing of CD45 positive 
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microparticles during the filtration process as this would cause an increase in the 
numbers of CD45 positive events in gate P4 following filtration. Although if this was 
the case it would be likely to be accompanied by a decrease in the number of CD45 
positive microparticles in gate P5 and this was not the case in these individuals. The 
increase in CD45 positive microparticles following filtration is potentially indicative of 
the fact that microparticles are capable of undergoing changes in conformation to 
facilitate passage through the filter membrane without manifesting an apparent loss of 
antigen expression, this theory is given weight by the fact that microparticles greater 
than 0.2μm in diameter can be detected in plasma following the filtration process. One 
of the most likely reasons for the apparent changes in CD45 expression may be the fact 
that the mechanical process of passing through the filter can cause a change in the 
expression levels of CD45. Although a mechanism for this change has yet to be 
elucidated. 
 
One of the other unanticipated results highlighted by the flow cytometry analysis was 
the decrease in the number of erythroid microparticles following filtration. It was 
anticipated that since microparticles of erythroid origin are described in the literature as 
typically smaller than 0.15μm in diameter (Piccin et al., 2007) they would not be 
removed via filtration as the filter apertures were 0.2μm in diameter. A total of 33 of the 
35 patients analysed by flow cytometry showed evidence of decreasing numbers of 
erythroid microparticles following plasma filtration, implying that they are removed 
during the filtration process and that by extension erythroid microparticles must be 
larger than 0.2μm. The results of these analyses do not therefore support the findings of 
Piccin et al. (2007).  
 
Other than the results presented above the filtration of plasma produced the anticipated 
effects on the numbers of microparticles, with decreasing levels of CD42b positive, 
CD15 positive and Annexin V positive events post filtration, consistent with the 
removal of platelet derived microparticles, microparticles of monocyte origin and a 
decrease in the total number of microparticles post filtration. 
 
The investigation into the correlation between the change in thrombin generation 
parameters and microparticle numbers following filtration resulted in the most 
interesting findings of this phase of experimentation. The results demonstrated a 
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statistically significant correlation between the changes in ETP and peak height 
observed following filtration and the change in the numbers of CD15 positive 
microparticles post filtration. There was also a statistically significant correlation 
between peak height and both the number of CD42b positive and Annexin V positive 
events post filtration. These correlations are consistent with the removal of procoagulant 
material as hypothesised above. Since 91% of microparticles of monocyte origin (CD15 
positive) are known to express tissue factor (Hron et al., 2007) the above correlation is 
suggestive of the fact that increased levels of microparticles of monocyte origin and 
hence increased levels of tissue factor can act to enhance both the total thrombin 
generation capacity and the maximum rate of thrombin generation of an individuals 
plasma. The mechanism for this is likely to be an increase in tissue factor trigger 
available to initiate the thrombin generation reaction. The CAT assay used in this 
experimentation uses a fixed concentration of tissue factor in order to initiate thrombin 
generation (5pM), individuals with higher circulating levels of tissue factor expressing 
monocyte microparticles would effectively have a higher concentration of tissue factor 
available to initiate the thrombin generation reaction than those patients who 
demonstrate lower levels of circulating monocyte microparticles, the higher levels of 
tissue factor may lead to a sustained reaction and ultimately higher levels of thrombin 
generation. Although this hypothesis is theoretically plausible it is worthy of note that 
the data presented here does not show that CD15 microparticles (of monocyte origin) 
actually do express tissue factor. It may be that the correlation between the changes in 
ETP/peak height and the number of CD15 positive microparticles is due to another 
cause, such as the composition of phospholipids in the microparticle membrane for 
example. 
 
If the above hypothesis is correct it potentially implies that while most of an individuals 
thrombin generation capacity is due to the fixed level of tissue factor added in the 
reaction mixture a proportion of the total thrombin generation is due to the levels of 
tissue factor expressing microparticles in that patients plasma. This is true to an even 
greater extent when considering the peak height parameter as this is sensitive to the 
number of monocyte microparticles and the number of CD42b positive/ Annexin V 
positive events. It is important to note that the measurement of CD42b positive and 
Annexin V positive events should yield similar results as the number of Annexin V 
positive events is roughly analogous to the total number of microparticles present in the 
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plasma of an individual (since Annexin V binds to the phosphatidylserine  expressed in 
microparticle membranes) and platelet derived microparticles (CD42b positive) 
constitute between 70-90% of the total number of microparticles in circulation 
(Flaumenhaft, 2006). It is therefore anticipated that any correlations with thrombin 
generation parameters should be present for both of these measurements or in neither. 
The sensitivity of the peak height parameter to the number of microparticles present in a 
patient’s plasma is probably explained by the increased availability of binding sites for 
both the tenase and prothrombinase complexes provided by the phosphatidylserine rich 
microparticle membranes. The peak height is effectively a measurement of the 
maximum rate of thrombin generation of a sample and it is therefore perhaps 
unsurprising that an increase in the available material on which the generation of 
thrombin occurs above and beyond that which is routinely added to the analysis would 
result in an increased maximum rate of production. Nevertheless it is evident from this 
research that the maximum rate of thrombin generation in a sample is enhanced by both 
the presence of microparticles and the number of monocyte microparticles (which may 
or may not express tissue factor.) 
 
The correlations between the lag time and time to peak parameters were less profound 
(although still statistically significant) than those between the change in the number of 
microparticles and the ETP and peak height parameters. The pattern of these 
correlations were also different to that which was expected. Although as hypothesised 
above the removal of procoagulant microparticles would intuitively result in the 
increase of the lag time and time to peak post filtration due to a decrease in the available 
phospholipids on which the thrombin generation reaction occurs, the correlations appear 
to show decreasing lag time and time to peak parameters with decreasing microparticle 
numbers. This picture is consistent with the removal of microparticles expressing 
negative regulators of haemostasis which primarily impact upon the initiation phase of 
coagulation such as TFPI (discussed above). Although the observed correlation neatly 
dovetails with this hypothesis the picture is further confused by the fact that the 
majority of patients show either no change or an increase in both lag time and time to 
peak parameters post filtration. These patients also typically show the smallest decrease 
in the numbers of microparticles following filtration. It is worthy of note that these 
patients do still show a decrease in microparticle numbers however and therefore it is 
possible that these effects are due to the removal of procoagulant microparticles which 
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do not express negative regulators of haemostasis. It appears therefore that the exact 
effect that the number of microparticles in a patients plasma has on both the lag time 
and the time to peak parameters is dependent on whether or not the microparticles 
present express negative regulators of haemostasis or not. It is anticipated that an 
individual with increased numbers of microparticles in their circulation which do not 
express negative regulators of haemostasis will demonstrate a decreased lag time and 
time to peak when compared to an individual with a lower level of circulating 
microparticles. An individual with a high level of circulating microparticles expressing 
negative regulators of haemostasis would demonstrate the opposite effect. What is 
apparent in this analysis is that whilst the measurement of the lag time and time to peak 
parameters are affected by the number of microparticles present in an individuals 
circulation the exact impact that this is likely to have on the observed results is difficult 
to predict without further investigation as to the proteins expressed by those 
microparticles.  
 
As discussed in section 4.3.6 it was initially felt that although the correlation between 
the changes in the thrombin generation parameters and the changes in microparticle 
numbers post filtration were supportive of the hypotheses presented above, it was 
uncertain whether changes in the numbers of microparticles could plausibly be 
responsible for the magnitude of change seen in the thrombin generation capacity of a 
patients plasma following filtration. This was because the concentration of tissue factor 
and phospholipid used in the reaction trigger was felt to be much higher than the levels 
of tissue factor and phospholipid provided by the microparticles themselves. It is clear 
from the results presented in section 4.3.6 that the changes in thrombin generation seen 
post filtration are not likely to be caused by changes in the plasma concentration of 
clotting factors or negative regulators of haemostasis following filtration. Good 
evidence is provided by the experiments detailed in section 4.3.7 that microparticles are 
capable of initiating thrombin generation without the addition of exogenous tissue factor 
and phospholipids and that microparticles therefore can and probably do impact on the 
thrombin generation capacity of a patient’s plasma when measured by the CAT 
thrombin generation assay. It is worthy of note that the median change in peak height 
demonstrated by a cohort of 19 individuals post filtration shown in table 4.3 (-12.4 nM 
thrombin) is roughly analogous to the median peak height generated by the 
microparticle rich plasma shown in table 4.6 (14.15 nM thrombin). Although these 
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experiments dovetail nicely it is apparent that the actual concentration of microparticles 
in the plasma varies dramatically. It is clear from the literature however that the resting 
level of tissue factor present on the surface of circulating microparticles is insufficient 
to initiate thrombin generation in vivo (Butenas et al., 2005) but it may be the case that 
tissue factor expressing microparticles are recruited to the sites of vascular injury not to 
initiate clot formation but to stabilise the thrombus by inducing further fibrin (and 
therefore previously thrombin) production (Wagner, 2005). It is evident that although 
microparticles may not be responsible for the initiation of thrombin generation they 
obviously play an important role in thrombin generation in vivo, nowhere is this more 
apparent than in individuals who have deficiencies in microparticle numbers or a loss of 
microparticle functionality i.e. patients with Scott syndrome or Castamans defect who 
have marked bleeding tendencies. The fact that microparticles have such an impact on 
in vivo thrombin generation makes it almost counter intuitive to suggest that they cannot 
mediate a similar effect in an in vitro assay. 
 
The results of this experimentation suggest that the measurement of thrombin 
generation by the CAT assay is sensitive to and even partially dependent on both the 
number of microparticles and also potentially the number of microparticles expressing 
tissue factor in a patients plasma. Whilst the effects of these parameters can be predicted 
on both the ETP and peak height, the effects on both the lag time and time to peak are 
not clear cut.  
 
The results of this investigation do not support those reported by Lawrie et al. (2008) 
however who demonstrated no measurable effect on any parameter as measured by the 
CAT assay using the reagents described in section 4.2.9 following the filtration of 20 
fresh frozen plasma samples. Interestingly the authors did report similar findings to this 
investigation when lower concentrations of tissue factor trigger were employed. This 
effect became more profound when reduced concentrations of tissue factor trigger were 
used in combination with a reduced concentration of phospholipid. Sinauridze et al. 
showed an increase in ETP in line with increasing numbers of platelet derived 
microparticles; which is again contradictory to the findings of this investigation, where 
we showed no correlation between the ETP and the number of platelet derived 
microparticles in a patient’s plasma. It is worthy of note however that the experiments 
performed by Sinauridze et al. employed a different thrombin generation assay to the 
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CAT assay used in this investigation and that the platelet derived microparticles added 
to the reaction were the only source of phospholipid available. It is therefore 
unsurprising that there should be a direct correlation with the numbers of platelet 
derived microparticles and the resulting endogenous thrombin potential. 
 
The results of this investigation are consistent with the hypothesis discussed in chapter 3 
that the increased levels of both ETP and peak height described in patients with pre-
eclampsia are due to an increase in the number of microparticles present in the 
circulation of these women (Macey et al., 2010a). Martinez et al. (2005) suggested that 
microparticles of leukocyte origin are of particular importance in pre-eclampsia, this 
result provides further weight to our hypothesis if this also includes microparticles of 
monocyte origin. The most important aspect of this research is the fact that the CAT 
assay is sensitive to the presence of microparticles in the circulation of a patient's 
plasma and that pathological levels of microparticles can cause abnormally high levels 
of ETP and peak height as seen in the cohort of women with pre-eclampsia in chapter 3. 
This provides evidence for the potential use of the CAT thrombin generation assay in 
the monitoring and even the diagnosis of any conditions which display enhanced 
numbers of microparticles in the circulation, not just pre-eclampsia. 
 
It is worthy of note that it is possible to measure the activity of microparticles in plasma 
using a microparticle sensitive reagent designed for the CAT assay (essentially a reagent 
containing no phospholipids), although this was not commercially available at the onset 
of this study. It is an important distinction to make that the use of this reagent would 
only reveal the procoagulant activity of the microparticles present, whereas the method 
employed above gives a global indication of a patients capacity to generate thrombin 
following a procoagulant stimulus including both the effects of the plasma 
concentration of clotting factors and the patients endogenous concentration of 
phospholipids. The exogenous phospholipid added to the patients’ plasma in the 
reaction as described in section 4.2.9 is analogous to the phospholipid material provided 
by the patients’ platelets in a ‘normal’ clotting response; the exclusion of this material 
would therefore lead to an underestimate of a patient’s true thrombin generation 
capacity. It is certainly plausible to suggest that the CAT thrombin generation assay 
could be further optimised from the method described in section 4.2.9 by changing the 
concentration of tissue factor or phospholipids (or both) in order to make it more 
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sensitive to the presence of increased concentrations of microparticles in pathological 
conditions. 
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5.1 Assay Validation 
 
The initial aim of this project was to assess the Calibrated Automated Thrombogram 
thrombin generation assay in order to determine whether or not it was suitable for 
routine diagnostic use in the haemostasis laboratory. The criteria chosen for assessment 
in this project included measuring the inter and intra assay variation, investigating the 
effects of sample handling and storage, ascertaining the limits of detection for the assay 
and determining the variation of an individuals results over time. Once these 
experiments had been completed a normal range for the assay was determined and the 
impacts of both age and sex were ascertained. The assay validation process also 
examined the effects that the addition of CTI had on the results generated by the CAT 
assay. 
 
The above parameters were chosen for investigation as an understanding of these effects 
would enable the accurate interpretation of the results generated by the assay. Without 
knowing the levels of intra and inter assay variability (or the variation of results seen in 
an individual over time) for example it is difficult to establish the significance of 
borderline results generated by the assay. If this was the case, the use of the assay for 
either the monitoring of therapy or the diagnosis of bleeding/thrombotic tendencies 
would be called into question. 
 
The initial experimentation yielded undesirable results, although the levels of intra 
assay variation appeared good, the inter assay variability was high with statistically 
significant differences between runs when compared using the students t-test for three 
of the four thrombin generation parameters. There was also evidence of an intra assay 
trend of decreasing peak height with the order in which the samples were added to the 
plate. These effects were not ameliorated by decreasing the time taken to set up the 
assay by using an electronic pipette.  The reason for the high level of variation seen in 
these experiments is almost certainly due to the use of Control plasma P in the analysis. 
The intra and inter assay variability dropped to acceptable levels when the experiments 
were repeated using fresh pooled plasma instead of the lyophophilised Control plasma 
P. The high level of variation associated with Control plasma P is probably an artefact 
of particulate matter present in the plasma following an incomplete or inefficient 
reconstitution which disrupts the fluorescent signal generated by the assay. The 
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filtration experiments revealed that the level of variation observed when measuring 
Control plasma P could be reduced if the plasma was filtered prior to analysis. Although 
the optical density of the plasma was not measured pre and post filtration it was 
observable to the human eye that the plasma became clearer following the filtration 
process. This observation lends weight to the above hypothesis. What was interesting 
regarding this result was the apparent failure of the filtration process and subsequent 
reduction in variation to ameliorate the intra assay trends apparent in the analysis of 
Control plasma P. Over the course of the experimentation performed in this study the 
analysis of Control plasma P was associated with a number of intra assay trends 
including decreasing ETP and peak height with increasing plate position (i.e. the ETP 
and peak height parameters were elevated in the sample added to the plate first when 
compared to the sample added to the plate last) and increasing lag time with increasing 
plate position. These trends were not observed in the analysis of fresh pooled plasma. 
This implies that Control plasma P is possibly more sensitive to calcium independent 
auto activation with increased incubation time than fresh plasma and that this effect 
cannot be overcome by decreasing the incubation times using an electronic pipette. 
 
The use of fresh pooled plasma to determine the inter and intra assay variation produced 
results which were acceptable for all four of the measured thrombin generation 
parameters (CVs <10%) and eliminated all of the observed intra assay trends. These 
results were not perfect however, since there was still evidence of statistically 
significant differences between runs when analysed by the students t-test, although the 
magnitude of these differences were below the 10% cut off of acceptability. The 
majority of these differences were seen in the lag time and the time to peak parameters 
implying it is the initiation of thrombin generation which is subject to the highest degree 
of variation. The measurement of the lag time is reported to be more sensitive to 
decreasing levels of clotting factors in haemophiliacs (except prothrombin deficiency) 
than the ETP (Al Dieri et al., 2002) and is characteristically increased in patients with 
lupus anticoagulant (Regnault et al., 2004). It is therefore the use of the CAT assay for 
these applications which is most likely to be affected by the increased variation in the 
lag time, something that was not attempted in this study. It is worthy of note that based 
on the inter assay CV for the lag time reported in this study (8.64% table 2.15), a lag 
time of >22 seconds above the normal range is certain to be a true abnormal. Since a 
plasma with 10% normal levels of clotting factors used in the limit of detection 
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experiment in chapter 2 had a lag time of >50 seconds outside the normal range the 
assay should be more than capable of detecting patients with significant bleeding 
tendencies. The diagnosis of haemophilia is also not entirely dependent on the lag time, 
indeed van Veen et al. (2009) reported that the main differences in the thrombin 
generation profile of haemophiliacs when compared to normal individuals is a reduced 
ETP and peak height and an increased time to peak.  
 
The experiments investigating the effects of time between sample collection and 
processing and sample storage temperature produced pleasing results. It was shown that 
samples could be stored for up to 24 hours at room temperature before processing 
without an observable impact on the results produced; this result has large implications 
for the utility of the assay. Other types of diagnostic assay in the haematology 
department have restrictive handling procedures which limit their routine use (samples 
to be analysed for homocysteine for example must be kept on ice until received by the 
laboratory). The robust nature of the sample stability for the CAT assay means samples 
can be effectively taken in the community and subsequently transported to the hospital 
for analysis, without the need for the patient being tested to attend hospital based 
clinics, thereby saving both time and money. Separated samples can be stored frozen at 
temperatures ≤-20°C for up to four weeks without impacting upon the results generated. 
This result not only means that samples for thrombin generation analysis can be stored 
with samples from the same patient requiring other investigations in the haemostasis 
laboratory but more importantly samples can be run in batches, as this increases the 
efficiency of analysis and ultimately reduces the cost of the assay. 
 
The analysis of the assay limits of detection produced some interesting results, not least 
of which was the apparent inability of the CAT thrombin generation assay to correctly 
interpret a flat generation curve as a zero result. The lowest results which could be 
reliably calculated by the analysis software were produced using a 2% dilution of SHP 
in heat inactivated plasma. As highlighted in chapter 2 although the inability of the 
assay to calculate a zero result accurately appears a significant limitation, it is highly 
unlikely that any patients would manifest a pathological condition significant enough to 
demonstrate the thrombin generation characteristics defined in this experiment. This is 
because this would necessitate a patient having a thrombin generation profile analogous 
to that of 2 iu/dL for all plasma clotting factor levels. These levels would only be 
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obtained in severe consumptive disorders such as major trauma and subsequent massive 
transfusion or disseminated intravascular coagulation (DIC) and even then this level of 
clotting factor activity may not be consistent with the patient’s survival. 
 
A frustrating aspect to this phase of the experimentation was the failure to quantify the 
upper limit of detection, although one of the attempts to do so did lead to an interesting 
result. It was felt that substrate depletion may be achieved by producing a plasma with a 
high level of prothrombin. This theory was based on the fact that the dilution 
experiment to establish the lower limit of quantification described in chapter 2 produced 
evidence to corroborate the findings of Al Dieri et al. (2002); that there was a linear 
association between the ETP and the concentration of prothrombin in a sample. In order 
to produce a plasma with a high concentration of prothrombin it was decided to 
reconstitute the SHP used in the lower limit of quantification studies with half of the 
volume of water usually required (500µl as opposed to 1ml). This would produce a 
plasma with concentrations of all clotting factors (including prothrombin) of 
approximately 200 iu/dL. This is roughly analogous to twice the normal concentration. 
Analysis of this plasma however yielded a flat thrombin generation curve and 
consequently a result which was unquantifiable. Although this experiment was designed 
to produce a result which could not be calculated by the analysis software, the 
mechanism by which this was attained was supposed to be due to substrate depletion 
rather than a failure to produce a generation curve. Interestingly reconstituting the SHP 
with increasingly higher volumes of water up to the manufacturers specified 1ml 
resulted in thrombin generation parameters of increasing magnitude, but lower than 
those attained following the analysis of SHP reconstituted following the manufacturers 
guidelines (data not shown). This result has important implications for the analysis of 
diagnostic samples since the apparent reason for this finding was the increased opacity 
of the SHP with decreasing volume of water used in the reconstitution. When lower 
volumes of water were used it appeared that the fluorescent signal generated was largely 
absorbed by the sample itself and was therefore not quantified by the detector, leading 
to a flat thrombin generation curve. Whether the absorption of fluorescent signal was a 
consequence of particular matter present in the sample due to inefficient reconstitution 
of the reagent is unclear. The most important aspect regarding this finding is that there 
seems to be a level of sample optical density above which the accurate determination of 
thrombin generation is impossible. This is therefore a concern for the analysis of 
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patients with a degree of lipaemia or any other causes for raised plasma turbidity, since 
it is possible that a low thrombin generation result seen in such a patient may be in part 
due to the nature of the sample itself rather than any predisposition towards bleeding.  
 
The assessment of variation in the thrombin generation profiles of normal individuals 
across time produced pleasing results. The level of variation seen across time was 
consistent with the variance in the inter assay variability experimentation. This suggests 
that an individual’s capacity to generate thrombin is relatively constant across time 
(provided they remain healthy). An extension of this finding is that the diagnostic power 
of the assay should be high with little need for repeat testing as the results produced 
should be reliable. This means that the CAT assay is suitable for both routine diagnosis 
and therapeutic monitoring in the haemostasis laboratory. 
 
The normal range established for the CAT assay as described in chapter 2 simplifies the 
interpretation of assay results when analysing adult patients between 20-60 years of age, 
since no differences were detected in the thrombin generation parameters analysed with 
either age or sex. The analysis of patients outside this range however is problematical as 
an appropriate normal range has yet to be established. If the CAT assay is to be used in 
the routine diagnosis of haemophilia this will have to be rectified as most patients with 
congenital mutations will typically be identified from a young age. 
 
The analysis of the effect of the addition of CTI on the results produced by the CAT 
thrombin generation assay produced unanticipated results. It was found that the use of 
CTI did have an effect on the results produced by the CAT assay when a concentration 
of 5pM tissue factor was used as a reaction trigger. Specifically it was found that there 
was a statistically significant reduction in the peak height of the samples spiked with 
CTI when compared to those samples in which no CTI was added. There were no 
significant differences in any of the other thrombin generation parameters. These 
findings contradicted those published in the literature (van Veen et al., 2008) which 
reported that the addition of CTI was not required when 5pM tissue factor was used as a 
reaction trigger. This finding implies that part of the maximum rate of thrombin 
generation, as defined by the CAT assay, is dependent on contact activation. The 
magnitude of difference between the results obtained with and without CTI is smaller 
than 10%, which is the limit of variation deemed acceptable in prior experimentation. 
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The clinical significance of such a small difference is also uncertain, and it was decided 
that the potential benefits of using CTI in a routine laboratory setting did not outweigh 
the cost implications. 
 
The assay validation experiments performed in this study were on the whole successful 
and highlighted few prohibitive limitations, proving that the CAT thrombin generation 
assay was suitable for routine use in the clinical laboratory setting. 
 
5.2 The Clinical Utility of the CAT Assay 
 
Following the successful validation of the assay, the next stage of experimentation was 
to determine whether the CAT thrombin generation assay could produce results which 
were clinically useful. To this end it was chosen to investigate the thrombin generation 
profiles of women with pre-eclampsia, this cohort was chosen for a number of reasons, 
not least of which was the fact that there is very little published data on the 
measurement of thrombin generation in pre-eclampsia, therefore research into this field 
would provide a novel aspect to this study. Since pre-eclampsia is a condition 
associated with pro-thrombotic changes in the clotting cascade it was anticipated that 
these women would have elevated thrombin generation parameters, and therefore the 
use of CTI to prevent contact activation would be unnecessary. Women of child bearing 
age also fit neatly into the demographic for which the normal range was established, 
meaning abnormal results could be reliably detected.  
 
The analysis of thrombin generation in pre-eclampsia produced a number of promising 
results, most notability that the ETP and peak height parameters in the cohort of women 
with pre-eclampsia were significantly elevated when compared to those of a cohort of 
normotensive pregnant women. These findings were consistent with a prothrombotic 
shift in patients with pre-eclampsia. Whilst these changes were conserved in women 
with pre-eclampsia of any severity there was no correlation between disease severity 
and the magnitude of the elevation observed in either the peak height or the ETP. This 
finding implies that although an increase in thrombogenicity is associated with pre-
eclampsia the severity of the condition is affected by other factors which do not directly 
impact upon a patient’s capacity to generate thrombin. It may also be the case that 
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optimising the CAT assay may allow for more efficient stratification of disease severity 
in pre-eclamptic women.  
 
Although this study highlighted elevated thrombin generation parameters in women 
with pre-eclampsia, utilising this finding in order to predict which women had pre-
eclampsia in a retrospective manner proved problematical. The primary reason for this  
was the substantial overlap between the thrombin generation results of pregnant women 
with and without pre-eclampsia (figure 3.11) which made choosing a cut off for 
defining a patient as high or low risk difficult. The combination of the measurement of 
thrombin generation with the PRECOG score provided results with the greatest clinical 
utility. Defining a patient as high risk if they had thrombin generation parameters 
greater than 1SD below the mean of the case cohort (ETP > 2263nM Thrombin and a 
peak height of >445nM Thrombin) either alone or in conjunction with a high risk 
PRECOG score, resulted in a sensitivity and specificity of 86% and 43% respectively. 
Importantly 94% of those individuals who were classified as low risk by both thrombin 
generation and PRECOG did not have pre-eclampsia. This combination of screening 
tests provides a means for the separation of a cohort of women who are at very low risk 
of developing pre-eclampsia from a cohort of women in whom pre-eclampsia is 
prevalent, whilst minimising the number of false negative results. Such a screening test 
is much more effective than the use of the PRECOG score alone and therefore 
highlights a potential new application for the measurement of thrombin generation. 
 
Other potential new applications for the measurement of thrombin generation via the 
CAT assay were highlighted by the correlations of thrombin generation parameters with 
end point measurements of pregnancy. It is clear that the measurement of thrombin 
generation has little application in either determining the chances of women having a 
LSCS or the risk of developing a PPH. There were however statistically significant 
correlations suggestive of the fact that high thrombin generation parameters during 
pregnancy are indicative of low birth weights and increased length of stay in hospital at 
the time of delivery. Further optimisation of the assay may be necessary to enhance the 
clinical utility of these correlations. If this can be achieved it would mean that the 
measurement of thrombin generation could be used as a reliable indicator as to the level 
of post natal care required, therefore highlighting a novel and clinically valuable 
application for the CAT thrombin generation assay. 
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One of the most interesting findings highlighted by the investigation of pre-eclampsia 
was that the reported changes in both ETP and peak height were conserved in women of 
Caucasian and Asian ethnic origin but were absent in Black women. Indeed the 
normotensive pregnant Black women had both elevated ETP and peak height 
parameters which were analogous to the levels seen in pre-eclamptic patients of either 
Caucasian or Asian ethnic origins. This result implies that Black individuals may 
demonstrate levels of thrombin generation which are elevated when compared to 
individuals of other ethnic origins. The reasons for this have yet to be determined. As 
highlighted in chapter 3 there are no ethnic differences in any of the normal ranges 
employed in the haemostasis laboratory at the Royal London Hospital and although 
some studies have reported the prevalence of deficiencies of natural anticoagulants such 
as protein C, protein S and antithrombin to be similar in VTE patients of Black ethnic 
origin when compared to Caucasian patients (Patel et al., 2003) it is worth noting that 
others have described that healthy Black patients have a normal range for protein C and 
protein S which is significantly lower than that derived from a White population 
(Jerrard-Dunne et al., 2003). It has been suggested as a result of this finding that not 
employing ethnic specific reference ranges could lead to the misdiagnosis of patients of 
Black ethnic origin (Roberts et al., 2009). The measurement of thrombin generation is 
most sensitive to the plasma levels of antithrombin, fibrinogen, prothrombin, factor V 
and free tissue factor pathway inhibitor (TFPI) when high concentrations of tissue factor 
are used as a reaction trigger (Dielis et al., 2008). Black individuals have elevated levels 
of fibrinogen as wells as other clotting factors such as factor VIII (Folsom et al., 1992) 
when compared to Caucasians which may lead to an increased thrombin generation 
capacity. A reduced level of free protein S may exacerbate this effect since free protein 
S has been shown to act as a cofactor for TFPI (Hackeng and Rosing, 2009). A natural 
deficiency of free protein S may therefore result in a reduced efficacy of TFPI and 
consequently an increased ETP/peak height. It is plausible that a reduced level of 
natural anticoagulants as well as increased levels of some clotting factors may be 
responsible for the apparent differences in the thrombin generation profiles observed in 
the different ethnic groups in this study, although further experimentation may be 
necessary to prove this hypothesis. 
 
One of the most compelling findings of this phase of the study was the combination of 
the measurement of ETP with the numbers of platelets expressing P-selectin, P-selectin 
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expressing microparticles and platelet-monocyte aggregates analysed by flow cytometry 
in the same cohort of patients with and without pre-eclampsia (Macey et al., 2010a). 
This analysis provided the most successful screening test for pre-eclampsia with 
sensitivity and specificity values of 81% and 86% respectively and positive and 
negative predictive values of 83% and 84% respectively.  
 
The findings of this paper also highlighted the fact that the elevated thrombin generation 
parameters apparent in the cohort of women with pre-eclampsia may be due to the 
elevated numbers of microparticles in the circulation of women with pre-eclampsia 
rather than prothrombotic changes in the plasma concentration of clotting factors or 
negative regulators of haemostasis. The filtration experiments performed in chapter 4 
suggest this is likely to be the case, since plasma filtration had a predictable effect on 
both the ETP and peak height parameters as measured by the CAT assay (decrease in 
results) and that the magnitude of these changes showed a statistically significant 
correlation with decreasing levels of microparticle numbers post filtration. Further 
evidence in support of this hypothesis was provided by the fact that filtration did not 
alter the plasma concentrations of clotting factors in a manner which was likely to cause 
the reported changes in thrombin generation following the filtration process and that 
microparticles were able to initiate thrombin generation and are therefore likely to have 
an impact on a patients thrombin generation capacity.  
 
Decreasing ETP results correlated with decreasing numbers of CD15 positive 
microparticles whereas decreasing peak height results showed a correlation with 
decreasing numbers of CD15 positive, CD42b positive and Annexin V positive events. 
It is plausible therefore that the phosphotidylserine rich membranes provided by 
microparticles in general as well as elevated levels of tissue factor provided by CD15 
positive monocyte derived microparticles (although tissue factor expression by CD15 
positive microparticles was not demonstrated in this study) enhance the thrombin 
generation capacity of an individuals plasma by supplementing the exogenous tissue 
factor and phospholipid added to a patients plasma in order to trigger thrombin 
generation in the CAT assay. The effect of the presence of microparticles on both the 
lag time and time to peak parameters is far less predictable but is probably determined 
by the presence or absence of microparticles expressing negative regulators of 
haemostasis. 
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The results of this study suggest that pathological levels of microparticles can act to 
enhance the level of ETP and peak height of an individual as determined by the CAT 
thrombin generation assay. This finding is of importance since it means the CAT assay 
can potentially be employed in the diagnosis of any condition in which the numbers of 
microparticles are enhanced. As an extension of this the CAT assay could also be used 
to monitor a patient’s response to therapy if it is known that a treatment causes a 
reduction in the numbers of microparticles e.g. the use of Clopidogrel and Asprin in 
patients with cardiac disorders (Serebruany et al., 2003). It is of note that the variation 
over time experiment performed in chapter 2 revealed that there is little change in the 
thrombin generation capacity of an individual over the time course analysed, this 
implies that the level of microparticles present in an individual’s circulation over time 
must also remain constant. This is consistent with constant baseline levels of 
microparticles within individuals reported by Brogan et al. (2004). If this is indeed the 
case it implies that the measurement of thrombin generation is probably sensitive to 
acquired conditions characterised by changes in the number of microparticles present in 
the circulation of an individual.  
 
In summary this study has provided evidence that the CAT assay can not only be used 
in the diagnosis of conditions characterised by changes in the plasma concentrations of 
proteins involved in haemostasis but is also of potential benefit in the diagnosis and 
monitoring of conditions characterised by increased numbers of plasma microparticles. 
This has been demonstrated in principle via the analysis of a cohort of pregnant women 
with pre-eclampsia and the development of a screen which can be used to differentiate 
between women with low risk of developing the condition and those of higher risk. 
 
5.3 Future Work 
 
There are a myriad of further research projects that could be attempted following this 
study, all of which could produce useful data. The primary starting point would be 
continuing to investigate the use of thrombin generation in the diagnosis of pre-
eclampsia. As highlighted in chapter 3, although the data in this study suggests there is 
an elevation in both the ETP and peak height of a pregnant woman with pre-eclampsia 
when compared to a normotensive pregnant woman, the analysis was performed 
retrospectively. A prospective study is essential in order to determine whether or not 
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these parameters are elevated early in pregnancy or whether they are only characteristic 
of late stage disease. This would provide conclusive evidence as to whether the 
measurement of thrombin generation would constitute an effective screening test for 
pre-eclampsia or not. The fact that neither the ETP or peak height shows any significant 
trend with increasing gestational age implies that elevated thrombin generation 
parameters should be apparent at any time during pregnancy. It would be desirable to 
collect samples from women early in pregnancy and also after 20 weeks (when the 
diagnosis of pre-eclampsia is possible) in order to compare changes in results over this 
time. This type of study would need to rely on prospective collection of samples and 
retrospective analysis, once it is known whether a patient has developed disease or not, 
in order to minimise the cost. It would also be beneficial to analyse the numbers and 
types of microparticles present in this cohort of women as the original microparticle 
analysis performed in the pre-eclampsia cohort was limited to the number of P-selectin 
expressing microparticles. It would be of interest to characterise the types of 
microparticles present in women with pre-eclampsia in order to prove the hypothesis 
that an increase in the number of CD15 expressing microparticles is associated with the 
increased thrombin generation manifest in women with pre-eclampsia. It would also be 
of benefit to establish whether or not CD15 positive microparticles do actually express 
tissue factor. 
 
Before embarking on the prospective study outlined above it would be of use to attempt 
to optimise the CAT assay to make it more sensitive to the prothrombotic changes seen 
in women with pre-eclampsia. This may allow differences in the thrombin generation 
profiles of women with varying levels of disease severity to be determined. 
Optimisation of the assay may also enhance the sensitivity/specificity of the CAT assay 
in terms of the diagnosis of pre-eclampsia by decreasing the degree of overlap between 
the results of the case and control cohorts. Assay optimisation may also increase the 
degree of correlation between the ETP/peak height and the birth weight and length of 
stay in hospital at the time of delivery. 
 
It would also be beneficial to further investigate the impact of microparticles on the 
CAT assay. A starting point for this would be the analysis of plasma pre and post 
filtration using a low concentration of tissue factor as a reaction trigger. If the analysis is 
affected by the number of tissue factor expressing microparticles the use of a lower 
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concentration of tissue factor should make the assay more sensitive to the presence of 
these microparticles, although the use of CTI would be essential in order to prevent 
contact activation impacting on the results of the analysis. It would also be of interest to 
determine the sensitivity of the CAT assay in the detection of elevated thrombin 
generation parameters in other conditions characterised by increased levels of 
microparticles in order to prove that the assay is indeed sensitive to these conditions.  
 
An experiment of interest would be to study the persistence of microparticles following 
delivery in a cohort of patients with and without pre-eclampsia to see when and if they 
return to a baseline normal level; this could also be correlated with the measurement of 
thrombin generation. This investigation is of interest in providing a link between pre-
eclampsia and cardiovascular disease in later life, since it is known there is an 
association between the two and that the presence of microparticles are implicated in 
both diseases, it may be that a persistence of a pathological level of microparticles is 
causative of this effect. 
 
It would also be of interest to investigate the thrombin generation in a cohort of 
individuals of Black ethnic origin to see if it is necessary to establish a separate normal 
range. If there are differences in the thrombin generation capacities of individuals of 
different ethnic origins it would be beneficial to try and determine the basis for these 
changes. In the absence of any differences in the plasma concentration of clotting 
factors it may be that differences in the number and or type of circulating microparticles 
may be responsible for any differences observed. 
 
A final consideration for further experimentation would be the investigation of the 
paediatric normal range, which as highlighted above would be essential if the CAT 
assay is to be introduced in the diagnosis of haemophilia. 
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7.1 Distribution of t 
 
Degrees 
of 
Freedom 
 
 
0.5 
 
 
0.1 
Probability 
 
0.05 
 
 
0.02 
 
 
0.01 
 
 
0.001 
1 1.000 6.314 12.706 31.821 63.657 636.619 
2 0.816 2.920 4.303 6.965 9.925 31.598 
3 0.765 2.353 3.182 4.541 5.841 12.941 
4 0.741 2.132 2.776 3.747 4.604 8.610 
5 0.727 2.015 2.571 3.365 4.032 6.859 
6 0.718 1.943 2.447 3.143 3.707 5.959 
7 0.711 1.895 2.365 2.998 3.499 5.405 
8 0.706 1.860 2.306 2.896 3.355 5.041 
9 0.703 1.833 2.262 2.821 3.250 4.781 
10 0.700 1.812 2.228 2.764 3.169 4.587 
11 0.697 1.796 2.201 2.718 3.106 4.437 
12 0.695 1.782 2.179 2.681 3.055 4.318 
13 0.694 1.771 2.160 2.650 3.012 4.221 
14 0.692 1.761 2.145 2.624 2.977 4.140 
15 0.691 1.753 2.131 2.602 2.947 4.073 
16 0.690 1.746 2.120 2.583 2.921 4.015 
17 0.689 1.740 2.110 2.567 2.898 3.965 
18 0.688 1.734 2.101 2.552 2.878 3.922 
19 0.688 1.729 2.093 2.539 2.861 3.883 
20 0.687 1.725 2.086 2.528 2.845 3.850 
21 0.686 1.721 2.080 2.518 2.831 3.819 
22 0.686 1.717 2.074 2.508 2.819 3.792 
23 0.685 1.714 2.069 2.500 2.807 3.767 
24 0.685 1.711 2.064 2.492 2.797 3.745 
25 0.684 1.708 2.060 2.485 2.787 3.725 
26 0.684 1.706 2.056 2.479 2.779 3.707 
27 0.684 1.703 2.052 2.473 2.771 3.690 
28 0.683 1.701 2.048 2.467 2.763 3.674 
29 0.683 1.699 2.045 2.462 2.756 3.659 
30 0.683 1.697 2.042 2.457 2.750 3.646 
40 0.681 1.684 2.021 2.423 2.704 3.551 
60 0.679 1.671 2.000 2.390 2.660 3.460 
120 0.677 1.658 1.980 2.358 2.617 3.737 
∞ 0.674 1.645 1.960 2.326 2.576 3.291 
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